Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2020-10-23
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
## human mouse jmod jsev
## A4GALT -14.988939 0.8182771 5.5001019 22.047763204
## AAAS -2.435804 0.3877972 0.7776159 11.429984487
## AACS -1.581711 4.1420212 11.1737053 7.273099739
## AAED1 -1.286093 -0.8848853 -39.4294484 -81.594009264
## AAGAB -1.722220 -1.3839648 0.2777522 -0.008090687
## AAK1 14.833940 0.4269837 -1.5398326 -0.582853337Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genes_in_profile | 10584 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 6179 |
| num_profile_genes_not_in_sets | 4405 |
Here is a plot of the input profiles. Note the dynamic ranges. 
Here is the contour plot of the profile including all detected genes. 
Input genesets
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt
| Gene sets metrics | |
|---|---|
| num_genesets | 2408 |
| num_genesets_excluded | 1177 |
| num_genesets_included | 1231 |
| human | mouse | jmod | jsev | Count | |
|---|---|---|---|---|---|
| 1 | -1 | -1 | -1 | -1 | 1994 |
| 2 | 0 | -1 | -1 | -1 | 1 |
| 3 | 1 | -1 | -1 | -1 | 1360 |
| 4 | -1 | 1 | -1 | -1 | 558 |
| 5 | 1 | 1 | -1 | -1 | 768 |
| 6 | -1 | -1 | 0 | -1 | 1 |
| 7 | -1 | -1 | 1 | -1 | 285 |
| 8 | 1 | -1 | 1 | -1 | 169 |
| 9 | -1 | 1 | 1 | -1 | 185 |
| 10 | 1 | 1 | 1 | -1 | 186 |
| 11 | 1 | -1 | 1 | 0 | 1 |
| 12 | -1 | -1 | -1 | 1 | 135 |
| 13 | 1 | -1 | -1 | 1 | 148 |
| 14 | -1 | 1 | -1 | 1 | 126 |
| 15 | 1 | 1 | -1 | 1 | 244 |
| 16 | -1 | -1 | 1 | 1 | 718 |
| 17 | 1 | -1 | 1 | 1 | 527 |
| 18 | 1 | 0 | 1 | 1 | 1 |
| 19 | -1 | 1 | 1 | 1 | 1581 |
| 20 | 1 | 1 | 1 | 1 | 1596 |
Gene sets by sector
| s.human | s.mouse | s.jmod | s.jsev | Count | |
|---|---|---|---|---|---|
| 1 | -1 | -1 | -1 | -1 | 55 |
| 2 | 1 | -1 | -1 | -1 | 13 |
| 3 | -1 | 1 | -1 | -1 | 13 |
| 4 | 1 | 1 | -1 | -1 | 95 |
| 5 | -1 | -1 | 1 | -1 | 3 |
| 6 | -1 | 1 | 1 | -1 | 4 |
| 7 | 1 | 1 | 1 | -1 | 23 |
| 8 | -1 | -1 | -1 | 1 | 1 |
| 9 | 1 | -1 | -1 | 1 | 2 |
| 10 | -1 | 1 | -1 | 1 | 9 |
| 11 | 1 | 1 | -1 | 1 | 45 |
| 12 | -1 | -1 | 1 | 1 | 28 |
| 13 | 1 | -1 | 1 | 1 | 4 |
| 14 | -1 | 1 | 1 | 1 | 126 |
| 15 | 1 | 1 | 1 | 1 | 164 |
Interactive enrichment scatterplot
All sets with FDR<0.05. Try hovering over the points.
A heatmap of S values for top results
A plot of effect size versus significance
Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.
Results table
Top N= 50 gene sets
| set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.human | s.mouse | s.jmod | s.jsev | p.human | p.mouse | p.jmod | p.jsev |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interleukin-10 signaling | 11 | 8.18e-06 | 5.19e-05 | 1.290 | -0.25300 | 0.74700 | 0.742 | 0.708 | 1.47e-01 | 1.77e-05 | 2.01e-05 | 4.80e-05 |
| Citric acid cycle (TCA cycle) | 21 | 5.50e-07 | 5.01e-06 | 1.100 | -0.24400 | -0.59600 | -0.585 | -0.669 | 5.32e-02 | 2.25e-06 | 3.44e-06 | 1.11e-07 |
| Degradation of cysteine and homocysteine | 12 | 4.05e-04 | 1.61e-03 | 1.100 | -0.30300 | -0.40700 | -0.688 | -0.687 | 6.89e-02 | 1.48e-02 | 3.64e-05 | 3.80e-05 |
| Branched-chain amino acid catabolism | 20 | 1.63e-06 | 1.30e-05 | 1.060 | -0.07510 | -0.53100 | -0.586 | -0.703 | 5.61e-01 | 3.93e-05 | 5.70e-06 | 5.19e-08 |
| Prolactin receptor signaling | 10 | 5.55e-03 | 1.46e-02 | 1.050 | -0.24700 | -0.53600 | -0.590 | -0.635 | 1.76e-01 | 3.36e-03 | 1.23e-03 | 5.03e-04 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 10 | 3.23e-03 | 9.45e-03 | 1.040 | 0.11300 | 0.47500 | 0.697 | 0.593 | 5.35e-01 | 9.32e-03 | 1.34e-04 | 1.17e-03 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 49 | 5.00e-16 | 2.12e-14 | 1.040 | -0.26400 | -0.55900 | -0.522 | -0.649 | 1.40e-03 | 1.32e-11 | 2.68e-10 | 3.75e-15 |
| Complex I biogenesis | 52 | 4.86e-19 | 2.85e-17 | 1.030 | -0.19700 | -0.40000 | -0.575 | -0.736 | 1.40e-02 | 6.09e-07 | 7.54e-13 | 4.06e-20 |
| Glyoxylate metabolism and glycine degradation | 20 | 2.72e-07 | 2.77e-06 | 0.998 | -0.17300 | -0.51100 | -0.480 | -0.689 | 1.80e-01 | 7.63e-05 | 2.00e-04 | 9.61e-08 |
| The NLRP3 inflammasome | 10 | 5.84e-03 | 1.53e-02 | 0.992 | -0.09040 | 0.49000 | 0.646 | 0.566 | 6.21e-01 | 7.35e-03 | 4.06e-04 | 1.96e-03 |
| Signal regulatory protein family interactions | 10 | 1.08e-03 | 3.62e-03 | 0.985 | -0.41300 | 0.50700 | 0.505 | 0.537 | 2.38e-02 | 5.50e-03 | 5.72e-03 | 3.27e-03 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 10 | 6.43e-04 | 2.36e-03 | 0.969 | -0.24600 | 0.05040 | 0.663 | 0.660 | 1.78e-01 | 7.83e-01 | 2.84e-04 | 2.99e-04 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 6.30e-05 | 3.08e-04 | 0.964 | -0.16300 | -0.63000 | -0.411 | -0.580 | 2.74e-01 | 2.36e-05 | 5.92e-03 | 1.02e-04 |
| Mucopolysaccharidoses | 11 | 9.68e-05 | 4.46e-04 | 0.959 | -0.33600 | 0.00843 | 0.608 | 0.660 | 5.35e-02 | 9.61e-01 | 4.79e-04 | 1.49e-04 |
| Inflammasomes | 12 | 1.57e-03 | 5.01e-03 | 0.951 | -0.21900 | 0.44600 | 0.615 | 0.528 | 1.88e-01 | 7.50e-03 | 2.27e-04 | 1.54e-03 |
| Condensation of Prophase Chromosomes | 11 | 8.97e-04 | 3.07e-03 | 0.941 | 0.37200 | 0.18800 | 0.548 | 0.642 | 3.29e-02 | 2.80e-01 | 1.65e-03 | 2.27e-04 |
| Post-chaperonin tubulin folding pathway | 15 | 1.89e-06 | 1.42e-05 | 0.939 | -0.48300 | 0.55500 | 0.459 | 0.360 | 1.19e-03 | 1.97e-04 | 2.08e-03 | 1.59e-02 |
| The citric acid (TCA) cycle and respiratory electron transport | 142 | 1.87e-42 | 7.67e-40 | 0.928 | -0.20300 | -0.42300 | -0.482 | -0.640 | 3.20e-05 | 4.08e-18 | 4.17e-23 | 1.23e-39 |
| Pyruvate metabolism | 26 | 9.19e-08 | 1.11e-06 | 0.927 | -0.22900 | -0.52100 | -0.423 | -0.597 | 4.35e-02 | 4.23e-06 | 1.90e-04 | 1.39e-07 |
| N-Glycan antennae elongation | 12 | 1.66e-03 | 5.25e-03 | 0.923 | -0.26200 | 0.42900 | 0.505 | 0.586 | 1.17e-01 | 1.01e-02 | 2.44e-03 | 4.39e-04 |
| Respiratory electron transport | 92 | 2.14e-29 | 3.30e-27 | 0.922 | -0.17900 | -0.36700 | -0.489 | -0.666 | 3.12e-03 | 1.28e-09 | 5.26e-16 | 2.26e-28 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 13 | 3.76e-03 | 1.04e-02 | 0.917 | 0.11200 | 0.32400 | 0.623 | 0.580 | 4.86e-01 | 4.31e-02 | 1.01e-04 | 2.96e-04 |
| Interferon alpha/beta signaling | 36 | 1.57e-08 | 2.10e-07 | 0.902 | -0.00941 | 0.35000 | 0.552 | 0.621 | 9.22e-01 | 2.80e-04 | 1.01e-08 | 1.13e-10 |
| Unwinding of DNA | 10 | 4.52e-03 | 1.21e-02 | 0.894 | -0.03630 | 0.47300 | 0.437 | 0.619 | 8.43e-01 | 9.62e-03 | 1.68e-02 | 7.02e-04 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 13 | 2.18e-04 | 9.37e-04 | 0.893 | -0.16700 | 0.51300 | 0.403 | 0.587 | 2.97e-01 | 1.38e-03 | 1.20e-02 | 2.51e-04 |
| PECAM1 interactions | 10 | 1.16e-02 | 2.74e-02 | 0.892 | -0.25200 | 0.28300 | 0.594 | 0.546 | 1.68e-01 | 1.21e-01 | 1.14e-03 | 2.79e-03 |
| Gluconeogenesis | 22 | 2.11e-06 | 1.56e-05 | 0.886 | -0.57400 | -0.36000 | -0.378 | -0.427 | 3.12e-06 | 3.46e-03 | 2.16e-03 | 5.23e-04 |
| Mitochondrial Fatty Acid Beta-Oxidation | 30 | 1.98e-07 | 2.07e-06 | 0.884 | -0.33600 | -0.54800 | -0.385 | -0.469 | 1.44e-03 | 2.08e-07 | 2.61e-04 | 8.89e-06 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 96 | 5.01e-28 | 6.86e-26 | 0.882 | -0.17700 | -0.35800 | -0.464 | -0.635 | 2.73e-03 | 1.47e-09 | 4.17e-15 | 5.97e-27 |
| rRNA processing in the mitochondrion | 11 | 6.51e-04 | 2.38e-03 | 0.868 | -0.03850 | -0.36700 | -0.422 | -0.663 | 8.25e-01 | 3.52e-02 | 1.53e-02 | 1.42e-04 |
| Biotin transport and metabolism | 10 | 2.05e-02 | 4.39e-02 | 0.864 | -0.02120 | -0.53500 | -0.425 | -0.528 | 9.07e-01 | 3.41e-03 | 1.99e-02 | 3.87e-03 |
| Metabolism of steroid hormones | 12 | 9.67e-03 | 2.36e-02 | 0.852 | -0.11800 | 0.38700 | 0.570 | 0.487 | 4.80e-01 | 2.03e-02 | 6.32e-04 | 3.48e-03 |
| Carnitine metabolism | 11 | 4.65e-03 | 1.25e-02 | 0.847 | -0.43500 | -0.56700 | -0.272 | -0.365 | 1.26e-02 | 1.12e-03 | 1.18e-01 | 3.64e-02 |
| LDL clearance | 14 | 4.11e-03 | 1.12e-02 | 0.842 | 0.02170 | 0.21900 | 0.561 | 0.588 | 8.88e-01 | 1.57e-01 | 2.78e-04 | 1.40e-04 |
| Diseases associated with the TLR signaling cascade | 16 | 1.01e-03 | 3.41e-03 | 0.841 | -0.17500 | 0.31800 | 0.581 | 0.489 | 2.25e-01 | 2.79e-02 | 5.78e-05 | 7.13e-04 |
| Diseases of Immune System | 16 | 1.01e-03 | 3.41e-03 | 0.841 | -0.17500 | 0.31800 | 0.581 | 0.489 | 2.25e-01 | 2.79e-02 | 5.78e-05 | 7.13e-04 |
| Glycogen storage diseases | 11 | 5.47e-04 | 2.05e-03 | 0.837 | -0.40800 | -0.06070 | -0.443 | -0.579 | 1.93e-02 | 7.27e-01 | 1.10e-02 | 8.89e-04 |
| Leading Strand Synthesis | 14 | 1.02e-02 | 2.48e-02 | 0.833 | 0.22600 | 0.39100 | 0.469 | 0.518 | 1.43e-01 | 1.12e-02 | 2.36e-03 | 7.87e-04 |
| Polymerase switching | 14 | 1.02e-02 | 2.48e-02 | 0.833 | 0.22600 | 0.39100 | 0.469 | 0.518 | 1.43e-01 | 1.12e-02 | 2.36e-03 | 7.87e-04 |
| N-glycan antennae elongation in the medial/trans-Golgi | 17 | 2.09e-03 | 6.37e-03 | 0.819 | -0.12500 | 0.33900 | 0.497 | 0.542 | 3.73e-01 | 1.56e-02 | 3.88e-04 | 1.10e-04 |
| Sema3A PAK dependent Axon repulsion | 15 | 3.35e-03 | 9.65e-03 | 0.819 | -0.18400 | 0.39200 | 0.520 | 0.461 | 2.17e-01 | 8.61e-03 | 4.87e-04 | 2.00e-03 |
| Voltage gated Potassium channels | 11 | 8.12e-03 | 2.03e-02 | 0.817 | -0.52900 | -0.36100 | -0.365 | -0.352 | 2.39e-03 | 3.80e-02 | 3.61e-02 | 4.33e-02 |
| Formation of tubulin folding intermediates by CCT/TriC | 17 | 1.62e-05 | 9.07e-05 | 0.813 | -0.09560 | 0.68300 | 0.255 | 0.346 | 4.95e-01 | 1.09e-06 | 6.87e-02 | 1.35e-02 |
| Regulation of IFNA signaling | 12 | 2.55e-02 | 5.29e-02 | 0.810 | -0.03910 | 0.34500 | 0.490 | 0.543 | 8.14e-01 | 3.86e-02 | 3.30e-03 | 1.12e-03 |
| Defects in vitamin and cofactor metabolism | 17 | 5.20e-04 | 1.98e-03 | 0.804 | 0.10400 | -0.52300 | -0.368 | -0.476 | 4.58e-01 | 1.91e-04 | 8.68e-03 | 6.78e-04 |
| HS-GAG degradation | 16 | 4.75e-05 | 2.39e-04 | 0.801 | -0.43600 | -0.01370 | 0.472 | 0.479 | 2.56e-03 | 9.25e-01 | 1.08e-03 | 9.19e-04 |
| GPVI-mediated activation cascade | 18 | 3.72e-03 | 1.04e-02 | 0.801 | 0.15800 | 0.46100 | 0.445 | 0.454 | 2.45e-01 | 7.10e-04 | 1.09e-03 | 8.63e-04 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 10 | 3.60e-02 | 7.10e-02 | 0.801 | -0.38000 | -0.42500 | -0.356 | -0.435 | 3.76e-02 | 1.99e-02 | 5.15e-02 | 1.72e-02 |
| Acyl chain remodelling of PS | 10 | 2.14e-02 | 4.56e-02 | 0.797 | 0.21600 | 0.21500 | 0.569 | 0.468 | 2.36e-01 | 2.39e-01 | 1.83e-03 | 1.05e-02 |
| Phase 0 - rapid depolarisation | 17 | 1.66e-04 | 7.32e-04 | 0.791 | -0.57000 | -0.23500 | -0.315 | -0.384 | 4.79e-05 | 9.33e-02 | 2.47e-02 | 6.20e-03 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.human | s.mouse | s.jmod | s.jsev | p.human | p.mouse | p.jmod | p.jsev |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interleukin-10 signaling | 11 | 8.18e-06 | 5.19e-05 | 1.2900 | -2.53e-01 | 7.47e-01 | 7.42e-01 | 7.08e-01 | 1.47e-01 | 1.77e-05 | 2.01e-05 | 4.80e-05 |
| Citric acid cycle (TCA cycle) | 21 | 5.50e-07 | 5.01e-06 | 1.1000 | -2.44e-01 | -5.96e-01 | -5.85e-01 | -6.69e-01 | 5.32e-02 | 2.25e-06 | 3.44e-06 | 1.11e-07 |
| Degradation of cysteine and homocysteine | 12 | 4.05e-04 | 1.61e-03 | 1.1000 | -3.03e-01 | -4.07e-01 | -6.88e-01 | -6.87e-01 | 6.89e-02 | 1.48e-02 | 3.64e-05 | 3.80e-05 |
| Branched-chain amino acid catabolism | 20 | 1.63e-06 | 1.30e-05 | 1.0600 | -7.51e-02 | -5.31e-01 | -5.86e-01 | -7.03e-01 | 5.61e-01 | 3.93e-05 | 5.70e-06 | 5.19e-08 |
| Prolactin receptor signaling | 10 | 5.55e-03 | 1.46e-02 | 1.0500 | -2.47e-01 | -5.36e-01 | -5.90e-01 | -6.35e-01 | 1.76e-01 | 3.36e-03 | 1.23e-03 | 5.03e-04 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 10 | 3.23e-03 | 9.45e-03 | 1.0400 | 1.13e-01 | 4.75e-01 | 6.97e-01 | 5.93e-01 | 5.35e-01 | 9.32e-03 | 1.34e-04 | 1.17e-03 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 49 | 5.00e-16 | 2.12e-14 | 1.0400 | -2.64e-01 | -5.59e-01 | -5.22e-01 | -6.49e-01 | 1.40e-03 | 1.32e-11 | 2.68e-10 | 3.75e-15 |
| Complex I biogenesis | 52 | 4.86e-19 | 2.85e-17 | 1.0300 | -1.97e-01 | -4.00e-01 | -5.75e-01 | -7.36e-01 | 1.40e-02 | 6.09e-07 | 7.54e-13 | 4.06e-20 |
| Glyoxylate metabolism and glycine degradation | 20 | 2.72e-07 | 2.77e-06 | 0.9980 | -1.73e-01 | -5.11e-01 | -4.80e-01 | -6.89e-01 | 1.80e-01 | 7.63e-05 | 2.00e-04 | 9.61e-08 |
| The NLRP3 inflammasome | 10 | 5.84e-03 | 1.53e-02 | 0.9920 | -9.04e-02 | 4.90e-01 | 6.46e-01 | 5.66e-01 | 6.21e-01 | 7.35e-03 | 4.06e-04 | 1.96e-03 |
| Signal regulatory protein family interactions | 10 | 1.08e-03 | 3.62e-03 | 0.9850 | -4.13e-01 | 5.07e-01 | 5.05e-01 | 5.37e-01 | 2.38e-02 | 5.50e-03 | 5.72e-03 | 3.27e-03 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 10 | 6.43e-04 | 2.36e-03 | 0.9690 | -2.46e-01 | 5.04e-02 | 6.63e-01 | 6.60e-01 | 1.78e-01 | 7.83e-01 | 2.84e-04 | 2.99e-04 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 6.30e-05 | 3.08e-04 | 0.9640 | -1.63e-01 | -6.30e-01 | -4.11e-01 | -5.80e-01 | 2.74e-01 | 2.36e-05 | 5.92e-03 | 1.02e-04 |
| Mucopolysaccharidoses | 11 | 9.68e-05 | 4.46e-04 | 0.9590 | -3.36e-01 | 8.43e-03 | 6.08e-01 | 6.60e-01 | 5.35e-02 | 9.61e-01 | 4.79e-04 | 1.49e-04 |
| Inflammasomes | 12 | 1.57e-03 | 5.01e-03 | 0.9510 | -2.19e-01 | 4.46e-01 | 6.15e-01 | 5.28e-01 | 1.88e-01 | 7.50e-03 | 2.27e-04 | 1.54e-03 |
| Condensation of Prophase Chromosomes | 11 | 8.97e-04 | 3.07e-03 | 0.9410 | 3.72e-01 | 1.88e-01 | 5.48e-01 | 6.42e-01 | 3.29e-02 | 2.80e-01 | 1.65e-03 | 2.27e-04 |
| Post-chaperonin tubulin folding pathway | 15 | 1.89e-06 | 1.42e-05 | 0.9390 | -4.83e-01 | 5.55e-01 | 4.59e-01 | 3.60e-01 | 1.19e-03 | 1.97e-04 | 2.08e-03 | 1.59e-02 |
| The citric acid (TCA) cycle and respiratory electron transport | 142 | 1.87e-42 | 7.67e-40 | 0.9280 | -2.03e-01 | -4.23e-01 | -4.82e-01 | -6.40e-01 | 3.20e-05 | 4.08e-18 | 4.17e-23 | 1.23e-39 |
| Pyruvate metabolism | 26 | 9.19e-08 | 1.11e-06 | 0.9270 | -2.29e-01 | -5.21e-01 | -4.23e-01 | -5.97e-01 | 4.35e-02 | 4.23e-06 | 1.90e-04 | 1.39e-07 |
| N-Glycan antennae elongation | 12 | 1.66e-03 | 5.25e-03 | 0.9230 | -2.62e-01 | 4.29e-01 | 5.05e-01 | 5.86e-01 | 1.17e-01 | 1.01e-02 | 2.44e-03 | 4.39e-04 |
| Respiratory electron transport | 92 | 2.14e-29 | 3.30e-27 | 0.9220 | -1.79e-01 | -3.67e-01 | -4.89e-01 | -6.66e-01 | 3.12e-03 | 1.28e-09 | 5.26e-16 | 2.26e-28 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 13 | 3.76e-03 | 1.04e-02 | 0.9170 | 1.12e-01 | 3.24e-01 | 6.23e-01 | 5.80e-01 | 4.86e-01 | 4.31e-02 | 1.01e-04 | 2.96e-04 |
| Interferon alpha/beta signaling | 36 | 1.57e-08 | 2.10e-07 | 0.9020 | -9.41e-03 | 3.50e-01 | 5.52e-01 | 6.21e-01 | 9.22e-01 | 2.80e-04 | 1.01e-08 | 1.13e-10 |
| Unwinding of DNA | 10 | 4.52e-03 | 1.21e-02 | 0.8940 | -3.63e-02 | 4.73e-01 | 4.37e-01 | 6.19e-01 | 8.43e-01 | 9.62e-03 | 1.68e-02 | 7.02e-04 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 13 | 2.18e-04 | 9.37e-04 | 0.8930 | -1.67e-01 | 5.13e-01 | 4.03e-01 | 5.87e-01 | 2.97e-01 | 1.38e-03 | 1.20e-02 | 2.51e-04 |
| PECAM1 interactions | 10 | 1.16e-02 | 2.74e-02 | 0.8920 | -2.52e-01 | 2.83e-01 | 5.94e-01 | 5.46e-01 | 1.68e-01 | 1.21e-01 | 1.14e-03 | 2.79e-03 |
| Gluconeogenesis | 22 | 2.11e-06 | 1.56e-05 | 0.8860 | -5.74e-01 | -3.60e-01 | -3.78e-01 | -4.27e-01 | 3.12e-06 | 3.46e-03 | 2.16e-03 | 5.23e-04 |
| Mitochondrial Fatty Acid Beta-Oxidation | 30 | 1.98e-07 | 2.07e-06 | 0.8840 | -3.36e-01 | -5.48e-01 | -3.85e-01 | -4.69e-01 | 1.44e-03 | 2.08e-07 | 2.61e-04 | 8.89e-06 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 96 | 5.01e-28 | 6.86e-26 | 0.8820 | -1.77e-01 | -3.58e-01 | -4.64e-01 | -6.35e-01 | 2.73e-03 | 1.47e-09 | 4.17e-15 | 5.97e-27 |
| rRNA processing in the mitochondrion | 11 | 6.51e-04 | 2.38e-03 | 0.8680 | -3.85e-02 | -3.67e-01 | -4.22e-01 | -6.63e-01 | 8.25e-01 | 3.52e-02 | 1.53e-02 | 1.42e-04 |
| Biotin transport and metabolism | 10 | 2.05e-02 | 4.39e-02 | 0.8640 | -2.12e-02 | -5.35e-01 | -4.25e-01 | -5.28e-01 | 9.07e-01 | 3.41e-03 | 1.99e-02 | 3.87e-03 |
| Metabolism of steroid hormones | 12 | 9.67e-03 | 2.36e-02 | 0.8520 | -1.18e-01 | 3.87e-01 | 5.70e-01 | 4.87e-01 | 4.80e-01 | 2.03e-02 | 6.32e-04 | 3.48e-03 |
| Carnitine metabolism | 11 | 4.65e-03 | 1.25e-02 | 0.8470 | -4.35e-01 | -5.67e-01 | -2.72e-01 | -3.65e-01 | 1.26e-02 | 1.12e-03 | 1.18e-01 | 3.64e-02 |
| LDL clearance | 14 | 4.11e-03 | 1.12e-02 | 0.8420 | 2.17e-02 | 2.19e-01 | 5.61e-01 | 5.88e-01 | 8.88e-01 | 1.57e-01 | 2.78e-04 | 1.40e-04 |
| Diseases associated with the TLR signaling cascade | 16 | 1.01e-03 | 3.41e-03 | 0.8410 | -1.75e-01 | 3.18e-01 | 5.81e-01 | 4.89e-01 | 2.25e-01 | 2.79e-02 | 5.78e-05 | 7.13e-04 |
| Diseases of Immune System | 16 | 1.01e-03 | 3.41e-03 | 0.8410 | -1.75e-01 | 3.18e-01 | 5.81e-01 | 4.89e-01 | 2.25e-01 | 2.79e-02 | 5.78e-05 | 7.13e-04 |
| Glycogen storage diseases | 11 | 5.47e-04 | 2.05e-03 | 0.8370 | -4.08e-01 | -6.07e-02 | -4.43e-01 | -5.79e-01 | 1.93e-02 | 7.27e-01 | 1.10e-02 | 8.89e-04 |
| Leading Strand Synthesis | 14 | 1.02e-02 | 2.48e-02 | 0.8330 | 2.26e-01 | 3.91e-01 | 4.69e-01 | 5.18e-01 | 1.43e-01 | 1.12e-02 | 2.36e-03 | 7.87e-04 |
| Polymerase switching | 14 | 1.02e-02 | 2.48e-02 | 0.8330 | 2.26e-01 | 3.91e-01 | 4.69e-01 | 5.18e-01 | 1.43e-01 | 1.12e-02 | 2.36e-03 | 7.87e-04 |
| N-glycan antennae elongation in the medial/trans-Golgi | 17 | 2.09e-03 | 6.37e-03 | 0.8190 | -1.25e-01 | 3.39e-01 | 4.97e-01 | 5.42e-01 | 3.73e-01 | 1.56e-02 | 3.88e-04 | 1.10e-04 |
| Sema3A PAK dependent Axon repulsion | 15 | 3.35e-03 | 9.65e-03 | 0.8190 | -1.84e-01 | 3.92e-01 | 5.20e-01 | 4.61e-01 | 2.17e-01 | 8.61e-03 | 4.87e-04 | 2.00e-03 |
| Voltage gated Potassium channels | 11 | 8.12e-03 | 2.03e-02 | 0.8170 | -5.29e-01 | -3.61e-01 | -3.65e-01 | -3.52e-01 | 2.39e-03 | 3.80e-02 | 3.61e-02 | 4.33e-02 |
| Formation of tubulin folding intermediates by CCT/TriC | 17 | 1.62e-05 | 9.07e-05 | 0.8130 | -9.56e-02 | 6.83e-01 | 2.55e-01 | 3.46e-01 | 4.95e-01 | 1.09e-06 | 6.87e-02 | 1.35e-02 |
| Regulation of IFNA signaling | 12 | 2.55e-02 | 5.29e-02 | 0.8100 | -3.91e-02 | 3.45e-01 | 4.90e-01 | 5.43e-01 | 8.14e-01 | 3.86e-02 | 3.30e-03 | 1.12e-03 |
| Defects in vitamin and cofactor metabolism | 17 | 5.20e-04 | 1.98e-03 | 0.8040 | 1.04e-01 | -5.23e-01 | -3.68e-01 | -4.76e-01 | 4.58e-01 | 1.91e-04 | 8.68e-03 | 6.78e-04 |
| HS-GAG degradation | 16 | 4.75e-05 | 2.39e-04 | 0.8010 | -4.36e-01 | -1.37e-02 | 4.72e-01 | 4.79e-01 | 2.56e-03 | 9.25e-01 | 1.08e-03 | 9.19e-04 |
| GPVI-mediated activation cascade | 18 | 3.72e-03 | 1.04e-02 | 0.8010 | 1.58e-01 | 4.61e-01 | 4.45e-01 | 4.54e-01 | 2.45e-01 | 7.10e-04 | 1.09e-03 | 8.63e-04 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 10 | 3.60e-02 | 7.10e-02 | 0.8010 | -3.80e-01 | -4.25e-01 | -3.56e-01 | -4.35e-01 | 3.76e-02 | 1.99e-02 | 5.15e-02 | 1.72e-02 |
| Acyl chain remodelling of PS | 10 | 2.14e-02 | 4.56e-02 | 0.7970 | 2.16e-01 | 2.15e-01 | 5.69e-01 | 4.68e-01 | 2.36e-01 | 2.39e-01 | 1.83e-03 | 1.05e-02 |
| Phase 0 - rapid depolarisation | 17 | 1.66e-04 | 7.32e-04 | 0.7910 | -5.70e-01 | -2.35e-01 | -3.15e-01 | -3.84e-01 | 4.79e-05 | 9.33e-02 | 2.47e-02 | 6.20e-03 |
| Caspase activation via Death Receptors in the presence of ligand | 11 | 2.46e-02 | 5.13e-02 | 0.7900 | -2.40e-01 | 3.39e-01 | 4.59e-01 | 4.91e-01 | 1.68e-01 | 5.17e-02 | 8.41e-03 | 4.81e-03 |
| Mitochondrial tRNA aminoacylation | 18 | 1.93e-04 | 8.41e-04 | 0.7810 | 1.77e-01 | -5.64e-01 | -3.33e-01 | -3.86e-01 | 1.93e-01 | 3.41e-05 | 1.44e-02 | 4.54e-03 |
| Heme biosynthesis | 12 | 1.23e-02 | 2.88e-02 | 0.7800 | -1.29e-01 | -5.80e-01 | -3.16e-01 | -3.94e-01 | 4.40e-01 | 5.02e-04 | 5.81e-02 | 1.83e-02 |
| Postmitotic nuclear pore complex (NPC) reformation | 24 | 1.40e-06 | 1.14e-05 | 0.7700 | 5.42e-01 | 3.50e-01 | 2.09e-01 | 3.63e-01 | 4.28e-06 | 2.98e-03 | 7.59e-02 | 2.06e-03 |
| FCGR3A-mediated phagocytosis | 47 | 1.98e-07 | 2.07e-06 | 0.7680 | -1.32e-02 | 3.76e-01 | 4.68e-01 | 4.80e-01 | 8.76e-01 | 8.22e-06 | 2.92e-08 | 1.30e-08 |
| Leishmania phagocytosis | 47 | 1.98e-07 | 2.07e-06 | 0.7680 | -1.32e-02 | 3.76e-01 | 4.68e-01 | 4.80e-01 | 8.76e-01 | 8.22e-06 | 2.92e-08 | 1.30e-08 |
| Parasite infection | 47 | 1.98e-07 | 2.07e-06 | 0.7680 | -1.32e-02 | 3.76e-01 | 4.68e-01 | 4.80e-01 | 8.76e-01 | 8.22e-06 | 2.92e-08 | 1.30e-08 |
| Mitochondrial translation termination | 81 | 3.30e-20 | 2.26e-18 | 0.7680 | 1.55e-01 | -2.93e-01 | -4.10e-01 | -5.58e-01 | 1.62e-02 | 5.32e-06 | 1.85e-10 | 3.83e-18 |
| CS/DS degradation | 10 | 3.11e-02 | 6.27e-02 | 0.7630 | -2.66e-01 | 1.63e-01 | 4.86e-01 | 4.99e-01 | 1.46e-01 | 3.72e-01 | 7.79e-03 | 6.27e-03 |
| Mitochondrial translation elongation | 81 | 1.63e-20 | 1.18e-18 | 0.7610 | 1.57e-01 | -2.97e-01 | -3.98e-01 | -5.54e-01 | 1.46e-02 | 3.90e-06 | 5.93e-10 | 6.44e-18 |
| RHO GTPases Activate WASPs and WAVEs | 31 | 8.88e-05 | 4.14e-04 | 0.7600 | 8.92e-02 | 4.27e-01 | 4.41e-01 | 4.40e-01 | 3.90e-01 | 3.88e-05 | 2.17e-05 | 2.29e-05 |
| Activation of Matrix Metalloproteinases | 11 | 5.03e-04 | 1.95e-03 | 0.7590 | -3.08e-01 | 1.93e-01 | 3.50e-01 | 5.68e-01 | 7.71e-02 | 2.69e-01 | 4.44e-02 | 1.11e-03 |
| Mitochondrial translation | 87 | 1.05e-21 | 8.63e-20 | 0.7560 | 1.57e-01 | -3.14e-01 | -3.89e-01 | -5.45e-01 | 1.14e-02 | 4.19e-07 | 3.74e-10 | 1.56e-18 |
| Cell recruitment (pro-inflammatory response) | 12 | 3.18e-02 | 6.38e-02 | 0.7560 | -2.18e-02 | 3.47e-01 | 5.17e-01 | 4.28e-01 | 8.96e-01 | 3.74e-02 | 1.91e-03 | 1.03e-02 |
| Purinergic signaling in leishmaniasis infection | 12 | 3.18e-02 | 6.38e-02 | 0.7560 | -2.18e-02 | 3.47e-01 | 5.17e-01 | 4.28e-01 | 8.96e-01 | 3.74e-02 | 1.91e-03 | 1.03e-02 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 20 | 7.58e-05 | 3.58e-04 | 0.7520 | -4.23e-01 | 3.11e-01 | 4.10e-01 | 3.49e-01 | 1.05e-03 | 1.63e-02 | 1.52e-03 | 6.83e-03 |
| Sulfur amino acid metabolism | 21 | 1.51e-03 | 4.87e-03 | 0.7480 | -1.97e-01 | -2.36e-01 | -4.90e-01 | -4.74e-01 | 1.18e-01 | 6.18e-02 | 1.02e-04 | 1.69e-04 |
| DNA strand elongation | 30 | 6.77e-05 | 3.25e-04 | 0.7410 | 1.35e-01 | 3.54e-01 | 4.00e-01 | 4.95e-01 | 2.02e-01 | 7.83e-04 | 1.50e-04 | 2.69e-06 |
| Mitochondrial translation initiation | 81 | 1.58e-19 | 1.02e-17 | 0.7390 | 1.50e-01 | -2.90e-01 | -3.85e-01 | -5.40e-01 | 1.96e-02 | 6.52e-06 | 2.21e-09 | 4.56e-17 |
| Striated Muscle Contraction | 30 | 1.20e-07 | 1.38e-06 | 0.7340 | -6.03e-01 | -1.87e-01 | -2.54e-01 | -2.75e-01 | 1.09e-08 | 7.62e-02 | 1.63e-02 | 9.17e-03 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 19 | 5.38e-03 | 1.42e-02 | 0.7340 | -9.72e-02 | 3.77e-01 | 4.52e-01 | 4.27e-01 | 4.64e-01 | 4.47e-03 | 6.44e-04 | 1.28e-03 |
| tRNA Aminoacylation | 24 | 3.53e-04 | 1.43e-03 | 0.7330 | 1.83e-01 | -4.05e-01 | -4.01e-01 | -4.24e-01 | 1.21e-01 | 6.03e-04 | 6.76e-04 | 3.27e-04 |
| Retinoid metabolism and transport | 19 | 1.21e-03 | 4.03e-03 | 0.7330 | -2.63e-01 | 2.05e-01 | 4.50e-01 | 4.73e-01 | 4.72e-02 | 1.23e-01 | 6.93e-04 | 3.64e-04 |
| Signaling by NODAL | 10 | 5.73e-02 | 1.05e-01 | 0.7280 | -1.69e-01 | -1.36e-01 | -4.95e-01 | -4.89e-01 | 3.55e-01 | 4.56e-01 | 6.73e-03 | 7.47e-03 |
| Regulation of actin dynamics for phagocytic cup formation | 49 | 5.29e-07 | 4.89e-06 | 0.7280 | -2.37e-02 | 3.73e-01 | 4.40e-01 | 4.42e-01 | 7.74e-01 | 6.31e-06 | 9.76e-08 | 8.72e-08 |
| RIP-mediated NFkB activation via ZBP1 | 14 | 4.69e-02 | 8.84e-02 | 0.7220 | 7.55e-02 | 3.61e-01 | 4.50e-01 | 4.29e-01 | 6.25e-01 | 1.95e-02 | 3.59e-03 | 5.46e-03 |
| ZBP1(DAI) mediated induction of type I IFNs | 17 | 1.97e-02 | 4.25e-02 | 0.7220 | 9.40e-02 | 3.07e-01 | 4.61e-01 | 4.53e-01 | 5.02e-01 | 2.87e-02 | 9.90e-04 | 1.22e-03 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 1.12e-02 | 2.66e-02 | 0.7200 | -2.16e-01 | 2.56e-01 | 4.96e-01 | 4.00e-01 | 1.61e-01 | 9.68e-02 | 1.32e-03 | 9.50e-03 |
| Interleukin-4 and Interleukin-13 signaling | 64 | 3.59e-10 | 5.81e-09 | 0.7190 | -1.31e-01 | 4.01e-01 | 4.17e-01 | 4.07e-01 | 7.02e-02 | 2.95e-08 | 8.15e-09 | 1.91e-08 |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 10 | 6.46e-02 | 1.14e-01 | 0.7180 | 1.08e-01 | 5.40e-01 | 3.19e-01 | 3.34e-01 | 5.54e-01 | 3.14e-03 | 8.10e-02 | 6.77e-02 |
| CRMPs in Sema3A signaling | 12 | 4.51e-02 | 8.58e-02 | 0.7180 | -2.03e-01 | 3.35e-01 | 4.23e-01 | 4.28e-01 | 2.24e-01 | 4.48e-02 | 1.12e-02 | 1.03e-02 |
| rRNA modification in the nucleus and cytosol | 52 | 2.39e-15 | 8.93e-14 | 0.7130 | 5.99e-01 | 3.56e-01 | 1.16e-02 | 1.48e-01 | 7.55e-14 | 8.93e-06 | 8.85e-01 | 6.43e-02 |
| tRNA processing in the mitochondrion | 11 | 5.17e-04 | 1.98e-03 | 0.7130 | 2.01e-02 | -2.59e-01 | -3.07e-01 | -5.89e-01 | 9.08e-01 | 1.37e-01 | 7.84e-02 | 7.26e-04 |
| Scavenging by Class A Receptors | 13 | 2.89e-02 | 5.92e-02 | 0.7090 | -1.96e-01 | 2.03e-01 | 4.79e-01 | 4.40e-01 | 2.20e-01 | 2.04e-01 | 2.80e-03 | 5.99e-03 |
| Transport of the SLBP Dependant Mature mRNA | 29 | 3.61e-07 | 3.50e-06 | 0.7080 | 5.55e-01 | 3.07e-01 | 1.45e-01 | 2.78e-01 | 2.29e-07 | 4.20e-03 | 1.76e-01 | 9.51e-03 |
| SUMOylation of DNA replication proteins | 35 | 7.10e-08 | 9.11e-07 | 0.7060 | 4.98e-01 | 3.16e-01 | 2.01e-01 | 3.31e-01 | 3.46e-07 | 1.22e-03 | 4.00e-02 | 6.95e-04 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 14 | 3.49e-03 | 9.85e-03 | 0.7050 | -4.55e-01 | 2.12e-01 | 3.45e-01 | 3.56e-01 | 3.20e-03 | 1.70e-01 | 2.57e-02 | 2.12e-02 |
| Collagen degradation | 20 | 2.41e-05 | 1.29e-04 | 0.7050 | -2.76e-01 | 1.50e-02 | 4.04e-01 | 5.07e-01 | 3.30e-02 | 9.07e-01 | 1.76e-03 | 8.59e-05 |
| Interactions of Rev with host cellular proteins | 29 | 3.88e-07 | 3.70e-06 | 0.7050 | 4.98e-01 | 3.18e-01 | 1.77e-01 | 3.41e-01 | 3.54e-06 | 3.04e-03 | 9.88e-02 | 1.47e-03 |
| Retrograde neurotrophin signalling | 11 | 9.80e-02 | 1.59e-01 | 0.6990 | 2.16e-02 | 2.11e-01 | 4.79e-01 | 4.63e-01 | 9.01e-01 | 2.25e-01 | 5.94e-03 | 7.87e-03 |
| Mitochondrial protein import | 55 | 8.68e-11 | 1.64e-09 | 0.6960 | -8.85e-03 | -2.87e-01 | -3.64e-01 | -5.18e-01 | 9.10e-01 | 2.30e-04 | 2.99e-06 | 3.01e-11 |
| Other interleukin signaling | 13 | 4.66e-02 | 8.80e-02 | 0.6950 | -1.33e-01 | 2.67e-01 | 4.22e-01 | 4.64e-01 | 4.07e-01 | 9.57e-02 | 8.48e-03 | 3.75e-03 |
| Defective B4GALT7 causes EDS, progeroid type | 14 | 1.95e-03 | 6.02e-03 | 0.6940 | -4.94e-01 | 1.36e-01 | 3.09e-01 | 3.52e-01 | 1.37e-03 | 3.79e-01 | 4.51e-02 | 2.26e-02 |
| Chondroitin sulfate biosynthesis | 13 | 3.88e-02 | 7.52e-02 | 0.6910 | -1.07e-01 | 2.86e-01 | 3.97e-01 | 4.76e-01 | 5.03e-01 | 7.44e-02 | 1.31e-02 | 2.95e-03 |
| Nuclear import of Rev protein | 26 | 1.72e-06 | 1.34e-05 | 0.6900 | 5.32e-01 | 2.75e-01 | 1.49e-01 | 3.09e-01 | 2.62e-06 | 1.54e-02 | 1.88e-01 | 6.43e-03 |
| Transport of the SLBP independent Mature mRNA | 28 | 1.04e-06 | 8.78e-06 | 0.6880 | 5.55e-01 | 2.85e-01 | 1.29e-01 | 2.60e-01 | 3.71e-07 | 9.18e-03 | 2.38e-01 | 1.74e-02 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 8.10e-02 | 1.36e-01 | 0.6880 | 7.31e-03 | 3.22e-01 | 4.45e-01 | 4.14e-01 | 9.64e-01 | 4.43e-02 | 5.52e-03 | 9.83e-03 |
| Rev-mediated nuclear export of HIV RNA | 28 | 1.27e-06 | 1.04e-05 | 0.6870 | 4.89e-01 | 3.06e-01 | 1.71e-01 | 3.33e-01 | 7.56e-06 | 5.16e-03 | 1.19e-01 | 2.30e-03 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 11 | 5.87e-02 | 1.06e-01 | 0.6870 | 1.99e-01 | 4.97e-01 | 2.65e-01 | 3.40e-01 | 2.53e-01 | 4.35e-03 | 1.29e-01 | 5.12e-02 |
| Lagging Strand Synthesis | 20 | 9.59e-03 | 2.34e-02 | 0.6830 | 2.20e-01 | 2.95e-01 | 3.81e-01 | 4.32e-01 | 8.87e-02 | 2.27e-02 | 3.20e-03 | 8.20e-04 |
| Export of Viral Ribonucleoproteins from Nucleus | 26 | 2.51e-06 | 1.79e-05 | 0.6810 | 5.42e-01 | 2.74e-01 | 1.30e-01 | 2.80e-01 | 1.76e-06 | 1.55e-02 | 2.51e-01 | 1.36e-02 |
| Syndecan interactions | 17 | 2.91e-02 | 5.94e-02 | 0.6760 | -4.97e-02 | 3.57e-01 | 3.92e-01 | 4.17e-01 | 7.23e-01 | 1.09e-02 | 5.15e-03 | 2.95e-03 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 10 | 6.72e-02 | 1.17e-01 | 0.6750 | -1.42e-01 | -4.67e-01 | -3.71e-01 | -2.83e-01 | 4.38e-01 | 1.05e-02 | 4.23e-02 | 1.21e-01 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 15 | 3.93e-02 | 7.60e-02 | 0.6740 | -1.26e-01 | 3.32e-01 | 4.16e-01 | 3.94e-01 | 3.99e-01 | 2.60e-02 | 5.25e-03 | 8.27e-03 |
| ROS and RNS production in phagocytes | 20 | 2.16e-03 | 6.53e-03 | 0.6730 | -3.76e-02 | 2.24e-01 | 5.05e-01 | 3.83e-01 | 7.71e-01 | 8.30e-02 | 9.37e-05 | 3.01e-03 |
| Mitochondrial calcium ion transport | 21 | 3.42e-03 | 9.71e-03 | 0.6720 | -1.22e-02 | -3.38e-01 | -3.51e-01 | -4.63e-01 | 9.23e-01 | 7.37e-03 | 5.38e-03 | 2.42e-04 |
| TRAF3-dependent IRF activation pathway | 12 | 2.14e-02 | 4.56e-02 | 0.6670 | -1.15e-01 | 2.51e-02 | 4.49e-01 | 4.80e-01 | 4.91e-01 | 8.80e-01 | 7.14e-03 | 3.99e-03 |
| Activation of the pre-replicative complex | 27 | 3.35e-04 | 1.37e-03 | 0.6660 | 2.72e-01 | 2.61e-01 | 3.32e-01 | 4.37e-01 | 1.44e-02 | 1.88e-02 | 2.80e-03 | 8.62e-05 |
| Cristae formation | 10 | 1.76e-01 | 2.54e-01 | 0.6640 | 4.88e-02 | -2.93e-01 | -3.95e-01 | -4.44e-01 | 7.89e-01 | 1.09e-01 | 3.06e-02 | 1.51e-02 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 16 | 3.04e-03 | 8.95e-03 | 0.6620 | 2.37e-01 | 5.57e-02 | 3.95e-01 | 4.73e-01 | 1.01e-01 | 7.00e-01 | 6.31e-03 | 1.06e-03 |
| Glycosphingolipid metabolism | 32 | 5.53e-06 | 3.72e-05 | 0.6610 | -1.09e-01 | 9.39e-02 | 4.10e-01 | 4.97e-01 | 2.87e-01 | 3.59e-01 | 5.90e-05 | 1.13e-06 |
| Defective B3GAT3 causes JDSSDHD | 14 | 4.41e-03 | 1.19e-02 | 0.6600 | -4.95e-01 | 1.74e-01 | 2.86e-01 | 2.79e-01 | 1.34e-03 | 2.59e-01 | 6.38e-02 | 7.13e-02 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 23 | 2.97e-05 | 1.57e-04 | 0.6570 | 5.38e-01 | 2.35e-01 | 1.28e-01 | 2.67e-01 | 8.09e-06 | 5.10e-02 | 2.88e-01 | 2.70e-02 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 23 | 2.97e-05 | 1.57e-04 | 0.6570 | 5.38e-01 | 2.35e-01 | 1.28e-01 | 2.67e-01 | 8.09e-06 | 5.10e-02 | 2.88e-01 | 2.70e-02 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 25 | 6.21e-06 | 4.11e-05 | 0.6540 | 5.24e-01 | 2.45e-01 | 1.20e-01 | 2.81e-01 | 5.74e-06 | 3.38e-02 | 2.99e-01 | 1.52e-02 |
| Transport of Ribonucleoproteins into the Host Nucleus | 25 | 1.13e-05 | 6.71e-05 | 0.6530 | 5.40e-01 | 2.69e-01 | 9.58e-02 | 2.31e-01 | 2.94e-06 | 1.98e-02 | 4.07e-01 | 4.57e-02 |
| Chondroitin sulfate/dermatan sulfate metabolism | 37 | 6.44e-06 | 4.24e-05 | 0.6530 | -2.27e-01 | 1.94e-01 | 3.81e-01 | 4.39e-01 | 1.68e-02 | 4.17e-02 | 6.24e-05 | 3.93e-06 |
| SUMOylation of SUMOylation proteins | 27 | 4.10e-06 | 2.80e-05 | 0.6530 | 5.42e-01 | 2.54e-01 | 1.05e-01 | 2.39e-01 | 1.12e-06 | 2.27e-02 | 3.47e-01 | 3.14e-02 |
| Synthesis of bile acids and bile salts | 18 | 1.69e-02 | 3.77e-02 | 0.6520 | -9.97e-02 | -3.95e-01 | -3.90e-01 | -3.26e-01 | 4.64e-01 | 3.71e-03 | 4.16e-03 | 1.67e-02 |
| Binding and Uptake of Ligands by Scavenger Receptors | 23 | 2.86e-03 | 8.43e-03 | 0.6500 | -1.53e-01 | 1.57e-01 | 4.33e-01 | 4.32e-01 | 2.04e-01 | 1.92e-01 | 3.22e-04 | 3.39e-04 |
| Keratan sulfate/keratin metabolism | 22 | 3.25e-03 | 9.45e-03 | 0.6500 | -1.70e-01 | 1.45e-01 | 4.36e-01 | 4.27e-01 | 1.67e-01 | 2.38e-01 | 4.05e-04 | 5.29e-04 |
| Glycogen breakdown (glycogenolysis) | 14 | 8.18e-03 | 2.05e-02 | 0.6500 | -5.38e-01 | -2.59e-01 | -1.76e-01 | -1.85e-01 | 4.89e-04 | 9.37e-02 | 2.53e-01 | 2.31e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 20 | 2.07e-02 | 4.42e-02 | 0.6490 | -1.69e-01 | -3.78e-01 | -3.42e-01 | -3.65e-01 | 1.91e-01 | 3.46e-03 | 8.21e-03 | 4.71e-03 |
| Negative regulation of MET activity | 16 | 1.94e-02 | 4.20e-02 | 0.6450 | 1.81e-01 | 3.53e-01 | 2.91e-01 | 4.18e-01 | 2.11e-01 | 1.45e-02 | 4.37e-02 | 3.83e-03 |
| Nuclear Receptor transcription pathway | 37 | 7.25e-08 | 9.20e-07 | 0.6450 | -3.42e-01 | -2.74e-01 | -2.28e-01 | -4.14e-01 | 3.27e-04 | 3.91e-03 | 1.64e-02 | 1.32e-05 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 17 | 2.54e-02 | 5.29e-02 | 0.6430 | 2.28e-01 | 3.15e-01 | 3.89e-01 | 3.32e-01 | 1.04e-01 | 2.44e-02 | 5.45e-03 | 1.78e-02 |
| Collagen biosynthesis and modifying enzymes | 47 | 3.70e-08 | 4.85e-07 | 0.6410 | -3.53e-01 | 1.17e-01 | 3.80e-01 | 3.59e-01 | 2.85e-05 | 1.67e-01 | 6.77e-06 | 2.14e-05 |
| Processive synthesis on the lagging strand | 15 | 4.84e-02 | 9.07e-02 | 0.6400 | 1.20e-01 | 2.83e-01 | 3.48e-01 | 4.41e-01 | 4.23e-01 | 5.81e-02 | 1.98e-02 | 3.13e-03 |
| SUMOylation of ubiquitinylation proteins | 31 | 2.94e-06 | 2.07e-05 | 0.6390 | 5.29e-01 | 2.70e-01 | 1.12e-01 | 2.08e-01 | 3.49e-07 | 9.26e-03 | 2.83e-01 | 4.47e-02 |
| Mitochondrial biogenesis | 66 | 1.76e-07 | 1.90e-06 | 0.6370 | -7.20e-02 | -3.63e-01 | -3.82e-01 | -3.52e-01 | 3.13e-01 | 3.61e-07 | 8.55e-08 | 7.75e-07 |
| Long-term potentiation | 10 | 3.75e-02 | 7.31e-02 | 0.6370 | -5.08e-01 | -9.34e-02 | -2.37e-01 | -2.88e-01 | 5.41e-03 | 6.09e-01 | 1.95e-01 | 1.14e-01 |
| Zinc transporters | 11 | 1.03e-01 | 1.66e-01 | 0.6370 | 3.03e-01 | 2.88e-01 | 2.90e-01 | 3.84e-01 | 8.24e-02 | 9.88e-02 | 9.55e-02 | 2.75e-02 |
| Reduction of cytosolic Ca++ levels | 10 | 2.83e-02 | 5.80e-02 | 0.6360 | -5.32e-01 | -2.02e-01 | -2.34e-01 | -1.62e-01 | 3.57e-03 | 2.69e-01 | 2.01e-01 | 3.74e-01 |
| EPHB-mediated forward signaling | 32 | 1.98e-03 | 6.07e-03 | 0.6330 | 1.87e-02 | 3.22e-01 | 3.91e-01 | 3.80e-01 | 8.55e-01 | 1.64e-03 | 1.31e-04 | 1.99e-04 |
| Degradation of the extracellular matrix | 58 | 6.34e-09 | 9.51e-08 | 0.6220 | -3.02e-01 | 1.41e-01 | 3.70e-01 | 3.73e-01 | 7.20e-05 | 6.30e-02 | 1.10e-06 | 8.97e-07 |
| Metabolism of non-coding RNA | 45 | 1.06e-10 | 1.95e-09 | 0.6180 | 5.55e-01 | 2.36e-01 | -9.39e-03 | 1.36e-01 | 1.17e-10 | 6.26e-03 | 9.13e-01 | 1.15e-01 |
| snRNP Assembly | 45 | 1.06e-10 | 1.95e-09 | 0.6180 | 5.55e-01 | 2.36e-01 | -9.39e-03 | 1.36e-01 | 1.17e-10 | 6.26e-03 | 9.13e-01 | 1.15e-01 |
| Collagen formation | 63 | 3.48e-10 | 5.72e-09 | 0.6170 | -3.10e-01 | 8.06e-02 | 3.84e-01 | 3.62e-01 | 2.14e-05 | 2.69e-01 | 1.37e-07 | 6.85e-07 |
| Ion homeostasis | 37 | 1.02e-05 | 6.21e-05 | 0.6170 | -4.43e-01 | -3.01e-01 | -1.98e-01 | -2.35e-01 | 3.22e-06 | 1.55e-03 | 3.77e-02 | 1.36e-02 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 60 | 9.61e-18 | 4.93e-16 | 0.6160 | 5.19e-01 | 2.54e-01 | -1.27e-02 | 2.14e-01 | 3.53e-12 | 6.87e-04 | 8.66e-01 | 4.22e-03 |
| Metabolism of fat-soluble vitamins | 22 | 4.90e-03 | 1.30e-02 | 0.6160 | -2.36e-01 | 1.66e-01 | 3.80e-01 | 3.89e-01 | 5.57e-02 | 1.78e-01 | 2.03e-03 | 1.59e-03 |
| Vpr-mediated nuclear import of PICs | 27 | 1.78e-05 | 9.83e-05 | 0.6140 | 4.91e-01 | 2.86e-01 | 8.16e-02 | 2.19e-01 | 1.01e-05 | 1.01e-02 | 4.64e-01 | 4.94e-02 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 11 | 6.03e-02 | 1.09e-01 | 0.6140 | 1.48e-01 | -4.30e-01 | -2.43e-01 | -3.33e-01 | 3.95e-01 | 1.36e-02 | 1.63e-01 | 5.56e-02 |
| Peroxisomal protein import | 49 | 2.03e-05 | 1.10e-04 | 0.6130 | -1.17e-01 | -3.19e-01 | -3.20e-01 | -3.97e-01 | 1.56e-01 | 1.15e-04 | 1.08e-04 | 1.52e-06 |
| EPH-ephrin mediated repulsion of cells | 36 | 2.38e-04 | 1.02e-03 | 0.6130 | -1.28e-01 | 1.63e-01 | 4.11e-01 | 4.05e-01 | 1.83e-01 | 9.05e-02 | 2.03e-05 | 2.69e-05 |
| Polymerase switching on the C-strand of the telomere | 22 | 1.10e-02 | 2.64e-02 | 0.6130 | 2.51e-01 | 2.48e-01 | 3.20e-01 | 3.85e-01 | 4.20e-02 | 4.43e-02 | 9.40e-03 | 1.75e-03 |
| Transcriptional activation of mitochondrial biogenesis | 47 | 1.42e-05 | 8.16e-05 | 0.6120 | -4.59e-02 | -3.75e-01 | -3.69e-01 | -3.10e-01 | 5.86e-01 | 8.93e-06 | 1.20e-05 | 2.42e-04 |
| Constitutive Signaling by Overexpressed ERBB2 | 10 | 2.79e-01 | 3.64e-01 | 0.6120 | 9.19e-02 | 3.45e-01 | 3.60e-01 | 3.42e-01 | 6.15e-01 | 5.88e-02 | 4.87e-02 | 6.11e-02 |
| p130Cas linkage to MAPK signaling for integrins | 10 | 2.36e-02 | 4.97e-02 | 0.6110 | -1.42e-01 | 5.20e-01 | 1.41e-01 | 2.51e-01 | 4.36e-01 | 4.45e-03 | 4.40e-01 | 1.69e-01 |
| Telomere C-strand (Lagging Strand) Synthesis | 30 | 1.54e-03 | 4.92e-03 | 0.6100 | 2.36e-01 | 2.42e-01 | 3.25e-01 | 3.90e-01 | 2.53e-02 | 2.17e-02 | 2.08e-03 | 2.20e-04 |
| Class I peroxisomal membrane protein import | 20 | 1.53e-02 | 3.47e-02 | 0.6080 | 3.90e-02 | -3.10e-01 | -3.20e-01 | -4.13e-01 | 7.63e-01 | 1.66e-02 | 1.34e-02 | 1.40e-03 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 18 | 2.16e-03 | 6.53e-03 | 0.6060 | -4.14e-01 | 2.10e-01 | 2.47e-01 | 3.02e-01 | 2.37e-03 | 1.24e-01 | 6.94e-02 | 2.68e-02 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 16 | 2.16e-02 | 4.59e-02 | 0.6060 | -1.48e-02 | 1.40e-01 | 3.67e-01 | 4.61e-01 | 9.19e-01 | 3.32e-01 | 1.11e-02 | 1.42e-03 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 16 | 2.16e-02 | 4.59e-02 | 0.6060 | -1.48e-02 | 1.40e-01 | 3.67e-01 | 4.61e-01 | 9.19e-01 | 3.32e-01 | 1.11e-02 | 1.42e-03 |
| Cardiac conduction | 61 | 1.80e-09 | 2.84e-08 | 0.6050 | -4.51e-01 | -2.89e-01 | -1.80e-01 | -2.18e-01 | 1.17e-09 | 9.79e-05 | 1.53e-02 | 3.26e-03 |
| TNFR1-induced proapoptotic signaling | 11 | 5.96e-02 | 1.08e-01 | 0.6040 | -3.23e-01 | 2.54e-01 | 3.55e-01 | 2.65e-01 | 6.36e-02 | 1.45e-01 | 4.17e-02 | 1.29e-01 |
| STING mediated induction of host immune responses | 11 | 4.79e-02 | 8.99e-02 | 0.6040 | 1.48e-01 | -2.01e-02 | 4.19e-01 | 4.08e-01 | 3.96e-01 | 9.08e-01 | 1.61e-02 | 1.92e-02 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 36 | 6.19e-07 | 5.60e-06 | 0.6030 | 4.68e-01 | 2.90e-01 | 9.23e-02 | 2.29e-01 | 1.22e-06 | 2.63e-03 | 3.38e-01 | 1.74e-02 |
| DNA Damage/Telomere Stress Induced Senescence | 26 | 7.75e-03 | 1.95e-02 | 0.6020 | 2.24e-01 | 2.34e-01 | 3.46e-01 | 3.72e-01 | 4.83e-02 | 3.88e-02 | 2.28e-03 | 1.04e-03 |
| mRNA Splicing - Major Pathway | 161 | 7.97e-41 | 2.45e-38 | 0.6020 | 5.08e-01 | 2.99e-01 | -5.87e-02 | 1.08e-01 | 1.26e-28 | 6.27e-11 | 2.00e-01 | 1.84e-02 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 22 | 9.79e-04 | 3.32e-03 | 0.6020 | 1.23e-01 | 5.20e-01 | 1.70e-01 | 2.18e-01 | 3.19e-01 | 2.42e-05 | 1.68e-01 | 7.70e-02 |
| Unblocking of NMDA receptors, glutamate binding and activation | 10 | 8.70e-02 | 1.44e-01 | 0.5990 | -4.41e-01 | -1.23e-01 | -2.52e-01 | -2.94e-01 | 1.58e-02 | 4.99e-01 | 1.67e-01 | 1.08e-01 |
| Removal of the Flap Intermediate | 14 | 7.54e-02 | 1.28e-01 | 0.5970 | 1.66e-01 | 2.59e-01 | 3.06e-01 | 4.10e-01 | 2.82e-01 | 9.40e-02 | 4.72e-02 | 7.86e-03 |
| Triglyceride catabolism | 13 | 8.82e-02 | 1.46e-01 | 0.5950 | -2.75e-01 | -3.47e-01 | -2.32e-01 | -3.23e-01 | 8.58e-02 | 3.02e-02 | 1.47e-01 | 4.41e-02 |
| Caspase-mediated cleavage of cytoskeletal proteins | 11 | 8.34e-02 | 1.39e-01 | 0.5950 | -2.58e-01 | 2.39e-01 | 2.97e-01 | 3.77e-01 | 1.38e-01 | 1.71e-01 | 8.82e-02 | 3.04e-02 |
| Cell surface interactions at the vascular wall | 72 | 1.84e-09 | 2.86e-08 | 0.5940 | -2.65e-01 | 1.95e-01 | 3.67e-01 | 3.32e-01 | 1.06e-04 | 4.20e-03 | 7.24e-08 | 1.16e-06 |
| Interactions of Vpr with host cellular proteins | 29 | 1.48e-05 | 8.33e-05 | 0.5940 | 4.75e-01 | 2.80e-01 | 7.38e-02 | 2.09e-01 | 9.57e-06 | 9.23e-03 | 4.92e-01 | 5.17e-02 |
| Glycogen metabolism | 23 | 1.51e-03 | 4.88e-03 | 0.5890 | -4.15e-01 | -1.67e-01 | -2.29e-01 | -3.08e-01 | 5.73e-04 | 1.66e-01 | 5.79e-02 | 1.05e-02 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 67 | 1.14e-06 | 9.45e-06 | 0.5890 | -6.62e-02 | 2.55e-01 | 3.57e-01 | 3.88e-01 | 3.50e-01 | 3.06e-04 | 4.57e-07 | 4.24e-08 |
| Assembly of collagen fibrils and other multimeric structures | 42 | 9.03e-07 | 7.72e-06 | 0.5880 | -2.85e-01 | 2.62e-03 | 3.71e-01 | 3.57e-01 | 1.40e-03 | 9.77e-01 | 3.19e-05 | 6.44e-05 |
| NGF-stimulated transcription | 30 | 7.55e-05 | 3.57e-04 | 0.5860 | -3.34e-02 | 4.93e-01 | 1.89e-01 | 2.54e-01 | 7.52e-01 | 3.03e-06 | 7.31e-02 | 1.63e-02 |
| Caspase activation via extrinsic apoptotic signalling pathway | 20 | 1.30e-02 | 3.00e-02 | 0.5860 | -2.56e-01 | 1.79e-01 | 3.44e-01 | 3.57e-01 | 4.74e-02 | 1.66e-01 | 7.78e-03 | 5.73e-03 |
| NCAM1 interactions | 21 | 2.31e-04 | 9.86e-04 | 0.5850 | -4.87e-01 | -1.42e-01 | 2.16e-01 | 1.96e-01 | 1.12e-04 | 2.61e-01 | 8.63e-02 | 1.20e-01 |
| Insulin receptor recycling | 17 | 8.45e-04 | 2.96e-03 | 0.5850 | 1.71e-02 | 1.61e-01 | 4.89e-01 | 2.78e-01 | 9.03e-01 | 2.52e-01 | 4.80e-04 | 4.75e-02 |
| mRNA Splicing | 169 | 1.18e-40 | 2.90e-38 | 0.5850 | 5.00e-01 | 2.83e-01 | -7.36e-02 | 8.44e-02 | 4.35e-29 | 2.58e-10 | 1.00e-01 | 5.95e-02 |
| Viral Messenger RNA Synthesis | 35 | 1.33e-05 | 7.67e-05 | 0.5850 | 4.65e-01 | 2.95e-01 | 1.13e-01 | 1.61e-01 | 1.92e-06 | 2.53e-03 | 2.48e-01 | 9.93e-02 |
| ABC transporters in lipid homeostasis | 11 | 8.19e-03 | 2.05e-02 | 0.5850 | -1.24e-01 | -5.65e-01 | -3.89e-03 | -8.49e-02 | 4.78e-01 | 1.17e-03 | 9.82e-01 | 6.26e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 35 | 1.71e-06 | 1.34e-05 | 0.5840 | 4.65e-01 | 2.71e-01 | 7.78e-02 | 2.13e-01 | 1.95e-06 | 5.52e-03 | 4.26e-01 | 2.93e-02 |
| Metal ion SLC transporters | 17 | 1.08e-01 | 1.71e-01 | 0.5840 | 9.49e-02 | 2.71e-01 | 3.49e-01 | 3.70e-01 | 4.98e-01 | 5.30e-02 | 1.29e-02 | 8.25e-03 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 24 | 6.98e-04 | 2.51e-03 | 0.5840 | 6.69e-02 | 5.09e-01 | 1.72e-01 | 2.18e-01 | 5.71e-01 | 1.58e-05 | 1.45e-01 | 6.45e-02 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 11 | 7.04e-02 | 1.21e-01 | 0.5830 | -3.61e-01 | 1.62e-01 | 2.81e-01 | 3.24e-01 | 3.84e-02 | 3.53e-01 | 1.07e-01 | 6.28e-02 |
| Defective EXT2 causes exostoses 2 | 11 | 7.04e-02 | 1.21e-01 | 0.5830 | -3.61e-01 | 1.62e-01 | 2.81e-01 | 3.24e-01 | 3.84e-02 | 3.53e-01 | 1.07e-01 | 6.28e-02 |
| Transport of Mature Transcript to Cytoplasm | 69 | 7.59e-18 | 4.06e-16 | 0.5810 | 4.79e-01 | 2.67e-01 | -1.89e-02 | 1.91e-01 | 5.98e-12 | 1.29e-04 | 7.87e-01 | 6.16e-03 |
| Processing of Capped Intron-Containing Pre-mRNA | 212 | 8.71e-50 | 5.36e-47 | 0.5800 | 4.99e-01 | 2.72e-01 | -6.23e-02 | 9.52e-02 | 6.78e-36 | 9.85e-12 | 1.20e-01 | 1.75e-02 |
| Nephrin family interactions | 17 | 1.11e-01 | 1.75e-01 | 0.5790 | 1.35e-01 | 2.79e-01 | 3.39e-01 | 3.52e-01 | 3.34e-01 | 4.68e-02 | 1.55e-02 | 1.21e-02 |
| Defects in cobalamin (B12) metabolism | 10 | 7.23e-02 | 1.24e-01 | 0.5780 | 1.37e-01 | -4.36e-01 | -1.88e-01 | -3.00e-01 | 4.53e-01 | 1.70e-02 | 3.04e-01 | 1.01e-01 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 34 | 5.76e-05 | 2.85e-04 | 0.5780 | -2.74e-01 | 1.73e-01 | 3.01e-01 | 3.72e-01 | 5.81e-03 | 8.07e-02 | 2.42e-03 | 1.76e-04 |
| NS1 Mediated Effects on Host Pathways | 31 | 2.10e-05 | 1.13e-04 | 0.5770 | 4.50e-01 | 2.89e-01 | 7.84e-02 | 2.01e-01 | 1.43e-05 | 5.38e-03 | 4.50e-01 | 5.33e-02 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 11 | 8.98e-02 | 1.48e-01 | 0.5770 | 1.50e-01 | 3.25e-01 | 2.32e-01 | 3.88e-01 | 3.89e-01 | 6.17e-02 | 1.83e-01 | 2.59e-02 |
| Integrin cell surface interactions | 45 | 9.59e-06 | 5.93e-05 | 0.5750 | -2.32e-01 | 9.64e-02 | 3.72e-01 | 3.59e-01 | 7.04e-03 | 2.64e-01 | 1.57e-05 | 3.18e-05 |
| Muscle contraction | 117 | 2.29e-19 | 1.41e-17 | 0.5750 | -4.94e-01 | -1.63e-01 | -1.71e-01 | -1.75e-01 | 2.90e-20 | 2.45e-03 | 1.43e-03 | 1.09e-03 |
| Synthesis of PIPs at the Golgi membrane | 15 | 5.41e-02 | 9.97e-02 | 0.5730 | 3.25e-01 | 1.71e-01 | 3.25e-01 | 2.96e-01 | 2.92e-02 | 2.53e-01 | 2.94e-02 | 4.69e-02 |
| CLEC7A (Dectin-1) induces NFAT activation | 10 | 1.77e-01 | 2.56e-01 | 0.5730 | -3.30e-01 | -2.99e-01 | -2.76e-01 | -2.30e-01 | 7.04e-02 | 1.02e-01 | 1.31e-01 | 2.07e-01 |
| AKT phosphorylates targets in the nucleus | 10 | 1.85e-01 | 2.65e-01 | 0.5720 | -3.82e-01 | -2.82e-01 | -2.14e-01 | -2.37e-01 | 3.66e-02 | 1.23e-01 | 2.40e-01 | 1.94e-01 |
| Synthesis of PIPs at the early endosome membrane | 16 | 1.10e-01 | 1.74e-01 | 0.5720 | 1.51e-01 | 1.99e-01 | 3.66e-01 | 3.62e-01 | 2.95e-01 | 1.68e-01 | 1.14e-02 | 1.22e-02 |
| SUMOylation of intracellular receptors | 23 | 1.03e-02 | 2.50e-02 | 0.5700 | -2.48e-01 | -1.78e-01 | -3.04e-01 | -3.73e-01 | 3.96e-02 | 1.39e-01 | 1.16e-02 | 1.95e-03 |
| EPH-Ephrin signaling | 74 | 6.45e-07 | 5.80e-06 | 0.5700 | -8.49e-02 | 2.76e-01 | 3.39e-01 | 3.56e-01 | 2.07e-01 | 4.19e-05 | 4.94e-07 | 1.20e-07 |
| p75NTR signals via NF-kB | 13 | 7.04e-02 | 1.21e-01 | 0.5700 | 9.24e-04 | 4.65e-01 | 2.22e-01 | 2.44e-01 | 9.95e-01 | 3.73e-03 | 1.65e-01 | 1.28e-01 |
| Plasma lipoprotein remodeling | 11 | 6.06e-02 | 1.09e-01 | 0.5680 | -2.83e-01 | -5.12e-02 | 3.56e-01 | 3.37e-01 | 1.04e-01 | 7.69e-01 | 4.12e-02 | 5.33e-02 |
| Cyclin A/B1/B2 associated events during G2/M transition | 17 | 1.14e-02 | 2.70e-02 | 0.5660 | 3.94e-01 | 3.61e-01 | 9.19e-02 | 1.64e-01 | 4.93e-03 | 1.00e-02 | 5.12e-01 | 2.42e-01 |
| Collagen chain trimerization | 31 | 9.17e-05 | 4.26e-04 | 0.5630 | -3.07e-01 | -1.07e-02 | 3.41e-01 | 3.26e-01 | 3.10e-03 | 9.18e-01 | 1.03e-03 | 1.69e-03 |
| HIV Transcription Initiation | 40 | 1.12e-08 | 1.53e-07 | 0.5620 | 4.52e-01 | 3.13e-01 | -7.46e-02 | -9.41e-02 | 7.84e-07 | 6.22e-04 | 4.15e-01 | 3.04e-01 |
| RNA Polymerase II HIV Promoter Escape | 40 | 1.12e-08 | 1.53e-07 | 0.5620 | 4.52e-01 | 3.13e-01 | -7.46e-02 | -9.41e-02 | 7.84e-07 | 6.22e-04 | 4.15e-01 | 3.04e-01 |
| RNA Polymerase II Promoter Escape | 40 | 1.12e-08 | 1.53e-07 | 0.5620 | 4.52e-01 | 3.13e-01 | -7.46e-02 | -9.41e-02 | 7.84e-07 | 6.22e-04 | 4.15e-01 | 3.04e-01 |
| RNA Polymerase II Transcription Initiation | 40 | 1.12e-08 | 1.53e-07 | 0.5620 | 4.52e-01 | 3.13e-01 | -7.46e-02 | -9.41e-02 | 7.84e-07 | 6.22e-04 | 4.15e-01 | 3.04e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 40 | 1.12e-08 | 1.53e-07 | 0.5620 | 4.52e-01 | 3.13e-01 | -7.46e-02 | -9.41e-02 | 7.84e-07 | 6.22e-04 | 4.15e-01 | 3.04e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 40 | 1.12e-08 | 1.53e-07 | 0.5620 | 4.52e-01 | 3.13e-01 | -7.46e-02 | -9.41e-02 | 7.84e-07 | 6.22e-04 | 4.15e-01 | 3.04e-01 |
| Adherens junctions interactions | 11 | 9.18e-02 | 1.50e-01 | 0.5620 | -2.14e-01 | 5.00e-02 | 4.11e-01 | 3.14e-01 | 2.18e-01 | 7.74e-01 | 1.83e-02 | 7.13e-02 |
| MET activates PTK2 signaling | 14 | 1.99e-02 | 4.30e-02 | 0.5610 | -4.32e-01 | 3.61e-02 | 2.44e-01 | 2.60e-01 | 5.14e-03 | 8.15e-01 | 1.13e-01 | 9.24e-02 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 12 | 2.15e-01 | 2.97e-01 | 0.5610 | 2.19e-01 | 2.78e-01 | 2.75e-01 | 3.39e-01 | 1.90e-01 | 9.60e-02 | 9.95e-02 | 4.24e-02 |
| Elastic fibre formation | 34 | 4.74e-03 | 1.26e-02 | 0.5600 | -4.17e-02 | 2.79e-01 | 3.56e-01 | 3.27e-01 | 6.74e-01 | 4.84e-03 | 3.28e-04 | 9.70e-04 |
| Extracellular matrix organization | 192 | 1.94e-23 | 1.83e-21 | 0.5600 | -2.59e-01 | 1.42e-01 | 3.49e-01 | 3.23e-01 | 6.82e-10 | 7.23e-04 | 9.41e-17 | 1.57e-14 |
| SUMOylation of RNA binding proteins | 38 | 3.50e-07 | 3.45e-06 | 0.5580 | 4.51e-01 | 2.47e-01 | 5.32e-02 | 2.10e-01 | 1.52e-06 | 8.39e-03 | 5.71e-01 | 2.50e-02 |
| Carboxyterminal post-translational modifications of tubulin | 21 | 1.27e-02 | 2.93e-02 | 0.5570 | -1.54e-01 | 6.37e-02 | 3.71e-01 | 3.81e-01 | 2.23e-01 | 6.13e-01 | 3.28e-03 | 2.50e-03 |
| Post-translational protein phosphorylation | 62 | 1.15e-05 | 6.77e-05 | 0.5570 | -7.96e-02 | 1.87e-01 | 3.68e-01 | 3.65e-01 | 2.79e-01 | 1.11e-02 | 5.68e-07 | 6.78e-07 |
| Resolution of D-Loop Structures | 21 | 6.61e-03 | 1.70e-02 | 0.5560 | 1.17e-01 | 8.13e-02 | 3.32e-01 | 4.22e-01 | 3.55e-01 | 5.19e-01 | 8.43e-03 | 8.12e-04 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 21 | 6.61e-03 | 1.70e-02 | 0.5560 | 1.17e-01 | 8.13e-02 | 3.32e-01 | 4.22e-01 | 3.55e-01 | 5.19e-01 | 8.43e-03 | 8.12e-04 |
| Protein localization | 136 | 8.76e-15 | 2.70e-13 | 0.5560 | -4.68e-02 | -2.45e-01 | -2.97e-01 | -3.98e-01 | 3.48e-01 | 8.70e-07 | 2.55e-09 | 1.23e-15 |
| Glycosaminoglycan metabolism | 80 | 1.35e-08 | 1.82e-07 | 0.5550 | -1.46e-01 | 1.73e-01 | 3.34e-01 | 3.81e-01 | 2.47e-02 | 7.42e-03 | 2.42e-07 | 4.04e-09 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 10 | 6.28e-02 | 1.12e-01 | 0.5510 | -2.03e-01 | 4.49e-01 | 1.45e-01 | 2.00e-01 | 2.66e-01 | 1.39e-02 | 4.29e-01 | 2.74e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 65 | 5.80e-06 | 3.86e-05 | 0.5480 | -9.49e-02 | 1.69e-01 | 3.67e-01 | 3.58e-01 | 1.86e-01 | 1.89e-02 | 3.16e-07 | 6.12e-07 |
| Semaphorin interactions | 53 | 3.74e-05 | 1.91e-04 | 0.5480 | -1.74e-01 | 2.45e-01 | 3.29e-01 | 3.18e-01 | 2.87e-02 | 2.06e-03 | 3.46e-05 | 6.20e-05 |
| mRNA 3'-end processing | 49 | 5.38e-14 | 1.51e-12 | 0.5460 | 4.16e-01 | 2.98e-01 | -7.57e-02 | 1.73e-01 | 4.81e-07 | 3.07e-04 | 3.60e-01 | 3.60e-02 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 11 | 9.61e-02 | 1.56e-01 | 0.5450 | -3.00e-01 | -8.93e-03 | 3.33e-01 | 3.10e-01 | 8.46e-02 | 9.59e-01 | 5.55e-02 | 7.53e-02 |
| Nuclear Pore Complex (NPC) Disassembly | 27 | 3.38e-04 | 1.37e-03 | 0.5450 | 4.26e-01 | 2.07e-01 | 1.18e-01 | 2.41e-01 | 1.27e-04 | 6.28e-02 | 2.88e-01 | 3.01e-02 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 134 | 6.94e-30 | 1.22e-27 | 0.5440 | 3.57e-01 | 3.86e-01 | -4.10e-02 | 1.32e-01 | 1.01e-12 | 1.45e-14 | 4.15e-01 | 8.65e-03 |
| Activation of ATR in response to replication stress | 28 | 2.32e-03 | 6.96e-03 | 0.5420 | 3.04e-01 | 2.38e-01 | 2.11e-01 | 3.16e-01 | 5.38e-03 | 2.94e-02 | 5.37e-02 | 3.79e-03 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 4.32e-02 | 8.24e-02 | 0.5410 | 1.16e-01 | 5.03e-01 | 1.40e-01 | 7.60e-02 | 5.25e-01 | 5.84e-03 | 4.45e-01 | 6.77e-01 |
| rRNA processing in the nucleus and cytosol | 143 | 5.34e-32 | 1.09e-29 | 0.5390 | 3.66e-01 | 3.72e-01 | -5.25e-02 | 1.22e-01 | 4.70e-14 | 1.78e-14 | 2.80e-01 | 1.18e-02 |
| RNA Polymerase II Pre-transcription Events | 69 | 1.83e-12 | 4.34e-11 | 0.5380 | 4.31e-01 | 3.20e-01 | -2.51e-02 | -1.37e-02 | 5.99e-10 | 4.30e-06 | 7.19e-01 | 8.44e-01 |
| Interleukin-37 signaling | 16 | 1.07e-01 | 1.70e-01 | 0.5370 | 2.62e-02 | 3.52e-01 | 2.48e-01 | 3.20e-01 | 8.56e-01 | 1.47e-02 | 8.61e-02 | 2.67e-02 |
| Pausing and recovery of Tat-mediated HIV elongation | 25 | 7.95e-04 | 2.80e-03 | 0.5370 | 2.99e-01 | 4.24e-01 | 8.96e-02 | 1.04e-01 | 9.68e-03 | 2.43e-04 | 4.38e-01 | 3.67e-01 |
| Tat-mediated HIV elongation arrest and recovery | 25 | 7.95e-04 | 2.80e-03 | 0.5370 | 2.99e-01 | 4.24e-01 | 8.96e-02 | 1.04e-01 | 9.68e-03 | 2.43e-04 | 4.38e-01 | 3.67e-01 |
| ECM proteoglycans | 37 | 2.19e-04 | 9.39e-04 | 0.5370 | -2.71e-01 | 1.43e-01 | 3.41e-01 | 2.79e-01 | 4.44e-03 | 1.33e-01 | 3.32e-04 | 3.29e-03 |
| RNA Polymerase II Transcription Termination | 57 | 4.57e-15 | 1.56e-13 | 0.5360 | 4.07e-01 | 2.98e-01 | -6.49e-02 | 1.70e-01 | 1.09e-07 | 1.00e-04 | 3.98e-01 | 2.66e-02 |
| Transcription of the HIV genome | 59 | 1.89e-10 | 3.24e-09 | 0.5360 | 4.35e-01 | 3.10e-01 | -4.31e-02 | -1.16e-02 | 7.77e-09 | 3.95e-05 | 5.67e-01 | 8.78e-01 |
| Ephrin signaling | 17 | 3.56e-02 | 7.04e-02 | 0.5350 | -2.01e-01 | 3.33e-01 | 2.32e-01 | 2.86e-01 | 1.51e-01 | 1.77e-02 | 9.80e-02 | 4.11e-02 |
| Laminin interactions | 19 | 3.59e-03 | 1.01e-02 | 0.5350 | -3.45e-01 | -6.03e-02 | 2.69e-01 | 3.02e-01 | 9.20e-03 | 6.49e-01 | 4.28e-02 | 2.28e-02 |
| Signaling by Leptin | 10 | 1.61e-01 | 2.35e-01 | 0.5350 | -3.20e-01 | -1.57e-01 | -2.22e-01 | -3.31e-01 | 7.97e-02 | 3.91e-01 | 2.25e-01 | 6.96e-02 |
| Processing of SMDT1 | 15 | 4.22e-02 | 8.09e-02 | 0.5340 | 1.48e-01 | -2.67e-01 | -2.44e-01 | -3.64e-01 | 3.22e-01 | 7.32e-02 | 1.02e-01 | 1.47e-02 |
| G0 and Early G1 | 23 | 2.77e-03 | 8.21e-03 | 0.5330 | 2.84e-01 | 2.62e-01 | 1.72e-01 | 3.24e-01 | 1.86e-02 | 2.96e-02 | 1.53e-01 | 7.09e-03 |
| Listeria monocytogenes entry into host cells | 15 | 4.84e-02 | 9.07e-02 | 0.5330 | 1.61e-01 | 3.38e-01 | 1.87e-01 | 3.30e-01 | 2.82e-01 | 2.34e-02 | 2.10e-01 | 2.72e-02 |
| Effects of PIP2 hydrolysis | 19 | 1.14e-03 | 3.81e-03 | 0.5320 | -3.25e-01 | -3.88e-01 | -1.54e-01 | -5.20e-02 | 1.43e-02 | 3.40e-03 | 2.45e-01 | 6.95e-01 |
| Response of Mtb to phagocytosis | 18 | 6.18e-03 | 1.61e-02 | 0.5300 | 2.72e-01 | 4.42e-01 | 6.32e-02 | 8.76e-02 | 4.58e-02 | 1.16e-03 | 6.43e-01 | 5.20e-01 |
| Infection with Mycobacterium tuberculosis | 19 | 8.68e-03 | 2.15e-02 | 0.5290 | 2.53e-01 | 4.35e-01 | 9.26e-02 | 1.33e-01 | 5.60e-02 | 1.02e-03 | 4.85e-01 | 3.16e-01 |
| Diseases associated with glycosaminoglycan metabolism | 30 | 5.18e-03 | 1.37e-02 | 0.5290 | -2.18e-01 | 1.93e-01 | 3.11e-01 | 3.13e-01 | 3.88e-02 | 6.71e-02 | 3.18e-03 | 3.05e-03 |
| Response of EIF2AK1 (HRI) to heme deficiency | 14 | 1.27e-03 | 4.17e-03 | 0.5260 | 6.72e-02 | 3.66e-01 | -2.86e-01 | -2.37e-01 | 6.64e-01 | 1.78e-02 | 6.40e-02 | 1.25e-01 |
| Platelet degranulation | 86 | 9.71e-08 | 1.15e-06 | 0.5230 | -1.43e-01 | 1.58e-01 | 3.53e-01 | 3.22e-01 | 2.19e-02 | 1.13e-02 | 1.65e-08 | 2.57e-07 |
| FGFR2 alternative splicing | 22 | 6.96e-03 | 1.78e-02 | 0.5230 | 3.90e-01 | 2.91e-01 | 9.30e-02 | 1.67e-01 | 1.54e-03 | 1.84e-02 | 4.50e-01 | 1.75e-01 |
| DARPP-32 events | 21 | 2.75e-02 | 5.66e-02 | 0.5220 | -2.03e-01 | -9.00e-02 | -3.46e-01 | -3.21e-01 | 1.08e-01 | 4.75e-01 | 6.01e-03 | 1.09e-02 |
| Lysosome Vesicle Biogenesis | 26 | 3.69e-02 | 7.21e-02 | 0.5210 | 9.17e-02 | 2.39e-01 | 3.43e-01 | 2.97e-01 | 4.18e-01 | 3.50e-02 | 2.48e-03 | 8.71e-03 |
| Receptor Mediated Mitophagy | 11 | 2.25e-01 | 3.06e-01 | 0.5210 | 2.03e-01 | -9.68e-02 | -3.30e-01 | -3.35e-01 | 2.43e-01 | 5.79e-01 | 5.84e-02 | 5.47e-02 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 14 | 3.64e-02 | 7.14e-02 | 0.5210 | 3.07e-01 | 2.03e-01 | 1.71e-01 | 3.26e-01 | 4.67e-02 | 1.88e-01 | 2.68e-01 | 3.47e-02 |
| Nucleosome assembly | 14 | 3.64e-02 | 7.14e-02 | 0.5210 | 3.07e-01 | 2.03e-01 | 1.71e-01 | 3.26e-01 | 4.67e-02 | 1.88e-01 | 2.68e-01 | 3.47e-02 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 10 | 6.83e-02 | 1.19e-01 | 0.5210 | 3.36e-01 | 3.21e-01 | 5.21e-02 | 2.28e-01 | 6.55e-02 | 7.84e-02 | 7.76e-01 | 2.13e-01 |
| Attenuation phase | 20 | 5.04e-04 | 1.95e-03 | 0.5210 | 3.28e-01 | 3.90e-01 | -7.51e-02 | -7.47e-02 | 1.11e-02 | 2.53e-03 | 5.61e-01 | 5.63e-01 |
| Peroxisomal lipid metabolism | 22 | 1.18e-02 | 2.79e-02 | 0.5200 | -9.62e-02 | -4.05e-01 | -1.65e-01 | -2.65e-01 | 4.35e-01 | 1.02e-03 | 1.79e-01 | 3.17e-02 |
| Transcriptional regulation by small RNAs | 39 | 1.21e-04 | 5.48e-04 | 0.5200 | 4.05e-01 | 2.14e-01 | 1.45e-01 | 2.00e-01 | 1.24e-05 | 2.11e-02 | 1.19e-01 | 3.10e-02 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 12 | 6.96e-02 | 1.20e-01 | 0.5200 | -4.68e-01 | -7.96e-02 | -1.47e-01 | -1.53e-01 | 5.04e-03 | 6.33e-01 | 3.79e-01 | 3.59e-01 |
| Interaction between L1 and Ankyrins | 14 | 3.81e-02 | 7.41e-02 | 0.5190 | -4.48e-01 | -2.37e-01 | -2.74e-02 | -1.07e-01 | 3.71e-03 | 1.24e-01 | 8.59e-01 | 4.88e-01 |
| Keratinization | 11 | 4.22e-03 | 1.14e-02 | 0.5180 | -3.96e-01 | 2.70e-01 | 1.97e-01 | -4.31e-03 | 2.30e-02 | 1.21e-01 | 2.59e-01 | 9.80e-01 |
| Peptide chain elongation | 53 | 1.08e-14 | 3.25e-13 | 0.5180 | -7.01e-02 | 4.66e-01 | 5.89e-04 | 2.14e-01 | 3.78e-01 | 4.34e-09 | 9.94e-01 | 7.09e-03 |
| O-glycosylation of TSR domain-containing proteins | 25 | 7.46e-04 | 2.64e-03 | 0.5180 | -1.45e-01 | -3.86e-02 | 4.03e-01 | 2.88e-01 | 2.10e-01 | 7.38e-01 | 4.89e-04 | 1.27e-02 |
| Defective B3GALTL causes Peters-plus syndrome (PpS) | 24 | 5.85e-04 | 2.19e-03 | 0.5170 | -1.44e-01 | -6.56e-02 | 4.04e-01 | 2.83e-01 | 2.24e-01 | 5.78e-01 | 6.20e-04 | 1.66e-02 |
| Amyloid fiber formation | 29 | 1.06e-02 | 2.57e-02 | 0.5170 | -1.86e-01 | 2.45e-01 | 2.96e-01 | 2.91e-01 | 8.39e-02 | 2.23e-02 | 5.79e-03 | 6.79e-03 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 21 | 4.26e-03 | 1.15e-02 | 0.5160 | 2.84e-01 | 4.06e-01 | 1.13e-01 | 8.97e-02 | 2.41e-02 | 1.28e-03 | 3.70e-01 | 4.77e-01 |
| EPHA-mediated growth cone collapse | 13 | 1.36e-01 | 2.06e-01 | 0.5160 | -1.04e-01 | 3.25e-01 | 2.26e-01 | 3.14e-01 | 5.17e-01 | 4.24e-02 | 1.58e-01 | 5.04e-02 |
| Extension of Telomeres | 43 | 4.89e-04 | 1.91e-03 | 0.5150 | 2.80e-01 | 2.12e-01 | 2.34e-01 | 2.96e-01 | 1.49e-03 | 1.63e-02 | 8.13e-03 | 7.98e-04 |
| Signaling by FGFR2 IIIa TM | 16 | 3.41e-03 | 9.71e-03 | 0.5120 | 3.04e-01 | 4.09e-01 | 3.51e-02 | -2.65e-02 | 3.51e-02 | 4.59e-03 | 8.08e-01 | 8.54e-01 |
| MET activates RAP1 and RAC1 | 10 | 4.27e-02 | 8.16e-02 | 0.5090 | 4.49e-02 | 5.03e-01 | 8.74e-03 | 6.51e-02 | 8.06e-01 | 5.90e-03 | 9.62e-01 | 7.21e-01 |
| HS-GAG biosynthesis | 18 | 1.33e-02 | 3.06e-02 | 0.5080 | -2.93e-01 | 2.01e-01 | 2.05e-01 | 3.01e-01 | 3.15e-02 | 1.40e-01 | 1.33e-01 | 2.73e-02 |
| TRAF6 mediated NF-kB activation | 19 | 7.46e-02 | 1.27e-01 | 0.5070 | -1.35e-01 | 1.03e-01 | 3.46e-01 | 3.30e-01 | 3.09e-01 | 4.39e-01 | 9.06e-03 | 1.29e-02 |
| Formation of Fibrin Clot (Clotting Cascade) | 13 | 2.65e-01 | 3.49e-01 | 0.5070 | 7.17e-02 | 1.27e-01 | 3.35e-01 | 3.51e-01 | 6.54e-01 | 4.29e-01 | 3.64e-02 | 2.84e-02 |
| Integrin signaling | 20 | 1.86e-02 | 4.08e-02 | 0.5060 | -7.56e-02 | 4.05e-01 | 1.74e-01 | 2.36e-01 | 5.59e-01 | 1.71e-03 | 1.79e-01 | 6.82e-02 |
| RORA activates gene expression | 17 | 1.19e-02 | 2.79e-02 | 0.5040 | -1.06e-01 | -3.60e-01 | -2.97e-01 | -1.58e-01 | 4.48e-01 | 1.03e-02 | 3.41e-02 | 2.59e-01 |
| Calnexin/calreticulin cycle | 23 | 8.04e-02 | 1.35e-01 | 0.5030 | 1.23e-01 | 2.91e-01 | 2.87e-01 | 2.65e-01 | 3.08e-01 | 1.57e-02 | 1.71e-02 | 2.79e-02 |
| Diseases associated with O-glycosylation of proteins | 33 | 1.15e-04 | 5.22e-04 | 0.5020 | -1.88e-01 | -2.34e-03 | 3.84e-01 | 2.63e-01 | 6.23e-02 | 9.81e-01 | 1.37e-04 | 9.07e-03 |
| Class A/1 (Rhodopsin-like receptors) | 38 | 5.27e-03 | 1.39e-02 | 0.5010 | -7.06e-02 | 2.33e-01 | 2.84e-01 | 3.34e-01 | 4.52e-01 | 1.32e-02 | 2.43e-03 | 3.73e-04 |
| Smooth Muscle Contraction | 31 | 1.73e-06 | 1.34e-05 | 0.5010 | -4.71e-01 | 1.33e-01 | -1.06e-01 | -1.81e-02 | 5.79e-06 | 1.99e-01 | 3.06e-01 | 8.62e-01 |
| tRNA processing in the nucleus | 48 | 3.15e-07 | 3.18e-06 | 0.5000 | 4.44e-01 | 1.95e-01 | 7.58e-03 | 1.24e-01 | 1.07e-07 | 1.93e-02 | 9.28e-01 | 1.39e-01 |
| Activation of BAD and translocation to mitochondria | 13 | 2.08e-01 | 2.90e-01 | 0.4990 | -2.21e-01 | 2.00e-01 | 2.89e-01 | 2.76e-01 | 1.67e-01 | 2.12e-01 | 7.12e-02 | 8.46e-02 |
| Other semaphorin interactions | 14 | 1.90e-02 | 4.14e-02 | 0.4980 | -1.83e-01 | -1.23e-01 | 3.69e-01 | 2.52e-01 | 2.35e-01 | 4.26e-01 | 1.70e-02 | 1.03e-01 |
| Keratan sulfate biosynthesis | 17 | 1.05e-01 | 1.68e-01 | 0.4980 | -1.98e-01 | 1.45e-01 | 3.26e-01 | 2.85e-01 | 1.57e-01 | 3.00e-01 | 2.00e-02 | 4.23e-02 |
| Transcriptional regulation of granulopoiesis | 23 | 1.95e-02 | 4.23e-02 | 0.4980 | -8.28e-03 | 3.07e-01 | 2.15e-01 | 3.27e-01 | 9.45e-01 | 1.08e-02 | 7.49e-02 | 6.58e-03 |
| Signaling by BMP | 22 | 4.09e-03 | 1.12e-02 | 0.4960 | -5.66e-02 | 8.50e-02 | -3.50e-01 | -3.36e-01 | 6.46e-01 | 4.90e-01 | 4.46e-03 | 6.35e-03 |
| HIV elongation arrest and recovery | 27 | 8.95e-04 | 3.07e-03 | 0.4950 | 3.34e-01 | 3.60e-01 | 3.43e-02 | 5.56e-02 | 2.71e-03 | 1.23e-03 | 7.58e-01 | 6.17e-01 |
| Pausing and recovery of HIV elongation | 27 | 8.95e-04 | 3.07e-03 | 0.4950 | 3.34e-01 | 3.60e-01 | 3.43e-02 | 5.56e-02 | 2.71e-03 | 1.23e-03 | 7.58e-01 | 6.17e-01 |
| mRNA Splicing - Minor Pathway | 47 | 1.02e-07 | 1.18e-06 | 0.4950 | 3.97e-01 | 2.75e-01 | -1.05e-01 | -9.51e-03 | 2.47e-06 | 1.12e-03 | 2.12e-01 | 9.10e-01 |
| Neutrophil degranulation | 291 | 2.39e-21 | 1.84e-19 | 0.4940 | -6.30e-02 | 2.08e-01 | 3.32e-01 | 2.93e-01 | 6.66e-02 | 1.24e-09 | 2.88e-22 | 1.10e-17 |
| Diseases of programmed cell death | 24 | 8.18e-02 | 1.37e-01 | 0.4930 | -5.28e-02 | 2.06e-01 | 3.27e-01 | 3.03e-01 | 6.54e-01 | 8.14e-02 | 5.62e-03 | 1.03e-02 |
| Telomere C-strand synthesis initiation | 11 | 1.21e-01 | 1.87e-01 | 0.4930 | 2.60e-01 | 4.73e-02 | 2.39e-01 | 3.41e-01 | 1.36e-01 | 7.86e-01 | 1.70e-01 | 5.03e-02 |
| Synthesis of pyrophosphates in the cytosol | 10 | 5.10e-01 | 5.99e-01 | 0.4900 | 6.92e-03 | -2.16e-01 | -2.97e-01 | -3.25e-01 | 9.70e-01 | 2.38e-01 | 1.04e-01 | 7.54e-02 |
| Response to elevated platelet cytosolic Ca2+ | 89 | 4.24e-07 | 3.98e-06 | 0.4890 | -1.39e-01 | 1.39e-01 | 3.30e-01 | 3.02e-01 | 2.33e-02 | 2.36e-02 | 7.62e-08 | 8.69e-07 |
| Viral mRNA Translation | 53 | 3.27e-14 | 9.37e-13 | 0.4880 | -5.65e-02 | 4.47e-01 | -2.92e-02 | 1.85e-01 | 4.77e-01 | 1.80e-08 | 7.13e-01 | 2.02e-02 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 63 | 1.02e-16 | 5.05e-15 | 0.4880 | -3.26e-02 | 4.60e-01 | -5.00e-02 | 1.50e-01 | 6.55e-01 | 2.70e-10 | 4.93e-01 | 3.94e-02 |
| TRAF6 mediated IRF7 activation | 14 | 1.48e-01 | 2.20e-01 | 0.4880 | 3.56e-02 | 6.54e-02 | 3.11e-01 | 3.68e-01 | 8.17e-01 | 6.72e-01 | 4.39e-02 | 1.71e-02 |
| Eukaryotic Translation Elongation | 56 | 4.77e-15 | 1.59e-13 | 0.4880 | -8.98e-02 | 4.40e-01 | -2.37e-02 | 1.88e-01 | 2.46e-01 | 1.22e-08 | 7.59e-01 | 1.51e-02 |
| Bile acid and bile salt metabolism | 20 | 4.61e-02 | 8.71e-02 | 0.4880 | -1.17e-01 | -3.17e-01 | -2.87e-01 | -2.04e-01 | 3.66e-01 | 1.42e-02 | 2.64e-02 | 1.15e-01 |
| Selenocysteine synthesis | 56 | 2.50e-15 | 9.05e-14 | 0.4870 | -3.16e-02 | 4.57e-01 | -5.62e-02 | 1.54e-01 | 6.83e-01 | 3.28e-09 | 4.68e-01 | 4.65e-02 |
| SRP-dependent cotranslational protein targeting to membrane | 74 | 3.71e-13 | 9.73e-12 | 0.4860 | 9.54e-02 | 4.51e-01 | 1.89e-02 | 1.53e-01 | 1.57e-01 | 2.00e-11 | 7.79e-01 | 2.30e-02 |
| Telomere Maintenance | 56 | 1.32e-04 | 5.92e-04 | 0.4850 | 2.92e-01 | 2.35e-01 | 2.09e-01 | 2.26e-01 | 1.59e-04 | 2.34e-03 | 6.85e-03 | 3.46e-03 |
| Sema4D in semaphorin signaling | 23 | 4.10e-03 | 1.12e-02 | 0.4840 | -2.47e-01 | 3.22e-01 | 1.47e-01 | 2.20e-01 | 4.07e-02 | 7.59e-03 | 2.23e-01 | 6.82e-02 |
| Basigin interactions | 17 | 6.12e-02 | 1.10e-01 | 0.4830 | -3.18e-01 | 1.23e-01 | 2.42e-01 | 2.43e-01 | 2.33e-02 | 3.81e-01 | 8.46e-02 | 8.24e-02 |
| Influenza Infection | 107 | 4.56e-16 | 2.00e-14 | 0.4830 | 1.68e-01 | 4.06e-01 | 5.58e-02 | 1.93e-01 | 2.75e-03 | 4.53e-13 | 3.20e-01 | 5.64e-04 |
| Thrombin signalling through proteinase activated receptors (PARs) | 20 | 1.33e-01 | 2.02e-01 | 0.4820 | -5.09e-02 | 1.87e-01 | 3.34e-01 | 2.88e-01 | 6.94e-01 | 1.47e-01 | 9.68e-03 | 2.56e-02 |
| Mitotic Telophase/Cytokinesis | 10 | 2.47e-03 | 7.38e-03 | 0.4820 | 3.97e-01 | -2.04e-01 | -1.45e-01 | 1.12e-01 | 2.97e-02 | 2.65e-01 | 4.29e-01 | 5.41e-01 |
| Meiotic recombination | 17 | 1.32e-02 | 3.04e-02 | 0.4810 | 3.18e-01 | 9.46e-03 | 1.94e-01 | 3.04e-01 | 2.31e-02 | 9.46e-01 | 1.65e-01 | 3.01e-02 |
| Activation of AMPK downstream of NMDARs | 10 | 4.05e-01 | 4.97e-01 | 0.4810 | -2.82e-01 | -2.02e-01 | -2.19e-01 | -2.51e-01 | 1.22e-01 | 2.68e-01 | 2.30e-01 | 1.69e-01 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 57 | 2.11e-15 | 8.11e-14 | 0.4810 | -2.01e-02 | 4.39e-01 | -3.52e-02 | 1.90e-01 | 7.93e-01 | 9.80e-09 | 6.46e-01 | 1.30e-02 |
| Cell-extracellular matrix interactions | 16 | 9.33e-02 | 1.52e-01 | 0.4790 | -2.59e-01 | 2.38e-01 | 2.21e-01 | 2.38e-01 | 7.27e-02 | 9.89e-02 | 1.26e-01 | 9.99e-02 |
| p75NTR recruits signalling complexes | 10 | 3.50e-01 | 4.39e-01 | 0.4780 | 1.10e-01 | 3.77e-01 | 1.68e-01 | 2.15e-01 | 5.46e-01 | 3.91e-02 | 3.58e-01 | 2.39e-01 |
| Gap junction trafficking | 10 | 5.30e-01 | 6.14e-01 | 0.4780 | 6.88e-02 | 1.74e-01 | 3.02e-01 | 3.20e-01 | 7.06e-01 | 3.42e-01 | 9.86e-02 | 7.96e-02 |
| Synthesis of PIPs at the late endosome membrane | 10 | 9.82e-02 | 1.59e-01 | 0.4780 | 2.57e-01 | -1.15e-01 | 2.83e-01 | 2.62e-01 | 1.60e-01 | 5.27e-01 | 1.21e-01 | 1.51e-01 |
| Sphingolipid metabolism | 63 | 1.56e-04 | 6.89e-04 | 0.4780 | -2.62e-02 | 2.01e-01 | 2.74e-01 | 3.34e-01 | 7.19e-01 | 5.84e-03 | 1.69e-04 | 4.57e-06 |
| Mitophagy | 24 | 2.85e-02 | 5.83e-02 | 0.4770 | 1.33e-01 | -8.78e-02 | -2.95e-01 | -3.40e-01 | 2.59e-01 | 4.57e-01 | 1.25e-02 | 3.95e-03 |
| Chromosome Maintenance | 68 | 9.72e-06 | 5.98e-05 | 0.4770 | 3.00e-01 | 2.21e-01 | 1.84e-01 | 2.35e-01 | 1.98e-05 | 1.67e-03 | 8.74e-03 | 8.06e-04 |
| rRNA processing | 154 | 3.75e-27 | 4.61e-25 | 0.4760 | 3.37e-01 | 3.19e-01 | -7.94e-02 | 6.58e-02 | 5.63e-13 | 9.03e-12 | 9.02e-02 | 1.61e-01 |
| Plasma lipoprotein clearance | 21 | 6.60e-02 | 1.16e-01 | 0.4740 | -1.11e-01 | 8.85e-02 | 3.02e-01 | 3.36e-01 | 3.79e-01 | 4.83e-01 | 1.65e-02 | 7.71e-03 |
| DAP12 interactions | 15 | 2.99e-01 | 3.85e-01 | 0.4740 | 2.55e-02 | 1.61e-01 | 3.00e-01 | 3.29e-01 | 8.64e-01 | 2.82e-01 | 4.46e-02 | 2.74e-02 |
| DAP12 signaling | 15 | 2.99e-01 | 3.85e-01 | 0.4740 | 2.55e-02 | 1.61e-01 | 3.00e-01 | 3.29e-01 | 8.64e-01 | 2.82e-01 | 4.46e-02 | 2.74e-02 |
| Platelet Aggregation (Plug Formation) | 21 | 4.43e-02 | 8.44e-02 | 0.4730 | -8.85e-02 | 3.63e-01 | 1.96e-01 | 2.13e-01 | 4.83e-01 | 3.99e-03 | 1.19e-01 | 9.07e-02 |
| PRC2 methylates histones and DNA | 14 | 1.99e-01 | 2.81e-01 | 0.4720 | 2.57e-01 | 2.99e-01 | 1.50e-01 | 2.12e-01 | 9.57e-02 | 5.24e-02 | 3.32e-01 | 1.70e-01 |
| Eukaryotic Translation Termination | 55 | 2.84e-14 | 8.32e-13 | 0.4690 | -4.95e-02 | 4.32e-01 | -4.15e-02 | 1.72e-01 | 5.26e-01 | 3.11e-08 | 5.95e-01 | 2.71e-02 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 1.27e-01 | 1.94e-01 | 0.4670 | 1.88e-01 | 2.86e-01 | 2.05e-01 | 2.43e-01 | 1.36e-01 | 2.32e-02 | 1.04e-01 | 5.42e-02 |
| Fatty acid metabolism | 102 | 7.60e-08 | 9.36e-07 | 0.4670 | -2.23e-01 | -3.01e-01 | -1.73e-01 | -2.19e-01 | 1.02e-04 | 1.59e-07 | 2.65e-03 | 1.33e-04 |
| Chaperone Mediated Autophagy | 14 | 2.97e-01 | 3.83e-01 | 0.4660 | -5.60e-02 | 2.92e-01 | 2.68e-01 | 2.40e-01 | 7.17e-01 | 5.89e-02 | 8.28e-02 | 1.20e-01 |
| Potassium Channels | 33 | 3.47e-03 | 9.82e-03 | 0.4650 | -3.42e-01 | -2.59e-01 | -1.18e-01 | -1.35e-01 | 6.89e-04 | 1.00e-02 | 2.42e-01 | 1.80e-01 |
| Processing of DNA double-strand break ends | 50 | 2.43e-04 | 1.03e-03 | 0.4640 | 2.93e-01 | 2.26e-01 | 1.57e-01 | 2.33e-01 | 3.38e-04 | 5.81e-03 | 5.55e-02 | 4.50e-03 |
| Late Phase of HIV Life Cycle | 112 | 4.68e-13 | 1.18e-11 | 0.4630 | 3.58e-01 | 2.85e-01 | 3.25e-02 | 6.57e-02 | 6.41e-11 | 2.00e-07 | 5.53e-01 | 2.31e-01 |
| Formation of RNA Pol II elongation complex | 50 | 3.33e-06 | 2.30e-05 | 0.4600 | 3.70e-01 | 2.73e-01 | -1.62e-03 | 1.31e-02 | 6.12e-06 | 8.59e-04 | 9.84e-01 | 8.73e-01 |
| RNA Polymerase II Transcription Elongation | 50 | 3.33e-06 | 2.30e-05 | 0.4600 | 3.70e-01 | 2.73e-01 | -1.62e-03 | 1.31e-02 | 6.12e-06 | 8.59e-04 | 9.84e-01 | 8.73e-01 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 20 | 5.93e-04 | 2.21e-03 | 0.4590 | -2.80e-01 | 2.97e-01 | 2.06e-01 | 4.48e-02 | 3.02e-02 | 2.14e-02 | 1.11e-01 | 7.29e-01 |
| Homologous DNA Pairing and Strand Exchange | 30 | 3.27e-03 | 9.50e-03 | 0.4570 | 2.52e-01 | 6.07e-02 | 2.20e-01 | 3.05e-01 | 1.69e-02 | 5.66e-01 | 3.68e-02 | 3.90e-03 |
| Regulated proteolysis of p75NTR | 11 | 5.17e-01 | 6.05e-01 | 0.4560 | 5.73e-02 | 1.48e-01 | 3.04e-01 | 3.00e-01 | 7.42e-01 | 3.95e-01 | 8.06e-02 | 8.51e-02 |
| Mitochondrial iron-sulfur cluster biogenesis | 12 | 1.39e-01 | 2.10e-01 | 0.4550 | -7.59e-02 | -1.51e-01 | -2.16e-01 | -3.63e-01 | 6.49e-01 | 3.64e-01 | 1.94e-01 | 2.96e-02 |
| RNA polymerase II transcribes snRNA genes | 67 | 7.27e-09 | 1.07e-07 | 0.4540 | 3.85e-01 | 1.98e-01 | -1.06e-01 | -8.72e-02 | 5.12e-08 | 5.13e-03 | 1.33e-01 | 2.18e-01 |
| Influenza Viral RNA Transcription and Replication | 91 | 1.34e-13 | 3.65e-12 | 0.4540 | 1.55e-01 | 3.89e-01 | 2.72e-02 | 1.73e-01 | 1.06e-02 | 1.46e-10 | 6.55e-01 | 4.34e-03 |
| Platelet calcium homeostasis | 18 | 3.06e-02 | 6.19e-02 | 0.4540 | -3.90e-01 | -1.92e-01 | -1.17e-01 | -6.40e-02 | 4.21e-03 | 1.59e-01 | 3.92e-01 | 6.39e-01 |
| Non-integrin membrane-ECM interactions | 35 | 3.28e-03 | 9.50e-03 | 0.4540 | -2.82e-01 | 9.36e-02 | 2.47e-01 | 2.39e-01 | 3.94e-03 | 3.38e-01 | 1.16e-02 | 1.43e-02 |
| Formation of a pool of free 40S subunits | 63 | 2.38e-12 | 5.33e-11 | 0.4540 | 1.54e-02 | 4.21e-01 | -6.16e-03 | 1.68e-01 | 8.33e-01 | 7.68e-09 | 9.33e-01 | 2.14e-02 |
| Activation of SMO | 12 | 1.33e-02 | 3.05e-02 | 0.4540 | -1.90e-01 | -1.15e-01 | 1.91e-01 | 3.47e-01 | 2.55e-01 | 4.91e-01 | 2.53e-01 | 3.76e-02 |
| PINK1-PRKN Mediated Mitophagy | 17 | 7.31e-02 | 1.25e-01 | 0.4530 | 1.32e-01 | -6.79e-02 | -2.59e-01 | -3.41e-01 | 3.45e-01 | 6.28e-01 | 6.48e-02 | 1.50e-02 |
| HCMV Early Events | 50 | 6.99e-05 | 3.33e-04 | 0.4530 | 3.62e-01 | 1.44e-01 | 1.26e-01 | 1.93e-01 | 9.80e-06 | 7.81e-02 | 1.24e-01 | 1.83e-02 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 57 | 3.03e-05 | 1.59e-04 | 0.4520 | 3.52e-01 | 2.06e-01 | 1.08e-01 | 1.62e-01 | 4.29e-06 | 7.19e-03 | 1.59e-01 | 3.45e-02 |
| Amplification of signal from the kinetochores | 57 | 3.03e-05 | 1.59e-04 | 0.4520 | 3.52e-01 | 2.06e-01 | 1.08e-01 | 1.62e-01 | 4.29e-06 | 7.19e-03 | 1.59e-01 | 3.45e-02 |
| PERK regulates gene expression | 28 | 1.75e-03 | 5.50e-03 | 0.4520 | 3.54e-01 | 2.76e-01 | -3.21e-02 | 3.74e-02 | 1.18e-03 | 1.14e-02 | 7.69e-01 | 7.32e-01 |
| HIV Life Cycle | 122 | 1.77e-13 | 4.74e-12 | 0.4520 | 3.48e-01 | 2.79e-01 | 3.67e-02 | 6.28e-02 | 3.34e-11 | 1.15e-07 | 4.85e-01 | 2.32e-01 |
| FOXO-mediated transcription of cell death genes | 14 | 2.50e-01 | 3.35e-01 | 0.4510 | -1.29e-01 | -6.81e-02 | -3.14e-01 | -2.89e-01 | 4.03e-01 | 6.59e-01 | 4.17e-02 | 6.14e-02 |
| Regulation of KIT signaling | 14 | 1.92e-01 | 2.73e-01 | 0.4510 | -2.25e-01 | 2.52e-01 | 2.12e-01 | 2.10e-01 | 1.45e-01 | 1.03e-01 | 1.69e-01 | 1.73e-01 |
| E2F mediated regulation of DNA replication | 19 | 1.25e-01 | 1.92e-01 | 0.4510 | 2.39e-01 | 1.90e-01 | 1.95e-01 | 2.68e-01 | 7.09e-02 | 1.52e-01 | 1.42e-01 | 4.29e-02 |
| Processive synthesis on the C-strand of the telomere | 19 | 2.05e-01 | 2.88e-01 | 0.4510 | 1.08e-01 | 1.95e-01 | 2.45e-01 | 3.05e-01 | 4.14e-01 | 1.41e-01 | 6.45e-02 | 2.13e-02 |
| Metabolism of RNA | 567 | 8.19e-78 | 1.01e-74 | 0.4510 | 3.69e-01 | 2.47e-01 | -6.24e-02 | 4.56e-02 | 4.79e-50 | 2.92e-23 | 1.23e-02 | 6.73e-02 |
| Recycling pathway of L1 | 23 | 1.44e-01 | 2.16e-01 | 0.4500 | -4.29e-02 | 1.69e-01 | 3.09e-01 | 2.76e-01 | 7.22e-01 | 1.60e-01 | 1.03e-02 | 2.20e-02 |
| PKA activation | 15 | 6.46e-02 | 1.14e-01 | 0.4500 | -4.39e-01 | -8.98e-02 | 1.79e-02 | -3.31e-02 | 3.26e-03 | 5.47e-01 | 9.04e-01 | 8.25e-01 |
| Translation of structural proteins | 25 | 4.77e-02 | 8.98e-02 | 0.4490 | -1.94e-01 | 2.34e-01 | 2.31e-01 | 2.36e-01 | 9.27e-02 | 4.30e-02 | 4.54e-02 | 4.09e-02 |
| Signaling by Non-Receptor Tyrosine Kinases | 42 | 1.97e-03 | 6.04e-03 | 0.4490 | -5.16e-02 | 2.19e-01 | 2.23e-01 | 3.18e-01 | 5.63e-01 | 1.42e-02 | 1.26e-02 | 3.62e-04 |
| Signaling by PTK6 | 42 | 1.97e-03 | 6.04e-03 | 0.4490 | -5.16e-02 | 2.19e-01 | 2.23e-01 | 3.18e-01 | 5.63e-01 | 1.42e-02 | 1.26e-02 | 3.62e-04 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 4.94e-01 | 5.82e-01 | 0.4490 | -1.41e-01 | -2.19e-01 | -2.27e-01 | -2.87e-01 | 4.18e-01 | 2.09e-01 | 1.93e-01 | 9.99e-02 |
| Regulation of MECP2 expression and activity | 26 | 7.87e-02 | 1.33e-01 | 0.4470 | -7.90e-02 | -3.20e-01 | -2.14e-01 | -2.15e-01 | 4.86e-01 | 4.79e-03 | 5.96e-02 | 5.84e-02 |
| RHO GTPases Activate Formins | 80 | 2.08e-05 | 1.12e-04 | 0.4460 | 2.21e-01 | 2.67e-01 | 1.76e-01 | 2.19e-01 | 6.31e-04 | 3.68e-05 | 6.71e-03 | 7.31e-04 |
| Peptide ligand-binding receptors | 22 | 9.01e-02 | 1.48e-01 | 0.4450 | -7.25e-02 | 1.94e-01 | 2.38e-01 | 3.14e-01 | 5.56e-01 | 1.15e-01 | 5.30e-02 | 1.09e-02 |
| Pentose phosphate pathway | 12 | 2.91e-01 | 3.76e-01 | 0.4450 | 1.66e-01 | 3.06e-01 | 1.43e-01 | 2.38e-01 | 3.20e-01 | 6.65e-02 | 3.92e-01 | 1.54e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE | 24 | 2.68e-03 | 7.95e-03 | 0.4430 | 3.76e-01 | 2.01e-01 | -6.72e-02 | -1.01e-01 | 1.45e-03 | 8.86e-02 | 5.69e-01 | 3.91e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 24 | 2.68e-03 | 7.95e-03 | 0.4430 | 3.76e-01 | 2.01e-01 | -6.72e-02 | -1.01e-01 | 1.45e-03 | 8.86e-02 | 5.69e-01 | 3.91e-01 |
| Transferrin endocytosis and recycling | 21 | 1.04e-03 | 3.50e-03 | 0.4410 | 4.34e-02 | 5.92e-02 | 3.91e-01 | 1.90e-01 | 7.31e-01 | 6.39e-01 | 1.93e-03 | 1.32e-01 |
| Sema4D induced cell migration and growth-cone collapse | 19 | 2.27e-02 | 4.81e-02 | 0.4410 | -2.07e-01 | 2.86e-01 | 1.29e-01 | 2.31e-01 | 1.19e-01 | 3.11e-02 | 3.31e-01 | 8.15e-02 |
| Interferon Signaling | 119 | 1.36e-07 | 1.52e-06 | 0.4410 | 1.47e-01 | 2.40e-01 | 2.01e-01 | 2.72e-01 | 5.65e-03 | 6.55e-06 | 1.54e-04 | 3.02e-07 |
| O-linked glycosylation of mucins | 21 | 1.45e-01 | 2.17e-01 | 0.4390 | -1.41e-01 | 2.25e-01 | 2.39e-01 | 2.55e-01 | 2.63e-01 | 7.41e-02 | 5.79e-02 | 4.34e-02 |
| Processing of Capped Intronless Pre-mRNA | 25 | 1.24e-03 | 4.11e-03 | 0.4380 | 2.63e-01 | 3.15e-01 | -6.53e-03 | 1.53e-01 | 2.31e-02 | 6.37e-03 | 9.55e-01 | 1.85e-01 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 29 | 5.14e-03 | 1.36e-02 | 0.4380 | 2.60e-01 | 5.10e-02 | 2.01e-01 | 2.86e-01 | 1.56e-02 | 6.35e-01 | 6.17e-02 | 7.80e-03 |
| Regulation of HSF1-mediated heat shock response | 65 | 6.86e-07 | 6.07e-06 | 0.4380 | 3.60e-01 | 2.44e-01 | 6.94e-03 | 5.07e-02 | 5.31e-07 | 6.87e-04 | 9.23e-01 | 4.81e-01 |
| Selenoamino acid metabolism | 68 | 4.47e-16 | 2.00e-14 | 0.4370 | -1.48e-02 | 4.15e-01 | -8.85e-02 | 1.04e-01 | 8.33e-01 | 3.38e-09 | 2.07e-01 | 1.37e-01 |
| Negative epigenetic regulation of rRNA expression | 43 | 1.53e-04 | 6.79e-04 | 0.4370 | 3.88e-01 | 1.97e-01 | 1.61e-03 | 4.44e-02 | 1.11e-05 | 2.58e-02 | 9.85e-01 | 6.15e-01 |
| B-WICH complex positively regulates rRNA expression | 28 | 9.44e-03 | 2.31e-02 | 0.4360 | 2.26e-01 | 3.42e-01 | 6.93e-02 | 1.35e-01 | 3.90e-02 | 1.77e-03 | 5.26e-01 | 2.18e-01 |
| O-linked glycosylation | 51 | 2.00e-04 | 8.69e-04 | 0.4360 | -1.63e-01 | 7.23e-02 | 3.21e-01 | 2.35e-01 | 4.39e-02 | 3.73e-01 | 7.42e-05 | 3.69e-03 |
| ADP signalling through P2Y purinoceptor 12 | 13 | 2.80e-01 | 3.65e-01 | 0.4350 | 4.72e-02 | 2.08e-02 | 3.06e-01 | 3.05e-01 | 7.69e-01 | 8.97e-01 | 5.60e-02 | 5.69e-02 |
| G-protein activation | 13 | 2.80e-01 | 3.65e-01 | 0.4350 | 4.72e-02 | 2.08e-02 | 3.06e-01 | 3.05e-01 | 7.69e-01 | 8.97e-01 | 5.60e-02 | 5.69e-02 |
| Inactivation, recovery and regulation of the phototransduction cascade | 12 | 1.77e-01 | 2.55e-01 | 0.4340 | -7.52e-02 | 2.65e-02 | -2.69e-01 | -3.31e-01 | 6.52e-01 | 8.74e-01 | 1.06e-01 | 4.74e-02 |
| The phototransduction cascade | 12 | 1.77e-01 | 2.55e-01 | 0.4340 | -7.52e-02 | 2.65e-02 | -2.69e-01 | -3.31e-01 | 6.52e-01 | 8.74e-01 | 1.06e-01 | 4.74e-02 |
| mRNA Capping | 26 | 3.56e-03 | 1.00e-02 | 0.4340 | 3.69e-01 | 2.18e-01 | -4.26e-02 | -5.14e-02 | 1.14e-03 | 5.41e-02 | 7.07e-01 | 6.51e-01 |
| NF-kB is activated and signals survival | 10 | 1.67e-01 | 2.43e-01 | 0.4330 | -1.42e-01 | 3.80e-01 | 1.27e-01 | 8.29e-02 | 4.36e-01 | 3.77e-02 | 4.86e-01 | 6.50e-01 |
| Leishmania infection | 118 | 1.84e-06 | 1.40e-05 | 0.4330 | -8.00e-02 | 1.70e-01 | 2.74e-01 | 2.77e-01 | 1.34e-01 | 1.49e-03 | 2.82e-07 | 2.14e-07 |
| Resolution of Sister Chromatid Cohesion | 66 | 2.32e-06 | 1.67e-05 | 0.4300 | 3.62e-01 | 1.57e-01 | 7.29e-02 | 1.54e-01 | 3.89e-07 | 2.74e-02 | 3.07e-01 | 3.07e-02 |
| Plasma lipoprotein assembly, remodeling, and clearance | 39 | 1.53e-03 | 4.91e-03 | 0.4290 | -2.09e-01 | -5.62e-03 | 2.57e-01 | 2.73e-01 | 2.42e-02 | 9.52e-01 | 5.47e-03 | 3.18e-03 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 36 | 8.95e-04 | 3.07e-03 | 0.4290 | 3.06e-01 | 2.96e-01 | 1.13e-02 | 5.66e-02 | 1.50e-03 | 2.15e-03 | 9.07e-01 | 5.57e-01 |
| HIV Transcription Elongation | 36 | 8.95e-04 | 3.07e-03 | 0.4290 | 3.06e-01 | 2.96e-01 | 1.13e-02 | 5.66e-02 | 1.50e-03 | 2.15e-03 | 9.07e-01 | 5.57e-01 |
| Tat-mediated elongation of the HIV-1 transcript | 36 | 8.95e-04 | 3.07e-03 | 0.4290 | 3.06e-01 | 2.96e-01 | 1.13e-02 | 5.66e-02 | 1.50e-03 | 2.15e-03 | 9.07e-01 | 5.57e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 15 | 9.84e-02 | 1.59e-01 | 0.4290 | 3.67e-01 | 2.04e-01 | 5.80e-03 | 8.79e-02 | 1.39e-02 | 1.71e-01 | 9.69e-01 | 5.56e-01 |
| Synaptic adhesion-like molecules | 12 | 1.66e-01 | 2.41e-01 | 0.4290 | -3.45e-01 | -7.81e-02 | 1.95e-01 | 1.46e-01 | 3.88e-02 | 6.40e-01 | 2.44e-01 | 3.81e-01 |
| Gap junction trafficking and regulation | 12 | 4.20e-01 | 5.09e-01 | 0.4280 | 1.18e-02 | 1.19e-01 | 2.60e-01 | 3.19e-01 | 9.44e-01 | 4.77e-01 | 1.19e-01 | 5.58e-02 |
| Adenylate cyclase inhibitory pathway | 11 | 2.08e-01 | 2.90e-01 | 0.4280 | -2.29e-01 | -3.79e-02 | 2.96e-01 | 2.04e-01 | 1.89e-01 | 8.28e-01 | 8.89e-02 | 2.42e-01 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 6.44e-02 | 1.14e-01 | 0.4280 | -8.02e-02 | 2.95e-01 | 1.13e-01 | 2.77e-01 | 6.17e-01 | 6.56e-02 | 4.81e-01 | 8.39e-02 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 1.08e-01 | 1.72e-01 | 0.4270 | 2.05e-01 | 2.54e-01 | 1.64e-01 | 2.20e-01 | 8.21e-02 | 3.11e-02 | 1.63e-01 | 6.25e-02 |
| Metabolism of cofactors | 16 | 3.81e-01 | 4.71e-01 | 0.4270 | -1.52e-01 | -2.36e-01 | -2.13e-01 | -2.41e-01 | 2.91e-01 | 1.02e-01 | 1.41e-01 | 9.58e-02 |
| Interferon gamma signaling | 43 | 1.89e-02 | 4.13e-02 | 0.4250 | -4.16e-02 | 2.10e-01 | 2.36e-01 | 2.81e-01 | 6.37e-01 | 1.71e-02 | 7.52e-03 | 1.47e-03 |
| SUMOylation of transcription factors | 14 | 7.39e-02 | 1.26e-01 | 0.4240 | 1.33e-01 | 3.85e-01 | 1.74e-02 | 1.17e-01 | 3.90e-01 | 1.27e-02 | 9.10e-01 | 4.48e-01 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 73 | 1.28e-11 | 2.73e-10 | 0.4230 | 7.47e-02 | 4.00e-01 | -2.61e-02 | 1.12e-01 | 2.70e-01 | 3.55e-09 | 7.00e-01 | 9.88e-02 |
| EML4 and NUDC in mitotic spindle formation | 61 | 6.73e-05 | 3.25e-04 | 0.4230 | 3.25e-01 | 1.97e-01 | 1.01e-01 | 1.56e-01 | 1.16e-05 | 8.01e-03 | 1.74e-01 | 3.54e-02 |
| Intrinsic Pathway for Apoptosis | 41 | 1.59e-02 | 3.58e-02 | 0.4230 | -9.35e-02 | 2.52e-01 | 2.16e-01 | 2.44e-01 | 3.01e-01 | 5.28e-03 | 1.66e-02 | 6.91e-03 |
| Processing of Intronless Pre-mRNAs | 17 | 1.53e-02 | 3.48e-02 | 0.4230 | 2.22e-01 | 3.24e-01 | -1.06e-02 | 1.55e-01 | 1.14e-01 | 2.06e-02 | 9.40e-01 | 2.68e-01 |
| RAF activation | 34 | 5.49e-03 | 1.44e-02 | 0.4220 | -1.72e-02 | -5.18e-02 | -2.52e-01 | -3.34e-01 | 8.62e-01 | 6.02e-01 | 1.11e-02 | 7.55e-04 |
| Uptake and function of anthrax toxins | 11 | 3.98e-01 | 4.89e-01 | 0.4220 | -2.25e-01 | -6.58e-02 | -2.52e-01 | -2.44e-01 | 1.97e-01 | 7.06e-01 | 1.47e-01 | 1.62e-01 |
| Regulation of Complement cascade | 13 | 1.19e-01 | 1.86e-01 | 0.4220 | 4.62e-02 | -9.45e-03 | 3.49e-01 | 2.32e-01 | 7.73e-01 | 9.53e-01 | 2.95e-02 | 1.47e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 43 | 3.25e-03 | 9.45e-03 | 0.4210 | 6.25e-02 | 2.61e-01 | 1.72e-01 | 2.76e-01 | 4.79e-01 | 3.15e-03 | 5.14e-02 | 1.78e-03 |
| MET promotes cell motility | 24 | 2.40e-02 | 5.02e-02 | 0.4200 | -2.48e-01 | 2.47e-01 | 1.44e-01 | 1.81e-01 | 3.53e-02 | 3.62e-02 | 2.22e-01 | 1.25e-01 |
| Formation of HIV elongation complex in the absence of HIV Tat | 38 | 5.46e-04 | 2.05e-03 | 0.4200 | 3.30e-01 | 2.57e-01 | -2.39e-02 | 2.45e-02 | 4.32e-04 | 6.23e-03 | 7.99e-01 | 7.94e-01 |
| Platelet activation, signaling and aggregation | 168 | 6.18e-09 | 9.40e-08 | 0.4190 | -9.02e-02 | 1.50e-01 | 2.70e-01 | 2.69e-01 | 4.47e-02 | 8.63e-04 | 1.84e-09 | 1.93e-09 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 71 | 2.38e-11 | 4.96e-10 | 0.4190 | 5.78e-02 | 3.97e-01 | -2.27e-02 | 1.21e-01 | 4.01e-01 | 7.80e-09 | 7.41e-01 | 7.94e-02 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 25 | 3.23e-02 | 6.47e-02 | 0.4190 | 2.93e-01 | 2.03e-01 | 1.02e-01 | 1.96e-01 | 1.13e-02 | 7.95e-02 | 3.79e-01 | 9.08e-02 |
| G1/S-Specific Transcription | 21 | 1.11e-02 | 2.64e-02 | 0.4180 | 1.36e-01 | 1.38e-01 | 1.65e-01 | 3.32e-01 | 2.79e-01 | 2.75e-01 | 1.91e-01 | 8.42e-03 |
| Frs2-mediated activation | 10 | 1.00e-01 | 1.62e-01 | 0.4180 | 1.37e-01 | 3.01e-01 | -1.89e-01 | -1.73e-01 | 4.52e-01 | 9.97e-02 | 3.01e-01 | 3.44e-01 |
| Synthesis of IP3 and IP4 in the cytosol | 19 | 3.20e-02 | 6.42e-02 | 0.4180 | -4.16e-01 | -2.86e-02 | -2.96e-02 | -3.51e-03 | 1.69e-03 | 8.29e-01 | 8.23e-01 | 9.79e-01 |
| Nuclear Envelope (NE) Reassembly | 59 | 6.03e-04 | 2.24e-03 | 0.4170 | 1.72e-01 | 3.09e-01 | 1.39e-01 | 1.70e-01 | 2.22e-02 | 4.06e-05 | 6.59e-02 | 2.41e-02 |
| Formation of the ternary complex, and subsequently, the 43S complex | 38 | 9.39e-06 | 5.84e-05 | 0.4160 | 9.56e-02 | 3.83e-01 | -1.78e-02 | 1.31e-01 | 3.08e-01 | 4.49e-05 | 8.49e-01 | 1.62e-01 |
| BBSome-mediated cargo-targeting to cilium | 18 | 5.76e-02 | 1.05e-01 | 0.4160 | 4.00e-01 | 4.98e-02 | 7.89e-02 | 6.74e-02 | 3.33e-03 | 7.15e-01 | 5.62e-01 | 6.21e-01 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | 18 | 2.24e-01 | 3.06e-01 | 0.4160 | -8.52e-02 | 1.90e-01 | 2.86e-01 | 2.18e-01 | 5.31e-01 | 1.63e-01 | 3.56e-02 | 1.09e-01 |
| Neurodegenerative Diseases | 18 | 2.24e-01 | 3.06e-01 | 0.4160 | -8.52e-02 | 1.90e-01 | 2.86e-01 | 2.18e-01 | 5.31e-01 | 1.63e-01 | 3.56e-02 | 1.09e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 52 | 8.21e-03 | 2.05e-02 | 0.4160 | -5.52e-02 | 2.10e-01 | 2.30e-01 | 2.70e-01 | 4.92e-01 | 8.91e-03 | 4.11e-03 | 7.76e-04 |
| Glycogen synthesis | 12 | 1.72e-02 | 3.82e-02 | 0.4140 | -1.45e-01 | 4.08e-02 | -1.56e-01 | -3.52e-01 | 3.84e-01 | 8.07e-01 | 3.50e-01 | 3.46e-02 |
| Interleukin-20 family signaling | 12 | 2.50e-01 | 3.35e-01 | 0.4130 | -3.16e-01 | 3.09e-03 | 2.06e-01 | 1.70e-01 | 5.82e-02 | 9.85e-01 | 2.18e-01 | 3.08e-01 |
| NoRC negatively regulates rRNA expression | 40 | 9.75e-04 | 3.32e-03 | 0.4130 | 3.66e-01 | 1.87e-01 | 1.32e-02 | 4.03e-02 | 6.39e-05 | 4.11e-02 | 8.85e-01 | 6.60e-01 |
| NCAM signaling for neurite out-growth | 38 | 3.18e-04 | 1.31e-03 | 0.4130 | -3.51e-01 | -1.12e-01 | 1.19e-01 | 1.43e-01 | 1.84e-04 | 2.32e-01 | 2.05e-01 | 1.28e-01 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 11 | 6.18e-01 | 6.91e-01 | 0.4120 | -8.69e-03 | 1.52e-01 | 2.60e-01 | 2.81e-01 | 9.60e-01 | 3.84e-01 | 1.36e-01 | 1.06e-01 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 24 | 2.17e-01 | 2.98e-01 | 0.4120 | -6.50e-02 | -2.61e-01 | -2.21e-01 | -2.20e-01 | 5.82e-01 | 2.70e-02 | 6.14e-02 | 6.19e-02 |
| PKA activation in glucagon signalling | 14 | 1.55e-01 | 2.27e-01 | 0.4090 | -3.97e-01 | -7.07e-02 | -3.22e-02 | -6.11e-02 | 1.01e-02 | 6.47e-01 | 8.35e-01 | 6.92e-01 |
| Triglyceride metabolism | 20 | 1.06e-01 | 1.69e-01 | 0.4080 | -1.64e-01 | -2.95e-01 | -1.09e-01 | -2.02e-01 | 2.05e-01 | 2.26e-02 | 4.00e-01 | 1.18e-01 |
| Stimuli-sensing channels | 41 | 6.59e-04 | 2.40e-03 | 0.4070 | -2.91e-01 | -2.76e-01 | -4.16e-03 | -6.91e-02 | 1.27e-03 | 2.29e-03 | 9.63e-01 | 4.44e-01 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 26 | 6.31e-02 | 1.12e-01 | 0.4060 | 4.37e-02 | 3.23e-01 | 1.39e-01 | 1.98e-01 | 7.00e-01 | 4.33e-03 | 2.20e-01 | 8.02e-02 |
| Pre-NOTCH Processing in Golgi | 14 | 6.57e-02 | 1.15e-01 | 0.4060 | -3.99e-01 | 6.20e-02 | -2.64e-02 | 4.04e-02 | 9.83e-03 | 6.88e-01 | 8.64e-01 | 7.94e-01 |
| FGFR2 mutant receptor activation | 18 | 1.49e-02 | 3.38e-02 | 0.4050 | 1.65e-01 | 3.56e-01 | 1.03e-01 | 8.35e-03 | 2.27e-01 | 8.94e-03 | 4.52e-01 | 9.51e-01 |
| Interleukin-12 family signaling | 35 | 2.45e-02 | 5.12e-02 | 0.4030 | -1.49e-02 | 3.00e-01 | 1.59e-01 | 2.16e-01 | 8.79e-01 | 2.14e-03 | 1.04e-01 | 2.70e-02 |
| Assembly Of The HIV Virion | 12 | 3.74e-02 | 7.30e-02 | 0.4030 | -1.48e-01 | 3.56e-01 | -6.97e-02 | -9.23e-02 | 3.76e-01 | 3.27e-02 | 6.76e-01 | 5.80e-01 |
| RHO GTPase Effectors | 173 | 7.60e-08 | 9.36e-07 | 0.4010 | 7.07e-02 | 2.47e-01 | 2.04e-01 | 2.32e-01 | 1.10e-01 | 2.43e-08 | 4.10e-06 | 1.62e-07 |
| RIPK1-mediated regulated necrosis | 22 | 2.14e-01 | 2.95e-01 | 0.4010 | -1.31e-01 | 1.84e-01 | 2.32e-01 | 2.37e-01 | 2.87e-01 | 1.35e-01 | 5.98e-02 | 5.44e-02 |
| Regulated Necrosis | 22 | 2.14e-01 | 2.95e-01 | 0.4010 | -1.31e-01 | 1.84e-01 | 2.32e-01 | 2.37e-01 | 2.87e-01 | 1.35e-01 | 5.98e-02 | 5.44e-02 |
| Regulation of necroptotic cell death | 22 | 2.14e-01 | 2.95e-01 | 0.4010 | -1.31e-01 | 1.84e-01 | 2.32e-01 | 2.37e-01 | 2.87e-01 | 1.35e-01 | 5.98e-02 | 5.44e-02 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 76 | 3.15e-04 | 1.30e-03 | 0.4010 | 1.93e-01 | 1.87e-01 | 1.79e-01 | 2.38e-01 | 3.61e-03 | 4.90e-03 | 7.12e-03 | 3.44e-04 |
| Signaling by MET | 52 | 1.23e-02 | 2.88e-02 | 0.3980 | 1.14e-02 | 2.51e-01 | 1.94e-01 | 2.40e-01 | 8.87e-01 | 1.74e-03 | 1.54e-02 | 2.82e-03 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 28 | 1.96e-03 | 6.04e-03 | 0.3980 | 1.72e-01 | 3.26e-01 | 4.91e-03 | 1.49e-01 | 1.15e-01 | 2.83e-03 | 9.64e-01 | 1.72e-01 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 25 | 3.02e-02 | 6.14e-02 | 0.3960 | 1.13e-01 | 6.22e-02 | -2.86e-01 | -2.42e-01 | 3.30e-01 | 5.91e-01 | 1.34e-02 | 3.62e-02 |
| Transport of vitamins, nucleosides, and related molecules | 24 | 7.68e-02 | 1.30e-01 | 0.3960 | -2.07e-01 | 6.98e-02 | 2.17e-01 | 2.50e-01 | 8.01e-02 | 5.54e-01 | 6.62e-02 | 3.44e-02 |
| Amino acid transport across the plasma membrane | 20 | 3.24e-02 | 6.47e-02 | 0.3960 | -3.04e-01 | 7.15e-02 | 1.26e-01 | 2.09e-01 | 1.88e-02 | 5.80e-01 | 3.29e-01 | 1.06e-01 |
| HDR through Homologous Recombination (HRR) | 49 | 4.06e-03 | 1.12e-02 | 0.3950 | 1.69e-01 | 1.31e-01 | 1.93e-01 | 2.70e-01 | 4.07e-02 | 1.14e-01 | 1.94e-02 | 1.07e-03 |
| Molecules associated with elastic fibres | 25 | 2.09e-01 | 2.91e-01 | 0.3940 | 3.22e-02 | 1.90e-01 | 2.65e-01 | 2.20e-01 | 7.81e-01 | 1.00e-01 | 2.21e-02 | 5.70e-02 |
| Ribosomal scanning and start codon recognition | 45 | 1.82e-05 | 1.00e-04 | 0.3940 | 1.24e-01 | 3.65e-01 | -2.60e-02 | 7.31e-02 | 1.51e-01 | 2.25e-05 | 7.63e-01 | 3.97e-01 |
| Formation of the Early Elongation Complex | 30 | 7.36e-03 | 1.87e-02 | 0.3930 | 2.98e-01 | 2.57e-01 | 1.15e-03 | 7.33e-03 | 4.79e-03 | 1.49e-02 | 9.91e-01 | 9.45e-01 |
| Formation of the HIV-1 Early Elongation Complex | 30 | 7.36e-03 | 1.87e-02 | 0.3930 | 2.98e-01 | 2.57e-01 | 1.15e-03 | 7.33e-03 | 4.79e-03 | 1.49e-02 | 9.91e-01 | 9.45e-01 |
| RHO GTPases activate CIT | 17 | 1.13e-01 | 1.77e-01 | 0.3930 | -1.52e-01 | 2.89e-01 | 1.15e-01 | 1.86e-01 | 2.78e-01 | 3.92e-02 | 4.11e-01 | 1.84e-01 |
| Membrane binding and targetting of GAG proteins | 10 | 6.50e-02 | 1.14e-01 | 0.3930 | -3.35e-02 | 2.60e-01 | -1.58e-01 | -2.46e-01 | 8.54e-01 | 1.55e-01 | 3.86e-01 | 1.77e-01 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 10 | 6.50e-02 | 1.14e-01 | 0.3930 | -3.35e-02 | 2.60e-01 | -1.58e-01 | -2.46e-01 | 8.54e-01 | 1.55e-01 | 3.86e-01 | 1.77e-01 |
| Recognition of DNA damage by PCNA-containing replication complex | 28 | 7.10e-02 | 1.22e-01 | 0.3920 | 2.51e-01 | 2.00e-01 | 1.27e-01 | 1.87e-01 | 2.17e-02 | 6.66e-02 | 2.47e-01 | 8.72e-02 |
| Cell-Cell communication | 71 | 6.00e-04 | 2.23e-03 | 0.3920 | -1.70e-01 | 1.62e-01 | 2.27e-01 | 2.17e-01 | 1.32e-02 | 1.83e-02 | 9.63e-04 | 1.63e-03 |
| activated TAK1 mediates p38 MAPK activation | 17 | 1.08e-01 | 1.72e-01 | 0.3900 | -1.71e-01 | 1.94e-02 | -2.16e-01 | -2.76e-01 | 2.22e-01 | 8.90e-01 | 1.23e-01 | 4.91e-02 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 14 | 2.87e-01 | 3.73e-01 | 0.3900 | 4.65e-02 | 8.65e-02 | 2.19e-01 | 3.08e-01 | 7.63e-01 | 5.75e-01 | 1.57e-01 | 4.61e-02 |
| Antiviral mechanism by IFN-stimulated genes | 64 | 3.99e-05 | 2.03e-04 | 0.3900 | 2.81e-01 | 2.27e-01 | 5.08e-02 | 1.38e-01 | 1.03e-04 | 1.70e-03 | 4.83e-01 | 5.58e-02 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 75 | 1.96e-12 | 4.48e-11 | 0.3900 | 6.43e-02 | 3.58e-01 | -4.08e-02 | 1.35e-01 | 3.36e-01 | 8.84e-08 | 5.42e-01 | 4.31e-02 |
| Nonsense-Mediated Decay (NMD) | 75 | 1.96e-12 | 4.48e-11 | 0.3900 | 6.43e-02 | 3.58e-01 | -4.08e-02 | 1.35e-01 | 3.36e-01 | 8.84e-08 | 5.42e-01 | 4.31e-02 |
| Interleukin-6 signaling | 10 | 5.38e-01 | 6.21e-01 | 0.3900 | -2.03e-01 | 1.59e-01 | 2.24e-01 | 1.88e-01 | 2.66e-01 | 3.85e-01 | 2.20e-01 | 3.04e-01 |
| G2/M DNA damage checkpoint | 49 | 7.12e-03 | 1.82e-02 | 0.3890 | 2.11e-01 | 1.88e-01 | 1.52e-01 | 2.20e-01 | 1.07e-02 | 2.30e-02 | 6.53e-02 | 7.66e-03 |
| Translesion synthesis by POLI | 15 | 2.00e-01 | 2.82e-01 | 0.3890 | 3.08e-01 | 8.92e-02 | 1.77e-01 | 1.31e-01 | 3.92e-02 | 5.50e-01 | 2.36e-01 | 3.79e-01 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 10 | 2.45e-01 | 3.30e-01 | 0.3880 | 1.97e-01 | 3.31e-01 | 4.70e-02 | 4.62e-03 | 2.80e-01 | 6.97e-02 | 7.97e-01 | 9.80e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 10 | 2.45e-01 | 3.30e-01 | 0.3880 | 1.97e-01 | 3.31e-01 | 4.70e-02 | 4.62e-03 | 2.80e-01 | 6.97e-02 | 7.97e-01 | 9.80e-01 |
| Visual phototransduction | 37 | 1.72e-02 | 3.82e-02 | 0.3880 | -2.18e-01 | 1.71e-01 | 1.84e-01 | 2.00e-01 | 2.16e-02 | 7.28e-02 | 5.32e-02 | 3.50e-02 |
| SUMOylation of chromatin organization proteins | 46 | 1.48e-05 | 8.33e-05 | 0.3870 | 3.32e-01 | 1.55e-01 | -2.78e-02 | 1.22e-01 | 1.01e-04 | 6.95e-02 | 7.44e-01 | 1.51e-01 |
| Signal amplification | 20 | 3.67e-01 | 4.58e-01 | 0.3870 | 5.77e-02 | 1.27e-01 | 2.62e-01 | 2.48e-01 | 6.55e-01 | 3.25e-01 | 4.29e-02 | 5.48e-02 |
| Homology Directed Repair | 82 | 1.43e-04 | 6.39e-04 | 0.3870 | 1.85e-01 | 1.83e-01 | 1.63e-01 | 2.35e-01 | 3.87e-03 | 4.24e-03 | 1.09e-02 | 2.41e-04 |
| Cap-dependent Translation Initiation | 79 | 1.35e-10 | 2.37e-09 | 0.3860 | 6.68e-02 | 3.69e-01 | -3.65e-02 | 8.20e-02 | 3.06e-01 | 1.49e-08 | 5.75e-01 | 2.08e-01 |
| Eukaryotic Translation Initiation | 79 | 1.35e-10 | 2.37e-09 | 0.3860 | 6.68e-02 | 3.69e-01 | -3.65e-02 | 8.20e-02 | 3.06e-01 | 1.49e-08 | 5.75e-01 | 2.08e-01 |
| Innate Immune System | 607 | 3.29e-26 | 3.68e-24 | 0.3860 | -4.47e-02 | 1.66e-01 | 2.58e-01 | 2.29e-01 | 6.38e-02 | 6.12e-12 | 7.36e-27 | 2.04e-21 |
| CaM pathway | 27 | 1.77e-02 | 3.90e-02 | 0.3850 | -3.82e-01 | -4.40e-02 | 2.35e-02 | -1.34e-02 | 5.99e-04 | 6.92e-01 | 8.33e-01 | 9.04e-01 |
| Calmodulin induced events | 27 | 1.77e-02 | 3.90e-02 | 0.3850 | -3.82e-01 | -4.40e-02 | 2.35e-02 | -1.34e-02 | 5.99e-04 | 6.92e-01 | 8.33e-01 | 9.04e-01 |
| Gene Silencing by RNA | 54 | 1.08e-04 | 4.95e-04 | 0.3850 | 3.51e-01 | 5.89e-02 | 6.43e-02 | 1.31e-01 | 8.12e-06 | 4.55e-01 | 4.15e-01 | 9.61e-02 |
| Regulation of TP53 Activity through Methylation | 14 | 4.13e-02 | 7.94e-02 | 0.3850 | 3.47e-01 | -7.85e-02 | -1.46e-01 | 8.99e-03 | 2.45e-02 | 6.11e-01 | 3.45e-01 | 9.54e-01 |
| Translation initiation complex formation | 44 | 5.68e-05 | 2.82e-04 | 0.3840 | 1.17e-01 | 3.55e-01 | -1.42e-02 | 8.60e-02 | 1.79e-01 | 4.66e-05 | 8.71e-01 | 3.24e-01 |
| IKK complex recruitment mediated by RIP1 | 14 | 1.50e-01 | 2.21e-01 | 0.3830 | 1.29e-01 | 3.50e-01 | 1.64e-02 | 8.49e-02 | 4.04e-01 | 2.32e-02 | 9.15e-01 | 5.82e-01 |
| Neurexins and neuroligins | 26 | 8.75e-03 | 2.16e-02 | 0.3830 | -1.06e-01 | 3.45e-01 | 5.16e-02 | 1.17e-01 | 3.50e-01 | 2.34e-03 | 6.49e-01 | 3.02e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 16 | 1.20e-01 | 1.87e-01 | 0.3830 | 3.15e-01 | 1.64e-01 | 2.79e-02 | 1.40e-01 | 2.91e-02 | 2.57e-01 | 8.47e-01 | 3.34e-01 |
| Transcription of E2F targets under negative control by DREAM complex | 17 | 5.46e-02 | 1.01e-01 | 0.3820 | 2.29e-01 | 1.60e-01 | 8.73e-02 | 2.46e-01 | 1.02e-01 | 2.55e-01 | 5.34e-01 | 7.91e-02 |
| PKA-mediated phosphorylation of CREB | 17 | 1.20e-01 | 1.87e-01 | 0.3820 | -3.73e-01 | -7.21e-02 | 3.68e-02 | 1.98e-02 | 7.79e-03 | 6.07e-01 | 7.93e-01 | 8.87e-01 |
| Peptide hormone metabolism | 39 | 6.69e-04 | 2.43e-03 | 0.3820 | 1.03e-02 | 4.39e-02 | 3.27e-01 | 1.91e-01 | 9.12e-01 | 6.36e-01 | 4.14e-04 | 3.88e-02 |
| p38MAPK events | 12 | 1.51e-01 | 2.22e-01 | 0.3800 | -3.66e-01 | -6.51e-03 | 9.36e-03 | -1.03e-01 | 2.83e-02 | 9.69e-01 | 9.55e-01 | 5.36e-01 |
| Sphingolipid de novo biosynthesis | 31 | 5.88e-02 | 1.06e-01 | 0.3800 | 5.91e-02 | 3.11e-01 | 1.32e-01 | 1.64e-01 | 5.69e-01 | 2.78e-03 | 2.03e-01 | 1.14e-01 |
| Regulation of RUNX1 Expression and Activity | 17 | 1.25e-01 | 1.92e-01 | 0.3790 | 6.25e-02 | -7.42e-02 | 2.66e-01 | 2.52e-01 | 6.56e-01 | 5.97e-01 | 5.76e-02 | 7.19e-02 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 15 | 1.70e-02 | 3.80e-02 | 0.3780 | 6.02e-02 | 1.87e-01 | 9.24e-02 | 3.10e-01 | 6.87e-01 | 2.09e-01 | 5.36e-01 | 3.80e-02 |
| Activation of gene expression by SREBF (SREBP) | 40 | 2.14e-03 | 6.47e-03 | 0.3770 | -2.16e-01 | -7.66e-02 | -2.53e-01 | -1.61e-01 | 1.84e-02 | 4.02e-01 | 5.61e-03 | 7.82e-02 |
| Regulation of signaling by CBL | 13 | 4.45e-01 | 5.32e-01 | 0.3770 | 3.25e-02 | 3.04e-01 | 1.36e-01 | 1.75e-01 | 8.39e-01 | 5.82e-02 | 3.94e-01 | 2.76e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 51 | 7.10e-04 | 2.55e-03 | 0.3770 | 3.21e-01 | 1.88e-01 | 1.94e-02 | 5.67e-02 | 7.26e-05 | 2.05e-02 | 8.11e-01 | 4.84e-01 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 45 | 1.49e-04 | 6.62e-04 | 0.3770 | 1.12e-01 | 3.47e-01 | 5.57e-03 | 9.62e-02 | 1.96e-01 | 5.78e-05 | 9.48e-01 | 2.65e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 24 | 3.39e-02 | 6.73e-02 | 0.3770 | 2.95e-01 | 2.30e-01 | -3.65e-02 | 1.52e-02 | 1.23e-02 | 5.11e-02 | 7.57e-01 | 8.97e-01 |
| DAG and IP3 signaling | 33 | 8.82e-03 | 2.17e-02 | 0.3760 | -3.54e-01 | -1.25e-01 | 1.01e-02 | 6.44e-03 | 4.30e-04 | 2.16e-01 | 9.20e-01 | 9.49e-01 |
| Translesion Synthesis by POLH | 16 | 1.79e-01 | 2.58e-01 | 0.3760 | 3.45e-01 | 1.36e-01 | 4.58e-02 | 3.58e-02 | 1.68e-02 | 3.45e-01 | 7.51e-01 | 8.05e-01 |
| Nuclear Envelope Breakdown | 42 | 1.92e-03 | 5.97e-03 | 0.3760 | 3.02e-01 | 1.51e-01 | 5.56e-02 | 1.55e-01 | 7.18e-04 | 9.11e-02 | 5.33e-01 | 8.17e-02 |
| Sialic acid metabolism | 23 | 6.42e-02 | 1.14e-01 | 0.3760 | -3.02e-01 | 2.09e-02 | 1.50e-01 | 1.64e-01 | 1.22e-02 | 8.62e-01 | 2.14e-01 | 1.74e-01 |
| Formation of TC-NER Pre-Incision Complex | 48 | 7.35e-04 | 2.62e-03 | 0.3750 | 2.66e-01 | 6.40e-02 | -1.96e-01 | -1.67e-01 | 1.45e-03 | 4.43e-01 | 1.92e-02 | 4.59e-02 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 19 | 9.00e-02 | 1.48e-01 | 0.3750 | 1.70e-01 | 8.14e-02 | -2.57e-01 | -1.98e-01 | 2.00e-01 | 5.39e-01 | 5.24e-02 | 1.35e-01 |
| SUMOylation of DNA damage response and repair proteins | 62 | 3.19e-05 | 1.66e-04 | 0.3740 | 3.17e-01 | 1.46e-01 | 3.22e-02 | 1.31e-01 | 1.60e-05 | 4.76e-02 | 6.62e-01 | 7.43e-02 |
| Activation of BH3-only proteins | 24 | 2.54e-01 | 3.40e-01 | 0.3740 | -6.49e-02 | 1.77e-01 | 2.09e-01 | 2.47e-01 | 5.82e-01 | 1.35e-01 | 7.68e-02 | 3.63e-02 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 29 | 7.25e-04 | 2.59e-03 | 0.3740 | -7.84e-02 | -1.42e-01 | -1.24e-01 | -3.13e-01 | 4.65e-01 | 1.85e-01 | 2.49e-01 | 3.55e-03 |
| Inwardly rectifying K+ channels | 16 | 2.24e-01 | 3.06e-01 | 0.3730 | -2.19e-01 | -2.84e-01 | -5.24e-02 | -9.10e-02 | 1.30e-01 | 4.94e-02 | 7.17e-01 | 5.29e-01 |
| Cytosolic sensors of pathogen-associated DNA | 52 | 1.26e-02 | 2.93e-02 | 0.3730 | 1.89e-01 | 1.49e-01 | 2.15e-01 | 1.86e-01 | 1.83e-02 | 6.38e-02 | 7.26e-03 | 2.05e-02 |
| Interleukin-12 signaling | 30 | 5.68e-02 | 1.04e-01 | 0.3720 | -1.79e-02 | 3.01e-01 | 1.28e-01 | 1.76e-01 | 8.65e-01 | 4.29e-03 | 2.24e-01 | 9.60e-02 |
| IRE1alpha activates chaperones | 47 | 4.99e-04 | 1.95e-03 | 0.3720 | 1.13e-02 | 3.35e-01 | 1.39e-01 | 8.49e-02 | 8.94e-01 | 7.36e-05 | 1.00e-01 | 3.15e-01 |
| Nucleotide salvage | 18 | 6.31e-02 | 1.12e-01 | 0.3710 | -3.08e-01 | 9.08e-02 | 8.51e-02 | 1.66e-01 | 2.37e-02 | 5.05e-01 | 5.32e-01 | 2.24e-01 |
| Activation of GABAB receptors | 24 | 2.00e-02 | 4.30e-02 | 0.3690 | -2.18e-01 | -1.49e-01 | 2.15e-01 | 1.43e-01 | 6.45e-02 | 2.08e-01 | 6.83e-02 | 2.27e-01 |
| GABA B receptor activation | 24 | 2.00e-02 | 4.30e-02 | 0.3690 | -2.18e-01 | -1.49e-01 | 2.15e-01 | 1.43e-01 | 6.45e-02 | 2.08e-01 | 6.83e-02 | 2.27e-01 |
| Signaling by PDGFRA extracellular domain mutants | 11 | 7.28e-01 | 7.81e-01 | 0.3680 | 9.78e-02 | 2.08e-01 | 2.03e-01 | 2.04e-01 | 5.74e-01 | 2.32e-01 | 2.43e-01 | 2.42e-01 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 11 | 7.28e-01 | 7.81e-01 | 0.3680 | 9.78e-02 | 2.08e-01 | 2.03e-01 | 2.04e-01 | 5.74e-01 | 2.32e-01 | 2.43e-01 | 2.42e-01 |
| Ras activation upon Ca2+ influx through NMDA receptor | 13 | 2.43e-01 | 3.27e-01 | 0.3680 | -2.10e-01 | -1.28e-01 | -1.19e-01 | -2.46e-01 | 1.91e-01 | 4.25e-01 | 4.56e-01 | 1.24e-01 |
| RHO GTPases activate PKNs | 29 | 1.62e-01 | 2.36e-01 | 0.3680 | -4.32e-02 | 2.50e-01 | 1.80e-01 | 1.95e-01 | 6.87e-01 | 1.97e-02 | 9.39e-02 | 6.87e-02 |
| MHC class II antigen presentation | 71 | 3.74e-03 | 1.04e-02 | 0.3670 | 8.94e-02 | 1.20e-01 | 2.55e-01 | 2.17e-01 | 1.93e-01 | 8.02e-02 | 2.02e-04 | 1.60e-03 |
| Disorders of Developmental Biology | 10 | 7.46e-01 | 7.94e-01 | 0.3670 | -4.21e-02 | -1.58e-01 | -2.12e-01 | -2.51e-01 | 8.18e-01 | 3.87e-01 | 2.47e-01 | 1.69e-01 |
| Disorders of Nervous System Development | 10 | 7.46e-01 | 7.94e-01 | 0.3670 | -4.21e-02 | -1.58e-01 | -2.12e-01 | -2.51e-01 | 8.18e-01 | 3.87e-01 | 2.47e-01 | 1.69e-01 |
| Loss of function of MECP2 in Rett syndrome | 10 | 7.46e-01 | 7.94e-01 | 0.3670 | -4.21e-02 | -1.58e-01 | -2.12e-01 | -2.51e-01 | 8.18e-01 | 3.87e-01 | 2.47e-01 | 1.69e-01 |
| Pervasive developmental disorders | 10 | 7.46e-01 | 7.94e-01 | 0.3670 | -4.21e-02 | -1.58e-01 | -2.12e-01 | -2.51e-01 | 8.18e-01 | 3.87e-01 | 2.47e-01 | 1.69e-01 |
| PIWI-interacting RNA (piRNA) biogenesis | 13 | 7.15e-02 | 1.23e-01 | 0.3670 | 2.45e-01 | 2.54e-01 | -6.44e-03 | -9.92e-02 | 1.27e-01 | 1.13e-01 | 9.68e-01 | 5.36e-01 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 19 | 1.68e-01 | 2.44e-01 | 0.3650 | 1.90e-01 | 2.89e-01 | 5.57e-02 | 1.04e-01 | 1.52e-01 | 2.94e-02 | 6.75e-01 | 4.31e-01 |
| Diseases of glycosylation | 96 | 3.11e-04 | 1.29e-03 | 0.3640 | -1.03e-01 | 1.02e-01 | 2.46e-01 | 2.27e-01 | 8.09e-02 | 8.54e-02 | 3.28e-05 | 1.29e-04 |
| Prolonged ERK activation events | 12 | 2.02e-01 | 2.84e-01 | 0.3640 | 2.19e-01 | 2.15e-01 | -1.51e-01 | -1.24e-01 | 1.90e-01 | 1.97e-01 | 3.65e-01 | 4.59e-01 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) | 33 | 3.72e-05 | 1.91e-04 | 0.3640 | 2.21e-01 | 2.71e-01 | 3.91e-02 | -9.09e-02 | 2.78e-02 | 7.16e-03 | 6.98e-01 | 3.66e-01 |
| Meiosis | 38 | 1.71e-03 | 5.40e-03 | 0.3630 | 2.60e-01 | -9.58e-03 | 1.32e-01 | 2.17e-01 | 5.66e-03 | 9.19e-01 | 1.59e-01 | 2.06e-02 |
| HIV Infection | 187 | 6.88e-15 | 2.17e-13 | 0.3630 | 2.42e-01 | 2.65e-01 | 4.82e-02 | 2.96e-02 | 1.25e-08 | 5.06e-10 | 2.58e-01 | 4.87e-01 |
| tRNA processing | 98 | 9.32e-08 | 1.11e-06 | 0.3630 | 3.46e-01 | 1.00e-01 | -5.03e-02 | 1.17e-05 | 3.59e-09 | 8.80e-02 | 3.91e-01 | 1.00e+00 |
| Activation of G protein gated Potassium channels | 13 | 1.50e-01 | 2.21e-01 | 0.3630 | -2.09e-01 | -2.42e-01 | 1.46e-01 | 9.05e-02 | 1.93e-01 | 1.31e-01 | 3.62e-01 | 5.72e-01 |
| G protein gated Potassium channels | 13 | 1.50e-01 | 2.21e-01 | 0.3630 | -2.09e-01 | -2.42e-01 | 1.46e-01 | 9.05e-02 | 1.93e-01 | 1.31e-01 | 3.62e-01 | 5.72e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 13 | 1.50e-01 | 2.21e-01 | 0.3630 | -2.09e-01 | -2.42e-01 | 1.46e-01 | 9.05e-02 | 1.93e-01 | 1.31e-01 | 3.62e-01 | 5.72e-01 |
| Interleukin receptor SHC signaling | 15 | 3.28e-01 | 4.15e-01 | 0.3630 | -4.49e-02 | 2.39e-01 | 1.41e-01 | 2.29e-01 | 7.63e-01 | 1.09e-01 | 3.43e-01 | 1.25e-01 |
| Early Phase of HIV Life Cycle | 11 | 5.10e-01 | 5.99e-01 | 0.3620 | 1.48e-01 | 2.63e-01 | 1.63e-01 | 1.16e-01 | 3.96e-01 | 1.30e-01 | 3.51e-01 | 5.06e-01 |
| Inhibition of DNA recombination at telomere | 19 | 6.20e-02 | 1.11e-01 | 0.3620 | 2.89e-01 | 1.92e-01 | 1.02e-01 | 1.99e-02 | 2.94e-02 | 1.48e-01 | 4.44e-01 | 8.81e-01 |
| Regulation of TNFR1 signaling | 26 | 8.63e-02 | 1.43e-01 | 0.3610 | -2.43e-01 | 4.38e-02 | 2.04e-01 | 1.66e-01 | 3.18e-02 | 6.99e-01 | 7.15e-02 | 1.43e-01 |
| RHO GTPases Activate ROCKs | 18 | 1.34e-01 | 2.03e-01 | 0.3610 | -1.95e-01 | 2.48e-01 | 9.74e-02 | 1.47e-01 | 1.53e-01 | 6.90e-02 | 4.75e-01 | 2.80e-01 |
| ISG15 antiviral mechanism | 59 | 2.72e-04 | 1.14e-03 | 0.3610 | 2.70e-01 | 2.12e-01 | 2.60e-02 | 1.08e-01 | 3.44e-04 | 4.82e-03 | 7.30e-01 | 1.51e-01 |
| Degradation of AXIN | 47 | 9.97e-08 | 1.17e-06 | 0.3610 | 9.99e-02 | 2.39e-01 | -1.12e-01 | -2.25e-01 | 2.37e-01 | 4.69e-03 | 1.84e-01 | 7.58e-03 |
| RNA Polymerase I Promoter Escape | 25 | 2.61e-02 | 5.40e-02 | 0.3600 | 2.91e-01 | 2.02e-01 | -3.56e-02 | -5.52e-02 | 1.18e-02 | 8.11e-02 | 7.58e-01 | 6.33e-01 |
| Complement cascade | 14 | 2.50e-01 | 3.35e-01 | 0.3600 | -9.73e-03 | -2.95e-02 | 2.91e-01 | 2.09e-01 | 9.50e-01 | 8.49e-01 | 5.93e-02 | 1.75e-01 |
| Protein-protein interactions at synapses | 41 | 9.05e-03 | 2.22e-02 | 0.3600 | -1.99e-01 | 2.24e-01 | 1.31e-01 | 1.49e-01 | 2.74e-02 | 1.33e-02 | 1.46e-01 | 9.80e-02 |
| Positive epigenetic regulation of rRNA expression | 41 | 3.05e-03 | 8.96e-03 | 0.3590 | 1.43e-01 | 2.73e-01 | 6.00e-02 | 1.75e-01 | 1.13e-01 | 2.53e-03 | 5.07e-01 | 5.34e-02 |
| tRNA modification in the nucleus and cytosol | 38 | 7.43e-03 | 1.88e-02 | 0.3590 | 3.21e-01 | 1.52e-01 | -6.45e-03 | 5.33e-02 | 6.23e-04 | 1.05e-01 | 9.45e-01 | 5.70e-01 |
| Epigenetic regulation of gene expression | 79 | 2.96e-06 | 2.07e-05 | 0.3590 | 2.78e-01 | 2.01e-01 | 8.48e-03 | 1.06e-01 | 2.04e-05 | 2.04e-03 | 8.97e-01 | 1.03e-01 |
| Metabolism of folate and pterines | 13 | 6.85e-04 | 2.47e-03 | 0.3590 | -2.66e-01 | -4.29e-02 | -3.71e-02 | 2.35e-01 | 9.75e-02 | 7.89e-01 | 8.17e-01 | 1.43e-01 |
| Mitotic Spindle Checkpoint | 74 | 1.22e-04 | 5.51e-04 | 0.3590 | 3.01e-01 | 1.34e-01 | 7.18e-02 | 1.22e-01 | 7.94e-06 | 4.59e-02 | 2.87e-01 | 7.04e-02 |
| Beta-catenin phosphorylation cascade | 15 | 5.38e-02 | 9.95e-02 | 0.3580 | 2.47e-01 | 2.22e-01 | -4.17e-02 | -1.26e-01 | 9.78e-02 | 1.38e-01 | 7.80e-01 | 3.97e-01 |
| trans-Golgi Network Vesicle Budding | 62 | 2.01e-02 | 4.32e-02 | 0.3570 | 1.51e-01 | 1.83e-01 | 1.88e-01 | 1.90e-01 | 4.03e-02 | 1.27e-02 | 1.07e-02 | 9.71e-03 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 46 | 7.58e-08 | 9.36e-07 | 0.3570 | 9.55e-02 | 2.73e-01 | -7.70e-02 | -1.94e-01 | 2.63e-01 | 1.36e-03 | 3.67e-01 | 2.29e-02 |
| Hyaluronan metabolism | 11 | 6.53e-01 | 7.18e-01 | 0.3570 | -7.38e-02 | 1.52e-01 | 1.97e-01 | 2.45e-01 | 6.72e-01 | 3.83e-01 | 2.59e-01 | 1.59e-01 |
| Dopamine Neurotransmitter Release Cycle | 11 | 7.57e-01 | 8.03e-01 | 0.3570 | -1.61e-02 | 1.77e-01 | 2.20e-01 | 2.17e-01 | 9.26e-01 | 3.08e-01 | 2.06e-01 | 2.13e-01 |
| Metabolism of porphyrins | 18 | 2.61e-01 | 3.48e-01 | 0.3560 | -1.44e-01 | -2.90e-01 | -8.48e-02 | -1.22e-01 | 2.89e-01 | 3.31e-02 | 5.34e-01 | 3.72e-01 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | 11 | 6.68e-02 | 1.16e-01 | 0.3560 | 2.37e-01 | -1.78e-01 | -1.85e-02 | -1.96e-01 | 1.73e-01 | 3.07e-01 | 9.15e-01 | 2.60e-01 |
| RHO GTPases activate KTN1 | 10 | 6.76e-01 | 7.37e-01 | 0.3560 | 1.06e-01 | 2.10e-01 | 2.13e-01 | 1.61e-01 | 5.64e-01 | 2.49e-01 | 2.44e-01 | 3.77e-01 |
| Host Interactions of HIV factors | 102 | 1.69e-06 | 1.34e-05 | 0.3550 | 1.77e-01 | 2.83e-01 | 9.02e-02 | 8.05e-02 | 2.03e-03 | 8.23e-07 | 1.16e-01 | 1.61e-01 |
| MTOR signalling | 40 | 5.22e-04 | 1.98e-03 | 0.3550 | -8.01e-02 | -1.45e-01 | -1.28e-01 | -2.87e-01 | 3.81e-01 | 1.12e-01 | 1.63e-01 | 1.71e-03 |
| FOXO-mediated transcription of cell cycle genes | 16 | 1.25e-01 | 1.92e-01 | 0.3550 | -1.64e-01 | -2.37e-04 | -2.68e-01 | -1.65e-01 | 2.55e-01 | 9.99e-01 | 6.40e-02 | 2.54e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 48 | 1.70e-07 | 1.85e-06 | 0.3540 | 1.06e-01 | 3.24e-01 | 1.93e-02 | -9.44e-02 | 2.04e-01 | 1.03e-04 | 8.18e-01 | 2.59e-01 |
| Glutathione conjugation | 21 | 2.62e-01 | 3.48e-01 | 0.3540 | -2.54e-01 | -1.55e-01 | -1.33e-01 | -1.40e-01 | 4.43e-02 | 2.19e-01 | 2.91e-01 | 2.68e-01 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 32 | 1.47e-01 | 2.18e-01 | 0.3540 | -1.00e-01 | 1.88e-01 | 2.13e-01 | 1.87e-01 | 3.27e-01 | 6.66e-02 | 3.69e-02 | 6.77e-02 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 4.06e-01 | 4.97e-01 | 0.3540 | 1.05e-01 | 3.10e-01 | 1.04e-01 | 8.54e-02 | 5.27e-01 | 6.30e-02 | 5.33e-01 | 6.09e-01 |
| Signaling by Retinoic Acid | 29 | 1.26e-01 | 1.92e-01 | 0.3530 | -1.77e-01 | -2.29e-01 | -1.09e-01 | -1.70e-01 | 9.83e-02 | 3.30e-02 | 3.09e-01 | 1.13e-01 |
| Removal of the Flap Intermediate from the C-strand | 17 | 4.31e-01 | 5.17e-01 | 0.3530 | 1.37e-01 | 1.29e-01 | 1.79e-01 | 2.39e-01 | 3.29e-01 | 3.56e-01 | 2.01e-01 | 8.87e-02 |
| Mitotic Prophase | 70 | 6.17e-04 | 2.28e-03 | 0.3530 | 2.72e-01 | 1.71e-01 | 7.96e-02 | 1.22e-01 | 8.36e-05 | 1.38e-02 | 2.50e-01 | 7.79e-02 |
| SHC-mediated cascade:FGFR2 | 10 | 3.05e-01 | 3.90e-01 | 0.3510 | -9.20e-02 | 2.13e-01 | 2.42e-01 | 1.05e-01 | 6.14e-01 | 2.43e-01 | 1.85e-01 | 5.65e-01 |
| Apoptotic cleavage of cellular proteins | 27 | 9.06e-02 | 1.49e-01 | 0.3500 | -1.27e-01 | 7.60e-02 | 1.89e-01 | 2.55e-01 | 2.53e-01 | 4.95e-01 | 8.86e-02 | 2.21e-02 |
| Hemostasis | 348 | 5.99e-15 | 1.94e-13 | 0.3500 | -1.40e-01 | 1.13e-01 | 2.13e-01 | 2.12e-01 | 8.75e-06 | 3.44e-04 | 1.37e-11 | 1.49e-11 |
| Translesion synthesis by REV1 | 14 | 2.50e-01 | 3.35e-01 | 0.3490 | 2.90e-01 | 6.16e-02 | 1.59e-01 | 9.41e-02 | 6.08e-02 | 6.90e-01 | 3.04e-01 | 5.42e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 27 | 8.72e-03 | 2.16e-02 | 0.3480 | 3.34e-01 | 7.16e-02 | 2.57e-02 | -5.98e-02 | 2.68e-03 | 5.20e-01 | 8.18e-01 | 5.91e-01 |
| Interleukin-6 family signaling | 16 | 3.06e-01 | 3.91e-01 | 0.3480 | -2.47e-01 | 5.89e-02 | 1.59e-01 | 1.76e-01 | 8.75e-02 | 6.84e-01 | 2.71e-01 | 2.22e-01 |
| Reproduction | 44 | 1.28e-03 | 4.19e-03 | 0.3480 | 2.11e-01 | -4.08e-03 | 1.48e-01 | 2.33e-01 | 1.54e-02 | 9.63e-01 | 9.02e-02 | 7.56e-03 |
| RHO GTPases activate PAKs | 19 | 1.03e-01 | 1.65e-01 | 0.3470 | -2.93e-01 | 1.63e-01 | 5.63e-02 | 6.75e-02 | 2.69e-02 | 2.18e-01 | 6.71e-01 | 6.11e-01 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 23 | 3.75e-01 | 4.65e-01 | 0.3460 | 1.54e-01 | 1.95e-01 | 1.60e-01 | 1.81e-01 | 2.02e-01 | 1.05e-01 | 1.85e-01 | 1.34e-01 |
| Signalling to RAS | 16 | 1.23e-01 | 1.90e-01 | 0.3460 | -3.28e-01 | 1.00e-01 | 2.18e-03 | -4.86e-02 | 2.32e-02 | 4.88e-01 | 9.88e-01 | 7.37e-01 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 56 | 9.36e-05 | 4.33e-04 | 0.3460 | -3.16e-01 | -7.74e-02 | 5.58e-02 | 1.04e-01 | 4.34e-05 | 3.17e-01 | 4.71e-01 | 1.80e-01 |
| FCGR3A-mediated IL10 synthesis | 25 | 4.95e-02 | 9.24e-02 | 0.3450 | -2.85e-01 | -7.58e-02 | 1.14e-01 | 1.37e-01 | 1.37e-02 | 5.12e-01 | 3.24e-01 | 2.36e-01 |
| Signaling by Hippo | 18 | 3.30e-01 | 4.16e-01 | 0.3440 | 1.05e-01 | 1.96e-01 | 1.35e-01 | 2.26e-01 | 4.40e-01 | 1.51e-01 | 3.21e-01 | 9.74e-02 |
| Regulation of RUNX3 expression and activity | 47 | 1.42e-07 | 1.57e-06 | 0.3440 | 1.02e-01 | 2.69e-01 | -5.94e-02 | -1.78e-01 | 2.25e-01 | 1.42e-03 | 4.81e-01 | 3.55e-02 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 1.97e-01 | 2.79e-01 | 0.3430 | -3.13e-01 | 7.15e-02 | -1.22e-01 | -1.11e-02 | 8.69e-02 | 6.96e-01 | 5.04e-01 | 9.51e-01 |
| Adrenaline,noradrenaline inhibits insulin secretion | 16 | 1.89e-01 | 2.70e-01 | 0.3430 | -3.81e-02 | -1.04e-01 | 2.46e-01 | 2.11e-01 | 7.92e-01 | 4.73e-01 | 8.85e-02 | 1.44e-01 |
| XBP1(S) activates chaperone genes | 45 | 1.25e-03 | 4.13e-03 | 0.3430 | -4.57e-03 | 3.18e-01 | 1.11e-01 | 6.11e-02 | 9.58e-01 | 2.23e-04 | 1.99e-01 | 4.78e-01 |
| WNT5A-dependent internalization of FZD4 | 13 | 5.30e-01 | 6.14e-01 | 0.3420 | -1.97e-01 | 1.21e-01 | 1.78e-01 | 1.80e-01 | 2.20e-01 | 4.51e-01 | 2.66e-01 | 2.62e-01 |
| Telomere Extension By Telomerase | 19 | 1.79e-01 | 2.58e-01 | 0.3420 | 3.24e-01 | 7.57e-02 | 2.92e-02 | 7.64e-02 | 1.46e-02 | 5.68e-01 | 8.25e-01 | 5.64e-01 |
| SARS-CoV-2 Infection | 56 | 5.84e-02 | 1.06e-01 | 0.3420 | 1.29e-02 | 1.88e-01 | 2.11e-01 | 1.92e-01 | 8.67e-01 | 1.52e-02 | 6.29e-03 | 1.29e-02 |
| Translesion synthesis by POLK | 15 | 2.04e-01 | 2.87e-01 | 0.3420 | 3.17e-01 | 3.79e-03 | 1.11e-01 | 6.49e-02 | 3.37e-02 | 9.80e-01 | 4.58e-01 | 6.64e-01 |
| Signaling by PDGF | 46 | 2.00e-02 | 4.30e-02 | 0.3420 | -1.82e-01 | 1.18e-01 | 1.69e-01 | 2.02e-01 | 3.28e-02 | 1.67e-01 | 4.72e-02 | 1.77e-02 |
| Translation | 222 | 4.45e-13 | 1.14e-11 | 0.3410 | 1.43e-01 | 3.96e-03 | -2.04e-01 | -2.33e-01 | 2.57e-04 | 9.19e-01 | 1.93e-07 | 2.80e-09 |
| NRAGE signals death through JNK | 43 | 3.81e-03 | 1.06e-02 | 0.3390 | -3.01e-01 | -5.07e-02 | 9.35e-02 | 1.15e-01 | 6.46e-04 | 5.66e-01 | 2.89e-01 | 1.92e-01 |
| GABA receptor activation | 26 | 2.78e-02 | 5.71e-02 | 0.3390 | -2.27e-01 | -1.66e-01 | 1.62e-01 | 9.63e-02 | 4.48e-02 | 1.43e-01 | 1.54e-01 | 3.95e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 17 | 1.46e-01 | 2.18e-01 | 0.3390 | 1.95e-01 | 2.73e-01 | -3.67e-02 | 3.05e-02 | 1.64e-01 | 5.18e-02 | 7.93e-01 | 8.28e-01 |
| DNA Damage Recognition in GG-NER | 34 | 5.61e-02 | 1.03e-01 | 0.3370 | 1.69e-01 | 8.34e-03 | -2.17e-01 | -1.94e-01 | 8.85e-02 | 9.33e-01 | 2.85e-02 | 5.03e-02 |
| Ca-dependent events | 29 | 3.98e-02 | 7.69e-02 | 0.3370 | -3.35e-01 | -2.06e-02 | 2.91e-02 | -7.79e-03 | 1.81e-03 | 8.48e-01 | 7.86e-01 | 9.42e-01 |
| HSF1 activation | 22 | 4.02e-02 | 7.76e-02 | 0.3370 | 1.78e-01 | 2.57e-01 | -1.01e-01 | -7.38e-02 | 1.50e-01 | 3.69e-02 | 4.11e-01 | 5.49e-01 |
| Detoxification of Reactive Oxygen Species | 26 | 6.86e-02 | 1.19e-01 | 0.3360 | -2.92e-01 | 8.40e-02 | 9.21e-02 | 1.12e-01 | 1.01e-02 | 4.59e-01 | 4.16e-01 | 3.22e-01 |
| Pre-NOTCH Transcription and Translation | 31 | 8.37e-02 | 1.40e-01 | 0.3360 | 3.31e-02 | 9.63e-02 | 1.80e-01 | 2.65e-01 | 7.50e-01 | 3.54e-01 | 8.23e-02 | 1.07e-02 |
| Myogenesis | 26 | 6.28e-02 | 1.12e-01 | 0.3360 | -2.79e-01 | -6.65e-02 | 1.19e-01 | 1.27e-01 | 1.37e-02 | 5.57e-01 | 2.95e-01 | 2.63e-01 |
| Cellular response to heat stress | 82 | 2.03e-05 | 1.10e-04 | 0.3360 | 2.30e-01 | 2.43e-01 | 8.54e-03 | 2.85e-02 | 3.31e-04 | 1.46e-04 | 8.94e-01 | 6.57e-01 |
| Formation of Incision Complex in GG-NER | 39 | 4.18e-02 | 8.02e-02 | 0.3350 | 1.72e-01 | -3.40e-02 | -2.23e-01 | -1.78e-01 | 6.29e-02 | 7.14e-01 | 1.61e-02 | 5.45e-02 |
| Golgi Associated Vesicle Biogenesis | 48 | 5.24e-02 | 9.76e-02 | 0.3350 | 2.02e-01 | 1.63e-01 | 1.42e-01 | 1.56e-01 | 1.53e-02 | 5.10e-02 | 8.98e-02 | 6.20e-02 |
| Deadenylation of mRNA | 24 | 6.91e-02 | 1.20e-01 | 0.3350 | 3.16e-01 | 4.74e-02 | -9.61e-02 | -2.60e-02 | 7.42e-03 | 6.88e-01 | 4.15e-01 | 8.25e-01 |
| Signaling by NTRK3 (TRKC) | 16 | 3.82e-01 | 4.72e-01 | 0.3340 | -1.56e-01 | 2.75e-02 | 2.33e-01 | 1.79e-01 | 2.80e-01 | 8.49e-01 | 1.06e-01 | 2.15e-01 |
| Vpu mediated degradation of CD4 | 43 | 8.47e-07 | 7.34e-06 | 0.3340 | 7.97e-02 | 2.05e-01 | -9.83e-02 | -2.31e-01 | 3.66e-01 | 1.99e-02 | 2.65e-01 | 8.86e-03 |
| Purine ribonucleoside monophosphate biosynthesis | 12 | 5.86e-01 | 6.64e-01 | 0.3330 | 2.28e-02 | -2.70e-01 | -1.40e-01 | -1.35e-01 | 8.91e-01 | 1.05e-01 | 4.02e-01 | 4.19e-01 |
| Unfolded Protein Response (UPR) | 82 | 6.30e-05 | 3.08e-04 | 0.3330 | 1.26e-01 | 2.91e-01 | 7.16e-02 | 7.21e-02 | 4.90e-02 | 5.52e-06 | 2.63e-01 | 2.60e-01 |
| Metabolism of water-soluble vitamins and cofactors | 89 | 1.31e-03 | 4.27e-03 | 0.3330 | -2.28e-02 | -2.58e-01 | -1.39e-01 | -1.56e-01 | 7.11e-01 | 2.71e-05 | 2.35e-02 | 1.11e-02 |
| Senescence-Associated Secretory Phenotype (SASP) | 45 | 1.07e-01 | 1.71e-01 | 0.3330 | 4.51e-02 | 2.22e-01 | 1.57e-01 | 1.86e-01 | 6.01e-01 | 9.94e-03 | 6.94e-02 | 3.08e-02 |
| G2/M Checkpoints | 106 | 6.03e-05 | 2.97e-04 | 0.3330 | 1.70e-01 | 2.43e-01 | 1.07e-01 | 1.06e-01 | 2.56e-03 | 1.60e-05 | 5.78e-02 | 5.96e-02 |
| Apoptotic factor-mediated response | 13 | 6.37e-01 | 7.05e-01 | 0.3320 | -1.57e-02 | 2.45e-01 | 1.60e-01 | 1.57e-01 | 9.22e-01 | 1.27e-01 | 3.19e-01 | 3.26e-01 |
| Signaling by Rho GTPases | 268 | 6.59e-09 | 9.78e-08 | 0.3320 | -4.06e-04 | 1.79e-01 | 1.76e-01 | 2.17e-01 | 9.91e-01 | 5.09e-07 | 8.45e-07 | 1.15e-09 |
| RNA Polymerase III Chain Elongation | 17 | 3.40e-02 | 6.74e-02 | 0.3320 | 2.96e-01 | 1.18e-01 | 5.72e-02 | -7.09e-02 | 3.44e-02 | 3.98e-01 | 6.83e-01 | 6.13e-01 |
| HSF1-dependent transactivation | 30 | 5.35e-04 | 2.03e-03 | 0.3310 | 3.47e-02 | 2.55e-01 | -1.02e-01 | -1.81e-01 | 7.43e-01 | 1.55e-02 | 3.32e-01 | 8.58e-02 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 42 | 6.78e-07 | 6.05e-06 | 0.3300 | 8.33e-02 | 2.55e-01 | -5.11e-02 | -1.85e-01 | 3.51e-01 | 4.25e-03 | 5.67e-01 | 3.87e-02 |
| Cell Cycle Checkpoints | 191 | 1.64e-08 | 2.17e-07 | 0.3290 | 2.18e-01 | 1.97e-01 | 8.96e-02 | 1.19e-01 | 2.38e-07 | 2.99e-06 | 3.36e-02 | 4.94e-03 |
| Mitotic Prometaphase | 137 | 2.56e-07 | 2.63e-06 | 0.3280 | 2.41e-01 | 7.15e-02 | 1.18e-01 | 1.75e-01 | 1.20e-06 | 1.50e-01 | 1.70e-02 | 4.32e-04 |
| Signaling by Receptor Tyrosine Kinases | 354 | 1.48e-10 | 2.56e-09 | 0.3270 | -4.48e-02 | 1.59e-01 | 2.01e-01 | 1.99e-01 | 1.51e-01 | 3.70e-07 | 1.17e-10 | 1.72e-10 |
| SUMOylation of transcription cofactors | 38 | 1.23e-04 | 5.56e-04 | 0.3260 | 2.28e-01 | 2.29e-02 | -2.27e-01 | -5.34e-02 | 1.53e-02 | 8.08e-01 | 1.57e-02 | 5.70e-01 |
| SARS-CoV Infections | 121 | 1.30e-03 | 4.24e-03 | 0.3260 | -2.92e-03 | 1.85e-01 | 1.79e-01 | 2.00e-01 | 9.56e-01 | 4.68e-04 | 7.03e-04 | 1.46e-04 |
| PI-3K cascade:FGFR1 | 10 | 5.96e-01 | 6.74e-01 | 0.3260 | -3.45e-02 | -8.68e-03 | -2.60e-01 | -1.93e-01 | 8.50e-01 | 9.62e-01 | 1.54e-01 | 2.91e-01 |
| Activation of the AP-1 family of transcription factors | 10 | 2.84e-01 | 3.70e-01 | 0.3260 | -8.45e-03 | 1.82e-01 | -1.69e-01 | -2.11e-01 | 9.63e-01 | 3.19e-01 | 3.55e-01 | 2.49e-01 |
| Vif-mediated degradation of APOBEC3G | 43 | 4.73e-07 | 4.41e-06 | 0.3260 | 8.42e-02 | 2.10e-01 | -7.70e-02 | -2.21e-01 | 3.40e-01 | 1.72e-02 | 3.83e-01 | 1.23e-02 |
| Synthesis of very long-chain fatty acyl-CoAs | 10 | 5.98e-01 | 6.75e-01 | 0.3250 | 2.14e-03 | 9.75e-02 | 1.68e-01 | 2.61e-01 | 9.91e-01 | 5.94e-01 | 3.58e-01 | 1.53e-01 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 18 | 1.58e-01 | 2.31e-01 | 0.3240 | -7.87e-03 | 3.14e-01 | 6.20e-02 | 4.98e-02 | 9.54e-01 | 2.10e-02 | 6.49e-01 | 7.15e-01 |
| Circadian Clock | 63 | 3.64e-02 | 7.14e-02 | 0.3230 | -9.30e-02 | -9.77e-02 | -1.96e-01 | -2.18e-01 | 2.03e-01 | 1.81e-01 | 7.10e-03 | 2.74e-03 |
| PI-3K cascade:FGFR3 | 10 | 4.11e-01 | 5.01e-01 | 0.3230 | 6.44e-02 | 1.33e-01 | -2.30e-01 | -1.72e-01 | 7.25e-01 | 4.66e-01 | 2.08e-01 | 3.46e-01 |
| Iron uptake and transport | 42 | 3.44e-03 | 9.76e-03 | 0.3220 | -3.82e-02 | 6.56e-02 | 2.76e-01 | 1.49e-01 | 6.69e-01 | 4.62e-01 | 2.00e-03 | 9.56e-02 |
| AURKA Activation by TPX2 | 62 | 6.98e-03 | 1.79e-02 | 0.3210 | 1.20e-01 | 2.28e-02 | 1.98e-01 | 2.22e-01 | 1.03e-01 | 7.57e-01 | 7.24e-03 | 2.57e-03 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 35 | 8.54e-02 | 1.42e-01 | 0.3210 | 7.33e-02 | 5.60e-02 | 1.84e-01 | 2.46e-01 | 4.54e-01 | 5.66e-01 | 6.01e-02 | 1.18e-02 |
| Diseases of mitotic cell cycle | 35 | 8.54e-02 | 1.42e-01 | 0.3210 | 7.33e-02 | 5.60e-02 | 1.84e-01 | 2.46e-01 | 4.54e-01 | 5.66e-01 | 6.01e-02 | 1.18e-02 |
| mRNA decay by 3' to 5' exoribonuclease | 15 | 1.47e-01 | 2.19e-01 | 0.3210 | 2.31e-01 | 1.80e-01 | -1.29e-01 | -1.47e-02 | 1.21e-01 | 2.27e-01 | 3.87e-01 | 9.21e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 38 | 1.32e-01 | 2.01e-01 | 0.3210 | -1.35e-01 | 1.47e-01 | 1.74e-01 | 1.80e-01 | 1.51e-01 | 1.17e-01 | 6.32e-02 | 5.44e-02 |
| Acyl chain remodelling of PE | 11 | 5.19e-01 | 6.06e-01 | 0.3200 | 1.78e-01 | -2.79e-02 | 1.80e-01 | 1.94e-01 | 3.07e-01 | 8.73e-01 | 3.00e-01 | 2.65e-01 |
| Insulin processing | 19 | 5.15e-02 | 9.60e-02 | 0.3200 | 8.94e-02 | -2.27e-02 | 2.74e-01 | 1.38e-01 | 5.00e-01 | 8.64e-01 | 3.86e-02 | 2.99e-01 |
| E3 ubiquitin ligases ubiquitinate target proteins | 39 | 6.41e-03 | 1.66e-02 | 0.3200 | 1.97e-01 | 1.45e-01 | -1.42e-01 | -1.49e-01 | 3.36e-02 | 1.18e-01 | 1.25e-01 | 1.07e-01 |
| Termination of translesion DNA synthesis | 28 | 3.62e-01 | 4.51e-01 | 0.3200 | 9.09e-02 | 1.70e-01 | 1.58e-01 | 2.01e-01 | 4.06e-01 | 1.21e-01 | 1.49e-01 | 6.62e-02 |
| Regulation of IFNG signaling | 13 | 5.60e-01 | 6.40e-01 | 0.3200 | 1.34e-01 | 2.55e-01 | 7.82e-02 | 1.15e-01 | 4.02e-01 | 1.12e-01 | 6.26e-01 | 4.74e-01 |
| GAB1 signalosome | 12 | 1.03e-01 | 1.65e-01 | 0.3190 | -2.44e-01 | 1.60e-01 | -1.31e-01 | -4.41e-03 | 1.44e-01 | 3.38e-01 | 4.33e-01 | 9.79e-01 |
| Erythropoietin activates RAS | 11 | 2.85e-01 | 3.71e-01 | 0.3190 | 3.63e-02 | 2.97e-01 | 1.10e-01 | 2.07e-02 | 8.35e-01 | 8.82e-02 | 5.29e-01 | 9.05e-01 |
| Ubiquitin-dependent degradation of Cyclin D | 44 | 2.21e-06 | 1.62e-05 | 0.3180 | 8.56e-02 | 2.54e-01 | -4.56e-02 | -1.64e-01 | 3.26e-01 | 3.59e-03 | 6.01e-01 | 5.94e-02 |
| Degradation of DVL | 48 | 1.14e-06 | 9.45e-06 | 0.3170 | 1.50e-02 | 1.88e-01 | -1.10e-01 | -2.31e-01 | 8.57e-01 | 2.46e-02 | 1.89e-01 | 5.74e-03 |
| SCF-beta-TrCP mediated degradation of Emi1 | 45 | 1.74e-06 | 1.35e-05 | 0.3170 | 6.04e-02 | 2.05e-01 | -9.13e-02 | -2.16e-01 | 4.84e-01 | 1.73e-02 | 2.90e-01 | 1.24e-02 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 16 | 5.15e-01 | 6.04e-01 | 0.3170 | -7.54e-02 | -2.46e-02 | -2.19e-01 | -2.16e-01 | 6.02e-01 | 8.65e-01 | 1.30e-01 | 1.35e-01 |
| G alpha (12/13) signalling events | 54 | 3.38e-03 | 9.69e-03 | 0.3170 | -2.32e-01 | -2.98e-02 | 1.41e-01 | 1.61e-01 | 3.16e-03 | 7.05e-01 | 7.41e-02 | 4.16e-02 |
| Potential therapeutics for SARS | 66 | 1.11e-02 | 2.64e-02 | 0.3170 | -2.75e-02 | 1.89e-01 | 1.43e-01 | 2.08e-01 | 7.00e-01 | 7.96e-03 | 4.44e-02 | 3.55e-03 |
| SCF(Skp2)-mediated degradation of p27/p21 | 52 | 1.48e-05 | 8.34e-05 | 0.3160 | 1.05e-01 | 2.92e-01 | 4.60e-02 | -4.31e-02 | 1.92e-01 | 2.75e-04 | 5.66e-01 | 5.92e-01 |
| DNA Double-Strand Break Repair | 109 | 4.80e-04 | 1.88e-03 | 0.3160 | 1.82e-01 | 1.20e-01 | 1.40e-01 | 1.81e-01 | 1.06e-03 | 3.05e-02 | 1.17e-02 | 1.10e-03 |
| Protein folding | 75 | 2.18e-02 | 4.61e-02 | 0.3160 | 8.32e-02 | 2.14e-01 | 1.46e-01 | 1.61e-01 | 2.14e-01 | 1.35e-03 | 2.91e-02 | 1.63e-02 |
| G alpha (z) signalling events | 28 | 9.66e-02 | 1.57e-01 | 0.3160 | -2.13e-01 | -2.09e-02 | 1.90e-01 | 1.34e-01 | 5.16e-02 | 8.48e-01 | 8.14e-02 | 2.19e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 16 | 2.59e-01 | 3.46e-01 | 0.3160 | -1.77e-01 | -1.14e-01 | 1.69e-01 | 1.63e-01 | 2.19e-01 | 4.29e-01 | 2.42e-01 | 2.58e-01 |
| VEGFA-VEGFR2 Pathway | 77 | 6.56e-03 | 1.70e-02 | 0.3160 | -1.29e-01 | 1.57e-01 | 1.63e-01 | 1.79e-01 | 5.11e-02 | 1.74e-02 | 1.37e-02 | 6.72e-03 |
| Assembly and cell surface presentation of NMDA receptors | 13 | 4.24e-01 | 5.13e-01 | 0.3160 | -2.80e-01 | -2.72e-02 | -7.19e-02 | -1.23e-01 | 8.01e-02 | 8.65e-01 | 6.54e-01 | 4.41e-01 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 43 | 7.68e-06 | 4.90e-05 | 0.3160 | 9.97e-02 | 2.43e-01 | -5.58e-02 | -1.66e-01 | 2.58e-01 | 5.83e-03 | 5.27e-01 | 6.01e-02 |
| p53-Independent DNA Damage Response | 43 | 7.68e-06 | 4.90e-05 | 0.3160 | 9.97e-02 | 2.43e-01 | -5.58e-02 | -1.66e-01 | 2.58e-01 | 5.83e-03 | 5.27e-01 | 6.01e-02 |
| p53-Independent G1/S DNA damage checkpoint | 43 | 7.68e-06 | 4.90e-05 | 0.3160 | 9.97e-02 | 2.43e-01 | -5.58e-02 | -1.66e-01 | 2.58e-01 | 5.83e-03 | 5.27e-01 | 6.01e-02 |
| DNA Replication | 111 | 3.05e-04 | 1.27e-03 | 0.3150 | 1.52e-01 | 2.20e-01 | 1.20e-01 | 1.16e-01 | 5.78e-03 | 6.32e-05 | 2.99e-02 | 3.52e-02 |
| Signaling by ERBB2 TMD/JMD mutants | 14 | 5.47e-01 | 6.29e-01 | 0.3150 | -1.07e-01 | 9.68e-02 | 1.69e-01 | 2.24e-01 | 4.89e-01 | 5.31e-01 | 2.75e-01 | 1.47e-01 |
| Infectious disease | 533 | 5.38e-18 | 3.01e-16 | 0.3150 | 9.02e-02 | 2.31e-01 | 1.26e-01 | 1.49e-01 | 4.37e-04 | 2.15e-19 | 9.54e-07 | 6.44e-09 |
| RNA Polymerase I Transcription Termination | 25 | 5.34e-02 | 9.92e-02 | 0.3150 | 2.47e-01 | 1.75e-01 | -4.01e-02 | -7.55e-02 | 3.28e-02 | 1.29e-01 | 7.29e-01 | 5.14e-01 |
| Meiotic synapsis | 22 | 1.64e-01 | 2.39e-01 | 0.3150 | 2.24e-01 | 1.99e-02 | 1.20e-01 | 1.84e-01 | 6.88e-02 | 8.72e-01 | 3.31e-01 | 1.35e-01 |
| G alpha (i) signalling events | 125 | 1.84e-06 | 1.40e-05 | 0.3140 | -2.22e-01 | 4.81e-02 | 1.39e-01 | 1.67e-01 | 1.96e-05 | 3.54e-01 | 7.56e-03 | 1.28e-03 |
| SHC-mediated cascade:FGFR3 | 10 | 5.50e-01 | 6.32e-01 | 0.3130 | 8.09e-02 | 2.42e-01 | 1.61e-01 | 8.18e-02 | 6.58e-01 | 1.86e-01 | 3.77e-01 | 6.54e-01 |
| Synthesis of substrates in N-glycan biosythesis | 52 | 3.88e-02 | 7.52e-02 | 0.3130 | -1.08e-01 | 1.64e-01 | 1.93e-01 | 1.48e-01 | 1.79e-01 | 4.10e-02 | 1.62e-02 | 6.52e-02 |
| G1/S Transition | 112 | 4.60e-04 | 1.81e-03 | 0.3120 | 1.26e-01 | 2.28e-01 | 1.08e-01 | 1.34e-01 | 2.19e-02 | 3.13e-05 | 4.92e-02 | 1.49e-02 |
| Diseases of carbohydrate metabolism | 26 | 1.29e-01 | 1.96e-01 | 0.3120 | -3.02e-01 | -5.50e-02 | -2.99e-02 | -4.69e-02 | 7.71e-03 | 6.27e-01 | 7.92e-01 | 6.79e-01 |
| Signaling by Interleukins | 276 | 7.52e-11 | 1.45e-09 | 0.3120 | -5.63e-02 | 2.34e-01 | 1.46e-01 | 1.34e-01 | 1.10e-01 | 3.19e-11 | 3.34e-05 | 1.34e-04 |
| Association of TriC/CCT with target proteins during biosynthesis | 36 | 4.22e-02 | 8.09e-02 | 0.3110 | 2.09e-01 | 1.96e-01 | 3.28e-02 | 1.16e-01 | 2.98e-02 | 4.20e-02 | 7.34e-01 | 2.29e-01 |
| CD209 (DC-SIGN) signaling | 17 | 5.07e-01 | 5.96e-01 | 0.3110 | -4.95e-02 | 8.96e-02 | 2.36e-01 | 1.74e-01 | 7.24e-01 | 5.23e-01 | 9.17e-02 | 2.15e-01 |
| SHC-mediated cascade:FGFR4 | 10 | 6.36e-01 | 7.04e-01 | 0.3110 | -8.95e-02 | 1.01e-01 | 2.38e-01 | 1.48e-01 | 6.24e-01 | 5.81e-01 | 1.93e-01 | 4.19e-01 |
| Transcriptional Regulation by E2F6 | 29 | 4.33e-03 | 1.17e-02 | 0.3100 | 2.67e-01 | 1.01e-01 | -4.92e-02 | 1.11e-01 | 1.30e-02 | 3.47e-01 | 6.47e-01 | 3.01e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 23 | 2.74e-01 | 3.59e-01 | 0.3100 | -3.37e-02 | 4.78e-03 | 2.03e-01 | 2.32e-01 | 7.79e-01 | 9.68e-01 | 9.27e-02 | 5.46e-02 |
| Platelet sensitization by LDL | 13 | 1.10e-01 | 1.74e-01 | 0.3100 | 1.17e-01 | 2.60e-01 | -2.63e-02 | -1.16e-01 | 4.64e-01 | 1.04e-01 | 8.70e-01 | 4.68e-01 |
| Dectin-1 mediated noncanonical NF-kB signaling | 51 | 2.05e-07 | 2.13e-06 | 0.3090 | 8.27e-02 | 2.44e-01 | -3.89e-02 | -1.66e-01 | 3.08e-01 | 2.56e-03 | 6.32e-01 | 4.10e-02 |
| Formation of the beta-catenin:TCF transactivating complex | 28 | 3.69e-01 | 4.59e-01 | 0.3090 | 1.57e-01 | 1.51e-01 | 1.42e-01 | 1.66e-01 | 1.50e-01 | 1.67e-01 | 1.93e-01 | 1.29e-01 |
| G-protein mediated events | 40 | 2.56e-02 | 5.31e-02 | 0.3090 | -2.69e-01 | -4.20e-02 | 1.07e-01 | 9.95e-02 | 3.29e-03 | 6.46e-01 | 2.43e-01 | 2.77e-01 |
| AMER1 mutants destabilize the destruction complex | 13 | 2.36e-01 | 3.19e-01 | 0.3080 | 1.89e-01 | 1.93e-01 | -7.89e-02 | -1.26e-01 | 2.39e-01 | 2.27e-01 | 6.22e-01 | 4.31e-01 |
| APC truncation mutants have impaired AXIN binding | 13 | 2.36e-01 | 3.19e-01 | 0.3080 | 1.89e-01 | 1.93e-01 | -7.89e-02 | -1.26e-01 | 2.39e-01 | 2.27e-01 | 6.22e-01 | 4.31e-01 |
| AXIN missense mutants destabilize the destruction complex | 13 | 2.36e-01 | 3.19e-01 | 0.3080 | 1.89e-01 | 1.93e-01 | -7.89e-02 | -1.26e-01 | 2.39e-01 | 2.27e-01 | 6.22e-01 | 4.31e-01 |
| AXIN mutants destabilize the destruction complex, activating WNT signaling | 13 | 2.36e-01 | 3.19e-01 | 0.3080 | 1.89e-01 | 1.93e-01 | -7.89e-02 | -1.26e-01 | 2.39e-01 | 2.27e-01 | 6.22e-01 | 4.31e-01 |
| Truncations of AMER1 destabilize the destruction complex | 13 | 2.36e-01 | 3.19e-01 | 0.3080 | 1.89e-01 | 1.93e-01 | -7.89e-02 | -1.26e-01 | 2.39e-01 | 2.27e-01 | 6.22e-01 | 4.31e-01 |
| truncated APC mutants destabilize the destruction complex | 13 | 2.36e-01 | 3.19e-01 | 0.3080 | 1.89e-01 | 1.93e-01 | -7.89e-02 | -1.26e-01 | 2.39e-01 | 2.27e-01 | 6.22e-01 | 4.31e-01 |
| Nuclear Events (kinase and transcription factor activation) | 52 | 1.07e-02 | 2.57e-02 | 0.3080 | -1.12e-01 | 2.44e-01 | 1.01e-01 | 1.13e-01 | 1.64e-01 | 2.36e-03 | 2.09e-01 | 1.60e-01 |
| Protein ubiquitination | 56 | 1.21e-03 | 4.03e-03 | 0.3080 | 1.84e-01 | 1.24e-01 | -1.53e-01 | -1.48e-01 | 1.71e-02 | 1.08e-01 | 4.83e-02 | 5.52e-02 |
| Chaperonin-mediated protein folding | 69 | 3.24e-02 | 6.47e-02 | 0.3070 | 1.05e-01 | 2.07e-01 | 1.29e-01 | 1.55e-01 | 1.32e-01 | 2.98e-03 | 6.53e-02 | 2.62e-02 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 44 | 1.13e-05 | 6.71e-05 | 0.3070 | 9.35e-02 | 2.08e-01 | -7.80e-02 | -1.90e-01 | 2.84e-01 | 1.69e-02 | 3.71e-01 | 2.94e-02 |
| SLC-mediated transmembrane transport | 120 | 4.11e-06 | 2.80e-05 | 0.3070 | -2.35e-01 | 2.50e-02 | 1.29e-01 | 1.47e-01 | 8.93e-06 | 6.38e-01 | 1.51e-02 | 5.40e-03 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 40 | 2.93e-06 | 2.07e-05 | 0.3070 | 5.67e-02 | 2.25e-01 | -5.12e-02 | -1.94e-01 | 5.35e-01 | 1.39e-02 | 5.76e-01 | 3.38e-02 |
| L1CAM interactions | 69 | 1.38e-02 | 3.16e-02 | 0.3060 | -1.37e-01 | 6.01e-02 | 1.99e-01 | 1.78e-01 | 4.98e-02 | 3.89e-01 | 4.32e-03 | 1.06e-02 |
| Cholesterol biosynthesis | 23 | 1.88e-02 | 4.12e-02 | 0.3060 | -2.76e-01 | 1.07e-01 | -5.83e-02 | 5.06e-02 | 2.20e-02 | 3.75e-01 | 6.29e-01 | 6.75e-01 |
| Signaling by VEGF | 83 | 8.79e-03 | 2.17e-02 | 0.3050 | -1.21e-01 | 1.36e-01 | 1.70e-01 | 1.77e-01 | 5.69e-02 | 3.23e-02 | 7.55e-03 | 5.49e-03 |
| Degradation of beta-catenin by the destruction complex | 72 | 6.18e-09 | 9.40e-08 | 0.3050 | 1.07e-01 | 2.02e-01 | -7.86e-02 | -1.86e-01 | 1.19e-01 | 3.02e-03 | 2.50e-01 | 6.39e-03 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 11 | 5.36e-01 | 6.19e-01 | 0.3050 | -2.03e-01 | -7.55e-02 | 1.51e-01 | 1.54e-01 | 2.45e-01 | 6.65e-01 | 3.88e-01 | 3.77e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 11 | 5.36e-01 | 6.19e-01 | 0.3050 | -2.03e-01 | -7.55e-02 | 1.51e-01 | 1.54e-01 | 2.45e-01 | 6.65e-01 | 3.88e-01 | 3.77e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 15 | 3.24e-01 | 4.10e-01 | 0.3050 | 2.53e-01 | 1.11e-01 | 2.69e-02 | 1.25e-01 | 8.94e-02 | 4.55e-01 | 8.57e-01 | 4.01e-01 |
| DNA Replication Pre-Initiation | 70 | 9.15e-04 | 3.12e-03 | 0.3050 | 1.38e-01 | 2.50e-01 | 9.14e-02 | 5.59e-02 | 4.59e-02 | 3.06e-04 | 1.87e-01 | 4.20e-01 |
| Ovarian tumor domain proteases | 31 | 3.75e-01 | 4.65e-01 | 0.3050 | 7.90e-02 | 1.80e-01 | 1.73e-01 | 1.57e-01 | 4.47e-01 | 8.33e-02 | 9.64e-02 | 1.32e-01 |
| Nucleobase biosynthesis | 15 | 3.60e-01 | 4.50e-01 | 0.3050 | 3.04e-02 | -2.36e-01 | -1.68e-01 | -8.91e-02 | 8.39e-01 | 1.13e-01 | 2.61e-01 | 5.50e-01 |
| Downstream TCR signaling | 67 | 3.57e-07 | 3.48e-06 | 0.3050 | 8.55e-02 | 2.20e-01 | -9.52e-02 | -1.68e-01 | 2.27e-01 | 1.92e-03 | 1.79e-01 | 1.76e-02 |
| NIK-->noncanonical NF-kB signaling | 50 | 3.70e-07 | 3.56e-06 | 0.3040 | 7.65e-02 | 2.32e-01 | -4.70e-02 | -1.75e-01 | 3.50e-01 | 4.59e-03 | 5.66e-01 | 3.24e-02 |
| Mitotic G1 phase and G1/S transition | 127 | 3.96e-04 | 1.58e-03 | 0.3040 | 9.87e-02 | 2.19e-01 | 1.14e-01 | 1.47e-01 | 5.55e-02 | 2.17e-05 | 2.65e-02 | 4.38e-03 |
| Negative regulators of DDX58/IFIH1 signaling | 29 | 2.89e-01 | 3.75e-01 | 0.3040 | -1.13e-01 | 1.48e-01 | 1.56e-01 | 1.82e-01 | 2.91e-01 | 1.69e-01 | 1.47e-01 | 8.92e-02 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 46 | 3.56e-06 | 2.45e-05 | 0.3030 | 8.95e-02 | 1.83e-01 | -8.17e-02 | -2.09e-01 | 2.94e-01 | 3.16e-02 | 3.38e-01 | 1.42e-02 |
| Regulation of Apoptosis | 45 | 1.45e-06 | 1.16e-05 | 0.3030 | 7.70e-02 | 1.95e-01 | -6.80e-02 | -2.07e-01 | 3.72e-01 | 2.37e-02 | 4.31e-01 | 1.62e-02 |
| Constitutive Signaling by AKT1 E17K in Cancer | 26 | 1.94e-01 | 2.76e-01 | 0.3020 | -1.78e-01 | -4.62e-02 | -1.38e-01 | -1.97e-01 | 1.17e-01 | 6.84e-01 | 2.23e-01 | 8.25e-02 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 28 | 3.03e-01 | 3.89e-01 | 0.3020 | -7.94e-02 | 1.98e-01 | 1.39e-01 | 1.63e-01 | 4.67e-01 | 7.00e-02 | 2.05e-01 | 1.35e-01 |
| Vitamin B5 (pantothenate) metabolism | 15 | 3.34e-01 | 4.21e-01 | 0.3020 | 1.19e-01 | -2.28e-01 | -6.90e-02 | -1.43e-01 | 4.25e-01 | 1.27e-01 | 6.44e-01 | 3.38e-01 |
| Spry regulation of FGF signaling | 14 | 1.93e-01 | 2.74e-01 | 0.3020 | 2.41e-02 | 2.99e-01 | 8.04e-03 | -3.05e-02 | 8.76e-01 | 5.26e-02 | 9.58e-01 | 8.43e-01 |
| Class B/2 (Secretin family receptors) | 33 | 1.43e-01 | 2.14e-01 | 0.3020 | -2.37e-01 | -1.55e-01 | -6.55e-02 | -8.20e-02 | 1.87e-02 | 1.23e-01 | 5.15e-01 | 4.15e-01 |
| PLC beta mediated events | 39 | 3.57e-02 | 7.05e-02 | 0.3020 | -2.61e-01 | -4.39e-02 | 1.08e-01 | 9.68e-02 | 4.86e-03 | 6.36e-01 | 2.44e-01 | 2.96e-01 |
| HATs acetylate histones | 71 | 6.48e-06 | 4.24e-05 | 0.3020 | 2.33e-01 | 1.23e-01 | -1.44e-01 | -2.46e-02 | 6.98e-04 | 7.29e-02 | 3.60e-02 | 7.21e-01 |
| Degradation of GLI2 by the proteasome | 50 | 2.32e-06 | 1.67e-05 | 0.3010 | 2.92e-02 | 1.86e-01 | -9.80e-02 | -2.14e-01 | 7.21e-01 | 2.33e-02 | 2.31e-01 | 8.92e-03 |
| Synthesis of IP2, IP, and Ins in the cytosol | 12 | 7.47e-01 | 7.95e-01 | 0.3010 | -3.37e-02 | 1.86e-01 | 1.42e-01 | 1.87e-01 | 8.40e-01 | 2.66e-01 | 3.96e-01 | 2.63e-01 |
| Signaling by FGFR | 60 | 1.55e-02 | 3.51e-02 | 0.3010 | 1.85e-01 | 2.10e-01 | 7.06e-02 | 8.26e-02 | 1.32e-02 | 4.88e-03 | 3.45e-01 | 2.69e-01 |
| Synthesis of DNA | 106 | 4.39e-04 | 1.73e-03 | 0.3000 | 1.45e-01 | 2.20e-01 | 1.07e-01 | 9.47e-02 | 9.89e-03 | 9.16e-05 | 5.82e-02 | 9.28e-02 |
| DCC mediated attractive signaling | 13 | 6.20e-01 | 6.93e-01 | 0.3000 | -1.57e-01 | 1.82e-02 | 1.79e-01 | 1.80e-01 | 3.26e-01 | 9.09e-01 | 2.63e-01 | 2.61e-01 |
| Negative regulation of NOTCH4 signaling | 47 | 1.07e-06 | 8.99e-06 | 0.2990 | 3.82e-02 | 2.44e-01 | -3.84e-02 | -1.65e-01 | 6.51e-01 | 3.89e-03 | 6.49e-01 | 5.01e-02 |
| Phase I - Functionalization of compounds | 39 | 3.29e-02 | 6.56e-02 | 0.2990 | -2.27e-01 | -1.26e-01 | -1.31e-01 | -6.93e-02 | 1.41e-02 | 1.74e-01 | 1.57e-01 | 4.54e-01 |
| Signaling by FGFR2 | 52 | 1.39e-02 | 3.18e-02 | 0.2990 | 1.99e-01 | 2.15e-01 | 3.57e-02 | 4.34e-02 | 1.29e-02 | 7.36e-03 | 6.56e-01 | 5.89e-01 |
| NOTCH3 Intracellular Domain Regulates Transcription | 18 | 1.95e-01 | 2.76e-01 | 0.2980 | -4.63e-02 | 5.39e-02 | 1.42e-01 | 2.53e-01 | 7.34e-01 | 6.93e-01 | 2.96e-01 | 6.37e-02 |
| Rho GTPase cycle | 103 | 3.26e-04 | 1.34e-03 | 0.2980 | -1.08e-01 | 8.72e-02 | 1.57e-01 | 2.12e-01 | 5.83e-02 | 1.27e-01 | 5.99e-03 | 2.08e-04 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 25 | 7.91e-02 | 1.33e-01 | 0.2980 | 2.69e-01 | 1.22e-01 | 2.46e-02 | -3.27e-02 | 2.01e-02 | 2.90e-01 | 8.32e-01 | 7.77e-01 |
| G beta:gamma signalling through CDC42 | 13 | 2.06e-01 | 2.88e-01 | 0.2970 | -1.72e-02 | -9.13e-02 | 2.52e-01 | 1.27e-01 | 9.15e-01 | 5.69e-01 | 1.16e-01 | 4.30e-01 |
| Regulation of expression of SLITs and ROBOs | 114 | 1.53e-09 | 2.44e-08 | 0.2970 | 2.47e-02 | 2.90e-01 | -5.25e-02 | 1.81e-02 | 6.50e-01 | 9.16e-08 | 3.34e-01 | 7.39e-01 |
| Neurotransmitter release cycle | 22 | 4.14e-01 | 5.03e-01 | 0.2960 | 4.22e-03 | 2.41e-01 | 1.20e-01 | 1.23e-01 | 9.73e-01 | 5.01e-02 | 3.32e-01 | 3.18e-01 |
| GPCR downstream signalling | 243 | 6.99e-11 | 1.37e-09 | 0.2960 | -2.05e-01 | 1.69e-02 | 1.44e-01 | 1.57e-01 | 4.63e-08 | 6.52e-01 | 1.21e-04 | 2.79e-05 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 14 | 2.10e-01 | 2.91e-01 | 0.2960 | 1.71e-01 | 5.44e-02 | 8.14e-02 | 2.20e-01 | 2.69e-01 | 7.25e-01 | 5.98e-01 | 1.53e-01 |
| Negative regulation of FGFR3 signaling | 19 | 9.82e-02 | 1.59e-01 | 0.2950 | 7.87e-02 | 2.78e-01 | -2.86e-02 | -5.54e-02 | 5.53e-01 | 3.61e-02 | 8.29e-01 | 6.76e-01 |
| Cyclin D associated events in G1 | 41 | 4.61e-02 | 8.71e-02 | 0.2950 | 7.71e-02 | 1.75e-01 | 1.02e-01 | 2.01e-01 | 3.94e-01 | 5.31e-02 | 2.60e-01 | 2.61e-02 |
| G1 Phase | 41 | 4.61e-02 | 8.71e-02 | 0.2950 | 7.71e-02 | 1.75e-01 | 1.02e-01 | 2.01e-01 | 3.94e-01 | 5.31e-02 | 2.60e-01 | 2.61e-02 |
| HDR through Single Strand Annealing (SSA) | 30 | 4.41e-02 | 8.40e-02 | 0.2950 | 1.96e-01 | 2.40e-02 | 9.79e-02 | 1.96e-01 | 6.37e-02 | 8.20e-01 | 3.54e-01 | 6.30e-02 |
| SHC1 events in ERBB2 signaling | 15 | 5.33e-01 | 6.18e-01 | 0.2940 | -1.63e-01 | 1.25e-01 | 1.27e-01 | 1.68e-01 | 2.75e-01 | 4.01e-01 | 3.95e-01 | 2.59e-01 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 75 | 1.69e-05 | 9.42e-05 | 0.2940 | 1.49e-01 | 2.45e-01 | -3.43e-02 | -5.73e-02 | 2.61e-02 | 2.55e-04 | 6.09e-01 | 3.91e-01 |
| Hh mutants abrogate ligand secretion | 47 | 7.34e-06 | 4.75e-05 | 0.2940 | 1.12e-01 | 2.42e-01 | -6.51e-03 | -1.24e-01 | 1.86e-01 | 4.17e-03 | 9.39e-01 | 1.40e-01 |
| FCERI mediated NF-kB activation | 65 | 2.06e-06 | 1.53e-05 | 0.2940 | 4.42e-02 | 1.77e-01 | -1.20e-01 | -1.97e-01 | 5.38e-01 | 1.36e-02 | 9.57e-02 | 6.15e-03 |
| Glucagon signaling in metabolic regulation | 23 | 2.00e-01 | 2.81e-01 | 0.2940 | -2.75e-01 | -9.16e-02 | 3.51e-02 | 3.42e-02 | 2.26e-02 | 4.47e-01 | 7.71e-01 | 7.76e-01 |
| Signal transduction by L1 | 20 | 4.60e-01 | 5.47e-01 | 0.2930 | -1.32e-01 | 1.19e-01 | 1.87e-01 | 1.39e-01 | 3.09e-01 | 3.58e-01 | 1.49e-01 | 2.81e-01 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 11 | 7.14e-01 | 7.71e-01 | 0.2920 | 5.81e-02 | 2.26e-01 | 8.93e-02 | 1.52e-01 | 7.39e-01 | 1.95e-01 | 6.08e-01 | 3.83e-01 |
| Cell junction organization | 45 | 4.09e-02 | 7.87e-02 | 0.2920 | -2.29e-01 | 5.23e-02 | 1.37e-01 | 1.07e-01 | 7.90e-03 | 5.44e-01 | 1.11e-01 | 2.16e-01 |
| Metabolic disorders of biological oxidation enzymes | 13 | 2.27e-01 | 3.08e-01 | 0.2910 | -1.81e-01 | 2.06e-02 | -2.09e-01 | -9.09e-02 | 2.59e-01 | 8.97e-01 | 1.93e-01 | 5.71e-01 |
| FOXO-mediated transcription | 51 | 1.22e-01 | 1.88e-01 | 0.2910 | -1.22e-01 | -1.03e-01 | -1.84e-01 | -1.60e-01 | 1.33e-01 | 2.02e-01 | 2.35e-02 | 4.88e-02 |
| Hh mutants that don't undergo autocatalytic processing are degraded by ERAD | 46 | 5.72e-06 | 3.83e-05 | 0.2910 | 1.03e-01 | 2.32e-01 | -1.70e-02 | -1.42e-01 | 2.30e-01 | 6.62e-03 | 8.42e-01 | 9.58e-02 |
| Downregulation of ERBB2 signaling | 18 | 5.22e-01 | 6.09e-01 | 0.2910 | -2.77e-02 | 1.21e-01 | 1.50e-01 | 2.16e-01 | 8.39e-01 | 3.73e-01 | 2.72e-01 | 1.13e-01 |
| Misspliced GSK3beta mutants stabilize beta-catenin | 14 | 2.64e-01 | 3.49e-01 | 0.2910 | 2.02e-01 | 1.70e-01 | -5.64e-02 | -1.08e-01 | 1.91e-01 | 2.72e-01 | 7.15e-01 | 4.83e-01 |
| S33 mutants of beta-catenin aren't phosphorylated | 14 | 2.64e-01 | 3.49e-01 | 0.2910 | 2.02e-01 | 1.70e-01 | -5.64e-02 | -1.08e-01 | 1.91e-01 | 2.72e-01 | 7.15e-01 | 4.83e-01 |
| S37 mutants of beta-catenin aren't phosphorylated | 14 | 2.64e-01 | 3.49e-01 | 0.2910 | 2.02e-01 | 1.70e-01 | -5.64e-02 | -1.08e-01 | 1.91e-01 | 2.72e-01 | 7.15e-01 | 4.83e-01 |
| S45 mutants of beta-catenin aren't phosphorylated | 14 | 2.64e-01 | 3.49e-01 | 0.2910 | 2.02e-01 | 1.70e-01 | -5.64e-02 | -1.08e-01 | 1.91e-01 | 2.72e-01 | 7.15e-01 | 4.83e-01 |
| T41 mutants of beta-catenin aren't phosphorylated | 14 | 2.64e-01 | 3.49e-01 | 0.2910 | 2.02e-01 | 1.70e-01 | -5.64e-02 | -1.08e-01 | 1.91e-01 | 2.72e-01 | 7.15e-01 | 4.83e-01 |
| phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex | 14 | 2.64e-01 | 3.49e-01 | 0.2910 | 2.02e-01 | 1.70e-01 | -5.64e-02 | -1.08e-01 | 1.91e-01 | 2.72e-01 | 7.15e-01 | 4.83e-01 |
| RNA Polymerase III Transcription Initiation | 34 | 1.63e-02 | 3.67e-02 | 0.2900 | 2.71e-01 | 8.96e-02 | 3.73e-02 | -3.82e-02 | 6.26e-03 | 3.67e-01 | 7.07e-01 | 7.00e-01 |
| Orc1 removal from chromatin | 59 | 6.79e-05 | 3.25e-04 | 0.2900 | 1.13e-01 | 2.63e-01 | 3.52e-02 | -3.49e-02 | 1.32e-01 | 4.91e-04 | 6.40e-01 | 6.43e-01 |
| Regulation of TP53 Activity through Phosphorylation | 74 | 1.80e-03 | 5.62e-03 | 0.2900 | 2.47e-01 | 1.44e-01 | 5.49e-03 | 5.28e-02 | 2.51e-04 | 3.26e-02 | 9.35e-01 | 4.33e-01 |
| G beta:gamma signalling through PLC beta | 12 | 4.77e-01 | 5.62e-01 | 0.2900 | -1.20e-01 | -1.17e-01 | 1.71e-01 | 1.63e-01 | 4.71e-01 | 4.83e-01 | 3.04e-01 | 3.28e-01 |
| Presynaptic function of Kainate receptors | 12 | 4.77e-01 | 5.62e-01 | 0.2900 | -1.20e-01 | -1.17e-01 | 1.71e-01 | 1.63e-01 | 4.71e-01 | 4.83e-01 | 3.04e-01 | 3.28e-01 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 22 | 2.73e-01 | 3.58e-01 | 0.2900 | -9.03e-02 | 2.42e-01 | 9.12e-02 | 9.49e-02 | 4.64e-01 | 4.94e-02 | 4.59e-01 | 4.41e-01 |
| Mitotic Anaphase | 171 | 3.29e-07 | 3.27e-06 | 0.2900 | 2.02e-01 | 1.94e-01 | 5.06e-02 | 5.41e-02 | 5.52e-06 | 1.32e-05 | 2.56e-01 | 2.24e-01 |
| Mitotic Metaphase and Anaphase | 171 | 3.29e-07 | 3.27e-06 | 0.2900 | 2.02e-01 | 1.94e-01 | 5.06e-02 | 5.41e-02 | 5.52e-06 | 1.32e-05 | 2.56e-01 | 2.24e-01 |
| HDMs demethylate histones | 19 | 9.28e-02 | 1.51e-01 | 0.2890 | 1.59e-01 | 2.24e-01 | -7.90e-02 | 4.31e-02 | 2.29e-01 | 9.15e-02 | 5.51e-01 | 7.45e-01 |
| Stabilization of p53 | 48 | 6.39e-05 | 3.11e-04 | 0.2890 | 1.20e-01 | 1.80e-01 | -8.07e-02 | -1.74e-01 | 1.52e-01 | 3.12e-02 | 3.34e-01 | 3.71e-02 |
| IL-6-type cytokine receptor ligand interactions | 10 | 5.53e-01 | 6.33e-01 | 0.2890 | -2.54e-01 | -1.22e-01 | -6.52e-02 | -4.07e-03 | 1.65e-01 | 5.05e-01 | 7.21e-01 | 9.82e-01 |
| Loss of Nlp from mitotic centrosomes | 60 | 2.31e-02 | 4.87e-02 | 0.2880 | 9.90e-02 | 1.48e-02 | 1.79e-01 | 2.03e-01 | 1.85e-01 | 8.43e-01 | 1.68e-02 | 6.62e-03 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 60 | 2.31e-02 | 4.87e-02 | 0.2880 | 9.90e-02 | 1.48e-02 | 1.79e-01 | 2.03e-01 | 1.85e-01 | 8.43e-01 | 1.68e-02 | 6.62e-03 |
| Cell Cycle, Mitotic | 397 | 1.18e-12 | 2.90e-11 | 0.2880 | 1.82e-01 | 1.44e-01 | 9.87e-02 | 1.39e-01 | 7.68e-10 | 9.96e-07 | 8.33e-04 | 2.38e-06 |
| Cellular response to hypoxia | 62 | 3.56e-05 | 1.84e-04 | 0.2880 | 3.33e-02 | 1.16e-01 | -1.41e-01 | -2.20e-01 | 6.51e-01 | 1.16e-01 | 5.53e-02 | 2.72e-03 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 3.45e-01 | 4.33e-01 | 0.2880 | 4.04e-02 | -2.70e-01 | 4.91e-02 | 7.74e-02 | 8.25e-01 | 1.40e-01 | 7.88e-01 | 6.72e-01 |
| Activation of NF-kappaB in B cells | 56 | 1.77e-06 | 1.36e-05 | 0.2870 | 6.17e-02 | 2.43e-01 | -3.57e-02 | -1.36e-01 | 4.25e-01 | 1.70e-03 | 6.44e-01 | 7.82e-02 |
| Signaling by high-kinase activity BRAF mutants | 27 | 8.33e-02 | 1.39e-01 | 0.2870 | -8.91e-02 | 2.34e-01 | 1.28e-01 | 5.71e-02 | 4.23e-01 | 3.52e-02 | 2.50e-01 | 6.08e-01 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 31 | 2.05e-01 | 2.87e-01 | 0.2870 | 1.07e-01 | 1.80e-01 | 1.64e-01 | 1.07e-01 | 3.04e-01 | 8.25e-02 | 1.14e-01 | 3.05e-01 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 55 | 2.68e-05 | 1.43e-04 | 0.2870 | 3.04e-02 | 1.43e-01 | -1.22e-01 | -2.14e-01 | 6.97e-01 | 6.76e-02 | 1.18e-01 | 6.00e-03 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 11 | 1.70e-01 | 2.47e-01 | 0.2860 | 1.87e-01 | 1.88e-01 | 2.53e-02 | -1.05e-01 | 2.82e-01 | 2.82e-01 | 8.85e-01 | 5.48e-01 |
| Hedgehog ligand biogenesis | 50 | 1.78e-05 | 9.83e-05 | 0.2860 | 9.37e-02 | 2.54e-01 | 1.39e-02 | -9.05e-02 | 2.53e-01 | 1.88e-03 | 8.65e-01 | 2.69e-01 |
| Regulation of ornithine decarboxylase (ODC) | 44 | 4.16e-07 | 3.94e-06 | 0.2860 | 6.65e-02 | 2.11e-01 | -1.62e-02 | -1.80e-01 | 4.46e-01 | 1.55e-02 | 8.53e-01 | 3.85e-02 |
| GLI3 is processed to GLI3R by the proteasome | 50 | 1.04e-05 | 6.32e-05 | 0.2850 | 4.77e-02 | 1.73e-01 | -9.05e-02 | -2.02e-01 | 5.60e-01 | 3.47e-02 | 2.69e-01 | 1.34e-02 |
| EGFR downregulation | 22 | 1.50e-01 | 2.22e-01 | 0.2850 | 1.53e-01 | 1.47e-01 | 5.80e-02 | 1.81e-01 | 2.15e-01 | 2.31e-01 | 6.38e-01 | 1.43e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 56 | 2.39e-02 | 5.02e-02 | 0.2850 | -1.57e-01 | 7.96e-03 | 1.58e-01 | 1.77e-01 | 4.25e-02 | 9.18e-01 | 4.09e-02 | 2.21e-02 |
| Leishmania parasite growth and survival | 56 | 2.39e-02 | 5.02e-02 | 0.2850 | -1.57e-01 | 7.96e-03 | 1.58e-01 | 1.77e-01 | 4.25e-02 | 9.18e-01 | 4.09e-02 | 2.21e-02 |
| Antigen processing-Cross presentation | 69 | 9.01e-04 | 3.08e-03 | 0.2840 | 4.73e-02 | 2.33e-01 | 1.41e-01 | 6.62e-02 | 4.97e-01 | 8.34e-04 | 4.32e-02 | 3.42e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 20 | 4.18e-01 | 5.08e-01 | 0.2840 | -1.04e-01 | -1.16e-01 | -1.22e-01 | -2.04e-01 | 4.19e-01 | 3.70e-01 | 3.45e-01 | 1.15e-01 |
| Thromboxane signalling through TP receptor | 14 | 6.71e-01 | 7.32e-01 | 0.2840 | 5.40e-02 | 3.75e-02 | 2.14e-01 | 1.74e-01 | 7.26e-01 | 8.08e-01 | 1.66e-01 | 2.59e-01 |
| Signaling by SCF-KIT | 32 | 4.48e-01 | 5.34e-01 | 0.2840 | -4.48e-02 | 1.28e-01 | 1.81e-01 | 1.70e-01 | 6.61e-01 | 2.10e-01 | 7.61e-02 | 9.55e-02 |
| RAF-independent MAPK1/3 activation | 21 | 1.26e-01 | 1.92e-01 | 0.2830 | -1.58e-01 | 2.33e-01 | 3.30e-02 | 7.76e-03 | 2.10e-01 | 6.48e-02 | 7.93e-01 | 9.51e-01 |
| Acyl chain remodelling of PC | 11 | 5.53e-01 | 6.33e-01 | 0.2830 | 7.26e-02 | -8.32e-02 | 1.81e-01 | 1.87e-01 | 6.77e-01 | 6.33e-01 | 2.99e-01 | 2.82e-01 |
| Separation of Sister Chromatids | 125 | 1.06e-05 | 6.39e-05 | 0.2810 | 2.41e-01 | 1.45e-01 | 1.23e-03 | 4.78e-03 | 3.57e-06 | 5.19e-03 | 9.81e-01 | 9.27e-01 |
| Interleukin-15 signaling | 11 | 4.67e-01 | 5.54e-01 | 0.2810 | -2.48e-01 | 1.15e-01 | -5.77e-02 | -3.32e-02 | 1.55e-01 | 5.10e-01 | 7.40e-01 | 8.49e-01 |
| CDT1 association with the CDC6:ORC:origin complex | 48 | 7.64e-05 | 3.59e-04 | 0.2810 | 1.18e-01 | 1.82e-01 | -6.84e-02 | -1.65e-01 | 1.56e-01 | 2.94e-02 | 4.13e-01 | 4.86e-02 |
| Degradation of GLI1 by the proteasome | 51 | 1.30e-05 | 7.53e-05 | 0.2810 | 6.08e-02 | 1.56e-01 | -9.20e-02 | -2.06e-01 | 4.53e-01 | 5.44e-02 | 2.56e-01 | 1.10e-02 |
| HCMV Infection | 68 | 1.26e-02 | 2.93e-02 | 0.2810 | 2.38e-01 | 9.98e-02 | 7.75e-02 | 7.82e-02 | 6.92e-04 | 1.55e-01 | 2.70e-01 | 2.66e-01 |
| Signaling by cytosolic FGFR1 fusion mutants | 17 | 5.73e-01 | 6.54e-01 | 0.2810 | -4.36e-03 | -1.27e-01 | -2.08e-01 | -1.40e-01 | 9.75e-01 | 3.67e-01 | 1.38e-01 | 3.19e-01 |
| Signaling by GPCR | 268 | 5.20e-11 | 1.03e-09 | 0.2800 | -2.09e-01 | 2.01e-02 | 1.26e-01 | 1.37e-01 | 5.08e-09 | 5.74e-01 | 4.25e-04 | 1.22e-04 |
| Cell Cycle | 484 | 9.99e-16 | 4.10e-14 | 0.2800 | 1.92e-01 | 1.34e-01 | 8.48e-02 | 1.29e-01 | 9.44e-13 | 6.29e-07 | 1.60e-03 | 1.53e-06 |
| Diseases associated with N-glycosylation of proteins | 16 | 4.72e-01 | 5.58e-01 | 0.2800 | 1.29e-01 | 1.82e-01 | 6.54e-02 | 1.56e-01 | 3.72e-01 | 2.09e-01 | 6.51e-01 | 2.79e-01 |
| Signaling by ERBB2 | 37 | 3.37e-01 | 4.25e-01 | 0.2800 | -7.15e-02 | 1.16e-01 | 1.66e-01 | 1.79e-01 | 4.52e-01 | 2.24e-01 | 8.03e-02 | 5.93e-02 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 19 | 2.62e-01 | 3.48e-01 | 0.2800 | -5.98e-03 | 4.03e-02 | 1.41e-01 | 2.38e-01 | 9.64e-01 | 7.61e-01 | 2.86e-01 | 7.28e-02 |
| Dual incision in TC-NER | 60 | 7.52e-03 | 1.90e-02 | 0.2790 | 2.48e-01 | 1.24e-01 | -3.31e-02 | 5.97e-03 | 8.87e-04 | 9.85e-02 | 6.58e-01 | 9.36e-01 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 26 | 7.24e-02 | 1.24e-01 | 0.2780 | 2.45e-01 | 1.21e-01 | 3.99e-02 | -3.31e-02 | 3.07e-02 | 2.87e-01 | 7.25e-01 | 7.70e-01 |
| Nervous system development | 392 | 1.53e-12 | 3.69e-11 | 0.2780 | -1.15e-01 | 1.69e-01 | 1.23e-01 | 1.42e-01 | 1.16e-04 | 1.15e-08 | 3.23e-05 | 1.84e-06 |
| SLC transporter disorders | 51 | 1.75e-01 | 2.54e-01 | 0.2770 | 1.02e-01 | 1.41e-01 | 1.30e-01 | 1.72e-01 | 2.07e-01 | 8.13e-02 | 1.09e-01 | 3.40e-02 |
| ER Quality Control Compartment (ERQC) | 18 | 6.32e-01 | 7.02e-01 | 0.2770 | 9.98e-02 | 1.82e-01 | 1.43e-01 | 1.14e-01 | 4.64e-01 | 1.81e-01 | 2.93e-01 | 4.01e-01 |
| Tight junction interactions | 10 | 6.50e-01 | 7.16e-01 | 0.2770 | -1.32e-02 | 7.68e-02 | -1.96e-01 | -1.79e-01 | 9.43e-01 | 6.74e-01 | 2.82e-01 | 3.26e-01 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 13 | 6.45e-01 | 7.11e-01 | 0.2770 | -1.42e-01 | 1.78e-01 | 1.20e-01 | 1.01e-01 | 3.75e-01 | 2.66e-01 | 4.53e-01 | 5.27e-01 |
| Aquaporin-mediated transport | 29 | 2.16e-01 | 2.98e-01 | 0.2770 | -2.16e-01 | -1.64e-01 | -2.17e-02 | -4.86e-02 | 4.39e-02 | 1.27e-01 | 8.40e-01 | 6.51e-01 |
| G-protein beta:gamma signalling | 20 | 2.77e-01 | 3.63e-01 | 0.2760 | -7.74e-02 | -5.48e-02 | 2.15e-01 | 1.46e-01 | 5.49e-01 | 6.71e-01 | 9.69e-02 | 2.59e-01 |
| Signaling by NTRKs | 111 | 4.14e-04 | 1.64e-03 | 0.2760 | -8.82e-02 | 2.11e-01 | 1.15e-01 | 1.02e-01 | 1.10e-01 | 1.24e-04 | 3.64e-02 | 6.38e-02 |
| TNFR1-induced NFkappaB signaling pathway | 21 | 2.64e-01 | 3.49e-01 | 0.2760 | -2.33e-01 | -3.04e-02 | 1.29e-01 | 6.29e-02 | 6.43e-02 | 8.10e-01 | 3.06e-01 | 6.18e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 53 | 1.78e-02 | 3.92e-02 | 0.2740 | -9.01e-02 | -7.20e-02 | -2.13e-01 | -1.28e-01 | 2.57e-01 | 3.65e-01 | 7.45e-03 | 1.08e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 40 | 1.08e-02 | 2.59e-02 | 0.2740 | 1.68e-01 | 1.99e-01 | -8.39e-02 | 6.85e-03 | 6.59e-02 | 2.99e-02 | 3.59e-01 | 9.40e-01 |
| Immune System | 1221 | 3.78e-24 | 3.87e-22 | 0.2730 | -2.49e-02 | 1.33e-01 | 1.76e-01 | 1.59e-01 | 1.56e-01 | 3.48e-14 | 9.49e-24 | 1.00e-19 |
| Nonhomologous End-Joining (NHEJ) | 30 | 1.25e-01 | 1.92e-01 | 0.2730 | 2.70e-01 | -2.80e-02 | -1.67e-02 | -2.54e-02 | 1.05e-02 | 7.91e-01 | 8.74e-01 | 8.10e-01 |
| Transcriptional regulation of pluripotent stem cells | 11 | 4.08e-01 | 4.99e-01 | 0.2730 | -1.21e-01 | 2.42e-01 | -3.73e-02 | 2.45e-03 | 4.88e-01 | 1.65e-01 | 8.31e-01 | 9.89e-01 |
| Assembly of the pre-replicative complex | 56 | 3.93e-04 | 1.57e-03 | 0.2720 | 9.37e-02 | 2.52e-01 | 2.68e-02 | -3.58e-02 | 2.26e-01 | 1.14e-03 | 7.29e-01 | 6.44e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 59 | 1.10e-02 | 2.64e-02 | 0.2720 | 2.37e-01 | 1.29e-01 | -2.76e-02 | 1.71e-02 | 1.64e-03 | 8.62e-02 | 7.15e-01 | 8.20e-01 |
| G beta:gamma signalling through BTK | 10 | 6.24e-01 | 6.94e-01 | 0.2710 | -5.31e-02 | -1.07e-01 | 1.84e-01 | 1.58e-01 | 7.71e-01 | 5.56e-01 | 3.14e-01 | 3.86e-01 |
| Deadenylation-dependent mRNA decay | 53 | 4.18e-03 | 1.13e-02 | 0.2700 | 2.47e-01 | 6.32e-02 | -8.91e-02 | 3.19e-03 | 1.91e-03 | 4.27e-01 | 2.62e-01 | 9.68e-01 |
| Role of phospholipids in phagocytosis | 14 | 6.24e-02 | 1.12e-01 | 0.2700 | -1.66e-01 | -1.70e-01 | -2.58e-02 | 1.25e-01 | 2.83e-01 | 2.71e-01 | 8.67e-01 | 4.17e-01 |
| Nucleotide Excision Repair | 102 | 1.01e-04 | 4.63e-04 | 0.2700 | 2.17e-01 | 9.48e-02 | -1.07e-01 | -7.07e-02 | 1.53e-04 | 9.90e-02 | 6.31e-02 | 2.18e-01 |
| Signaling by NOTCH2 | 24 | 1.83e-01 | 2.63e-01 | 0.2700 | -2.70e-02 | -4.82e-02 | 1.57e-01 | 2.12e-01 | 8.19e-01 | 6.83e-01 | 1.84e-01 | 7.21e-02 |
| Downregulation of TGF-beta receptor signaling | 24 | 1.29e-01 | 1.97e-01 | 0.2690 | 1.14e-01 | 1.64e-01 | -1.29e-01 | -1.26e-01 | 3.33e-01 | 1.64e-01 | 2.73e-01 | 2.87e-01 |
| TICAM1, RIP1-mediated IKK complex recruitment | 14 | 4.40e-01 | 5.27e-01 | 0.2690 | 1.10e-01 | 2.35e-01 | -7.53e-03 | 7.11e-02 | 4.74e-01 | 1.29e-01 | 9.61e-01 | 6.45e-01 |
| Negative regulation of MAPK pathway | 39 | 3.18e-03 | 9.32e-03 | 0.2690 | 5.72e-02 | 1.58e-01 | -1.08e-01 | -1.80e-01 | 5.37e-01 | 8.80e-02 | 2.43e-01 | 5.21e-02 |
| Apoptotic execution phase | 35 | 2.65e-01 | 3.49e-01 | 0.2680 | -4.04e-02 | 1.05e-01 | 1.42e-01 | 1.98e-01 | 6.79e-01 | 2.84e-01 | 1.47e-01 | 4.28e-02 |
| Signaling by NTRK1 (TRKA) | 95 | 2.31e-03 | 6.96e-03 | 0.2680 | -7.64e-02 | 2.13e-01 | 9.92e-02 | 1.03e-01 | 1.99e-01 | 3.34e-04 | 9.55e-02 | 8.49e-02 |
| Trafficking of GluR2-containing AMPA receptors | 10 | 6.99e-01 | 7.57e-01 | 0.2670 | -1.63e-01 | 1.84e-01 | 7.31e-02 | 7.57e-02 | 3.72e-01 | 3.15e-01 | 6.89e-01 | 6.78e-01 |
| Intraflagellar transport | 35 | 3.64e-02 | 7.14e-02 | 0.2670 | 1.21e-01 | -1.07e-01 | 1.40e-01 | 1.61e-01 | 2.17e-01 | 2.75e-01 | 1.53e-01 | 1.00e-01 |
| Negative regulation of FGFR2 signaling | 19 | 1.16e-01 | 1.82e-01 | 0.2670 | -1.24e-02 | 2.63e-01 | 1.39e-02 | -4.32e-02 | 9.26e-01 | 4.75e-02 | 9.17e-01 | 7.44e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 12 | 5.85e-01 | 6.64e-01 | 0.2670 | 3.06e-02 | 1.51e-01 | 9.15e-02 | 1.97e-01 | 8.55e-01 | 3.64e-01 | 5.83e-01 | 2.37e-01 |
| Defective CFTR causes cystic fibrosis | 50 | 8.52e-06 | 5.35e-05 | 0.2660 | 9.81e-02 | 2.17e-01 | 7.78e-03 | -1.19e-01 | 2.31e-01 | 8.03e-03 | 9.24e-01 | 1.45e-01 |
| Selective autophagy | 51 | 1.39e-01 | 2.10e-01 | 0.2660 | 3.21e-02 | -8.94e-02 | -1.51e-01 | -1.98e-01 | 6.92e-01 | 2.70e-01 | 6.25e-02 | 1.47e-02 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 21 | 4.28e-01 | 5.16e-01 | 0.2650 | -1.79e-01 | 3.21e-03 | 1.32e-01 | 1.44e-01 | 1.56e-01 | 9.80e-01 | 2.94e-01 | 2.54e-01 |
| eNOS activation | 10 | 6.65e-01 | 7.28e-01 | 0.2650 | -1.83e-01 | 1.59e-01 | 5.21e-02 | 9.20e-02 | 3.15e-01 | 3.84e-01 | 7.76e-01 | 6.14e-01 |
| FCERI mediated Ca+2 mobilization | 18 | 2.25e-01 | 3.07e-01 | 0.2640 | -2.24e-01 | -9.15e-02 | 3.22e-02 | 1.00e-01 | 1.00e-01 | 5.02e-01 | 8.13e-01 | 4.62e-01 |
| Cytochrome P450 - arranged by substrate type | 18 | 8.22e-02 | 1.38e-01 | 0.2640 | -1.91e-01 | -1.59e-01 | -6.93e-02 | 5.23e-02 | 1.60e-01 | 2.43e-01 | 6.11e-01 | 7.01e-01 |
| Signaling by PDGFR in disease | 17 | 5.39e-01 | 6.22e-01 | 0.2630 | 9.19e-02 | 1.85e-01 | 6.88e-02 | 1.48e-01 | 5.12e-01 | 1.87e-01 | 6.23e-01 | 2.91e-01 |
| VLDLR internalisation and degradation | 11 | 7.90e-01 | 8.31e-01 | 0.2630 | -1.71e-01 | 7.71e-02 | 1.31e-01 | 1.30e-01 | 3.27e-01 | 6.58e-01 | 4.51e-01 | 4.54e-01 |
| Anchoring of the basal body to the plasma membrane | 83 | 6.77e-03 | 1.74e-02 | 0.2630 | 1.20e-01 | 1.63e-02 | 1.45e-01 | 1.82e-01 | 5.86e-02 | 7.98e-01 | 2.25e-02 | 4.24e-03 |
| ER-Phagosome pathway | 61 | 5.48e-05 | 2.74e-04 | 0.2620 | 6.24e-02 | 2.39e-01 | 8.77e-02 | -1.61e-02 | 4.00e-01 | 1.29e-03 | 2.37e-01 | 8.28e-01 |
| Rap1 signalling | 14 | 6.59e-01 | 7.23e-01 | 0.2620 | 7.75e-02 | 1.77e-01 | 1.51e-01 | 9.24e-02 | 6.16e-01 | 2.51e-01 | 3.28e-01 | 5.50e-01 |
| Estrogen-dependent gene expression | 75 | 3.29e-03 | 9.51e-03 | 0.2620 | 2.26e-01 | 1.28e-01 | -3.42e-02 | 1.36e-02 | 7.38e-04 | 5.65e-02 | 6.09e-01 | 8.39e-01 |
| Regulation of RUNX2 expression and activity | 61 | 6.76e-06 | 4.40e-05 | 0.2620 | 4.00e-02 | 1.05e-01 | -9.58e-02 | -2.16e-01 | 5.90e-01 | 1.56e-01 | 1.97e-01 | 3.56e-03 |
| Transcriptional Regulation by MECP2 | 42 | 1.08e-01 | 1.72e-01 | 0.2620 | -1.52e-01 | -2.03e-01 | -3.65e-02 | -5.03e-02 | 8.76e-02 | 2.28e-02 | 6.82e-01 | 5.73e-01 |
| Retrograde transport at the Trans-Golgi-Network | 43 | 5.75e-02 | 1.05e-01 | 0.2610 | 1.90e-01 | -1.20e-01 | -7.14e-02 | -1.13e-01 | 3.15e-02 | 1.73e-01 | 4.18e-01 | 2.01e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 13 | 7.49e-01 | 7.96e-01 | 0.2610 | 1.15e-01 | 2.13e-02 | 1.67e-01 | 1.63e-01 | 4.72e-01 | 8.94e-01 | 2.97e-01 | 3.09e-01 |
| Metabolism of polyamines | 50 | 1.02e-06 | 8.66e-06 | 0.2610 | 8.86e-02 | 1.95e-01 | 3.47e-03 | -1.49e-01 | 2.79e-01 | 1.69e-02 | 9.66e-01 | 6.91e-02 |
| Macroautophagy | 98 | 2.02e-05 | 1.10e-04 | 0.2610 | 7.53e-02 | -7.45e-02 | -1.08e-01 | -2.13e-01 | 1.99e-01 | 2.04e-01 | 6.57e-02 | 2.82e-04 |
| Regulation of TP53 Activity through Acetylation | 28 | 1.12e-01 | 1.76e-01 | 0.2610 | 1.61e-01 | 1.38e-01 | 3.49e-02 | 1.48e-01 | 1.41e-01 | 2.08e-01 | 7.50e-01 | 1.75e-01 |
| Purine catabolism | 14 | 4.10e-01 | 5.00e-01 | 0.2610 | -1.19e-01 | -1.29e-01 | 1.20e-01 | 1.50e-01 | 4.40e-01 | 4.02e-01 | 4.38e-01 | 3.30e-01 |
| VEGFR2 mediated cell proliferation | 16 | 4.34e-01 | 5.20e-01 | 0.2600 | -1.59e-01 | -1.05e-01 | 1.20e-01 | 1.29e-01 | 2.70e-01 | 4.66e-01 | 4.04e-01 | 3.71e-01 |
| FCERI mediated MAPK activation | 23 | 4.23e-01 | 5.12e-01 | 0.2600 | -6.75e-03 | 4.84e-02 | 2.11e-01 | 1.44e-01 | 9.55e-01 | 6.88e-01 | 7.99e-02 | 2.33e-01 |
| PI-3K cascade:FGFR2 | 10 | 6.14e-01 | 6.87e-01 | 0.2590 | -1.08e-01 | 1.05e-01 | -1.50e-01 | -1.49e-01 | 5.53e-01 | 5.67e-01 | 4.13e-01 | 4.15e-01 |
| GPCR ligand binding | 73 | 1.67e-02 | 3.73e-02 | 0.2590 | -1.61e-01 | 3.40e-02 | 1.30e-01 | 1.53e-01 | 1.79e-02 | 6.16e-01 | 5.57e-02 | 2.42e-02 |
| Axon guidance | 375 | 2.23e-10 | 3.75e-09 | 0.2580 | -1.00e-01 | 1.62e-01 | 1.12e-01 | 1.33e-01 | 9.49e-04 | 8.80e-08 | 2.14e-04 | 1.26e-05 |
| Signaling by NOTCH3 | 38 | 1.19e-01 | 1.85e-01 | 0.2580 | -1.16e-01 | 2.33e-02 | 1.33e-01 | 1.86e-01 | 2.15e-01 | 8.04e-01 | 1.56e-01 | 4.71e-02 |
| S Phase | 144 | 7.46e-04 | 2.64e-03 | 0.2580 | 1.42e-01 | 1.70e-01 | 7.33e-02 | 1.10e-01 | 3.42e-03 | 4.51e-04 | 1.30e-01 | 2.37e-02 |
| Ion channel transport | 89 | 3.05e-04 | 1.27e-03 | 0.2580 | -2.02e-01 | -1.28e-01 | 9.04e-02 | 3.07e-02 | 1.02e-03 | 3.66e-02 | 1.42e-01 | 6.18e-01 |
| Base Excision Repair | 43 | 2.87e-01 | 3.73e-01 | 0.2570 | 1.08e-01 | 1.22e-01 | 1.16e-01 | 1.61e-01 | 2.19e-01 | 1.66e-01 | 1.89e-01 | 6.77e-02 |
| Ion transport by P-type ATPases | 34 | 1.35e-01 | 2.04e-01 | 0.2570 | -2.42e-01 | -7.94e-02 | 1.74e-02 | 3.05e-02 | 1.48e-02 | 4.24e-01 | 8.61e-01 | 7.58e-01 |
| Interleukin-1 family signaling | 102 | 1.86e-06 | 1.40e-05 | 0.2570 | 3.89e-02 | 2.52e-01 | 1.47e-02 | -2.66e-02 | 4.98e-01 | 1.14e-05 | 7.98e-01 | 6.44e-01 |
| M Phase | 275 | 1.46e-07 | 1.61e-06 | 0.2560 | 1.94e-01 | 1.20e-01 | 7.56e-02 | 8.86e-02 | 3.56e-08 | 6.92e-04 | 3.21e-02 | 1.21e-02 |
| TGF-beta receptor signaling activates SMADs | 29 | 7.75e-02 | 1.31e-01 | 0.2550 | 9.41e-02 | 1.79e-01 | -1.08e-01 | -1.13e-01 | 3.81e-01 | 9.60e-02 | 3.16e-01 | 2.91e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 34 | 5.11e-01 | 5.99e-01 | 0.2550 | 1.11e-01 | 1.17e-01 | 1.35e-01 | 1.45e-01 | 2.62e-01 | 2.40e-01 | 1.74e-01 | 1.44e-01 |
| Regulation of PTEN mRNA translation | 11 | 4.50e-01 | 5.36e-01 | 0.2540 | 8.96e-02 | -1.98e-01 | 1.02e-01 | 8.39e-02 | 6.07e-01 | 2.56e-01 | 5.58e-01 | 6.30e-01 |
| RUNX3 regulates NOTCH signaling | 13 | 5.82e-01 | 6.60e-01 | 0.2540 | 7.93e-02 | 1.10e-01 | 9.19e-02 | 1.94e-01 | 6.21e-01 | 4.92e-01 | 5.66e-01 | 2.25e-01 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation | 28 | 2.10e-01 | 2.91e-01 | 0.2540 | -8.50e-02 | -8.20e-02 | 1.61e-01 | 1.57e-01 | 4.36e-01 | 4.53e-01 | 1.41e-01 | 1.51e-01 |
| Cytokine Signaling in Immune system | 515 | 5.29e-12 | 1.16e-10 | 0.2540 | -2.72e-02 | 1.89e-01 | 1.17e-01 | 1.20e-01 | 2.97e-01 | 4.28e-13 | 6.88e-06 | 4.49e-06 |
| COPI-dependent Golgi-to-ER retrograde traffic | 62 | 9.18e-02 | 1.50e-01 | 0.2540 | 1.36e-01 | 1.48e-01 | 1.22e-01 | 9.55e-02 | 6.49e-02 | 4.39e-02 | 9.73e-02 | 1.94e-01 |
| G beta:gamma signalling through PI3Kgamma | 15 | 6.22e-01 | 6.94e-01 | 0.2530 | -6.30e-02 | -4.38e-02 | 1.76e-01 | 1.65e-01 | 6.73e-01 | 7.69e-01 | 2.38e-01 | 2.67e-01 |
| p75 NTR receptor-mediated signalling | 73 | 1.86e-02 | 4.08e-02 | 0.2530 | -1.56e-01 | 5.36e-02 | 1.18e-01 | 1.51e-01 | 2.17e-02 | 4.29e-01 | 8.16e-02 | 2.59e-02 |
| ERK/MAPK targets | 22 | 3.92e-01 | 4.82e-01 | 0.2520 | -2.29e-01 | -9.09e-02 | -2.00e-03 | -5.38e-02 | 6.28e-02 | 4.61e-01 | 9.87e-01 | 6.63e-01 |
| DNA Damage Bypass | 43 | 2.61e-01 | 3.48e-01 | 0.2510 | 1.54e-01 | 1.01e-01 | 1.00e-01 | 1.38e-01 | 8.11e-02 | 2.54e-01 | 2.57e-01 | 1.18e-01 |
| Regulation of TP53 Activity | 134 | 5.49e-05 | 2.74e-04 | 0.2500 | 2.28e-01 | 9.46e-02 | -9.50e-03 | 4.16e-02 | 5.67e-06 | 5.94e-02 | 8.50e-01 | 4.07e-01 |
| Signaling by FGFR2 in disease | 28 | 1.54e-01 | 2.26e-01 | 0.2500 | 1.22e-01 | 2.13e-01 | 4.83e-02 | 4.55e-03 | 2.62e-01 | 5.16e-02 | 6.58e-01 | 9.67e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 73 | 6.25e-03 | 1.62e-02 | 0.2500 | 2.05e-01 | 9.18e-02 | -8.90e-02 | -6.55e-02 | 2.54e-03 | 1.76e-01 | 1.89e-01 | 3.34e-01 |
| Repression of WNT target genes | 11 | 6.29e-01 | 6.98e-01 | 0.2500 | 5.70e-02 | 2.15e-01 | 1.07e-01 | 4.00e-02 | 7.44e-01 | 2.18e-01 | 5.39e-01 | 8.18e-01 |
| TCR signaling | 79 | 1.46e-05 | 8.31e-05 | 0.2500 | 5.59e-02 | 2.37e-01 | 1.72e-02 | -4.99e-02 | 3.92e-01 | 2.71e-04 | 7.91e-01 | 4.44e-01 |
| Glutamate Neurotransmitter Release Cycle | 12 | 8.94e-01 | 9.22e-01 | 0.2490 | -2.59e-02 | 1.50e-01 | 1.37e-01 | 1.42e-01 | 8.77e-01 | 3.70e-01 | 4.12e-01 | 3.94e-01 |
| Cell death signalling via NRAGE, NRIF and NADE | 57 | 1.91e-02 | 4.16e-02 | 0.2490 | -2.00e-01 | -5.36e-03 | 8.19e-02 | 1.23e-01 | 9.12e-03 | 9.44e-01 | 2.86e-01 | 1.09e-01 |
| MECP2 regulates neuronal receptors and channels | 10 | 1.61e-01 | 2.35e-01 | 0.2480 | 1.53e-01 | 1.13e-01 | -5.90e-02 | 1.49e-01 | 4.03e-01 | 5.37e-01 | 7.47e-01 | 4.14e-01 |
| Interleukin-1 signaling | 84 | 2.30e-06 | 1.67e-05 | 0.2480 | 3.56e-02 | 2.27e-01 | -2.71e-02 | -9.03e-02 | 5.74e-01 | 3.29e-04 | 6.68e-01 | 1.54e-01 |
| TNFR2 non-canonical NF-kB pathway | 63 | 8.26e-06 | 5.21e-05 | 0.2480 | -2.54e-02 | 2.34e-01 | 6.06e-02 | -5.19e-02 | 7.28e-01 | 1.34e-03 | 4.06e-01 | 4.77e-01 |
| ADP signalling through P2Y purinoceptor 1 | 15 | 7.06e-01 | 7.63e-01 | 0.2480 | -3.75e-02 | 2.05e-02 | 1.95e-01 | 1.46e-01 | 8.02e-01 | 8.91e-01 | 1.90e-01 | 3.28e-01 |
| G1/S DNA Damage Checkpoints | 57 | 2.10e-03 | 6.40e-03 | 0.2470 | 1.04e-01 | 2.16e-01 | -1.88e-02 | -5.88e-02 | 1.77e-01 | 4.88e-03 | 8.06e-01 | 4.44e-01 |
| Recruitment of NuMA to mitotic centrosomes | 70 | 1.57e-02 | 3.54e-02 | 0.2470 | 7.42e-02 | -2.35e-02 | 1.51e-01 | 1.79e-01 | 2.84e-01 | 7.34e-01 | 2.93e-02 | 9.53e-03 |
| Methylation | 10 | 7.90e-01 | 8.31e-01 | 0.2460 | -4.93e-02 | -2.15e-01 | -9.06e-02 | -5.99e-02 | 7.87e-01 | 2.39e-01 | 6.20e-01 | 7.43e-01 |
| Regulation of PTEN stability and activity | 59 | 6.42e-05 | 3.11e-04 | 0.2460 | 1.06e-01 | 1.43e-01 | -5.92e-02 | -1.59e-01 | 1.58e-01 | 5.83e-02 | 4.32e-01 | 3.54e-02 |
| Regulation of TP53 Activity through Association with Co-factors | 12 | 9.18e-01 | 9.31e-01 | 0.2460 | 1.69e-02 | 1.12e-01 | 1.50e-01 | 1.58e-01 | 9.19e-01 | 5.01e-01 | 3.68e-01 | 3.44e-01 |
| Nicotinate metabolism | 20 | 4.42e-01 | 5.28e-01 | 0.2450 | -1.29e-01 | -1.94e-01 | -1.18e-02 | -7.46e-02 | 3.18e-01 | 1.32e-01 | 9.27e-01 | 5.64e-01 |
| G alpha (s) signalling events | 51 | 3.13e-02 | 6.30e-02 | 0.2450 | -1.62e-01 | -7.63e-02 | 1.43e-01 | 8.63e-02 | 4.54e-02 | 3.46e-01 | 7.74e-02 | 2.87e-01 |
| Signaling by EGFR | 41 | 2.07e-01 | 2.89e-01 | 0.2450 | 4.26e-02 | 1.28e-01 | 1.03e-01 | 1.76e-01 | 6.37e-01 | 1.55e-01 | 2.56e-01 | 5.14e-02 |
| Activation of kainate receptors upon glutamate binding | 17 | 4.13e-01 | 5.03e-01 | 0.2440 | -1.81e-01 | -7.22e-02 | 7.98e-02 | 1.23e-01 | 1.95e-01 | 6.06e-01 | 5.69e-01 | 3.79e-01 |
| Cilium Assembly | 158 | 1.12e-05 | 6.71e-05 | 0.2440 | 1.13e-01 | -3.87e-02 | 1.49e-01 | 1.53e-01 | 1.47e-02 | 4.03e-01 | 1.30e-03 | 9.58e-04 |
| APC/C:Cdc20 mediated degradation of Securin | 59 | 3.34e-04 | 1.37e-03 | 0.2440 | 1.06e-01 | 1.27e-01 | -7.89e-02 | -1.61e-01 | 1.59e-01 | 9.26e-02 | 2.95e-01 | 3.23e-02 |
| Signaling by ROBO receptors | 151 | 5.77e-08 | 7.48e-07 | 0.2440 | -2.21e-02 | 2.39e-01 | -1.55e-02 | 3.73e-02 | 6.40e-01 | 4.16e-07 | 7.44e-01 | 4.30e-01 |
| Endogenous sterols | 13 | 5.48e-02 | 1.01e-01 | 0.2430 | -5.51e-02 | -1.59e-01 | -1.73e-01 | 2.64e-02 | 7.31e-01 | 3.21e-01 | 2.79e-01 | 8.69e-01 |
| Death Receptor Signalling | 106 | 3.40e-03 | 9.71e-03 | 0.2420 | -1.72e-01 | 3.90e-02 | 1.09e-01 | 1.25e-01 | 2.25e-03 | 4.89e-01 | 5.27e-02 | 2.62e-02 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 19 | 3.29e-01 | 4.16e-01 | 0.2420 | -1.90e-01 | 5.41e-02 | -6.79e-02 | -1.23e-01 | 1.51e-01 | 6.83e-01 | 6.09e-01 | 3.55e-01 |
| Trafficking of AMPA receptors | 19 | 3.29e-01 | 4.16e-01 | 0.2420 | -1.90e-01 | 5.41e-02 | -6.79e-02 | -1.23e-01 | 1.51e-01 | 6.83e-01 | 6.09e-01 | 3.55e-01 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 27 | 3.53e-01 | 4.41e-01 | 0.2420 | -2.10e-01 | -1.19e-01 | 2.25e-03 | -2.72e-02 | 5.95e-02 | 2.87e-01 | 9.84e-01 | 8.07e-01 |
| p53-Dependent G1 DNA Damage Response | 56 | 1.77e-03 | 5.55e-03 | 0.2420 | 9.06e-02 | 2.12e-01 | -2.33e-02 | -7.12e-02 | 2.42e-01 | 6.20e-03 | 7.63e-01 | 3.58e-01 |
| p53-Dependent G1/S DNA damage checkpoint | 56 | 1.77e-03 | 5.55e-03 | 0.2420 | 9.06e-02 | 2.12e-01 | -2.33e-02 | -7.12e-02 | 2.42e-01 | 6.20e-03 | 7.63e-01 | 3.58e-01 |
| Resolution of Abasic Sites (AP sites) | 36 | 4.41e-01 | 5.27e-01 | 0.2410 | 8.20e-02 | 1.30e-01 | 1.05e-01 | 1.53e-01 | 3.95e-01 | 1.77e-01 | 2.77e-01 | 1.13e-01 |
| Nicotinamide salvaging | 12 | 4.25e-01 | 5.14e-01 | 0.2410 | -7.09e-02 | -5.08e-02 | 2.07e-01 | 8.68e-02 | 6.71e-01 | 7.61e-01 | 2.15e-01 | 6.03e-01 |
| Maturation of nucleoprotein | 10 | 9.37e-01 | 9.45e-01 | 0.2400 | -6.66e-03 | 8.46e-02 | 1.59e-01 | 1.59e-01 | 9.71e-01 | 6.43e-01 | 3.83e-01 | 3.84e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 55 | 1.53e-03 | 4.91e-03 | 0.2400 | 9.34e-02 | 1.89e-01 | -4.92e-02 | -1.03e-01 | 2.31e-01 | 1.52e-02 | 5.29e-01 | 1.87e-01 |
| mTORC1-mediated signalling | 23 | 5.30e-02 | 9.86e-02 | 0.2390 | -2.29e-02 | -3.77e-02 | -7.44e-02 | -2.23e-01 | 8.50e-01 | 7.54e-01 | 5.37e-01 | 6.45e-02 |
| Cleavage of the damaged purine | 10 | 6.05e-01 | 6.80e-01 | 0.2390 | 7.49e-02 | 3.37e-02 | 9.33e-02 | 2.04e-01 | 6.82e-01 | 8.54e-01 | 6.09e-01 | 2.64e-01 |
| Depurination | 10 | 6.05e-01 | 6.80e-01 | 0.2390 | 7.49e-02 | 3.37e-02 | 9.33e-02 | 2.04e-01 | 6.82e-01 | 8.54e-01 | 6.09e-01 | 2.64e-01 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 10 | 6.05e-01 | 6.80e-01 | 0.2390 | 7.49e-02 | 3.37e-02 | 9.33e-02 | 2.04e-01 | 6.82e-01 | 8.54e-01 | 6.09e-01 | 2.64e-01 |
| PI Metabolism | 68 | 1.15e-01 | 1.80e-01 | 0.2390 | 9.75e-02 | 3.76e-02 | 1.53e-01 | 1.51e-01 | 1.65e-01 | 5.93e-01 | 2.96e-02 | 3.18e-02 |
| Neddylation | 200 | 2.44e-06 | 1.74e-05 | 0.2390 | -6.44e-03 | -1.67e-02 | -1.38e-01 | -1.93e-01 | 8.76e-01 | 6.85e-01 | 7.79e-04 | 2.66e-06 |
| SUMOylation | 137 | 8.00e-07 | 6.99e-06 | 0.2380 | 2.02e-01 | 8.65e-02 | -1.08e-02 | 9.22e-02 | 4.79e-05 | 8.16e-02 | 8.27e-01 | 6.34e-02 |
| Downstream signaling events of B Cell Receptor (BCR) | 67 | 5.34e-06 | 3.61e-05 | 0.2380 | -1.00e-02 | 1.80e-01 | -4.74e-02 | -1.48e-01 | 8.87e-01 | 1.09e-02 | 5.03e-01 | 3.65e-02 |
| Interconversion of nucleotide di- and triphosphates | 21 | 1.97e-01 | 2.78e-01 | 0.2380 | -9.74e-02 | 9.97e-02 | 6.71e-02 | 1.80e-01 | 4.40e-01 | 4.29e-01 | 5.95e-01 | 1.53e-01 |
| Switching of origins to a post-replicative state | 79 | 1.82e-03 | 5.69e-03 | 0.2370 | 1.33e-01 | 1.94e-01 | 2.69e-02 | -9.61e-03 | 4.16e-02 | 2.88e-03 | 6.80e-01 | 8.83e-01 |
| Signaling by FGFR3 fusions in cancer | 10 | 7.50e-01 | 7.96e-01 | 0.2370 | 1.91e-01 | 1.24e-01 | -6.26e-02 | -1.30e-02 | 2.95e-01 | 4.96e-01 | 7.32e-01 | 9.43e-01 |
| Clathrin-mediated endocytosis | 108 | 5.41e-02 | 9.97e-02 | 0.2360 | 9.40e-02 | 1.21e-01 | 1.12e-01 | 1.41e-01 | 9.25e-02 | 3.04e-02 | 4.44e-02 | 1.18e-02 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 78 | 1.16e-02 | 2.75e-02 | 0.2350 | 1.92e-01 | 5.50e-02 | -1.00e-01 | -7.22e-02 | 3.41e-03 | 4.02e-01 | 1.26e-01 | 2.72e-01 |
| Asymmetric localization of PCP proteins | 55 | 3.70e-04 | 1.49e-03 | 0.2340 | 4.30e-02 | 1.76e-01 | -5.65e-02 | -1.37e-01 | 5.82e-01 | 2.39e-02 | 4.69e-01 | 7.93e-02 |
| Signaling by KIT in disease | 17 | 6.24e-01 | 6.94e-01 | 0.2340 | -1.40e-01 | -4.87e-03 | 1.55e-01 | 1.06e-01 | 3.18e-01 | 9.72e-01 | 2.68e-01 | 4.50e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 17 | 6.24e-01 | 6.94e-01 | 0.2340 | -1.40e-01 | -4.87e-03 | 1.55e-01 | 1.06e-01 | 3.18e-01 | 9.72e-01 | 2.68e-01 | 4.50e-01 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 63 | 5.13e-04 | 1.97e-03 | 0.2340 | 1.33e-01 | 1.58e-01 | -3.39e-02 | -1.06e-01 | 6.85e-02 | 3.08e-02 | 6.42e-01 | 1.48e-01 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 63 | 5.13e-04 | 1.97e-03 | 0.2340 | 1.33e-01 | 1.58e-01 | -3.39e-02 | -1.06e-01 | 6.85e-02 | 3.08e-02 | 6.42e-01 | 1.48e-01 |
| Metalloprotease DUBs | 15 | 4.99e-01 | 5.87e-01 | 0.2340 | 2.21e-01 | 4.56e-02 | -4.84e-02 | 3.59e-02 | 1.38e-01 | 7.60e-01 | 7.46e-01 | 8.10e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 15 | 3.68e-01 | 4.58e-01 | 0.2330 | 9.02e-04 | 1.08e-01 | 6.92e-02 | 1.95e-01 | 9.95e-01 | 4.71e-01 | 6.43e-01 | 1.91e-01 |
| HCMV Late Events | 43 | 1.23e-01 | 1.90e-01 | 0.2330 | 2.20e-01 | 7.05e-02 | 3.43e-02 | 9.58e-03 | 1.28e-02 | 4.24e-01 | 6.98e-01 | 9.14e-01 |
| VEGFR2 mediated vascular permeability | 23 | 5.44e-01 | 6.27e-01 | 0.2330 | -7.99e-02 | 1.19e-01 | 1.55e-01 | 9.90e-02 | 5.07e-01 | 3.23e-01 | 1.99e-01 | 4.11e-01 |
| Regulation of RAS by GAPs | 57 | 1.79e-04 | 7.84e-04 | 0.2330 | 8.77e-02 | 1.96e-01 | 5.13e-03 | -9.02e-02 | 2.53e-01 | 1.06e-02 | 9.47e-01 | 2.39e-01 |
| Centrosome maturation | 71 | 2.59e-02 | 5.36e-02 | 0.2320 | 9.05e-02 | -1.88e-02 | 1.36e-01 | 1.64e-01 | 1.88e-01 | 7.84e-01 | 4.87e-02 | 1.68e-02 |
| Recruitment of mitotic centrosome proteins and complexes | 71 | 2.59e-02 | 5.36e-02 | 0.2320 | 9.05e-02 | -1.88e-02 | 1.36e-01 | 1.64e-01 | 1.88e-01 | 7.84e-01 | 4.87e-02 | 1.68e-02 |
| UCH proteinases | 74 | 7.14e-05 | 3.39e-04 | 0.2320 | 7.06e-02 | 1.80e-01 | -5.26e-02 | -1.17e-01 | 2.95e-01 | 7.41e-03 | 4.35e-01 | 8.35e-02 |
| RNA Polymerase I Promoter Clearance | 43 | 1.08e-01 | 1.71e-01 | 0.2310 | 1.60e-01 | 1.55e-01 | -5.76e-03 | 6.16e-02 | 6.93e-02 | 7.96e-02 | 9.48e-01 | 4.85e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 77 | 8.60e-03 | 2.14e-02 | 0.2300 | 9.34e-02 | 2.08e-01 | 3.04e-02 | 1.82e-02 | 1.57e-01 | 1.67e-03 | 6.45e-01 | 7.82e-01 |
| Cargo concentration in the ER | 21 | 3.85e-01 | 4.75e-01 | 0.2300 | 2.08e-01 | 1.91e-02 | 8.90e-02 | 3.74e-02 | 9.92e-02 | 8.80e-01 | 4.80e-01 | 7.67e-01 |
| CDK-mediated phosphorylation and removal of Cdc6 | 63 | 8.41e-04 | 2.95e-03 | 0.2300 | 1.24e-01 | 1.74e-01 | -1.58e-02 | -8.28e-02 | 8.99e-02 | 1.69e-02 | 8.29e-01 | 2.57e-01 |
| Interleukin-2 family signaling | 22 | 3.42e-01 | 4.31e-01 | 0.2300 | -1.69e-01 | 8.77e-02 | 5.26e-02 | 1.18e-01 | 1.71e-01 | 4.77e-01 | 6.70e-01 | 3.40e-01 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 58 | 3.72e-04 | 1.49e-03 | 0.2290 | 8.09e-02 | 1.65e-01 | -4.59e-02 | -1.29e-01 | 2.87e-01 | 3.04e-02 | 5.46e-01 | 8.97e-02 |
| FGFR1 mutant receptor activation | 23 | 5.16e-01 | 6.04e-01 | 0.2290 | -4.52e-03 | -7.92e-02 | -1.83e-01 | -1.12e-01 | 9.70e-01 | 5.11e-01 | 1.29e-01 | 3.52e-01 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 36 | 3.03e-02 | 6.14e-02 | 0.2290 | -1.67e-01 | 1.22e-01 | -2.39e-02 | -9.41e-02 | 8.26e-02 | 2.05e-01 | 8.04e-01 | 3.29e-01 |
| Signaling by RAS mutants | 36 | 3.03e-02 | 6.14e-02 | 0.2290 | -1.67e-01 | 1.22e-01 | -2.39e-02 | -9.41e-02 | 8.26e-02 | 2.05e-01 | 8.04e-01 | 3.29e-01 |
| Signaling by moderate kinase activity BRAF mutants | 36 | 3.03e-02 | 6.14e-02 | 0.2290 | -1.67e-01 | 1.22e-01 | -2.39e-02 | -9.41e-02 | 8.26e-02 | 2.05e-01 | 8.04e-01 | 3.29e-01 |
| Signaling downstream of RAS mutants | 36 | 3.03e-02 | 6.14e-02 | 0.2290 | -1.67e-01 | 1.22e-01 | -2.39e-02 | -9.41e-02 | 8.26e-02 | 2.05e-01 | 8.04e-01 | 3.29e-01 |
| Cytosolic sulfonation of small molecules | 11 | 4.11e-01 | 5.01e-01 | 0.2280 | 2.86e-02 | -1.01e-01 | 8.44e-02 | 1.84e-01 | 8.69e-01 | 5.63e-01 | 6.28e-01 | 2.90e-01 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 62 | 6.40e-04 | 2.35e-03 | 0.2280 | 1.19e-01 | 1.69e-01 | -1.97e-02 | -9.36e-02 | 1.05e-01 | 2.19e-02 | 7.89e-01 | 2.03e-01 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 62 | 6.40e-04 | 2.35e-03 | 0.2280 | 1.19e-01 | 1.69e-01 | -1.97e-02 | -9.36e-02 | 1.05e-01 | 2.19e-02 | 7.89e-01 | 2.03e-01 |
| MAP2K and MAPK activation | 31 | 9.11e-02 | 1.49e-01 | 0.2270 | -7.50e-02 | 1.93e-01 | 9.36e-02 | 1.51e-02 | 4.70e-01 | 6.36e-02 | 3.67e-01 | 8.85e-01 |
| RUNX2 regulates osteoblast differentiation | 20 | 5.81e-01 | 6.60e-01 | 0.2270 | -4.20e-02 | -4.17e-02 | 1.61e-01 | 1.49e-01 | 7.45e-01 | 7.47e-01 | 2.13e-01 | 2.48e-01 |
| Pre-NOTCH Expression and Processing | 45 | 4.90e-02 | 9.16e-02 | 0.2260 | -9.13e-02 | 6.38e-02 | 8.78e-02 | 1.77e-01 | 2.90e-01 | 4.59e-01 | 3.08e-01 | 4.07e-02 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 50 | 1.29e-02 | 2.99e-02 | 0.2260 | -9.70e-02 | -1.84e-01 | 8.73e-02 | 1.12e-02 | 2.36e-01 | 2.44e-02 | 2.86e-01 | 8.91e-01 |
| RNA Polymerase I Transcription | 44 | 9.60e-02 | 1.56e-01 | 0.2260 | 1.44e-01 | 1.67e-01 | -1.72e-02 | 4.75e-02 | 9.97e-02 | 5.58e-02 | 8.44e-01 | 5.86e-01 |
| Metabolism of amino acids and derivatives | 224 | 1.42e-06 | 1.15e-05 | 0.2260 | -7.51e-02 | 3.55e-02 | -1.49e-01 | -1.48e-01 | 5.42e-02 | 3.63e-01 | 1.36e-04 | 1.44e-04 |
| SUMO E3 ligases SUMOylate target proteins | 131 | 1.17e-05 | 6.86e-05 | 0.2260 | 1.92e-01 | 8.30e-02 | -1.01e-02 | 8.43e-02 | 1.58e-04 | 1.02e-01 | 8.42e-01 | 9.67e-02 |
| Autophagy | 108 | 1.30e-05 | 7.53e-05 | 0.2250 | 4.62e-02 | -4.34e-02 | -8.92e-02 | -1.97e-01 | 4.08e-01 | 4.37e-01 | 1.10e-01 | 4.14e-04 |
| Mismatch Repair | 14 | 6.77e-01 | 7.37e-01 | 0.2250 | 1.68e-01 | -3.12e-02 | 9.52e-02 | 1.11e-01 | 2.76e-01 | 8.40e-01 | 5.38e-01 | 4.71e-01 |
| FRS-mediated FGFR3 signaling | 12 | 4.72e-01 | 5.58e-01 | 0.2250 | 8.49e-02 | 1.79e-01 | -4.12e-02 | -9.88e-02 | 6.11e-01 | 2.83e-01 | 8.05e-01 | 5.54e-01 |
| Metabolism of carbohydrates | 203 | 4.03e-05 | 2.04e-04 | 0.2240 | -1.54e-01 | 3.34e-02 | 1.04e-01 | 1.21e-01 | 1.63e-04 | 4.15e-01 | 1.12e-02 | 3.15e-03 |
| Purine salvage | 13 | 4.30e-01 | 5.17e-01 | 0.2240 | -2.08e-01 | 4.01e-02 | -2.52e-02 | 6.74e-02 | 1.94e-01 | 8.03e-01 | 8.75e-01 | 6.74e-01 |
| CLEC7A (Dectin-1) signaling | 80 | 3.61e-05 | 1.86e-04 | 0.2230 | -1.92e-02 | 1.74e-01 | -6.26e-02 | -1.25e-01 | 7.67e-01 | 7.40e-03 | 3.34e-01 | 5.45e-02 |
| Metabolism of vitamins and cofactors | 126 | 7.40e-03 | 1.88e-02 | 0.2230 | -7.23e-02 | -1.86e-01 | -6.12e-02 | -7.82e-02 | 1.63e-01 | 3.20e-04 | 2.37e-01 | 1.31e-01 |
| Signaling by RAF1 mutants | 32 | 6.27e-02 | 1.12e-01 | 0.2230 | -1.76e-01 | 1.20e-01 | 1.11e-02 | -6.32e-02 | 8.45e-02 | 2.39e-01 | 9.14e-01 | 5.36e-01 |
| Neuronal System | 173 | 3.21e-05 | 1.67e-04 | 0.2230 | -2.18e-01 | 6.61e-03 | 4.33e-02 | 2.01e-02 | 8.56e-07 | 8.81e-01 | 3.28e-01 | 6.49e-01 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 30 | 2.66e-01 | 3.49e-01 | 0.2220 | 1.60e-01 | -2.64e-02 | 8.51e-02 | 1.26e-01 | 1.29e-01 | 8.02e-01 | 4.20e-01 | 2.32e-01 |
| Glycerophospholipid biosynthesis | 80 | 5.06e-03 | 1.35e-02 | 0.2220 | -1.48e-01 | -1.59e-01 | 4.32e-02 | -1.88e-02 | 2.28e-02 | 1.44e-02 | 5.05e-01 | 7.72e-01 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 23 | 5.81e-01 | 6.60e-01 | 0.2210 | 4.51e-02 | 1.64e-01 | 6.41e-02 | 1.26e-01 | 7.08e-01 | 1.75e-01 | 5.95e-01 | 2.95e-01 |
| Programmed Cell Death | 144 | 1.58e-03 | 5.04e-03 | 0.2210 | -4.83e-02 | 1.70e-01 | 1.08e-01 | 7.70e-02 | 3.18e-01 | 4.46e-04 | 2.62e-02 | 1.12e-01 |
| ADORA2B mediated anti-inflammatory cytokines production | 38 | 2.68e-01 | 3.51e-01 | 0.2210 | -1.40e-01 | -3.61e-02 | 1.29e-01 | 1.06e-01 | 1.36e-01 | 7.00e-01 | 1.68e-01 | 2.60e-01 |
| G alpha (q) signalling events | 78 | 1.71e-02 | 3.80e-02 | 0.2210 | -1.42e-01 | -3.60e-02 | 1.04e-01 | 1.29e-01 | 3.07e-02 | 5.83e-01 | 1.14e-01 | 4.99e-02 |
| ABC-family proteins mediated transport | 76 | 1.87e-03 | 5.82e-03 | 0.2210 | 4.98e-02 | -1.26e-02 | -9.97e-02 | -1.90e-01 | 4.54e-01 | 8.49e-01 | 1.34e-01 | 4.27e-03 |
| Negative regulation of FGFR1 signaling | 19 | 3.08e-01 | 3.92e-01 | 0.2200 | 2.66e-02 | 2.03e-01 | -4.46e-02 | -6.64e-02 | 8.41e-01 | 1.25e-01 | 7.37e-01 | 6.17e-01 |
| Post NMDA receptor activation events | 44 | 1.85e-01 | 2.65e-01 | 0.2200 | -1.89e-01 | -3.12e-03 | -7.04e-02 | -8.81e-02 | 3.06e-02 | 9.71e-01 | 4.19e-01 | 3.12e-01 |
| RAS processing | 18 | 2.06e-01 | 2.88e-01 | 0.2200 | -1.57e-01 | 1.09e-01 | -1.30e-02 | -1.08e-01 | 2.51e-01 | 4.23e-01 | 9.24e-01 | 4.27e-01 |
| Opioid Signalling | 64 | 7.01e-02 | 1.21e-01 | 0.2190 | -2.01e-01 | -8.77e-02 | 4.90e-03 | -8.84e-03 | 5.51e-03 | 2.26e-01 | 9.46e-01 | 9.03e-01 |
| Miscellaneous transport and binding events | 16 | 5.47e-02 | 1.01e-01 | 0.2190 | 1.49e-01 | -9.23e-02 | 1.21e-01 | -5.17e-02 | 3.03e-01 | 5.23e-01 | 4.02e-01 | 7.21e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 74 | 7.42e-02 | 1.26e-01 | 0.2180 | 1.25e-01 | 2.44e-02 | 1.09e-01 | 1.40e-01 | 6.42e-02 | 7.17e-01 | 1.04e-01 | 3.79e-02 |
| Developmental Biology | 582 | 2.79e-10 | 4.65e-09 | 0.2170 | -7.01e-02 | 1.36e-01 | 1.01e-01 | 1.18e-01 | 4.43e-03 | 3.63e-08 | 4.40e-05 | 1.77e-06 |
| Cell-cell junction organization | 22 | 5.54e-01 | 6.34e-01 | 0.2170 | -1.41e-01 | 6.74e-02 | 1.30e-01 | 7.54e-02 | 2.54e-01 | 5.84e-01 | 2.91e-01 | 5.41e-01 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 10 | 8.68e-01 | 9.02e-01 | 0.2160 | -1.98e-01 | -3.41e-02 | -5.03e-02 | -6.39e-02 | 2.79e-01 | 8.52e-01 | 7.83e-01 | 7.26e-01 |
| alpha-linolenic acid (ALA) metabolism | 10 | 8.68e-01 | 9.02e-01 | 0.2160 | -1.98e-01 | -3.41e-02 | -5.03e-02 | -6.39e-02 | 2.79e-01 | 8.52e-01 | 7.83e-01 | 7.26e-01 |
| RAB geranylgeranylation | 41 | 6.63e-02 | 1.16e-01 | 0.2160 | 2.04e-01 | 2.19e-02 | 6.75e-02 | 4.86e-05 | 2.36e-02 | 8.08e-01 | 4.55e-01 | 1.00e+00 |
| Signaling by TGF-beta Receptor Complex | 66 | 1.02e-02 | 2.48e-02 | 0.2160 | 1.18e-01 | 1.60e-01 | -8.17e-02 | -2.73e-02 | 9.92e-02 | 2.49e-02 | 2.52e-01 | 7.02e-01 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 63 | 7.46e-04 | 2.64e-03 | 0.2160 | 1.16e-01 | 1.49e-01 | -2.27e-02 | -1.03e-01 | 1.12e-01 | 4.16e-02 | 7.56e-01 | 1.60e-01 |
| Netrin-1 signaling | 38 | 1.89e-01 | 2.70e-01 | 0.2160 | -2.07e-01 | -4.03e-02 | 1.69e-02 | -4.20e-02 | 2.72e-02 | 6.68e-01 | 8.57e-01 | 6.54e-01 |
| Cyclin E associated events during G1/S transition | 75 | 1.22e-02 | 2.87e-02 | 0.2150 | 8.58e-02 | 1.97e-01 | 1.62e-02 | 1.59e-03 | 2.00e-01 | 3.29e-03 | 8.09e-01 | 9.81e-01 |
| Notch-HLH transcription pathway | 24 | 3.68e-01 | 4.58e-01 | 0.2150 | -2.07e-01 | 1.41e-02 | -5.62e-02 | -1.58e-02 | 8.00e-02 | 9.05e-01 | 6.34e-01 | 8.94e-01 |
| PI-3K cascade:FGFR4 | 10 | 8.43e-01 | 8.81e-01 | 0.2150 | -1.06e-01 | -7.81e-03 | -1.54e-01 | -1.06e-01 | 5.62e-01 | 9.66e-01 | 4.00e-01 | 5.61e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 95 | 1.23e-02 | 2.88e-02 | 0.2140 | -1.96e-01 | -1.51e-02 | 7.24e-02 | 4.54e-02 | 9.93e-04 | 8.00e-01 | 2.23e-01 | 4.46e-01 |
| RNA Polymerase III Abortive And Retractive Initiation | 39 | 6.18e-02 | 1.11e-01 | 0.2140 | 1.94e-01 | 4.91e-02 | -4.62e-03 | -7.55e-02 | 3.65e-02 | 5.96e-01 | 9.60e-01 | 4.15e-01 |
| RNA Polymerase III Transcription | 39 | 6.18e-02 | 1.11e-01 | 0.2140 | 1.94e-01 | 4.91e-02 | -4.62e-03 | -7.55e-02 | 3.65e-02 | 5.96e-01 | 9.60e-01 | 4.15e-01 |
| Fanconi Anemia Pathway | 25 | 2.21e-01 | 3.04e-01 | 0.2130 | 1.92e-01 | 5.97e-02 | -4.76e-02 | 5.28e-02 | 9.67e-02 | 6.06e-01 | 6.81e-01 | 6.48e-01 |
| Apoptosis | 134 | 3.30e-03 | 9.51e-03 | 0.2130 | -4.33e-02 | 1.72e-01 | 9.60e-02 | 6.94e-02 | 3.89e-01 | 6.12e-04 | 5.57e-02 | 1.67e-01 |
| Signaling by ERBB2 in Cancer | 18 | 6.35e-01 | 7.04e-01 | 0.2130 | -1.27e-02 | 1.01e-01 | 8.78e-02 | 1.65e-01 | 9.26e-01 | 4.59e-01 | 5.19e-01 | 2.26e-01 |
| Regulation of TP53 Degradation | 32 | 3.77e-01 | 4.67e-01 | 0.2120 | 2.09e-01 | 3.72e-02 | -7.11e-05 | 3.99e-03 | 4.09e-02 | 7.16e-01 | 9.99e-01 | 9.69e-01 |
| Regulation of APC/C activators between G1/S and early anaphase | 67 | 1.09e-03 | 3.65e-03 | 0.2110 | 1.07e-01 | 1.55e-01 | -2.35e-02 | -9.21e-02 | 1.30e-01 | 2.82e-02 | 7.40e-01 | 1.93e-01 |
| Transcriptional regulation by RUNX3 | 86 | 3.88e-03 | 1.07e-02 | 0.2110 | 4.60e-03 | 2.03e-01 | 5.58e-02 | 1.69e-02 | 9.41e-01 | 1.20e-03 | 3.72e-01 | 7.87e-01 |
| APC/C-mediated degradation of cell cycle proteins | 72 | 1.42e-03 | 4.61e-03 | 0.2100 | 1.34e-01 | 1.46e-01 | -4.98e-03 | -7.06e-02 | 5.05e-02 | 3.30e-02 | 9.42e-01 | 3.01e-01 |
| Regulation of mitotic cell cycle | 72 | 1.42e-03 | 4.61e-03 | 0.2100 | 1.34e-01 | 1.46e-01 | -4.98e-03 | -7.06e-02 | 5.05e-02 | 3.30e-02 | 9.42e-01 | 3.01e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 15 | 9.06e-01 | 9.25e-01 | 0.2090 | 9.12e-02 | 1.12e-01 | 9.47e-02 | 1.17e-01 | 5.41e-01 | 4.51e-01 | 5.25e-01 | 4.34e-01 |
| Signaling by TGFB family members | 84 | 3.97e-03 | 1.09e-02 | 0.2080 | 5.22e-02 | 1.11e-01 | -1.38e-01 | -9.57e-02 | 4.09e-01 | 7.85e-02 | 2.87e-02 | 1.30e-01 |
| Disease | 1012 | 7.50e-12 | 1.62e-10 | 0.2080 | 7.39e-03 | 1.34e-01 | 1.08e-01 | 1.17e-01 | 6.99e-01 | 2.34e-12 | 1.58e-08 | 7.33e-10 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 62 | 2.65e-01 | 3.49e-01 | 0.2080 | -6.02e-03 | 1.63e-01 | 9.21e-02 | 8.90e-02 | 9.35e-01 | 2.64e-02 | 2.10e-01 | 2.26e-01 |
| Signalling to ERKs | 29 | 1.46e-01 | 2.18e-01 | 0.2070 | -5.96e-02 | 1.67e-01 | -6.51e-02 | -8.51e-02 | 5.79e-01 | 1.20e-01 | 5.44e-01 | 4.28e-01 |
| Regulation of insulin secretion | 46 | 2.53e-01 | 3.38e-01 | 0.2060 | -1.18e-01 | -2.38e-02 | 1.15e-01 | 1.22e-01 | 1.68e-01 | 7.80e-01 | 1.76e-01 | 1.53e-01 |
| Negative regulation of the PI3K/AKT network | 69 | 1.53e-01 | 2.26e-01 | 0.2060 | 1.40e-02 | 1.63e-01 | 1.02e-01 | 7.39e-02 | 8.40e-01 | 1.95e-02 | 1.44e-01 | 2.89e-01 |
| Biological oxidations | 85 | 3.69e-02 | 7.21e-02 | 0.2060 | -1.42e-01 | -1.18e-01 | -8.05e-02 | -4.37e-02 | 2.40e-02 | 5.98e-02 | 2.01e-01 | 4.87e-01 |
| RNA Polymerase III Transcription Termination | 22 | 1.39e-01 | 2.10e-01 | 0.2060 | 1.53e-01 | 4.01e-02 | -2.16e-02 | -1.30e-01 | 2.13e-01 | 7.45e-01 | 8.61e-01 | 2.93e-01 |
| COPII-mediated vesicle transport | 56 | 2.35e-03 | 7.03e-03 | 0.2060 | 1.79e-01 | 6.63e-02 | 3.28e-02 | -6.82e-02 | 2.04e-02 | 3.91e-01 | 6.72e-01 | 3.78e-01 |
| Glucagon-type ligand receptors | 11 | 7.80e-01 | 8.23e-01 | 0.2060 | -9.73e-02 | -1.08e-01 | 1.08e-01 | 9.82e-02 | 5.77e-01 | 5.36e-01 | 5.37e-01 | 5.73e-01 |
| DNA Repair | 242 | 1.28e-05 | 7.44e-05 | 0.2050 | 1.83e-01 | 7.26e-02 | 1.60e-02 | 5.57e-02 | 1.04e-06 | 5.31e-02 | 6.69e-01 | 1.38e-01 |
| Inositol phosphate metabolism | 39 | 3.23e-01 | 4.10e-01 | 0.2050 | -1.88e-01 | -6.82e-02 | -4.08e-02 | -2.54e-02 | 4.26e-02 | 4.61e-01 | 6.59e-01 | 7.84e-01 |
| Negative regulation of FGFR4 signaling | 19 | 4.08e-01 | 4.99e-01 | 0.2050 | -1.11e-02 | 2.04e-01 | 1.17e-02 | -2.07e-02 | 9.34e-01 | 1.25e-01 | 9.30e-01 | 8.76e-01 |
| Regulation of TP53 Expression and Degradation | 33 | 3.79e-01 | 4.69e-01 | 0.2050 | 2.04e-01 | 9.14e-03 | 1.73e-03 | 1.69e-02 | 4.27e-02 | 9.28e-01 | 9.86e-01 | 8.67e-01 |
| Asparagine N-linked glycosylation | 237 | 9.33e-06 | 5.83e-05 | 0.2050 | 5.47e-02 | 1.14e-01 | 1.41e-01 | 7.78e-02 | 1.50e-01 | 2.67e-03 | 1.97e-04 | 4.03e-02 |
| Transmission across Chemical Synapses | 123 | 4.49e-03 | 1.21e-02 | 0.2050 | -1.85e-01 | -4.94e-03 | 7.50e-02 | 4.59e-02 | 4.15e-04 | 9.25e-01 | 1.52e-01 | 3.81e-01 |
| TBC/RABGAPs | 39 | 1.07e-01 | 1.71e-01 | 0.2050 | 5.57e-02 | 1.23e-01 | -9.56e-02 | -1.20e-01 | 5.48e-01 | 1.83e-01 | 3.02e-01 | 1.94e-01 |
| Synthesis of PA | 21 | 6.09e-01 | 6.83e-01 | 0.2040 | -1.33e-01 | -1.52e-01 | 5.54e-03 | -3.03e-02 | 2.91e-01 | 2.28e-01 | 9.65e-01 | 8.10e-01 |
| Signaling by Insulin receptor | 48 | 1.13e-01 | 1.78e-01 | 0.2040 | 4.09e-02 | 1.02e-01 | 1.55e-01 | 7.40e-02 | 6.24e-01 | 2.21e-01 | 6.29e-02 | 3.76e-01 |
| Signaling by EGFR in Cancer | 18 | 7.49e-01 | 7.96e-01 | 0.2040 | 1.11e-01 | 1.38e-01 | 3.91e-02 | 9.19e-02 | 4.16e-01 | 3.09e-01 | 7.74e-01 | 5.00e-01 |
| Prostacyclin signalling through prostacyclin receptor | 12 | 8.35e-01 | 8.75e-01 | 0.2020 | -9.04e-02 | -4.90e-02 | 1.31e-01 | 1.15e-01 | 5.88e-01 | 7.69e-01 | 4.32e-01 | 4.91e-01 |
| Late endosomal microautophagy | 23 | 3.41e-02 | 6.75e-02 | 0.2020 | -1.28e-01 | 8.21e-02 | 1.55e-02 | -1.33e-01 | 2.90e-01 | 4.96e-01 | 8.98e-01 | 2.70e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 32 | 4.69e-01 | 5.57e-01 | 0.2010 | -5.62e-02 | -1.97e-02 | 1.25e-01 | 1.45e-01 | 5.83e-01 | 8.47e-01 | 2.20e-01 | 1.55e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 66 | 3.52e-01 | 4.40e-01 | 0.2000 | -3.87e-02 | 1.16e-01 | 1.21e-01 | 1.03e-01 | 5.88e-01 | 1.05e-01 | 8.95e-02 | 1.49e-01 |
| Signaling by FGFR3 | 29 | 2.89e-01 | 3.75e-01 | 0.2000 | 9.84e-02 | 1.68e-01 | -2.08e-02 | -3.90e-02 | 3.59e-01 | 1.17e-01 | 8.46e-01 | 7.17e-01 |
| Tie2 Signaling | 13 | 6.61e-01 | 7.24e-01 | 0.1990 | 1.57e-01 | 3.65e-02 | 1.11e-01 | 3.66e-02 | 3.26e-01 | 8.20e-01 | 4.89e-01 | 8.19e-01 |
| Cellular responses to external stimuli | 410 | 4.85e-11 | 9.78e-10 | 0.1990 | 4.88e-02 | 1.91e-01 | 1.27e-02 | 2.49e-02 | 9.34e-02 | 4.74e-11 | 6.61e-01 | 3.92e-01 |
| Cargo trafficking to the periciliary membrane | 42 | 7.99e-02 | 1.35e-01 | 0.1990 | 1.37e-01 | -5.96e-02 | 1.19e-01 | 5.66e-02 | 1.26e-01 | 5.04e-01 | 1.83e-01 | 5.26e-01 |
| Integration of energy metabolism | 71 | 1.13e-01 | 1.77e-01 | 0.1980 | -1.86e-01 | -5.27e-02 | -2.07e-02 | -3.55e-02 | 6.73e-03 | 4.43e-01 | 7.63e-01 | 6.06e-01 |
| Cellular responses to stress | 406 | 4.37e-11 | 8.97e-10 | 0.1980 | 4.79e-02 | 1.90e-01 | 8.03e-03 | 2.14e-02 | 1.01e-01 | 6.80e-11 | 7.83e-01 | 4.64e-01 |
| Downstream signal transduction | 27 | 3.44e-01 | 4.32e-01 | 0.1980 | -1.76e-01 | 8.08e-02 | -5.55e-03 | 3.70e-02 | 1.13e-01 | 4.68e-01 | 9.60e-01 | 7.39e-01 |
| RHO GTPases Activate NADPH Oxidases | 13 | 8.37e-01 | 8.76e-01 | 0.1970 | -6.05e-02 | 1.63e-01 | 7.31e-02 | 5.72e-02 | 7.06e-01 | 3.09e-01 | 6.48e-01 | 7.21e-01 |
| Nucleobase catabolism | 21 | 6.01e-01 | 6.77e-01 | 0.1970 | -1.47e-01 | -9.17e-02 | 6.95e-02 | 6.28e-02 | 2.45e-01 | 4.67e-01 | 5.81e-01 | 6.18e-01 |
| Cleavage of the damaged pyrimidine | 14 | 9.04e-01 | 9.25e-01 | 0.1960 | 5.28e-02 | 2.69e-02 | 1.26e-01 | 1.38e-01 | 7.33e-01 | 8.62e-01 | 4.14e-01 | 3.71e-01 |
| Depyrimidination | 14 | 9.04e-01 | 9.25e-01 | 0.1960 | 5.28e-02 | 2.69e-02 | 1.26e-01 | 1.38e-01 | 7.33e-01 | 8.62e-01 | 4.14e-01 | 3.71e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 14 | 9.04e-01 | 9.25e-01 | 0.1960 | 5.28e-02 | 2.69e-02 | 1.26e-01 | 1.38e-01 | 7.33e-01 | 8.62e-01 | 4.14e-01 | 3.71e-01 |
| APC-Cdc20 mediated degradation of Nek2A | 21 | 5.96e-01 | 6.73e-01 | 0.1950 | 1.90e-01 | 1.89e-02 | -1.94e-02 | 3.00e-02 | 1.31e-01 | 8.81e-01 | 8.78e-01 | 8.12e-01 |
| Activated NTRK2 signals through FRS2 and FRS3 | 10 | 5.51e-01 | 6.32e-01 | 0.1940 | 4.68e-02 | 1.74e-01 | 6.11e-02 | -4.09e-02 | 7.98e-01 | 3.42e-01 | 7.38e-01 | 8.23e-01 |
| PCP/CE pathway | 79 | 8.96e-04 | 3.07e-03 | 0.1940 | -1.44e-02 | 1.87e-01 | 8.66e-03 | -4.90e-02 | 8.26e-01 | 4.11e-03 | 8.94e-01 | 4.52e-01 |
| AKT phosphorylates targets in the cytosol | 14 | 5.48e-01 | 6.30e-01 | 0.1940 | -1.49e-01 | 1.08e-01 | 5.97e-02 | -2.09e-02 | 3.36e-01 | 4.86e-01 | 6.99e-01 | 8.93e-01 |
| Base-Excision Repair, AP Site Formation | 16 | 6.49e-01 | 7.16e-01 | 0.1940 | 3.01e-02 | -2.48e-04 | 9.63e-02 | 1.66e-01 | 8.35e-01 | 9.99e-01 | 5.05e-01 | 2.52e-01 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 5.26e-01 | 6.11e-01 | 0.1940 | -1.26e-01 | -2.46e-02 | -8.08e-02 | -1.21e-01 | 2.25e-01 | 8.13e-01 | 4.37e-01 | 2.45e-01 |
| Interleukin-7 signaling | 12 | 5.29e-01 | 6.14e-01 | 0.1940 | -1.68e-01 | -4.27e-02 | 5.16e-02 | -6.89e-02 | 3.13e-01 | 7.98e-01 | 7.57e-01 | 6.79e-01 |
| Arachidonic acid metabolism | 19 | 6.72e-01 | 7.33e-01 | 0.1940 | -1.54e-01 | -7.47e-02 | 7.72e-02 | 4.56e-02 | 2.44e-01 | 5.73e-01 | 5.60e-01 | 7.31e-01 |
| Ub-specific processing proteases | 145 | 1.15e-05 | 6.77e-05 | 0.1930 | 9.78e-02 | 8.85e-02 | -6.75e-02 | -1.24e-01 | 4.28e-02 | 6.69e-02 | 1.62e-01 | 1.04e-02 |
| VxPx cargo-targeting to cilium | 17 | 3.50e-01 | 4.39e-01 | 0.1930 | -4.19e-02 | -1.18e-01 | 1.41e-01 | 3.90e-02 | 7.65e-01 | 4.00e-01 | 3.14e-01 | 7.81e-01 |
| Budding and maturation of HIV virion | 22 | 1.65e-02 | 3.70e-02 | 0.1920 | 4.63e-02 | 1.37e-01 | 1.07e-01 | -6.62e-02 | 7.07e-01 | 2.66e-01 | 3.86e-01 | 5.91e-01 |
| RNA Polymerase I Transcription Initiation | 40 | 2.19e-01 | 3.02e-01 | 0.1920 | 1.43e-01 | 1.19e-01 | -3.63e-02 | 2.84e-02 | 1.18e-01 | 1.95e-01 | 6.91e-01 | 7.56e-01 |
| MAP kinase activation | 59 | 1.46e-01 | 2.18e-01 | 0.1910 | -9.23e-02 | 2.34e-02 | -1.04e-01 | -1.30e-01 | 2.21e-01 | 7.56e-01 | 1.68e-01 | 8.53e-02 |
| Glutathione synthesis and recycling | 10 | 7.86e-01 | 8.29e-01 | 0.1910 | -6.29e-02 | 1.13e-01 | -9.58e-02 | -1.03e-01 | 7.31e-01 | 5.36e-01 | 6.00e-01 | 5.73e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 15 | 7.42e-01 | 7.93e-01 | 0.1910 | 1.30e-01 | -4.85e-02 | 9.63e-02 | 8.97e-02 | 3.85e-01 | 7.45e-01 | 5.19e-01 | 5.48e-01 |
| Toll-like Receptor Cascades | 115 | 9.28e-02 | 1.51e-01 | 0.1900 | -3.06e-02 | 1.41e-01 | 8.72e-02 | 8.77e-02 | 5.72e-01 | 9.03e-03 | 1.07e-01 | 1.05e-01 |
| Signal Transduction | 1391 | 4.35e-16 | 2.00e-14 | 0.1900 | -6.30e-02 | 1.02e-01 | 9.79e-02 | 1.10e-01 | 1.48e-04 | 6.65e-10 | 3.68e-09 | 3.32e-11 |
| Cytochrome c-mediated apoptotic response | 10 | 8.91e-01 | 9.21e-01 | 0.1900 | -1.13e-02 | 1.70e-01 | 7.15e-02 | 4.40e-02 | 9.51e-01 | 3.53e-01 | 6.96e-01 | 8.10e-01 |
| G2/M Transition | 153 | 9.04e-03 | 2.22e-02 | 0.1890 | 1.43e-01 | 1.11e-01 | 4.22e-02 | 3.66e-02 | 2.33e-03 | 1.85e-02 | 3.69e-01 | 4.36e-01 |
| CTLA4 inhibitory signaling | 17 | 6.08e-01 | 6.82e-01 | 0.1890 | -2.88e-02 | 1.44e-01 | 1.13e-01 | 3.88e-02 | 8.37e-01 | 3.04e-01 | 4.22e-01 | 7.82e-01 |
| Signaling by FGFR1 in disease | 30 | 5.67e-01 | 6.48e-01 | 0.1890 | 1.14e-02 | -1.03e-01 | -1.37e-01 | -7.91e-02 | 9.14e-01 | 3.29e-01 | 1.96e-01 | 4.54e-01 |
| Metabolism | 1368 | 1.31e-15 | 5.20e-14 | 0.1890 | -1.15e-01 | -9.36e-02 | -7.52e-02 | -8.96e-02 | 5.87e-12 | 2.19e-08 | 6.82e-06 | 8.49e-08 |
| Signaling by BRAF and RAF fusions | 52 | 1.25e-01 | 1.92e-01 | 0.1870 | -1.74e-01 | 6.34e-02 | 2.04e-02 | -1.73e-02 | 3.00e-02 | 4.29e-01 | 7.99e-01 | 8.29e-01 |
| Signaling by NOTCH4 | 70 | 5.80e-03 | 1.52e-02 | 0.1870 | 2.40e-02 | 1.81e-01 | 2.53e-02 | -3.30e-02 | 7.29e-01 | 9.01e-03 | 7.15e-01 | 6.34e-01 |
| Gene expression (Transcription) | 994 | 9.15e-22 | 8.04e-20 | 0.1870 | 1.67e-01 | 7.00e-02 | -4.63e-02 | -4.50e-03 | 3.56e-18 | 2.72e-04 | 1.60e-02 | 8.15e-01 |
| Golgi-to-ER retrograde transport | 89 | 5.86e-02 | 1.06e-01 | 0.1870 | 9.81e-02 | 1.05e-01 | 1.05e-01 | 5.63e-02 | 1.11e-01 | 8.63e-02 | 8.75e-02 | 3.59e-01 |
| Regulation of FZD by ubiquitination | 11 | 6.22e-01 | 6.94e-01 | 0.1870 | -1.02e-01 | 1.18e-01 | -1.00e-01 | -2.05e-02 | 5.57e-01 | 4.97e-01 | 5.66e-01 | 9.06e-01 |
| Oncogene Induced Senescence | 29 | 4.03e-01 | 4.94e-01 | 0.1870 | 1.12e-01 | 5.86e-02 | 4.88e-02 | 1.28e-01 | 2.97e-01 | 5.85e-01 | 6.49e-01 | 2.32e-01 |
| Mitotic G2-G2/M phases | 155 | 1.19e-02 | 2.79e-02 | 0.1860 | 1.36e-01 | 1.13e-01 | 4.34e-02 | 3.95e-02 | 3.68e-03 | 1.55e-02 | 3.53e-01 | 3.98e-01 |
| FRS-mediated FGFR2 signaling | 12 | 4.14e-01 | 5.03e-01 | 0.1860 | -5.92e-02 | 1.55e-01 | 2.59e-02 | -7.95e-02 | 7.23e-01 | 3.52e-01 | 8.76e-01 | 6.34e-01 |
| Signaling by FGFR1 | 34 | 4.29e-01 | 5.16e-01 | 0.1850 | 8.82e-02 | 1.58e-01 | 3.69e-02 | 1.65e-02 | 3.74e-01 | 1.12e-01 | 7.10e-01 | 8.68e-01 |
| Protein methylation | 10 | 3.23e-01 | 4.10e-01 | 0.1850 | -5.13e-03 | 1.23e-01 | 8.28e-03 | -1.38e-01 | 9.78e-01 | 5.01e-01 | 9.64e-01 | 4.51e-01 |
| Activation of NMDA receptors and postsynaptic events | 52 | 2.11e-01 | 2.93e-01 | 0.1840 | -1.81e-01 | 2.27e-02 | -9.28e-03 | -2.46e-02 | 2.43e-02 | 7.78e-01 | 9.08e-01 | 7.59e-01 |
| Transport to the Golgi and subsequent modification | 136 | 3.46e-04 | 1.40e-03 | 0.1830 | 6.55e-02 | 8.60e-02 | 1.38e-01 | 5.46e-02 | 1.89e-01 | 8.45e-02 | 5.70e-03 | 2.73e-01 |
| Uptake and actions of bacterial toxins | 21 | 4.61e-01 | 5.48e-01 | 0.1830 | -1.28e-01 | 1.18e-01 | -2.10e-02 | -5.42e-02 | 3.10e-01 | 3.50e-01 | 8.68e-01 | 6.67e-01 |
| Synthesis of PIPs at the plasma membrane | 44 | 4.73e-01 | 5.58e-01 | 0.1810 | 9.47e-02 | 1.49e-02 | 1.19e-01 | 9.83e-02 | 2.78e-01 | 8.64e-01 | 1.74e-01 | 2.60e-01 |
| Cellular Senescence | 117 | 1.64e-01 | 2.39e-01 | 0.1810 | 7.39e-02 | 1.04e-01 | 7.52e-02 | 1.04e-01 | 1.69e-01 | 5.17e-02 | 1.61e-01 | 5.26e-02 |
| PI3K Cascade | 23 | 6.61e-01 | 7.24e-01 | 0.1810 | 1.44e-02 | 3.59e-02 | -1.14e-01 | -1.36e-01 | 9.05e-01 | 7.66e-01 | 3.45e-01 | 2.60e-01 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 7.41e-01 | 7.93e-01 | 0.1800 | 1.20e-01 | -9.47e-05 | 7.75e-02 | 1.10e-01 | 3.55e-01 | 9.99e-01 | 5.49e-01 | 3.95e-01 |
| TP53 Regulates Metabolic Genes | 79 | 1.48e-02 | 3.38e-02 | 0.1800 | -6.97e-02 | -6.92e-02 | -4.93e-02 | -1.42e-01 | 2.85e-01 | 2.88e-01 | 4.50e-01 | 2.90e-02 |
| Glucose metabolism | 68 | 5.24e-01 | 6.09e-01 | 0.1800 | -2.89e-02 | -8.90e-02 | -1.17e-01 | -9.97e-02 | 6.81e-01 | 2.05e-01 | 9.66e-02 | 1.56e-01 |
| NR1H2 and NR1H3-mediated signaling | 34 | 6.67e-01 | 7.29e-01 | 0.1800 | -9.90e-02 | -1.11e-01 | -8.01e-02 | -5.98e-02 | 3.18e-01 | 2.61e-01 | 4.19e-01 | 5.46e-01 |
| Activation of HOX genes during differentiation | 48 | 3.07e-01 | 3.92e-01 | 0.1790 | 1.54e-01 | 8.80e-02 | -2.32e-02 | 1.23e-02 | 6.49e-02 | 2.92e-01 | 7.81e-01 | 8.83e-01 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 48 | 3.07e-01 | 3.92e-01 | 0.1790 | 1.54e-01 | 8.80e-02 | -2.32e-02 | 1.23e-02 | 6.49e-02 | 2.92e-01 | 7.81e-01 | 8.83e-01 |
| Amino acids regulate mTORC1 | 45 | 6.40e-02 | 1.13e-01 | 0.1790 | -4.57e-02 | 1.25e-01 | 1.18e-01 | 2.33e-02 | 5.96e-01 | 1.47e-01 | 1.72e-01 | 7.87e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 19 | 6.44e-01 | 7.11e-01 | 0.1790 | 1.70e-01 | -4.27e-02 | -1.14e-02 | 3.33e-02 | 1.99e-01 | 7.48e-01 | 9.31e-01 | 8.02e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 19 | 6.44e-01 | 7.11e-01 | 0.1790 | 1.70e-01 | -4.27e-02 | -1.14e-02 | 3.33e-02 | 1.99e-01 | 7.48e-01 | 9.31e-01 | 8.02e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 17 | 9.12e-01 | 9.28e-01 | 0.1780 | 7.55e-02 | 8.77e-02 | 7.72e-02 | 1.11e-01 | 5.90e-01 | 5.31e-01 | 5.82e-01 | 4.28e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 17 | 9.12e-01 | 9.28e-01 | 0.1780 | 7.55e-02 | 8.77e-02 | 7.72e-02 | 1.11e-01 | 5.90e-01 | 5.31e-01 | 5.82e-01 | 4.28e-01 |
| Costimulation by the CD28 family | 39 | 4.30e-01 | 5.17e-01 | 0.1780 | -1.05e-02 | 1.40e-01 | 9.64e-02 | 5.13e-02 | 9.10e-01 | 1.31e-01 | 2.98e-01 | 5.80e-01 |
| Regulation of PTEN gene transcription | 57 | 1.33e-01 | 2.02e-01 | 0.1770 | 5.10e-02 | 1.68e-01 | -1.66e-02 | 1.76e-02 | 5.06e-01 | 2.89e-02 | 8.29e-01 | 8.18e-01 |
| SHC-mediated cascade:FGFR1 | 10 | 8.83e-01 | 9.15e-01 | 0.1770 | -1.80e-02 | 1.00e-01 | 1.31e-01 | 6.10e-02 | 9.21e-01 | 5.84e-01 | 4.73e-01 | 7.38e-01 |
| WNT ligand biogenesis and trafficking | 12 | 9.35e-01 | 9.44e-01 | 0.1770 | -1.04e-01 | -2.59e-02 | -9.26e-02 | -1.06e-01 | 5.34e-01 | 8.77e-01 | 5.79e-01 | 5.26e-01 |
| PKMTs methylate histone lysines | 37 | 8.80e-02 | 1.46e-01 | 0.1760 | 1.51e-01 | -5.71e-02 | -2.99e-02 | 6.35e-02 | 1.11e-01 | 5.48e-01 | 7.53e-01 | 5.04e-01 |
| RA biosynthesis pathway | 11 | 9.52e-01 | 9.57e-01 | 0.1760 | -6.93e-02 | 6.12e-02 | 1.20e-01 | 9.02e-02 | 6.91e-01 | 7.25e-01 | 4.92e-01 | 6.05e-01 |
| CD28 co-stimulation | 25 | 7.88e-01 | 8.30e-01 | 0.1760 | -6.13e-02 | 7.76e-02 | 1.20e-01 | 8.28e-02 | 5.96e-01 | 5.02e-01 | 3.00e-01 | 4.74e-01 |
| RAF/MAP kinase cascade | 188 | 5.38e-07 | 4.94e-06 | 0.1760 | -7.03e-02 | 1.29e-01 | -4.38e-02 | -8.57e-02 | 9.79e-02 | 2.31e-03 | 3.03e-01 | 4.37e-02 |
| Metabolism of nucleotides | 74 | 1.44e-02 | 3.29e-02 | 0.1760 | -1.52e-01 | -3.55e-02 | 1.40e-02 | 7.92e-02 | 2.37e-02 | 5.98e-01 | 8.36e-01 | 2.40e-01 |
| Chromatin modifying enzymes | 179 | 1.26e-07 | 1.43e-06 | 0.1750 | 1.37e-01 | 5.30e-02 | -9.53e-02 | 1.20e-02 | 1.66e-03 | 2.23e-01 | 2.85e-02 | 7.84e-01 |
| Chromatin organization | 179 | 1.26e-07 | 1.43e-06 | 0.1750 | 1.37e-01 | 5.30e-02 | -9.53e-02 | 1.20e-02 | 1.66e-03 | 2.23e-01 | 2.85e-02 | 7.84e-01 |
| Antigen processing: Ubiquitination & Proteasome degradation | 265 | 2.05e-04 | 8.84e-04 | 0.1750 | 1.67e-02 | -3.02e-03 | -1.05e-01 | -1.39e-01 | 6.43e-01 | 9.33e-01 | 3.48e-03 | 1.13e-04 |
| Depolymerisation of the Nuclear Lamina | 13 | 8.44e-01 | 8.81e-01 | 0.1750 | 9.04e-02 | 1.40e-01 | -1.68e-03 | 5.24e-02 | 5.73e-01 | 3.82e-01 | 9.92e-01 | 7.44e-01 |
| TCF dependent signaling in response to WNT | 134 | 6.71e-04 | 2.43e-03 | 0.1740 | 3.14e-02 | 9.68e-02 | -8.40e-02 | -1.13e-01 | 5.32e-01 | 5.37e-02 | 9.41e-02 | 2.41e-02 |
| Dual Incision in GG-NER | 38 | 5.38e-01 | 6.21e-01 | 0.1740 | 1.58e-01 | 5.60e-02 | 1.55e-02 | 4.34e-02 | 9.29e-02 | 5.51e-01 | 8.69e-01 | 6.44e-01 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 29 | 4.29e-01 | 5.16e-01 | 0.1730 | 2.01e-02 | -1.71e-01 | -1.92e-02 | -3.89e-04 | 8.51e-01 | 1.11e-01 | 8.58e-01 | 9.97e-01 |
| FLT3 Signaling | 199 | 6.94e-07 | 6.10e-06 | 0.1730 | -6.96e-02 | 1.09e-01 | -5.72e-02 | -1.00e-01 | 9.23e-02 | 8.43e-03 | 1.66e-01 | 1.55e-02 |
| ESR-mediated signaling | 126 | 2.74e-02 | 5.64e-02 | 0.1720 | 1.47e-01 | 8.09e-02 | 9.52e-04 | 4.03e-02 | 4.57e-03 | 1.18e-01 | 9.85e-01 | 4.36e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 13 | 7.63e-01 | 8.08e-01 | 0.1710 | 1.11e-01 | -9.63e-02 | 5.06e-02 | 7.16e-02 | 4.87e-01 | 5.48e-01 | 7.52e-01 | 6.55e-01 |
| PPARA activates gene expression | 101 | 1.50e-01 | 2.21e-01 | 0.1710 | 8.64e-02 | -5.54e-02 | -1.12e-01 | -7.95e-02 | 1.35e-01 | 3.37e-01 | 5.28e-02 | 1.69e-01 |
| MAPK6/MAPK4 signaling | 73 | 2.03e-03 | 6.19e-03 | 0.1710 | 3.35e-02 | 1.46e-01 | -8.71e-03 | -8.32e-02 | 6.21e-01 | 3.18e-02 | 8.98e-01 | 2.20e-01 |
| MAPK1/MAPK3 signaling | 193 | 8.91e-07 | 7.67e-06 | 0.1700 | -7.26e-02 | 1.30e-01 | -3.39e-02 | -7.55e-02 | 8.36e-02 | 1.97e-03 | 4.19e-01 | 7.19e-02 |
| MicroRNA (miRNA) biogenesis | 22 | 6.11e-01 | 6.84e-01 | 0.1700 | 1.60e-01 | -3.84e-02 | 4.28e-02 | 8.37e-03 | 1.95e-01 | 7.55e-01 | 7.28e-01 | 9.46e-01 |
| Diseases of metabolism | 153 | 1.88e-02 | 4.12e-02 | 0.1700 | -1.23e-01 | -1.30e-02 | 9.09e-02 | 7.24e-02 | 8.96e-03 | 7.82e-01 | 5.31e-02 | 1.23e-01 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 38 | 4.70e-01 | 5.57e-01 | 0.1700 | -1.23e-01 | 7.45e-02 | 4.53e-02 | 7.78e-02 | 1.90e-01 | 4.27e-01 | 6.30e-01 | 4.07e-01 |
| C-type lectin receptors (CLRs) | 94 | 5.14e-04 | 1.97e-03 | 0.1700 | -1.76e-02 | 1.41e-01 | -2.56e-02 | -8.84e-02 | 7.68e-01 | 1.82e-02 | 6.69e-01 | 1.40e-01 |
| Regulation of lipid metabolism by PPARalpha | 103 | 1.22e-01 | 1.88e-01 | 0.1680 | 9.39e-02 | -4.87e-02 | -1.08e-01 | -7.17e-02 | 1.00e-01 | 3.94e-01 | 5.81e-02 | 2.10e-01 |
| Factors involved in megakaryocyte development and platelet production | 80 | 1.17e-01 | 1.83e-01 | 0.1670 | -1.15e-01 | 4.01e-02 | 5.92e-02 | 9.86e-02 | 7.66e-02 | 5.36e-01 | 3.61e-01 | 1.28e-01 |
| Regulation of localization of FOXO transcription factors | 11 | 9.01e-01 | 9.25e-01 | 0.1670 | -1.41e-01 | -6.31e-02 | 3.77e-02 | 5.12e-02 | 4.20e-01 | 7.17e-01 | 8.28e-01 | 7.69e-01 |
| mRNA decay by 5' to 3' exoribonuclease | 14 | 5.22e-01 | 6.09e-01 | 0.1670 | 1.42e-01 | -3.59e-02 | -3.32e-02 | 7.24e-02 | 3.58e-01 | 8.16e-01 | 8.30e-01 | 6.39e-01 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 20 | 7.24e-01 | 7.79e-01 | 0.1670 | 1.62e-01 | 9.94e-04 | -6.91e-03 | 3.79e-02 | 2.10e-01 | 9.94e-01 | 9.57e-01 | 7.69e-01 |
| ABC transporter disorders | 56 | 3.50e-03 | 9.87e-03 | 0.1660 | 3.37e-02 | 1.19e-01 | -1.10e-02 | -1.11e-01 | 6.63e-01 | 1.25e-01 | 8.87e-01 | 1.53e-01 |
| Constitutive Signaling by EGFRvIII | 15 | 9.20e-01 | 9.32e-01 | 0.1660 | 3.49e-02 | 1.90e-02 | 1.00e-01 | 1.26e-01 | 8.15e-01 | 8.99e-01 | 5.02e-01 | 3.98e-01 |
| Signaling by EGFRvIII in Cancer | 15 | 9.20e-01 | 9.32e-01 | 0.1660 | 3.49e-02 | 1.90e-02 | 1.00e-01 | 1.26e-01 | 8.15e-01 | 8.99e-01 | 5.02e-01 | 3.98e-01 |
| Synthesis of PC | 21 | 8.93e-01 | 9.22e-01 | 0.1650 | -9.65e-02 | -9.60e-02 | -5.28e-02 | -7.68e-02 | 4.44e-01 | 4.47e-01 | 6.75e-01 | 5.43e-01 |
| Signaling by ERBB2 KD Mutants | 17 | 6.61e-01 | 7.24e-01 | 0.1650 | -6.26e-02 | 5.07e-02 | 5.34e-02 | 1.33e-01 | 6.55e-01 | 7.17e-01 | 7.03e-01 | 3.42e-01 |
| Interleukin-17 signaling | 61 | 1.85e-01 | 2.65e-01 | 0.1640 | -1.00e-01 | 4.11e-02 | -7.43e-02 | -9.83e-02 | 1.78e-01 | 5.79e-01 | 3.17e-01 | 1.85e-01 |
| Transport of small molecules | 407 | 8.89e-08 | 1.08e-06 | 0.1640 | -1.37e-01 | -7.32e-02 | 5.08e-02 | 5.09e-03 | 2.62e-06 | 1.21e-02 | 8.19e-02 | 8.62e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 25 | 4.48e-01 | 5.34e-01 | 0.1630 | 5.56e-02 | 1.48e-01 | 7.52e-03 | -3.69e-02 | 6.30e-01 | 2.00e-01 | 9.48e-01 | 7.50e-01 |
| Extra-nuclear estrogen signaling | 53 | 6.54e-01 | 7.18e-01 | 0.1630 | 4.06e-02 | 4.00e-02 | 9.83e-02 | 1.16e-01 | 6.10e-01 | 6.15e-01 | 2.16e-01 | 1.44e-01 |
| RNA Polymerase II Transcription | 886 | 4.15e-15 | 1.46e-13 | 0.1620 | 1.39e-01 | 6.59e-02 | -5.02e-02 | -1.30e-02 | 6.22e-12 | 1.14e-03 | 1.33e-02 | 5.20e-01 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 148 | 6.05e-03 | 1.58e-02 | 0.1620 | 1.28e-01 | 5.72e-02 | 7.59e-02 | 2.91e-02 | 7.30e-03 | 2.32e-01 | 1.12e-01 | 5.42e-01 |
| Transcriptional Regulation by VENTX | 34 | 3.96e-01 | 4.88e-01 | 0.1620 | 7.13e-02 | -6.79e-02 | 7.56e-02 | 1.04e-01 | 4.72e-01 | 4.93e-01 | 4.46e-01 | 2.94e-01 |
| Hedgehog 'on' state | 71 | 1.85e-02 | 4.07e-02 | 0.1620 | 4.71e-02 | 1.38e-01 | -1.74e-02 | -6.72e-02 | 4.93e-01 | 4.41e-02 | 8.00e-01 | 3.28e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 13 | 8.03e-01 | 8.43e-01 | 0.1620 | -3.19e-03 | 1.59e-01 | -3.02e-02 | -1.32e-03 | 9.84e-01 | 3.22e-01 | 8.50e-01 | 9.93e-01 |
| PTEN Regulation | 127 | 4.08e-03 | 1.12e-02 | 0.1620 | 8.30e-02 | 1.23e-01 | -3.36e-02 | -5.55e-02 | 1.07e-01 | 1.74e-02 | 5.15e-01 | 2.82e-01 |
| Signaling by the B Cell Receptor (BCR) | 85 | 3.76e-03 | 1.04e-02 | 0.1610 | 5.60e-06 | 1.51e-01 | 1.86e-03 | -5.61e-02 | 1.00e+00 | 1.64e-02 | 9.76e-01 | 3.73e-01 |
| ERKs are inactivated | 13 | 8.94e-01 | 9.22e-01 | 0.1600 | -8.23e-02 | 1.15e-01 | 6.65e-02 | 3.74e-02 | 6.08e-01 | 4.75e-01 | 6.78e-01 | 8.16e-01 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 19 | 7.64e-01 | 8.08e-01 | 0.1590 | 1.15e-01 | -9.03e-02 | -5.92e-02 | -2.04e-02 | 3.86e-01 | 4.96e-01 | 6.55e-01 | 8.78e-01 |
| Disorders of transmembrane transporters | 107 | 6.32e-02 | 1.12e-01 | 0.1590 | 6.67e-02 | 1.30e-01 | 5.65e-02 | 2.42e-02 | 2.34e-01 | 2.04e-02 | 3.14e-01 | 6.66e-01 |
| Kinesins | 24 | 7.21e-01 | 7.76e-01 | 0.1590 | 7.65e-02 | -2.29e-02 | 8.13e-02 | 1.10e-01 | 5.17e-01 | 8.46e-01 | 4.91e-01 | 3.50e-01 |
| Phosphorylation of the APC/C | 18 | 7.14e-01 | 7.71e-01 | 0.1580 | 1.38e-01 | -6.59e-02 | 2.94e-03 | 4.22e-02 | 3.12e-01 | 6.28e-01 | 9.83e-01 | 7.57e-01 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 24 | 1.97e-01 | 2.79e-01 | 0.1570 | 7.97e-02 | 1.05e-01 | 1.42e-02 | -8.44e-02 | 4.99e-01 | 3.72e-01 | 9.05e-01 | 4.74e-01 |
| TNF signaling | 34 | 6.92e-01 | 7.51e-01 | 0.1570 | -1.24e-01 | -7.69e-04 | 7.45e-02 | 6.22e-02 | 2.12e-01 | 9.94e-01 | 4.53e-01 | 5.31e-01 |
| DNA Double Strand Break Response | 37 | 6.66e-01 | 7.28e-01 | 0.1570 | 1.09e-01 | 1.08e-01 | 1.96e-02 | 2.59e-02 | 2.52e-01 | 2.55e-01 | 8.37e-01 | 7.85e-01 |
| Fc epsilon receptor (FCERI) signaling | 104 | 1.49e-03 | 4.81e-03 | 0.1560 | 1.41e-02 | 1.19e-01 | -3.85e-02 | -9.27e-02 | 8.04e-01 | 3.68e-02 | 4.98e-01 | 1.03e-01 |
| Ca2+ pathway | 45 | 3.93e-01 | 4.84e-01 | 0.1550 | -2.36e-02 | -1.53e-01 | -1.98e-03 | -1.51e-02 | 7.84e-01 | 7.64e-02 | 9.82e-01 | 8.61e-01 |
| Transcriptional regulation of white adipocyte differentiation | 71 | 3.19e-01 | 4.05e-01 | 0.1550 | 1.46e-01 | 3.47e-02 | 1.63e-02 | 3.53e-02 | 3.38e-02 | 6.14e-01 | 8.13e-01 | 6.07e-01 |
| Signaling by ERBB2 ECD mutants | 15 | 8.66e-01 | 9.02e-01 | 0.1540 | -5.58e-02 | 2.52e-02 | 7.18e-02 | 1.21e-01 | 7.08e-01 | 8.66e-01 | 6.30e-01 | 4.16e-01 |
| SUMOylation of DNA methylation proteins | 15 | 6.78e-01 | 7.37e-01 | 0.1530 | 1.04e-01 | 9.33e-02 | -4.86e-02 | 4.18e-02 | 4.87e-01 | 5.32e-01 | 7.45e-01 | 7.80e-01 |
| SARS-CoV-1 Infection | 40 | 6.78e-01 | 7.37e-01 | 0.1530 | -2.29e-02 | 8.53e-02 | 1.06e-01 | 6.58e-02 | 8.03e-01 | 3.51e-01 | 2.47e-01 | 4.72e-01 |
| Intra-Golgi traffic | 38 | 2.95e-01 | 3.81e-01 | 0.1520 | 1.27e-01 | 7.32e-02 | 2.30e-02 | -3.46e-02 | 1.76e-01 | 4.35e-01 | 8.06e-01 | 7.12e-01 |
| Transcriptional Regulation by TP53 | 305 | 5.43e-04 | 2.05e-03 | 0.1520 | 1.27e-01 | 8.32e-02 | -6.01e-03 | 1.40e-02 | 1.57e-04 | 1.31e-02 | 8.58e-01 | 6.75e-01 |
| MyD88-independent TLR4 cascade | 83 | 5.36e-02 | 9.92e-02 | 0.1490 | -7.15e-02 | 1.26e-01 | -2.24e-02 | -2.84e-02 | 2.61e-01 | 4.74e-02 | 7.24e-01 | 6.55e-01 |
| TRIF(TICAM1)-mediated TLR4 signaling | 83 | 5.36e-02 | 9.92e-02 | 0.1490 | -7.15e-02 | 1.26e-01 | -2.24e-02 | -2.84e-02 | 2.61e-01 | 4.74e-02 | 7.24e-01 | 6.55e-01 |
| Signaling by Erythropoietin | 19 | 8.68e-01 | 9.02e-01 | 0.1490 | -8.64e-02 | 1.02e-02 | -9.37e-02 | -7.72e-02 | 5.15e-01 | 9.39e-01 | 4.80e-01 | 5.60e-01 |
| Deubiquitination | 212 | 2.95e-04 | 1.23e-03 | 0.1490 | 8.35e-02 | 7.83e-02 | -5.27e-02 | -8.01e-02 | 3.71e-02 | 5.07e-02 | 1.88e-01 | 4.55e-02 |
| Growth hormone receptor signaling | 17 | 8.95e-01 | 9.22e-01 | 0.1490 | -8.46e-02 | 9.74e-02 | 6.12e-02 | 4.33e-02 | 5.46e-01 | 4.87e-01 | 6.62e-01 | 7.57e-01 |
| Toll Like Receptor 4 (TLR4) Cascade | 102 | 6.61e-02 | 1.16e-01 | 0.1490 | -4.76e-02 | 1.39e-01 | 1.68e-02 | 1.84e-02 | 4.07e-01 | 1.54e-02 | 7.70e-01 | 7.49e-01 |
| Organelle biogenesis and maintenance | 224 | 1.94e-04 | 8.42e-04 | 0.1480 | 5.86e-02 | -1.36e-01 | -8.54e-03 | 3.14e-03 | 1.33e-01 | 4.88e-04 | 8.27e-01 | 9.36e-01 |
| Regulation of beta-cell development | 17 | 7.18e-01 | 7.74e-01 | 0.1480 | -8.79e-02 | 4.46e-02 | 3.41e-02 | 1.05e-01 | 5.30e-01 | 7.51e-01 | 8.08e-01 | 4.55e-01 |
| Transcriptional regulation by RUNX2 | 99 | 2.83e-03 | 8.38e-03 | 0.1480 | -3.46e-03 | 1.38e-01 | 4.77e-02 | -2.40e-02 | 9.53e-01 | 1.81e-02 | 4.14e-01 | 6.81e-01 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 19 | 4.32e-01 | 5.18e-01 | 0.1480 | -1.02e-01 | -3.07e-02 | -1.02e-01 | -1.12e-03 | 4.41e-01 | 8.17e-01 | 4.41e-01 | 9.93e-01 |
| RMTs methylate histone arginines | 28 | 7.39e-02 | 1.26e-01 | 0.1470 | -1.04e-01 | 4.81e-02 | -6.83e-02 | 6.22e-02 | 3.42e-01 | 6.60e-01 | 5.32e-01 | 5.69e-01 |
| FRS-mediated FGFR1 signaling | 12 | 8.32e-01 | 8.72e-01 | 0.1470 | 2.48e-03 | 6.08e-02 | -6.65e-02 | -1.16e-01 | 9.88e-01 | 7.15e-01 | 6.90e-01 | 4.86e-01 |
| MAPK family signaling cascades | 224 | 9.95e-06 | 6.09e-05 | 0.1460 | -6.76e-02 | 1.13e-01 | -2.32e-02 | -5.90e-02 | 8.30e-02 | 3.77e-03 | 5.52e-01 | 1.30e-01 |
| Downstream signaling of activated FGFR3 | 17 | 8.49e-01 | 8.86e-01 | 0.1460 | 9.22e-02 | 8.37e-02 | -5.35e-02 | -5.44e-02 | 5.11e-01 | 5.50e-01 | 7.03e-01 | 6.98e-01 |
| Signaling by NTRK2 (TRKB) | 21 | 9.03e-01 | 9.25e-01 | 0.1440 | 8.76e-03 | 7.32e-02 | 1.04e-01 | 6.57e-02 | 9.45e-01 | 5.62e-01 | 4.08e-01 | 6.03e-01 |
| Oncogenic MAPK signaling | 68 | 1.47e-01 | 2.18e-01 | 0.1440 | -1.12e-01 | 8.51e-02 | -8.92e-04 | -3.05e-02 | 1.12e-01 | 2.26e-01 | 9.90e-01 | 6.64e-01 |
| PI3K/AKT Signaling in Cancer | 65 | 3.10e-01 | 3.95e-01 | 0.1430 | -1.34e-01 | 3.32e-02 | -1.92e-02 | -3.11e-02 | 6.15e-02 | 6.44e-01 | 7.90e-01 | 6.65e-01 |
| Transcriptional regulation by RUNX1 | 139 | 7.88e-02 | 1.33e-01 | 0.1420 | 8.09e-02 | 1.14e-01 | 2.83e-03 | 2.43e-02 | 1.01e-01 | 2.05e-02 | 9.54e-01 | 6.22e-01 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 8.48e-02 | 1.41e-01 | 0.1420 | 5.92e-02 | 7.00e-02 | -1.08e-01 | 1.03e-02 | 5.39e-01 | 4.68e-01 | 2.63e-01 | 9.15e-01 |
| RET signaling | 28 | 6.83e-01 | 7.42e-01 | 0.1420 | -1.39e-01 | 1.70e-02 | -2.44e-02 | 4.72e-03 | 2.05e-01 | 8.77e-01 | 8.23e-01 | 9.66e-01 |
| PIP3 activates AKT signaling | 211 | 2.41e-04 | 1.02e-03 | 0.1410 | 4.45e-02 | 1.29e-01 | -7.67e-03 | -3.54e-02 | 2.67e-01 | 1.35e-03 | 8.48e-01 | 3.78e-01 |
| Phospholipid metabolism | 147 | 1.65e-02 | 3.70e-02 | 0.1370 | -4.09e-02 | -7.45e-02 | 9.17e-02 | 5.68e-02 | 3.94e-01 | 1.20e-01 | 5.60e-02 | 2.36e-01 |
| Phase II - Conjugation of compounds | 46 | 6.36e-01 | 7.04e-01 | 0.1370 | -6.83e-02 | -1.11e-01 | -3.70e-02 | -2.16e-02 | 4.23e-01 | 1.93e-01 | 6.65e-01 | 8.00e-01 |
| Diseases associated with glycosylation precursor biosynthesis | 18 | 9.03e-01 | 9.25e-01 | 0.1370 | 3.44e-02 | 8.78e-02 | 3.98e-02 | 9.09e-02 | 8.00e-01 | 5.19e-01 | 7.70e-01 | 5.05e-01 |
| Nuclear signaling by ERBB4 | 20 | 9.25e-01 | 9.36e-01 | 0.1370 | -7.38e-02 | 5.64e-03 | 9.02e-02 | 7.16e-02 | 5.68e-01 | 9.65e-01 | 4.85e-01 | 5.79e-01 |
| Toll Like Receptor 3 (TLR3) Cascade | 82 | 1.11e-01 | 1.74e-01 | 0.1360 | -7.26e-02 | 1.09e-01 | -2.43e-02 | -2.67e-02 | 2.57e-01 | 8.81e-02 | 7.04e-01 | 6.76e-01 |
| Cargo recognition for clathrin-mediated endocytosis | 72 | 5.23e-01 | 6.09e-01 | 0.1360 | 1.09e-01 | 6.33e-02 | 2.34e-02 | 4.46e-02 | 1.10e-01 | 3.54e-01 | 7.32e-01 | 5.13e-01 |
| Platelet homeostasis | 51 | 5.87e-01 | 6.64e-01 | 0.1310 | -1.22e-01 | -2.37e-02 | -6.55e-03 | -3.88e-02 | 1.31e-01 | 7.70e-01 | 9.36e-01 | 6.33e-01 |
| Aggrephagy | 16 | 8.90e-01 | 9.20e-01 | 0.1300 | 4.59e-02 | 1.21e-01 | 1.66e-02 | -3.73e-03 | 7.51e-01 | 4.04e-01 | 9.09e-01 | 9.79e-01 |
| NRIF signals cell death from the nucleus | 13 | 9.47e-01 | 9.53e-01 | 0.1300 | 7.43e-02 | 1.07e-01 | -6.02e-03 | 3.37e-03 | 6.43e-01 | 5.06e-01 | 9.70e-01 | 9.83e-01 |
| HDACs deacetylate histones | 30 | 2.30e-01 | 3.12e-01 | 0.1290 | 9.34e-02 | 6.89e-03 | -8.60e-02 | 2.33e-02 | 3.76e-01 | 9.48e-01 | 4.15e-01 | 8.25e-01 |
| Signaling by FGFR4 in disease | 11 | 8.57e-01 | 8.94e-01 | 0.1290 | -4.33e-02 | -9.86e-02 | 1.70e-02 | 6.81e-02 | 8.04e-01 | 5.71e-01 | 9.22e-01 | 6.96e-01 |
| Signaling by FGFR4 | 29 | 6.97e-01 | 7.56e-01 | 0.1270 | 3.95e-02 | 1.20e-01 | 5.61e-03 | -1.62e-02 | 7.13e-01 | 2.65e-01 | 9.58e-01 | 8.80e-01 |
| ER to Golgi Anterograde Transport | 114 | 7.94e-05 | 3.71e-04 | 0.1260 | 8.96e-02 | 4.14e-02 | 6.87e-02 | -3.86e-02 | 9.93e-02 | 4.47e-01 | 2.07e-01 | 4.78e-01 |
| Vesicle-mediated transport | 506 | 1.49e-04 | 6.62e-04 | 0.1260 | 5.83e-02 | 3.48e-02 | 9.08e-02 | 5.53e-02 | 2.67e-02 | 1.86e-01 | 5.53e-04 | 3.56e-02 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 36 | 7.95e-01 | 8.36e-01 | 0.1250 | 8.42e-02 | 9.22e-02 | 2.24e-03 | 9.85e-03 | 3.82e-01 | 3.39e-01 | 9.81e-01 | 9.19e-01 |
| MyD88 cascade initiated on plasma membrane | 75 | 2.23e-01 | 3.05e-01 | 0.1240 | -6.85e-02 | 7.01e-02 | -4.54e-02 | -6.18e-02 | 3.06e-01 | 2.95e-01 | 4.98e-01 | 3.56e-01 |
| Toll Like Receptor 10 (TLR10) Cascade | 75 | 2.23e-01 | 3.05e-01 | 0.1240 | -6.85e-02 | 7.01e-02 | -4.54e-02 | -6.18e-02 | 3.06e-01 | 2.95e-01 | 4.98e-01 | 3.56e-01 |
| Toll Like Receptor 5 (TLR5) Cascade | 75 | 2.23e-01 | 3.05e-01 | 0.1240 | -6.85e-02 | 7.01e-02 | -4.54e-02 | -6.18e-02 | 3.06e-01 | 2.95e-01 | 4.98e-01 | 3.56e-01 |
| Fatty acyl-CoA biosynthesis | 18 | 7.01e-01 | 7.58e-01 | 0.1240 | -6.26e-02 | 9.58e-02 | -4.13e-02 | 2.55e-02 | 6.46e-01 | 4.82e-01 | 7.62e-01 | 8.52e-01 |
| Deactivation of the beta-catenin transactivating complex | 32 | 9.10e-01 | 9.27e-01 | 0.1240 | -4.59e-02 | 4.70e-02 | 6.51e-02 | 8.27e-02 | 6.54e-01 | 6.46e-01 | 5.24e-01 | 4.19e-01 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 27 | 8.30e-01 | 8.71e-01 | 0.1240 | -1.01e-01 | -7.00e-02 | -1.99e-03 | 1.40e-02 | 3.62e-01 | 5.30e-01 | 9.86e-01 | 9.00e-01 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 76 | 1.90e-01 | 2.71e-01 | 0.1220 | -5.21e-02 | 9.01e-02 | -3.57e-02 | -5.21e-02 | 4.33e-01 | 1.75e-01 | 5.92e-01 | 4.33e-01 |
| IRS-mediated signalling | 27 | 7.34e-01 | 7.87e-01 | 0.1220 | 3.04e-02 | 2.85e-02 | -5.67e-02 | -9.92e-02 | 7.85e-01 | 7.98e-01 | 6.10e-01 | 3.73e-01 |
| MyD88 dependent cascade initiated on endosome | 77 | 1.95e-01 | 2.76e-01 | 0.1210 | -4.88e-02 | 9.90e-02 | -2.87e-02 | -4.03e-02 | 4.60e-01 | 1.34e-01 | 6.64e-01 | 5.42e-01 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 77 | 1.95e-01 | 2.76e-01 | 0.1210 | -4.88e-02 | 9.90e-02 | -2.87e-02 | -4.03e-02 | 4.60e-01 | 1.34e-01 | 6.64e-01 | 5.42e-01 |
| Oxidative Stress Induced Senescence | 59 | 5.75e-01 | 6.55e-01 | 0.1190 | 6.78e-02 | 9.59e-02 | -9.95e-03 | 1.71e-02 | 3.68e-01 | 2.03e-01 | 8.95e-01 | 8.20e-01 |
| Glycolysis | 54 | 5.95e-01 | 6.73e-01 | 0.1160 | 9.59e-02 | -2.63e-02 | -5.71e-02 | -1.94e-02 | 2.23e-01 | 7.39e-01 | 4.68e-01 | 8.06e-01 |
| NOD1/2 Signaling Pathway | 27 | 7.25e-01 | 7.80e-01 | 0.1150 | -9.85e-02 | 3.10e-02 | 7.54e-04 | 4.97e-02 | 3.76e-01 | 7.81e-01 | 9.95e-01 | 6.55e-01 |
| Generic Transcription Pathway | 777 | 2.21e-06 | 1.62e-05 | 0.1140 | 9.26e-02 | 3.64e-02 | -4.95e-02 | -2.42e-02 | 1.66e-05 | 9.08e-02 | 2.15e-02 | 2.60e-01 |
| Hedgehog 'off' state | 87 | 9.01e-02 | 1.48e-01 | 0.1130 | 1.90e-02 | 7.21e-02 | -3.28e-02 | -7.88e-02 | 7.60e-01 | 2.46e-01 | 5.98e-01 | 2.05e-01 |
| COPI-mediated anterograde transport | 73 | 1.60e-03 | 5.09e-03 | 0.1120 | 2.66e-02 | 3.99e-02 | 9.77e-02 | -2.65e-02 | 6.94e-01 | 5.57e-01 | 1.49e-01 | 6.96e-01 |
| RUNX2 regulates bone development | 26 | 9.58e-01 | 9.63e-01 | 0.1120 | -1.99e-02 | 9.87e-03 | 7.64e-02 | 7.87e-02 | 8.61e-01 | 9.31e-01 | 5.01e-01 | 4.88e-01 |
| Signaling by NOTCH | 148 | 2.90e-01 | 3.75e-01 | 0.1110 | -6.20e-02 | 7.44e-02 | 4.00e-02 | 3.56e-02 | 1.94e-01 | 1.19e-01 | 4.03e-01 | 4.57e-01 |
| Membrane Trafficking | 484 | 2.44e-04 | 1.03e-03 | 0.1100 | 6.78e-02 | 2.85e-02 | 7.34e-02 | 3.53e-02 | 1.17e-02 | 2.89e-01 | 6.29e-03 | 1.88e-01 |
| Signaling by FGFR in disease | 47 | 7.42e-01 | 7.93e-01 | 0.1100 | 7.82e-02 | 7.10e-02 | -2.69e-02 | -1.17e-02 | 3.54e-01 | 4.00e-01 | 7.50e-01 | 8.90e-01 |
| Metabolism of steroids | 93 | 1.17e-01 | 1.82e-01 | 0.1070 | -7.23e-02 | -1.16e-02 | -7.67e-02 | -1.70e-02 | 2.29e-01 | 8.47e-01 | 2.02e-01 | 7.78e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 81 | 3.04e-01 | 3.89e-01 | 0.1070 | -5.58e-02 | 6.99e-02 | -3.35e-02 | -4.85e-02 | 3.86e-01 | 2.78e-01 | 6.03e-01 | 4.52e-01 |
| Toll Like Receptor 2 (TLR2) Cascade | 81 | 3.04e-01 | 3.89e-01 | 0.1070 | -5.58e-02 | 6.99e-02 | -3.35e-02 | -4.85e-02 | 3.86e-01 | 2.78e-01 | 6.03e-01 | 4.52e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade | 81 | 3.04e-01 | 3.89e-01 | 0.1070 | -5.58e-02 | 6.99e-02 | -3.35e-02 | -4.85e-02 | 3.86e-01 | 2.78e-01 | 6.03e-01 | 4.52e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade | 81 | 3.04e-01 | 3.89e-01 | 0.1070 | -5.58e-02 | 6.99e-02 | -3.35e-02 | -4.85e-02 | 3.86e-01 | 2.78e-01 | 6.03e-01 | 4.52e-01 |
| Metabolism of proteins | 1399 | 1.19e-10 | 2.16e-09 | 0.1040 | 7.94e-02 | 6.45e-02 | 1.64e-02 | -6.56e-03 | 1.61e-06 | 9.87e-05 | 3.23e-01 | 6.92e-01 |
| Signaling by FGFR3 in disease | 14 | 9.72e-01 | 9.76e-01 | 0.1040 | 4.90e-02 | 3.39e-02 | -6.89e-02 | -4.98e-02 | 7.51e-01 | 8.26e-01 | 6.55e-01 | 7.47e-01 |
| Signaling by FGFR3 point mutants in cancer | 14 | 9.72e-01 | 9.76e-01 | 0.1040 | 4.90e-02 | 3.39e-02 | -6.89e-02 | -4.98e-02 | 7.51e-01 | 8.26e-01 | 6.55e-01 | 7.47e-01 |
| Intracellular signaling by second messengers | 243 | 3.41e-03 | 9.71e-03 | 0.1030 | -1.23e-02 | 9.82e-02 | -2.88e-03 | -2.97e-02 | 7.43e-01 | 8.80e-03 | 9.39e-01 | 4.28e-01 |
| Signaling by NOTCH1 | 62 | 8.75e-01 | 9.08e-01 | 0.1030 | -3.87e-02 | 3.48e-02 | 5.85e-02 | 6.72e-02 | 5.98e-01 | 6.36e-01 | 4.26e-01 | 3.61e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 35 | 7.39e-01 | 7.92e-01 | 0.1030 | 4.02e-02 | -6.12e-02 | 6.27e-02 | 3.55e-02 | 6.81e-01 | 5.31e-01 | 5.21e-01 | 7.17e-01 |
| Post-translational protein modification | 999 | 4.09e-05 | 2.07e-04 | 0.1010 | 6.05e-02 | 6.15e-02 | 4.59e-02 | 2.63e-02 | 1.62e-03 | 1.35e-03 | 1.67e-02 | 1.71e-01 |
| Downstream signaling of activated FGFR1 | 19 | 9.21e-01 | 9.32e-01 | 0.1010 | 3.45e-02 | 8.79e-02 | -2.15e-02 | -2.93e-02 | 7.95e-01 | 5.07e-01 | 8.71e-01 | 8.25e-01 |
| Signaling by WNT in cancer | 28 | 9.76e-01 | 9.78e-01 | 0.1000 | 3.54e-02 | -3.83e-02 | -5.96e-02 | -6.16e-02 | 7.46e-01 | 7.26e-01 | 5.85e-01 | 5.73e-01 |
| Toll Like Receptor 9 (TLR9) Cascade | 80 | 3.51e-01 | 4.39e-01 | 0.0998 | -2.45e-02 | 8.72e-02 | -2.29e-02 | -3.50e-02 | 7.06e-01 | 1.78e-01 | 7.23e-01 | 5.90e-01 |
| Class I MHC mediated antigen processing & presentation | 303 | 7.44e-03 | 1.88e-02 | 0.0977 | 2.98e-02 | 2.56e-02 | -4.51e-02 | -7.73e-02 | 3.77e-01 | 4.47e-01 | 1.80e-01 | 2.16e-02 |
| FRS-mediated FGFR4 signaling | 12 | 8.78e-01 | 9.11e-01 | 0.0974 | -5.71e-02 | 6.16e-02 | 2.25e-02 | -4.38e-02 | 7.32e-01 | 7.12e-01 | 8.93e-01 | 7.93e-01 |
| Metabolism of lipids | 490 | 7.80e-03 | 1.96e-02 | 0.0957 | -6.73e-02 | -6.77e-02 | 5.93e-03 | 2.59e-03 | 1.18e-02 | 1.12e-02 | 8.24e-01 | 9.23e-01 |
| NOTCH1 Intracellular Domain Regulates Transcription | 42 | 7.77e-01 | 8.22e-01 | 0.0920 | -4.35e-02 | 7.78e-02 | -1.81e-02 | -1.37e-02 | 6.26e-01 | 3.83e-01 | 8.39e-01 | 8.78e-01 |
| Adaptive Immune System | 477 | 4.09e-03 | 1.12e-02 | 0.0896 | 2.32e-02 | 6.92e-02 | 4.91e-02 | 1.70e-02 | 3.91e-01 | 1.05e-02 | 6.94e-02 | 5.31e-01 |
| Signaling by ERBB4 | 37 | 9.13e-01 | 9.28e-01 | 0.0875 | 9.91e-03 | -2.20e-02 | 5.40e-02 | 6.45e-02 | 9.17e-01 | 8.17e-01 | 5.70e-01 | 4.98e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 304 | 1.26e-02 | 2.93e-02 | 0.0858 | -2.72e-02 | 7.69e-02 | -8.00e-03 | -2.52e-02 | 4.17e-01 | 2.21e-02 | 8.12e-01 | 4.53e-01 |
| Beta-catenin independent WNT signaling | 117 | 1.42e-01 | 2.14e-01 | 0.0834 | -9.29e-03 | 7.69e-02 | 1.56e-02 | -2.67e-02 | 8.63e-01 | 1.52e-01 | 7.71e-01 | 6.19e-01 |
| Signaling by WNT | 202 | 1.10e-01 | 1.74e-01 | 0.0810 | 1.36e-02 | 5.71e-02 | -2.88e-02 | -4.79e-02 | 7.40e-01 | 1.64e-01 | 4.82e-01 | 2.43e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 31 | 9.18e-01 | 9.31e-01 | 0.0806 | 2.55e-02 | 6.23e-02 | 4.29e-02 | 1.13e-02 | 8.06e-01 | 5.49e-01 | 6.79e-01 | 9.14e-01 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 15 | 9.90e-01 | 9.91e-01 | 0.0804 | -9.90e-04 | 7.61e-02 | 1.35e-02 | 2.21e-02 | 9.95e-01 | 6.10e-01 | 9.28e-01 | 8.82e-01 |
| Downstream signaling of activated FGFR2 | 17 | 9.29e-01 | 9.38e-01 | 0.0792 | -9.55e-03 | 6.69e-02 | -6.05e-03 | -4.08e-02 | 9.46e-01 | 6.33e-01 | 9.66e-01 | 7.71e-01 |
| COPI-independent Golgi-to-ER retrograde traffic | 27 | 4.20e-01 | 5.09e-01 | 0.0744 | 1.07e-02 | 6.26e-03 | 6.50e-02 | -3.39e-02 | 9.23e-01 | 9.55e-01 | 5.59e-01 | 7.60e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 50 | 9.07e-01 | 9.25e-01 | 0.0711 | -6.87e-02 | -5.53e-03 | 1.29e-03 | 1.73e-02 | 4.01e-01 | 9.46e-01 | 9.87e-01 | 8.32e-01 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 50 | 9.07e-01 | 9.25e-01 | 0.0711 | -6.87e-02 | -5.53e-03 | 1.29e-03 | 1.73e-02 | 4.01e-01 | 9.46e-01 | 9.87e-01 | 8.32e-01 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 50 | 9.07e-01 | 9.25e-01 | 0.0711 | -6.87e-02 | -5.53e-03 | 1.29e-03 | 1.73e-02 | 4.01e-01 | 9.46e-01 | 9.87e-01 | 8.32e-01 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 50 | 9.07e-01 | 9.25e-01 | 0.0711 | -6.87e-02 | -5.53e-03 | 1.29e-03 | 1.73e-02 | 4.01e-01 | 9.46e-01 | 9.87e-01 | 8.32e-01 |
| Signaling by NOTCH1 in Cancer | 50 | 9.07e-01 | 9.25e-01 | 0.0711 | -6.87e-02 | -5.53e-03 | 1.29e-03 | 1.73e-02 | 4.01e-01 | 9.46e-01 | 9.87e-01 | 8.32e-01 |
| Insulin receptor signalling cascade | 32 | 8.84e-01 | 9.15e-01 | 0.0699 | 3.66e-02 | 4.99e-02 | -1.06e-03 | -3.24e-02 | 7.20e-01 | 6.25e-01 | 9.92e-01 | 7.51e-01 |
| CD28 dependent PI3K/Akt signaling | 17 | 9.92e-01 | 9.92e-01 | 0.0674 | -5.66e-02 | 9.73e-03 | -1.99e-02 | -2.92e-02 | 6.87e-01 | 9.45e-01 | 8.87e-01 | 8.35e-01 |
| Signaling by Nuclear Receptors | 175 | 6.04e-01 | 6.80e-01 | 0.0673 | 5.73e-02 | 2.20e-02 | -2.61e-02 | -9.27e-03 | 1.93e-01 | 6.17e-01 | 5.52e-01 | 8.33e-01 |
| Signaling by Hedgehog | 114 | 5.77e-01 | 6.57e-01 | 0.0655 | 3.16e-03 | 6.39e-02 | 5.54e-03 | -1.31e-02 | 9.54e-01 | 2.40e-01 | 9.19e-01 | 8.09e-01 |
| RAB GEFs exchange GTP for GDP on RABs | 81 | 8.40e-01 | 8.78e-01 | 0.0652 | 3.27e-02 | 9.84e-03 | 4.98e-02 | 2.48e-02 | 6.12e-01 | 8.79e-01 | 4.40e-01 | 7.00e-01 |
| IRS-related events triggered by IGF1R | 29 | 9.40e-01 | 9.47e-01 | 0.0613 | 3.69e-04 | 1.82e-02 | -2.27e-02 | -5.40e-02 | 9.97e-01 | 8.65e-01 | 8.32e-01 | 6.15e-01 |
| IGF1R signaling cascade | 30 | 9.32e-01 | 9.41e-01 | 0.0545 | 2.72e-02 | 4.05e-02 | 1.11e-02 | -2.17e-02 | 7.97e-01 | 7.01e-01 | 9.16e-01 | 8.37e-01 |
| Rab regulation of trafficking | 110 | 7.80e-01 | 8.23e-01 | 0.0365 | 1.94e-02 | 2.32e-02 | 8.89e-03 | -1.83e-02 | 7.25e-01 | 6.75e-01 | 8.72e-01 | 7.41e-01 |
| Downstream signaling of activated FGFR4 | 17 | 1.00e+00 | 1.00e+00 | 0.0196 | -8.08e-03 | 7.85e-04 | -8.50e-03 | -1.56e-02 | 9.54e-01 | 9.96e-01 | 9.52e-01 | 9.11e-01 |
Detailed Gene set reports
Interleukin-10 signaling
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 8.18e-06 |
| p.adjustMANOVA | 5.19e-05 |
| s.dist | 1.29 |
| s.human | -0.253 |
| s.mouse | 0.747 |
| s.jmod | 0.742 |
| s.jsev | 0.708 |
| p.human | 0.147 |
| p.mouse | 1.77e-05 |
| p.jmod | 2.01e-05 |
| p.jsev | 4.8e-05 |
| Gene | mouse | jmod |
|---|---|---|
| TIMP1 | 5205 | 5004 |
| TNFRSF1B | 4565 | 5131 |
| STAT3 | 5030 | 4363 |
| CCL2 | 5078 | 3977 |
| ICAM1 | 4143 | 4616 |
| CSF1 | 4328 | 3827 |
| TNFRSF1A | 3335 | 4794 |
| IL1R1 | 3881 | 4028 |
| IL10RB | 3218 | 4256 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| CCL2 | 2605 | 5078 | 3977 | 3671 |
| CSF1 | -4204 | 4328 | 3827 | 3537 |
| ICAM1 | 1048 | 4143 | 4616 | 4861 |
| IL10RB | 1229 | 3218 | 4256 | 4178 |
| IL1R1 | -2993 | 3881 | 4028 | 3896 |
| JAK1 | -1852 | 4199 | -1819 | -2166 |
| STAT3 | -3851 | 5030 | 4363 | 3440 |
| TIMP1 | -1306 | 5205 | 5004 | 5075 |
| TNFRSF1A | -4623 | 3335 | 4794 | 3835 |
| TNFRSF1B | -868 | 4565 | 5131 | 5002 |
| TYK2 | -3097 | -49 | 4527 | 3460 |
Citric acid cycle (TCA cycle)
| metric | value |
|---|---|
| setSize | 21 |
| pMANOVA | 5.5e-07 |
| p.adjustMANOVA | 5.01e-06 |
| s.dist | 1.1 |
| s.human | -0.244 |
| s.mouse | -0.596 |
| s.jmod | -0.585 |
| s.jsev | -0.669 |
| p.human | 0.0532 |
| p.mouse | 2.25e-06 |
| p.jmod | 3.44e-06 |
| p.jsev | 1.11e-07 |
| Gene | jsev | mouse |
|---|---|---|
| SUCLG2 | -4784 | -4260 |
| SDHA | -4448 | -4558 |
| ME3 | -5361 | -3692 |
| ACO2 | -4227 | -4394 |
| IDH3A | -4800 | -3796 |
| CS | -5099 | -3540 |
| SUCLA2 | -4148 | -4344 |
| DLD | -3732 | -4703 |
| SDHB | -4255 | -3680 |
| OGDH | -4298 | -3624 |
| IDH3G | -4663 | -3107 |
| MDH2 | -4902 | -2835 |
| SDHC | -4450 | -2980 |
| FAHD1 | -3090 | -4271 |
| FH | -4455 | -2874 |
| DLST | -3326 | -3501 |
| SUCLG1 | -5337 | -2121 |
| IDH3B | -5049 | -2158 |
| IDH2 | -2550 | -3827 |
| NNT | -773 | -2355 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ACO2 | -3789 | -4394 | -3940 | -4227 |
| CS | 3635 | -3540 | -4697 | -5099 |
| DLD | 1179 | -4703 | -2925 | -3732 |
| DLST | -323 | -3501 | -1782 | -3326 |
| FAHD1 | -1756 | -4271 | -2480 | -3090 |
| FH | 285 | -2874 | -3286 | -4455 |
| IDH2 | -5171 | -3827 | -2773 | -2550 |
| IDH3A | -2137 | -3796 | -4547 | -4800 |
| IDH3B | -2856 | -2158 | -4295 | -5049 |
| IDH3G | -4141 | -3107 | -3719 | -4663 |
| MDH2 | -4322 | -2835 | -2729 | -4902 |
| ME2 | -1774 | 3498 | 4816 | 5022 |
| ME3 | 4187 | -3692 | -5332 | -5361 |
| NNT | -3297 | -2355 | -263 | -773 |
| OGDH | -5223 | -3624 | -3565 | -4298 |
| SDHA | -4730 | -4558 | -4419 | -4448 |
| SDHB | 429 | -3680 | -3699 | -4255 |
| SDHC | -3681 | -2980 | -3055 | -4450 |
| SUCLA2 | 1506 | -4344 | -3701 | -4148 |
| SUCLG1 | -31 | -2121 | -5183 | -5337 |
| SUCLG2 | -1157 | -4260 | -4228 | -4784 |
Degradation of cysteine and homocysteine
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.000405 |
| p.adjustMANOVA | 0.00161 |
| s.dist | 1.1 |
| s.human | -0.303 |
| s.mouse | -0.407 |
| s.jmod | -0.688 |
| s.jsev | -0.687 |
| p.human | 0.0689 |
| p.mouse | 0.0148 |
| p.jmod | 3.64e-05 |
| p.jsev | 3.8e-05 |
| Gene | jmod | jsev |
|---|---|---|
| SUOX | -5324 | -5301 |
| MPST | -5127 | -5489 |
| TST | -5008 | -5449 |
| ADO | -4860 | -5142 |
| SQRDL | -4194 | -4648 |
| CTH | -4640 | -4017 |
| TXN2 | -3234 | -4288 |
| ETHE1 | -3024 | -3867 |
| CDO1 | -3172 | -2992 |
| GOT2 | -2435 | -3752 |
| GADL1 | -2806 | -1847 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ADO | 3186 | -2701 | -4860 | -5142 |
| CDO1 | 2026 | 2553 | -3172 | -2992 |
| CSAD | -2123 | -2604 | -351 | 647 |
| CTH | 4079 | 1066 | -4640 | -4017 |
| ETHE1 | -1835 | 1190 | -3024 | -3867 |
| GADL1 | -5082 | -4126 | -2806 | -1847 |
| GOT2 | -3673 | -3069 | -2435 | -3752 |
| MPST | -5152 | -4352 | -5127 | -5489 |
| SQRDL | -4013 | -4852 | -4194 | -4648 |
| SUOX | -2869 | -4895 | -5324 | -5301 |
| TST | -4472 | -5208 | -5008 | -5449 |
| TXN2 | -2814 | 636 | -3234 | -4288 |
Branched-chain amino acid catabolism
| metric | value |
|---|---|
| setSize | 20 |
| pMANOVA | 1.63e-06 |
| p.adjustMANOVA | 1.3e-05 |
| s.dist | 1.06 |
| s.human | -0.0751 |
| s.mouse | -0.531 |
| s.jmod | -0.586 |
| s.jsev | -0.703 |
| p.human | 0.561 |
| p.mouse | 3.93e-05 |
| p.jmod | 5.7e-06 |
| p.jsev | 5.19e-08 |
| Gene | jsev | jmod |
|---|---|---|
| BCKDHB | -5370 | -5262 |
| IVD | -5402 | -5101 |
| MCCC2 | -5496 | -4965 |
| BCAT2 | -5323 | -5073 |
| ALDH6A1 | -5311 | -5072 |
| BCKDK | -5269 | -4900 |
| DBT | -5170 | -4872 |
| HIBADH | -5042 | -4821 |
| MCCC1 | -5074 | -4587 |
| AUH | -4834 | -4736 |
| ACADSB | -4210 | -4316 |
| HIBCH | -4674 | -3333 |
| ACAT1 | -4103 | -3764 |
| DLD | -3732 | -2925 |
| SLC25A44 | -3286 | -2560 |
| PPM1K | -2930 | -2625 |
| ECHS1 | -3440 | -2029 |
| ACAD8 | -4238 | -185 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ACAD8 | -1249 | -5003 | -185 | -4238 |
| ACADSB | 3071 | -4901 | -4316 | -4210 |
| ACAT1 | 468 | -1920 | -3764 | -4103 |
| ALDH6A1 | -1385 | -5204 | -5072 | -5311 |
| AUH | -1283 | -3157 | -4736 | -4834 |
| BCAT1 | -3518 | 4027 | 4380 | 4303 |
| BCAT2 | -4145 | -4924 | -5073 | -5323 |
| BCKDHB | -4203 | -2613 | -5262 | -5370 |
| BCKDK | -4650 | -3598 | -4900 | -5269 |
| DBT | 1989 | 5174 | -4872 | -5170 |
| DLD | 1179 | -4703 | -2925 | -3732 |
| ECHS1 | -3861 | -4743 | -2029 | -3440 |
| HIBADH | -3997 | -2543 | -4821 | -5042 |
| HIBCH | 485 | -5042 | -3333 | -4674 |
| HSD17B10 | -1183 | -483 | 3980 | 7 |
| IVD | -4762 | -5079 | -5101 | -5402 |
| MCCC1 | 3993 | -4657 | -4587 | -5074 |
| MCCC2 | 2192 | -4933 | -4965 | -5496 |
| PPM1K | 2266 | -5180 | -2625 | -2930 |
| SLC25A44 | 4825 | 2423 | -2560 | -3286 |
Prolactin receptor signaling
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.00555 |
| p.adjustMANOVA | 0.0146 |
| s.dist | 1.05 |
| s.human | -0.247 |
| s.mouse | -0.536 |
| s.jmod | -0.59 |
| s.jsev | -0.635 |
| p.human | 0.176 |
| p.mouse | 0.00336 |
| p.jmod | 0.00123 |
| p.jsev | 0.000503 |
| Gene | jsev | jmod |
|---|---|---|
| STAT5B | -5459 | -5327 |
| GHR | -5453 | -5261 |
| JAK2 | -4844 | -4801 |
| SKP1 | -4917 | -4282 |
| RBX1 | -4521 | -4245 |
| BTRC | -3471 | -2903 |
| STAT5A | -2947 | -2307 |
| CUL1 | -1573 | -1583 |
| PTPN11 | -2125 | -1115 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| BTRC | -1177 | -2739 | -2903 | -3471 |
| CUL1 | -3095 | -1526 | -1583 | -1573 |
| GHR | 3977 | -4611 | -5261 | -5453 |
| JAK2 | -2548 | -5022 | -4801 | -4844 |
| PTPN11 | -1562 | -663 | -1115 | -2125 |
| RBX1 | -730 | -964 | -4245 | -4521 |
| SH2B1 | -3808 | -967 | 197 | -436 |
| SKP1 | 2016 | -2488 | -4282 | -4917 |
| STAT5A | -4088 | -4540 | -2307 | -2947 |
| STAT5B | -4977 | -5271 | -5327 | -5459 |
Formation of Senescence-Associated Heterochromatin Foci (SAHF)
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.00323 |
| p.adjustMANOVA | 0.00945 |
| s.dist | 1.04 |
| s.human | 0.113 |
| s.mouse | 0.475 |
| s.jmod | 0.697 |
| s.jsev | 0.593 |
| p.human | 0.535 |
| p.mouse | 0.00932 |
| p.jmod | 0.000134 |
| p.jsev | 0.00117 |
| Gene | jmod | jsev |
|---|---|---|
| RB1 | 5230 | 4931 |
| HMGA1 | 5110 | 4845 |
| CABIN1 | 4540 | 3783 |
| CDKN1A | 4244 | 3687 |
| LMNB1 | 3283 | 3849 |
| TP53 | 2821 | 2876 |
| EP400 | 2680 | 2090 |
| UBN1 | 3562 | 933 |
| HIRA | 1968 | 1392 |
| ASF1A | 3006 | 793 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ASF1A | 2502 | 2534 | 3006 | 793 |
| CABIN1 | -2019 | -281 | 4540 | 3783 |
| CDKN1A | -4884 | 5060 | 4244 | 3687 |
| EP400 | 2464 | -165 | 2680 | 2090 |
| HIRA | 825 | 681 | 1968 | 1392 |
| HMGA1 | 593 | 5066 | 5110 | 4845 |
| LMNB1 | 3375 | 2925 | 3283 | 3849 |
| RB1 | -2428 | 1453 | 5230 | 4931 |
| TP53 | 571 | 3722 | 2821 | 2876 |
| UBN1 | 2074 | 3640 | 3562 | 933 |
Pyruvate metabolism and Citric Acid (TCA) cycle
| metric | value |
|---|---|
| setSize | 49 |
| pMANOVA | 5e-16 |
| p.adjustMANOVA | 2.12e-14 |
| s.dist | 1.04 |
| s.human | -0.264 |
| s.mouse | -0.559 |
| s.jmod | -0.522 |
| s.jsev | -0.649 |
| p.human | 0.0014 |
| p.mouse | 1.32e-11 |
| p.jmod | 2.68e-10 |
| p.jsev | 3.75e-15 |
| Gene | jsev | mouse |
|---|---|---|
| D2HGDH | -4901 | -5299 |
| PDP1 | -5120 | -4569 |
| VDAC1 | -5055 | -4572 |
| GSTZ1 | -4993 | -4597 |
| RXRA | -5295 | -4162 |
| SUCLG2 | -4784 | -4260 |
| ME1 | -5163 | -3932 |
| SDHA | -4448 | -4558 |
| ME3 | -5361 | -3692 |
| L2HGDH | -5414 | -3615 |
| PDHX | -5012 | -3845 |
| ACO2 | -4227 | -4394 |
| IDH3A | -4800 | -3796 |
| CS | -5099 | -3540 |
| SUCLA2 | -4148 | -4344 |
| PDK2 | -5069 | -3509 |
| DLD | -3732 | -4703 |
| GLO1 | -4427 | -3858 |
| SDHB | -4255 | -3680 |
| OGDH | -4298 | -3624 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ACO2 | -3789 | -4394 | -3940 | -4227 |
| ADHFE1 | -4004 | -2458 | -4898 | -5307 |
| BSG | -2228 | -2098 | -5177 | -5266 |
| CS | 3635 | -3540 | -4697 | -5099 |
| D2HGDH | -4847 | -5299 | -4556 | -4901 |
| DLAT | -1942 | -3797 | -2588 | -3544 |
| DLD | 1179 | -4703 | -2925 | -3732 |
| DLST | -323 | -3501 | -1782 | -3326 |
| FAHD1 | -1756 | -4271 | -2480 | -3090 |
| FH | 285 | -2874 | -3286 | -4455 |
| GLO1 | -676 | -3858 | -4459 | -4427 |
| GSTZ1 | -2050 | -4597 | -3996 | -4993 |
| HAGH | -4468 | 1238 | -3052 | -3594 |
| IDH2 | -5171 | -3827 | -2773 | -2550 |
| IDH3A | -2137 | -3796 | -4547 | -4800 |
| IDH3B | -2856 | -2158 | -4295 | -5049 |
| IDH3G | -4141 | -3107 | -3719 | -4663 |
| L2HGDH | -262 | -3615 | -5258 | -5414 |
| LDHA | -3224 | -2890 | -3696 | -4159 |
| LDHB | -1478 | -1959 | -1561 | -3146 |
| MDH2 | -4322 | -2835 | -2729 | -4902 |
| ME1 | 1778 | -3932 | -4973 | -5163 |
| ME2 | -1774 | 3498 | 4816 | 5022 |
| ME3 | 4187 | -3692 | -5332 | -5361 |
| MPC1 | -3650 | -3211 | 4254 | -727 |
| MPC2 | 823 | -1724 | -3807 | -4615 |
| NNT | -3297 | -2355 | -263 | -773 |
| OGDH | -5223 | -3624 | -3565 | -4298 |
| PDHA1 | -2384 | -4419 | -782 | -3182 |
| PDHB | -133 | -3968 | -949 | -2718 |
| PDHX | -126 | -3845 | -4254 | -5012 |
| PDK1 | 4579 | -3210 | -4255 | -4412 |
| PDK2 | -5404 | -3509 | -5087 | -5069 |
| PDK3 | 4726 | 4833 | 4828 | 5011 |
| PDK4 | -709 | -5203 | -794 | -1125 |
| PDP1 | -2157 | -4569 | -4848 | -5120 |
| PDP2 | -2597 | -2422 | -2600 | -2676 |
| PDPR | -630 | -4796 | 2801 | -2923 |
| PPARD | -4175 | -2321 | -2662 | -4382 |
| RXRA | -5473 | -4162 | -5068 | -5295 |
| SDHA | -4730 | -4558 | -4419 | -4448 |
| SDHB | 429 | -3680 | -3699 | -4255 |
| SDHC | -3681 | -2980 | -3055 | -4450 |
| SLC16A1 | -979 | 5043 | 1678 | 138 |
| SLC16A3 | -4708 | -4129 | 22 | -2312 |
| SUCLA2 | 1506 | -4344 | -3701 | -4148 |
| SUCLG1 | -31 | -2121 | -5183 | -5337 |
| SUCLG2 | -1157 | -4260 | -4228 | -4784 |
| VDAC1 | -2884 | -4572 | -5208 | -5055 |
Complex I biogenesis
| metric | value |
|---|---|
| setSize | 52 |
| pMANOVA | 4.86e-19 |
| p.adjustMANOVA | 2.85e-17 |
| s.dist | 1.03 |
| s.human | -0.197 |
| s.mouse | -0.4 |
| s.jmod | -0.575 |
| s.jsev | -0.736 |
| p.human | 0.014 |
| p.mouse | 6.09e-07 |
| p.jmod | 7.54e-13 |
| p.jsev | 4.06e-20 |
| Gene | jsev | jmod |
|---|---|---|
| NDUFAF6 | -5376 | -5277 |
| NDUFB8 | -5273 | -5046 |
| NDUFB4 | -5147 | -5054 |
| NDUFA7 | -5425 | -4728 |
| ECSIT | -5003 | -5106 |
| NDUFS6 | -4922 | -5136 |
| NDUFS3 | -4866 | -5115 |
| NDUFS7 | -4759 | -5036 |
| NDUFA12 | -4687 | -5055 |
| NDUFAF5 | -5002 | -4687 |
| NDUFS5 | -4921 | -4742 |
| NDUFC1 | -4694 | -4759 |
| NDUFA13 | -4788 | -4526 |
| NDUFA5 | -4422 | -4680 |
| NDUFB9 | -4737 | -4338 |
| NDUFS2 | -4454 | -4572 |
| NDUFAF1 | -4705 | -4302 |
| NDUFV1 | -4550 | -4375 |
| TIMMDC1 | -4613 | -4154 |
| NDUFA2 | -4693 | -4039 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ACAD9 | -4536 | -4526 | -3774 | -4279 |
| ECSIT | -2633 | -2826 | -5106 | -5003 |
| MT-ND1 | -353 | -2196 | -3440 | -4873 |
| MT-ND2 | -1111 | -2072 | -2744 | -4949 |
| MT-ND4 | -2068 | -1583 | -2533 | -4907 |
| MT-ND5 | -3217 | -2307 | -2314 | -4573 |
| MT-ND6 | 810 | -4559 | -2351 | -4538 |
| NDUFA1 | -734 | 309 | -3280 | -3960 |
| NDUFA10 | -1937 | -3098 | -2972 | -4446 |
| NDUFA11 | -1025 | -1131 | -4153 | -4509 |
| NDUFA12 | -1304 | -656 | -5055 | -4687 |
| NDUFA13 | -2233 | -2537 | -4526 | -4788 |
| NDUFA2 | -1279 | -1963 | -4039 | -4693 |
| NDUFA3 | -3772 | -590 | -3702 | -4761 |
| NDUFA5 | 530 | -1658 | -4680 | -4422 |
| NDUFA6 | -77 | -3365 | 2217 | -2218 |
| NDUFA7 | -465 | -1812 | -4728 | -5425 |
| NDUFA8 | -600 | -2489 | -3140 | -4344 |
| NDUFA9 | -2843 | -2060 | -3862 | -3986 |
| NDUFAB1 | 1143 | -3233 | -1919 | -3628 |
| NDUFAF1 | 1167 | -4234 | -4302 | -4705 |
| NDUFAF2 | 3487 | -3224 | 1598 | -907 |
| NDUFAF3 | -3550 | -1257 | -810 | -2450 |
| NDUFAF4 | 3722 | -2005 | -3122 | -4016 |
| NDUFAF5 | 28 | -973 | -4687 | -5002 |
| NDUFAF6 | -2534 | -4067 | -5277 | -5376 |
| NDUFAF7 | 2955 | -455 | -808 | -1681 |
| NDUFB10 | -3343 | -2081 | -3566 | -4256 |
| NDUFB11 | -2085 | -2840 | 2200 | -1800 |
| NDUFB2 | -3701 | -958 | -3669 | -4852 |
| NDUFB3 | 845 | -1919 | -2561 | -3232 |
| NDUFB4 | -311 | -1512 | -5054 | -5147 |
| NDUFB5 | -2021 | -1171 | -1281 | -3475 |
| NDUFB6 | 921 | -306 | -4201 | -4365 |
| NDUFB7 | -4184 | -1979 | -3246 | -4170 |
| NDUFB8 | -2995 | -2896 | -5046 | -5273 |
| NDUFB9 | -988 | -3409 | -4338 | -4737 |
| NDUFC1 | -662 | -2883 | -4759 | -4694 |
| NDUFC2 | 32 | -2414 | -2946 | -4236 |
| NDUFS1 | -1531 | -4342 | -3946 | -4495 |
| NDUFS2 | -3001 | -2795 | -4572 | -4454 |
| NDUFS3 | -3536 | -2734 | -5115 | -4866 |
| NDUFS4 | -1675 | -2428 | 916 | -2652 |
| NDUFS5 | -1225 | -1909 | -4742 | -4921 |
| NDUFS6 | -1321 | -976 | -5136 | -4922 |
| NDUFS7 | -4828 | -1892 | -5036 | -4759 |
| NDUFS8 | -4286 | -1984 | -3538 | -4366 |
| NDUFV1 | -4188 | -2717 | -4375 | -4550 |
| NDUFV3 | -2357 | -2573 | -1934 | -3443 |
| NUBPL | -1528 | -3520 | 1662 | -451 |
| TIMMDC1 | 211 | -1103 | -4154 | -4613 |
| TMEM126B | 1017 | 1857 | 2341 | -876 |
Glyoxylate metabolism and glycine degradation
| metric | value |
|---|---|
| setSize | 20 |
| pMANOVA | 2.72e-07 |
| p.adjustMANOVA | 2.77e-06 |
| s.dist | 0.998 |
| s.human | -0.173 |
| s.mouse | -0.511 |
| s.jmod | -0.48 |
| s.jsev | -0.689 |
| p.human | 0.18 |
| p.mouse | 7.63e-05 |
| p.jmod | 2e-04 |
| p.jsev | 9.61e-08 |
| Gene | jsev | mouse |
|---|---|---|
| GRHPR | -5334 | -4004 |
| LIAS | -4570 | -4665 |
| PXMP2 | -5452 | -3807 |
| PDHX | -5012 | -3845 |
| ALDH4A1 | -5380 | -3439 |
| DLD | -3732 | -4703 |
| OGDH | -4298 | -3624 |
| PDHA1 | -3182 | -4419 |
| BCKDHB | -5370 | -2613 |
| DDO | -3221 | -4322 |
| DLAT | -3544 | -3797 |
| NDUFAB1 | -3628 | -3233 |
| DLST | -3326 | -3501 |
| GOT2 | -3752 | -3069 |
| DHTKD1 | -2710 | -4079 |
| PDHB | -2718 | -3968 |
| LIPT2 | -3093 | -2621 |
| GCSH | -2462 | -1030 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ALDH4A1 | -2283 | -3439 | -5066 | -5380 |
| BCKDHB | -4203 | -2613 | -5262 | -5370 |
| DBT | 1989 | 5174 | -4872 | -5170 |
| DDO | -3746 | -4322 | -2227 | -3221 |
| DHTKD1 | -419 | -4079 | -3073 | -2710 |
| DLAT | -1942 | -3797 | -2588 | -3544 |
| DLD | 1179 | -4703 | -2925 | -3732 |
| DLST | -323 | -3501 | -1782 | -3326 |
| GCSH | -140 | -1030 | 3397 | -2462 |
| GOT2 | -3673 | -3069 | -2435 | -3752 |
| GRHPR | -4687 | -4004 | -5041 | -5334 |
| LIAS | -1122 | -4665 | -3660 | -4570 |
| LIPT1 | 3399 | 4628 | 3578 | -1128 |
| LIPT2 | 297 | -2621 | -2962 | -3093 |
| NDUFAB1 | 1143 | -3233 | -1919 | -3628 |
| OGDH | -5223 | -3624 | -3565 | -4298 |
| PDHA1 | -2384 | -4419 | -782 | -3182 |
| PDHB | -133 | -3968 | -949 | -2718 |
| PDHX | -126 | -3845 | -4254 | -5012 |
| PXMP2 | -1726 | -3807 | -5217 | -5452 |
The NLRP3 inflammasome
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.00584 |
| p.adjustMANOVA | 0.0153 |
| s.dist | 0.992 |
| s.human | -0.0904 |
| s.mouse | 0.49 |
| s.jmod | 0.646 |
| s.jsev | 0.566 |
| p.human | 0.621 |
| p.mouse | 0.00735 |
| p.jmod | 0.000406 |
| p.jsev | 0.00196 |
| Gene | jmod | jsev |
|---|---|---|
| PYCARD | 4834 | 4967 |
| APP | 4907 | 4799 |
| NFKB2 | 5046 | 4427 |
| TXN | 4240 | 4843 |
| CASP1 | 4126 | 4201 |
| NFKB1 | 3098 | 3001 |
| RELA | 1895 | 1422 |
| PANX1 | 1609 | 1673 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| APP | -2769 | 578 | 4907 | 4799 |
| CASP1 | -1287 | 3148 | 4126 | 4201 |
| HSP90AB1 | -637 | 4599 | 725 | -382 |
| NFKB1 | -4195 | 3288 | 3098 | 3001 |
| NFKB2 | -3892 | 3309 | 5046 | 4427 |
| PANX1 | 1134 | 1056 | 1609 | 1673 |
| PYCARD | -2787 | 4673 | 4834 | 4967 |
| RELA | 1772 | 4501 | 1895 | 1422 |
| SUGT1 | 3123 | -4501 | 3238 | -1208 |
| TXN | 1844 | 4760 | 4240 | 4843 |
Signal regulatory protein family interactions
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.00108 |
| p.adjustMANOVA | 0.00362 |
| s.dist | 0.985 |
| s.human | -0.413 |
| s.mouse | 0.507 |
| s.jmod | 0.505 |
| s.jsev | 0.537 |
| p.human | 0.0238 |
| p.mouse | 0.0055 |
| p.jmod | 0.00572 |
| p.jsev | 0.00327 |
| Gene | jsev | mouse |
|---|---|---|
| PTPN6 | 5061 | 4768 |
| SIRPA | 5051 | 4193 |
| SKAP2 | 4943 | 3744 |
| PTK2B | 4515 | 3833 |
| FYB | 4921 | 3460 |
| CD47 | 3548 | 2663 |
| SRC | 1786 | 1368 |
| GRB2 | 512 | 4466 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| CD47 | -2165 | 2663 | 4567 | 3548 |
| FYB | -2216 | 3460 | 5149 | 4921 |
| GRB2 | -4015 | 4466 | 3 | 512 |
| PTK2 | -2476 | -1498 | -4025 | -1966 |
| PTK2B | -2440 | 3833 | 4360 | 4515 |
| PTPN11 | -1562 | -663 | -1115 | -2125 |
| PTPN6 | -924 | 4768 | 5071 | 5061 |
| SIRPA | -5581 | 4193 | 5242 | 5051 |
| SKAP2 | 514 | 3744 | 4730 | 4943 |
| SRC | -3876 | 1368 | 2278 | 1786 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.000643 |
| p.adjustMANOVA | 0.00236 |
| s.dist | 0.969 |
| s.human | -0.246 |
| s.mouse | 0.0504 |
| s.jmod | 0.663 |
| s.jsev | 0.66 |
| p.human | 0.178 |
| p.mouse | 0.783 |
| p.jmod | 0.000284 |
| p.jsev | 0.000299 |
| Gene | jmod | jsev |
|---|---|---|
| IFIH1 | 4817 | 4520 |
| CASP8 | 4121 | 4836 |
| CHUK | 4768 | 3474 |
| TRIM25 | 4133 | 3695 |
| IKBKB | 3745 | 3772 |
| DDX58 | 3129 | 4179 |
| FADD | 4131 | 2918 |
| RIPK1 | 2892 | 4118 |
| RNF135 | 2457 | 3278 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| CASP8 | -1632 | 3068 | 4121 | 4836 |
| CHUK | 214 | 950 | 4768 | 3474 |
| DDX58 | 1582 | -905 | 3129 | 4179 |
| FADD | -570 | 4846 | 4131 | 2918 |
| IFIH1 | -204 | -3095 | 4817 | 4520 |
| IKBKB | -4057 | 574 | 3745 | 3772 |
| MAVS | -4725 | -4826 | 425 | -2032 |
| RIPK1 | 323 | 714 | 2892 | 4118 |
| RNF135 | -3646 | 983 | 2457 | 3278 |
| TRIM25 | -3216 | -118 | 4133 | 3695 |
Regulation of pyruvate dehydrogenase (PDH) complex
| metric | value |
|---|---|
| setSize | 15 |
| pMANOVA | 6.3e-05 |
| p.adjustMANOVA | 0.000308 |
| s.dist | 0.964 |
| s.human | -0.163 |
| s.mouse | -0.63 |
| s.jmod | -0.411 |
| s.jsev | -0.58 |
| p.human | 0.274 |
| p.mouse | 2.36e-05 |
| p.jmod | 0.00592 |
| p.jsev | 0.000102 |
| Gene | mouse | jsev |
|---|---|---|
| PDP1 | -4569 | -5120 |
| GSTZ1 | -4597 | -4993 |
| RXRA | -4162 | -5295 |
| PDHX | -3845 | -5012 |
| PDK2 | -3509 | -5069 |
| DLD | -4703 | -3732 |
| PDK1 | -3210 | -4412 |
| PDHA1 | -4419 | -3182 |
| PDPR | -4796 | -2923 |
| DLAT | -3797 | -3544 |
| PDHB | -3968 | -2718 |
| PPARD | -2321 | -4382 |
| PDP2 | -2422 | -2676 |
| PDK4 | -5203 | -1125 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| DLAT | -1942 | -3797 | -2588 | -3544 |
| DLD | 1179 | -4703 | -2925 | -3732 |
| GSTZ1 | -2050 | -4597 | -3996 | -4993 |
| PDHA1 | -2384 | -4419 | -782 | -3182 |
| PDHB | -133 | -3968 | -949 | -2718 |
| PDHX | -126 | -3845 | -4254 | -5012 |
| PDK1 | 4579 | -3210 | -4255 | -4412 |
| PDK2 | -5404 | -3509 | -5087 | -5069 |
| PDK3 | 4726 | 4833 | 4828 | 5011 |
| PDK4 | -709 | -5203 | -794 | -1125 |
| PDP1 | -2157 | -4569 | -4848 | -5120 |
| PDP2 | -2597 | -2422 | -2600 | -2676 |
| PDPR | -630 | -4796 | 2801 | -2923 |
| PPARD | -4175 | -2321 | -2662 | -4382 |
| RXRA | -5473 | -4162 | -5068 | -5295 |
Mucopolysaccharidoses
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 9.68e-05 |
| p.adjustMANOVA | 0.000446 |
| s.dist | 0.959 |
| s.human | -0.336 |
| s.mouse | 0.00843 |
| s.jmod | 0.608 |
| s.jsev | 0.66 |
| p.human | 0.0535 |
| p.mouse | 0.961 |
| p.jmod | 0.000479 |
| p.jsev | 0.000149 |
| Gene | jsev | jmod |
|---|---|---|
| GUSB | 4989 | 5113 |
| GALNS | 4734 | 4969 |
| GNS | 4576 | 4565 |
| NAGLU | 4536 | 4350 |
| GLB1 | 4940 | 3750 |
| SGSH | 3172 | 3944 |
| ARSB | 3395 | 3597 |
| IDS | 2739 | 4432 |
| HYAL1 | 1396 | 129 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ARSB | -993 | 2812 | 3597 | 3395 |
| GALNS | -3925 | 4515 | 4969 | 4734 |
| GLB1 | -2225 | 919 | 3750 | 4940 |
| GNS | 99 | -975 | 4565 | 4576 |
| GUSB | 1911 | 4124 | 5113 | 4989 |
| HGSNAT | -4558 | -3503 | -30 | 2231 |
| HYAL1 | -3812 | 1594 | 129 | 1396 |
| IDS | -2452 | -3595 | 4432 | 2739 |
| IDUA | -3833 | -4704 | 75 | -679 |
| NAGLU | -3677 | -709 | 4350 | 4536 |
| SGSH | 705 | -510 | 3944 | 3172 |
Inflammasomes
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.00157 |
| p.adjustMANOVA | 0.00501 |
| s.dist | 0.951 |
| s.human | -0.219 |
| s.mouse | 0.446 |
| s.jmod | 0.615 |
| s.jsev | 0.528 |
| p.human | 0.188 |
| p.mouse | 0.0075 |
| p.jmod | 0.000227 |
| p.jsev | 0.00154 |
| Gene | jmod | jsev |
|---|---|---|
| PYCARD | 4834 | 4967 |
| APP | 4907 | 4799 |
| NFKB2 | 5046 | 4427 |
| TXN | 4240 | 4843 |
| CASP1 | 4126 | 4201 |
| NFKB1 | 3098 | 3001 |
| BCL2 | 2817 | 1494 |
| BCL2L1 | 1945 | 1676 |
| RELA | 1895 | 1422 |
| PANX1 | 1609 | 1673 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| APP | -2769 | 578 | 4907 | 4799 |
| BCL2 | -4591 | -1104 | 2817 | 1494 |
| BCL2L1 | -5136 | 3407 | 1945 | 1676 |
| CASP1 | -1287 | 3148 | 4126 | 4201 |
| HSP90AB1 | -637 | 4599 | 725 | -382 |
| NFKB1 | -4195 | 3288 | 3098 | 3001 |
| NFKB2 | -3892 | 3309 | 5046 | 4427 |
| PANX1 | 1134 | 1056 | 1609 | 1673 |
| PYCARD | -2787 | 4673 | 4834 | 4967 |
| RELA | 1772 | 4501 | 1895 | 1422 |
| SUGT1 | 3123 | -4501 | 3238 | -1208 |
| TXN | 1844 | 4760 | 4240 | 4843 |
Condensation of Prophase Chromosomes
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.000897 |
| p.adjustMANOVA | 0.00307 |
| s.dist | 0.941 |
| s.human | 0.372 |
| s.mouse | 0.188 |
| s.jmod | 0.548 |
| s.jsev | 0.642 |
| p.human | 0.0329 |
| p.mouse | 0.28 |
| p.jmod | 0.00165 |
| p.jsev | 0.000227 |
| Gene | jsev | jmod |
|---|---|---|
| RB1 | 4931 | 5230 |
| SMC2 | 4996 | 5041 |
| H2AFX | 4957 | 4878 |
| CDK1 | 5050 | 4743 |
| NCAPG2 | 4906 | 4783 |
| SMC4 | 4995 | 3746 |
| NCAPD3 | 2065 | 4727 |
| MCPH1 | 2882 | 1879 |
| PHF8 | 1449 | 437 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| CDK1 | 1569 | 3237 | 4743 | 5050 |
| H2AFX | 2343 | 5031 | 4878 | 4957 |
| MCPH1 | 2164 | -1840 | 1879 | 2882 |
| NCAPD3 | 2986 | -4862 | 4727 | 2065 |
| NCAPG2 | -13 | 1148 | 4783 | 4906 |
| NCAPH2 | -1829 | -2809 | -1820 | -2498 |
| PHF8 | 3376 | 2121 | 437 | 1449 |
| RB1 | -2428 | 1453 | 5230 | 4931 |
| SET | 3665 | 2115 | -2241 | 1229 |
| SMC2 | 2463 | 3740 | 5041 | 4996 |
| SMC4 | 4107 | 1092 | 3746 | 4995 |
Post-chaperonin tubulin folding pathway
| metric | value |
|---|---|
| setSize | 15 |
| pMANOVA | 1.89e-06 |
| p.adjustMANOVA | 1.42e-05 |
| s.dist | 0.939 |
| s.human | -0.483 |
| s.mouse | 0.555 |
| s.jmod | 0.459 |
| s.jsev | 0.36 |
| p.human | 0.00119 |
| p.mouse | 0.000197 |
| p.jmod | 0.00208 |
| p.jsev | 0.0159 |
| Gene | mouse | human |
|---|---|---|
| TUBB6 | 5170 | -5015 |
| TUBA1B | 4883 | -5279 |
| TUBA1C | 5092 | -4840 |
| TUBB2B | 4929 | -4661 |
| TUBB2A | 4418 | -4633 |
| TUBA1A | 3686 | -5183 |
| TUBA4A | 2057 | -5297 |
| TBCA | 1794 | -2561 |
| TBCE | 496 | -454 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ARL2 | -4105 | -521 | -3594 | -3516 |
| TBCA | -2561 | 1794 | 3706 | 3169 |
| TBCB | 1107 | 3224 | 3480 | 2274 |
| TBCC | 3014 | 4688 | 2746 | 1557 |
| TBCD | -4096 | -593 | 3518 | 4124 |
| TBCE | -454 | 496 | 783 | -1844 |
| TUBA1A | -5183 | 3686 | 3799 | 4737 |
| TUBA1B | -5279 | 4883 | 4983 | 5054 |
| TUBA1C | -4840 | 5092 | 5026 | 5030 |
| TUBA4A | -5297 | 2057 | -3275 | -4243 |
| TUBA8 | -1107 | -884 | -2996 | -3153 |
| TUBB2A | -4633 | 4418 | 4726 | 5046 |
| TUBB2B | -4661 | 4929 | 4804 | 4923 |
| TUBB4B | 428 | 4865 | 2872 | -2918 |
| TUBB6 | -5015 | 5170 | 5184 | 5047 |
The citric acid (TCA) cycle and respiratory electron transport
| metric | value |
|---|---|
| setSize | 142 |
| pMANOVA | 1.87e-42 |
| p.adjustMANOVA | 7.67e-40 |
| s.dist | 0.928 |
| s.human | -0.203 |
| s.mouse | -0.423 |
| s.jmod | -0.482 |
| s.jsev | -0.64 |
| p.human | 3.2e-05 |
| p.mouse | 4.08e-18 |
| p.jmod | 4.17e-23 |
| p.jsev | 1.23e-39 |
| Gene | jsev | jmod |
|---|---|---|
| ME3 | -5361 | -5332 |
| L2HGDH | -5414 | -5258 |
| NDUFAF6 | -5376 | -5277 |
| SUCLG1 | -5337 | -5183 |
| BSG | -5266 | -5177 |
| RXRA | -5295 | -5068 |
| NDUFB8 | -5273 | -5046 |
| VDAC1 | -5055 | -5208 |
| NDUFB4 | -5147 | -5054 |
| ADHFE1 | -5307 | -4898 |
| PDK2 | -5069 | -5087 |
| ME1 | -5163 | -4973 |
| NDUFA7 | -5425 | -4728 |
| ECSIT | -5003 | -5106 |
| NDUFS6 | -4922 | -5136 |
| NDUFS3 | -4866 | -5115 |
| PDP1 | -5120 | -4848 |
| NDUFS7 | -4759 | -5036 |
| CS | -5099 | -4697 |
| TRAP1 | -4947 | -4798 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ACAD9 | -4536 | -4526 | -3774 | -4279 |
| ACO2 | -3789 | -4394 | -3940 | -4227 |
| ADHFE1 | -4004 | -2458 | -4898 | -5307 |
| BSG | -2228 | -2098 | -5177 | -5266 |
| COQ10A | -3522 | -2636 | -3298 | -4456 |
| COQ10B | 4324 | 4226 | -581 | -2292 |
| COX11 | -2836 | -1161 | -4331 | -3619 |
| COX14 | -2749 | -4337 | -2334 | -3781 |
| COX16 | -2239 | -1928 | -3032 | -5048 |
| COX18 | -553 | 631 | -1589 | -1593 |
| COX19 | 3037 | 3465 | -1018 | -2770 |
| COX20 | 1096 | -2260 | -2841 | -2946 |
| COX4I1 | -2336 | -1282 | -2577 | -3829 |
| COX5A | -2490 | -2534 | -3091 | -4127 |
| COX5B | -2538 | 456 | -2535 | -3988 |
| COX6A1 | 2247 | 2225 | 2160 | 3365 |
| COX6B1 | -2212 | -851 | -1781 | -3712 |
| COX6C | -18 | -841 | -1021 | -3527 |
| COX7B | 142 | -725 | -361 | -3184 |
| COX7C | -1482 | -175 | -1756 | -2432 |
| COX8A | -4298 | 2625 | 2143 | 3026 |
| CS | 3635 | -3540 | -4697 | -5099 |
| CYC1 | -4110 | -4002 | -3222 | -4341 |
| D2HGDH | -4847 | -5299 | -4556 | -4901 |
| DLAT | -1942 | -3797 | -2588 | -3544 |
| DLD | 1179 | -4703 | -2925 | -3732 |
| DLST | -323 | -3501 | -1782 | -3326 |
| ECSIT | -2633 | -2826 | -5106 | -5003 |
| ETFA | 3143 | -2742 | -462 | -2287 |
| ETFB | -3583 | -2721 | -4137 | -4750 |
| ETFDH | 1872 | -4553 | -2700 | -3396 |
| FAHD1 | -1756 | -4271 | -2480 | -3090 |
| FH | 285 | -2874 | -3286 | -4455 |
| GLO1 | -676 | -3858 | -4459 | -4427 |
| GSTZ1 | -2050 | -4597 | -3996 | -4993 |
| HAGH | -4468 | 1238 | -3052 | -3594 |
| IDH2 | -5171 | -3827 | -2773 | -2550 |
| IDH3A | -2137 | -3796 | -4547 | -4800 |
| IDH3B | -2856 | -2158 | -4295 | -5049 |
| IDH3G | -4141 | -3107 | -3719 | -4663 |
| L2HGDH | -262 | -3615 | -5258 | -5414 |
| LDHA | -3224 | -2890 | -3696 | -4159 |
| LDHB | -1478 | -1959 | -1561 | -3146 |
| LRPPRC | 1645 | -4358 | -3038 | -3737 |
| MDH2 | -4322 | -2835 | -2729 | -4902 |
| ME1 | 1778 | -3932 | -4973 | -5163 |
| ME2 | -1774 | 3498 | 4816 | 5022 |
| ME3 | 4187 | -3692 | -5332 | -5361 |
| MPC1 | -3650 | -3211 | 4254 | -727 |
| MPC2 | 823 | -1724 | -3807 | -4615 |
| MT-CO1 | -3141 | -4085 | -3674 | -4681 |
| MT-CYB | -1344 | -2337 | -2487 | -4813 |
| MT-ND1 | -353 | -2196 | -3440 | -4873 |
| MT-ND2 | -1111 | -2072 | -2744 | -4949 |
| MT-ND4 | -2068 | -1583 | -2533 | -4907 |
| MT-ND5 | -3217 | -2307 | -2314 | -4573 |
| MT-ND6 | 810 | -4559 | -2351 | -4538 |
| NDUFA1 | -734 | 309 | -3280 | -3960 |
| NDUFA10 | -1937 | -3098 | -2972 | -4446 |
| NDUFA11 | -1025 | -1131 | -4153 | -4509 |
| NDUFA12 | -1304 | -656 | -5055 | -4687 |
| NDUFA13 | -2233 | -2537 | -4526 | -4788 |
| NDUFA2 | -1279 | -1963 | -4039 | -4693 |
| NDUFA3 | -3772 | -590 | -3702 | -4761 |
| NDUFA4 | -393 | -679 | -3216 | -4029 |
| NDUFA5 | 530 | -1658 | -4680 | -4422 |
| NDUFA6 | -77 | -3365 | 2217 | -2218 |
| NDUFA7 | -465 | -1812 | -4728 | -5425 |
| NDUFA8 | -600 | -2489 | -3140 | -4344 |
| NDUFA9 | -2843 | -2060 | -3862 | -3986 |
| NDUFAB1 | 1143 | -3233 | -1919 | -3628 |
| NDUFAF1 | 1167 | -4234 | -4302 | -4705 |
| NDUFAF2 | 3487 | -3224 | 1598 | -907 |
| NDUFAF3 | -3550 | -1257 | -810 | -2450 |
| NDUFAF4 | 3722 | -2005 | -3122 | -4016 |
| NDUFAF5 | 28 | -973 | -4687 | -5002 |
| NDUFAF6 | -2534 | -4067 | -5277 | -5376 |
| NDUFAF7 | 2955 | -455 | -808 | -1681 |
| NDUFB10 | -3343 | -2081 | -3566 | -4256 |
| NDUFB11 | -2085 | -2840 | 2200 | -1800 |
| NDUFB2 | -3701 | -958 | -3669 | -4852 |
| NDUFB3 | 845 | -1919 | -2561 | -3232 |
| NDUFB4 | -311 | -1512 | -5054 | -5147 |
| NDUFB5 | -2021 | -1171 | -1281 | -3475 |
| NDUFB6 | 921 | -306 | -4201 | -4365 |
| NDUFB7 | -4184 | -1979 | -3246 | -4170 |
| NDUFB8 | -2995 | -2896 | -5046 | -5273 |
| NDUFB9 | -988 | -3409 | -4338 | -4737 |
| NDUFC1 | -662 | -2883 | -4759 | -4694 |
| NDUFC2 | 32 | -2414 | -2946 | -4236 |
| NDUFS1 | -1531 | -4342 | -3946 | -4495 |
| NDUFS2 | -3001 | -2795 | -4572 | -4454 |
| NDUFS3 | -3536 | -2734 | -5115 | -4866 |
| NDUFS4 | -1675 | -2428 | 916 | -2652 |
| NDUFS5 | -1225 | -1909 | -4742 | -4921 |
| NDUFS6 | -1321 | -976 | -5136 | -4922 |
| NDUFS7 | -4828 | -1892 | -5036 | -4759 |
| NDUFS8 | -4286 | -1984 | -3538 | -4366 |
| NDUFV1 | -4188 | -2717 | -4375 | -4550 |
| NDUFV3 | -2357 | -2573 | -1934 | -3443 |
| NNT | -3297 | -2355 | -263 | -773 |
| NUBPL | -1528 | -3520 | 1662 | -451 |
| OGDH | -5223 | -3624 | -3565 | -4298 |
| PDHA1 | -2384 | -4419 | -782 | -3182 |
| PDHB | -133 | -3968 | -949 | -2718 |
| PDHX | -126 | -3845 | -4254 | -5012 |
| PDK1 | 4579 | -3210 | -4255 | -4412 |
| PDK2 | -5404 | -3509 | -5087 | -5069 |
| PDK3 | 4726 | 4833 | 4828 | 5011 |
| PDK4 | -709 | -5203 | -794 | -1125 |
| PDP1 | -2157 | -4569 | -4848 | -5120 |
| PDP2 | -2597 | -2422 | -2600 | -2676 |
| PDPR | -630 | -4796 | 2801 | -2923 |
| PPARD | -4175 | -2321 | -2662 | -4382 |
| RXRA | -5473 | -4162 | -5068 | -5295 |
| SCO1 | 3560 | 1696 | 2351 | 1489 |
| SCO2 | -1924 | -768 | 742 | -1345 |
| SDHA | -4730 | -4558 | -4419 | -4448 |
| SDHB | 429 | -3680 | -3699 | -4255 |
| SDHC | -3681 | -2980 | -3055 | -4450 |
| SLC16A1 | -979 | 5043 | 1678 | 138 |
| SLC16A3 | -4708 | -4129 | 22 | -2312 |
| SLC25A14 | 3815 | 1859 | 2420 | 2905 |
| SLC25A27 | -2457 | -4829 | -4574 | -4646 |
| SUCLA2 | 1506 | -4344 | -3701 | -4148 |
| SUCLG1 | -31 | -2121 | -5183 | -5337 |
| SUCLG2 | -1157 | -4260 | -4228 | -4784 |
| SURF1 | -1733 | -4070 | -1572 | -3889 |
| TACO1 | 646 | -4231 | -4409 | -4822 |
| TIMMDC1 | 211 | -1103 | -4154 | -4613 |
| TMEM126B | 1017 | 1857 | 2341 | -876 |
| TRAP1 | -5220 | -2048 | -4798 | -4947 |
| UCP2 | -4905 | 5008 | 5034 | 4864 |
| UCP3 | -682 | -5325 | -501 | -2029 |
| UQCR10 | -3113 | -258 | 2839 | -2153 |
| UQCRB | 401 | -3688 | -1452 | -3263 |
| UQCRC1 | -3304 | -3641 | -4077 | -4622 |
| UQCRC2 | 547 | -3880 | -3357 | -4026 |
| UQCRFS1 | -151 | -3041 | -2852 | -3937 |
| UQCRH | -1519 | -1741 | -1925 | -3886 |
| UQCRQ | -1752 | -1842 | 0 | -3044 |
| VDAC1 | -2884 | -4572 | -5208 | -5055 |
Pyruvate metabolism
| metric | value |
|---|---|
| setSize | 26 |
| pMANOVA | 9.19e-08 |
| p.adjustMANOVA | 1.11e-06 |
| s.dist | 0.927 |
| s.human | -0.229 |
| s.mouse | -0.521 |
| s.jmod | -0.423 |
| s.jsev | -0.597 |
| p.human | 0.0435 |
| p.mouse | 4.23e-06 |
| p.jmod | 0.00019 |
| p.jsev | 1.39e-07 |
| Gene | jsev | mouse |
|---|---|---|
| PDP1 | -5120 | -4569 |
| VDAC1 | -5055 | -4572 |
| GSTZ1 | -4993 | -4597 |
| RXRA | -5295 | -4162 |
| ME1 | -5163 | -3932 |
| PDHX | -5012 | -3845 |
| PDK2 | -5069 | -3509 |
| DLD | -3732 | -4703 |
| GLO1 | -4427 | -3858 |
| PDK1 | -4412 | -3210 |
| PDHA1 | -3182 | -4419 |
| PDPR | -2923 | -4796 |
| DLAT | -3544 | -3797 |
| LDHA | -4159 | -2890 |
| BSG | -5266 | -2098 |
| PDHB | -2718 | -3968 |
| PPARD | -4382 | -2321 |
| SLC16A3 | -2312 | -4129 |
| MPC2 | -4615 | -1724 |
| PDP2 | -2676 | -2422 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| BSG | -2228 | -2098 | -5177 | -5266 |
| DLAT | -1942 | -3797 | -2588 | -3544 |
| DLD | 1179 | -4703 | -2925 | -3732 |
| GLO1 | -676 | -3858 | -4459 | -4427 |
| GSTZ1 | -2050 | -4597 | -3996 | -4993 |
| HAGH | -4468 | 1238 | -3052 | -3594 |
| LDHA | -3224 | -2890 | -3696 | -4159 |
| LDHB | -1478 | -1959 | -1561 | -3146 |
| ME1 | 1778 | -3932 | -4973 | -5163 |
| MPC1 | -3650 | -3211 | 4254 | -727 |
| MPC2 | 823 | -1724 | -3807 | -4615 |
| PDHA1 | -2384 | -4419 | -782 | -3182 |
| PDHB | -133 | -3968 | -949 | -2718 |
| PDHX | -126 | -3845 | -4254 | -5012 |
| PDK1 | 4579 | -3210 | -4255 | -4412 |
| PDK2 | -5404 | -3509 | -5087 | -5069 |
| PDK3 | 4726 | 4833 | 4828 | 5011 |
| PDK4 | -709 | -5203 | -794 | -1125 |
| PDP1 | -2157 | -4569 | -4848 | -5120 |
| PDP2 | -2597 | -2422 | -2600 | -2676 |
| PDPR | -630 | -4796 | 2801 | -2923 |
| PPARD | -4175 | -2321 | -2662 | -4382 |
| RXRA | -5473 | -4162 | -5068 | -5295 |
| SLC16A1 | -979 | 5043 | 1678 | 138 |
| SLC16A3 | -4708 | -4129 | 22 | -2312 |
| VDAC1 | -2884 | -4572 | -5208 | -5055 |
N-Glycan antennae elongation
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.00166 |
| p.adjustMANOVA | 0.00525 |
| s.dist | 0.923 |
| s.human | -0.262 |
| s.mouse | 0.429 |
| s.jmod | 0.505 |
| s.jsev | 0.586 |
| p.human | 0.117 |
| p.mouse | 0.0101 |
| p.jmod | 0.00244 |
| p.jsev | 0.000439 |
| Gene | jsev | jmod |
|---|---|---|
| B4GALT6 | 5059 | 5176 |
| B4GALT5 | 4775 | 5090 |
| ST8SIA2 | 4419 | 4308 |
| MGAT5 | 3970 | 3847 |
| ST3GAL4 | 3879 | 3269 |
| ST6GAL1 | 3481 | 3401 |
| B4GALT4 | 1989 | 2920 |
| B4GALT2 | 2202 | 2626 |
| B4GALT1 | 2853 | 1646 |
| MGAT4A | 1526 | 945 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| B4GALT1 | -1303 | 2572 | 1646 | 2853 |
| B4GALT2 | -4996 | 2201 | 2626 | 2202 |
| B4GALT3 | 967 | 1161 | -437 | 929 |
| B4GALT4 | 1630 | -697 | 2920 | 1989 |
| B4GALT5 | -4031 | 4137 | 5090 | 4775 |
| B4GALT6 | 2689 | 3059 | 5176 | 5059 |
| MGAT4A | 266 | 3290 | 945 | 1526 |
| MGAT4B | -4664 | -1201 | -1241 | -491 |
| MGAT5 | 2998 | 2710 | 3847 | 3970 |
| ST3GAL4 | -2921 | 3742 | 3269 | 3879 |
| ST6GAL1 | -5343 | 1742 | 3401 | 3481 |
| ST8SIA2 | -5378 | 3934 | 4308 | 4419 |
Respiratory electron transport
| metric | value |
|---|---|
| setSize | 92 |
| pMANOVA | 2.14e-29 |
| p.adjustMANOVA | 3.3e-27 |
| s.dist | 0.922 |
| s.human | -0.179 |
| s.mouse | -0.367 |
| s.jmod | -0.489 |
| s.jsev | -0.666 |
| p.human | 0.00312 |
| p.mouse | 1.28e-09 |
| p.jmod | 5.26e-16 |
| p.jsev | 2.26e-28 |
| Gene | jsev | jmod |
|---|---|---|
| NDUFAF6 | -5376 | -5277 |
| NDUFB8 | -5273 | -5046 |
| NDUFB4 | -5147 | -5054 |
| NDUFA7 | -5425 | -4728 |
| ECSIT | -5003 | -5106 |
| NDUFS6 | -4922 | -5136 |
| NDUFS3 | -4866 | -5115 |
| NDUFS7 | -4759 | -5036 |
| TRAP1 | -4947 | -4798 |
| NDUFA12 | -4687 | -5055 |
| NDUFAF5 | -5002 | -4687 |
| NDUFS5 | -4921 | -4742 |
| NDUFC1 | -4694 | -4759 |
| NDUFA13 | -4788 | -4526 |
| TACO1 | -4822 | -4409 |
| NDUFA5 | -4422 | -4680 |
| NDUFB9 | -4737 | -4338 |
| NDUFS2 | -4454 | -4572 |
| NDUFAF1 | -4705 | -4302 |
| NDUFV1 | -4550 | -4375 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ACAD9 | -4536 | -4526 | -3774 | -4279 |
| COQ10A | -3522 | -2636 | -3298 | -4456 |
| COQ10B | 4324 | 4226 | -581 | -2292 |
| COX11 | -2836 | -1161 | -4331 | -3619 |
| COX14 | -2749 | -4337 | -2334 | -3781 |
| COX16 | -2239 | -1928 | -3032 | -5048 |
| COX18 | -553 | 631 | -1589 | -1593 |
| COX19 | 3037 | 3465 | -1018 | -2770 |
| COX20 | 1096 | -2260 | -2841 | -2946 |
| COX4I1 | -2336 | -1282 | -2577 | -3829 |
| COX5A | -2490 | -2534 | -3091 | -4127 |
| COX5B | -2538 | 456 | -2535 | -3988 |
| COX6A1 | 2247 | 2225 | 2160 | 3365 |
| COX6B1 | -2212 | -851 | -1781 | -3712 |
| COX6C | -18 | -841 | -1021 | -3527 |
| COX7B | 142 | -725 | -361 | -3184 |
| COX7C | -1482 | -175 | -1756 | -2432 |
| COX8A | -4298 | 2625 | 2143 | 3026 |
| CYC1 | -4110 | -4002 | -3222 | -4341 |
| ECSIT | -2633 | -2826 | -5106 | -5003 |
| ETFA | 3143 | -2742 | -462 | -2287 |
| ETFB | -3583 | -2721 | -4137 | -4750 |
| ETFDH | 1872 | -4553 | -2700 | -3396 |
| LRPPRC | 1645 | -4358 | -3038 | -3737 |
| MT-CO1 | -3141 | -4085 | -3674 | -4681 |
| MT-CYB | -1344 | -2337 | -2487 | -4813 |
| MT-ND1 | -353 | -2196 | -3440 | -4873 |
| MT-ND2 | -1111 | -2072 | -2744 | -4949 |
| MT-ND4 | -2068 | -1583 | -2533 | -4907 |
| MT-ND5 | -3217 | -2307 | -2314 | -4573 |
| MT-ND6 | 810 | -4559 | -2351 | -4538 |
| NDUFA1 | -734 | 309 | -3280 | -3960 |
| NDUFA10 | -1937 | -3098 | -2972 | -4446 |
| NDUFA11 | -1025 | -1131 | -4153 | -4509 |
| NDUFA12 | -1304 | -656 | -5055 | -4687 |
| NDUFA13 | -2233 | -2537 | -4526 | -4788 |
| NDUFA2 | -1279 | -1963 | -4039 | -4693 |
| NDUFA3 | -3772 | -590 | -3702 | -4761 |
| NDUFA4 | -393 | -679 | -3216 | -4029 |
| NDUFA5 | 530 | -1658 | -4680 | -4422 |
| NDUFA6 | -77 | -3365 | 2217 | -2218 |
| NDUFA7 | -465 | -1812 | -4728 | -5425 |
| NDUFA8 | -600 | -2489 | -3140 | -4344 |
| NDUFA9 | -2843 | -2060 | -3862 | -3986 |
| NDUFAB1 | 1143 | -3233 | -1919 | -3628 |
| NDUFAF1 | 1167 | -4234 | -4302 | -4705 |
| NDUFAF2 | 3487 | -3224 | 1598 | -907 |
| NDUFAF3 | -3550 | -1257 | -810 | -2450 |
| NDUFAF4 | 3722 | -2005 | -3122 | -4016 |
| NDUFAF5 | 28 | -973 | -4687 | -5002 |
| NDUFAF6 | -2534 | -4067 | -5277 | -5376 |
| NDUFAF7 | 2955 | -455 | -808 | -1681 |
| NDUFB10 | -3343 | -2081 | -3566 | -4256 |
| NDUFB11 | -2085 | -2840 | 2200 | -1800 |
| NDUFB2 | -3701 | -958 | -3669 | -4852 |
| NDUFB3 | 845 | -1919 | -2561 | -3232 |
| NDUFB4 | -311 | -1512 | -5054 | -5147 |
| NDUFB5 | -2021 | -1171 | -1281 | -3475 |
| NDUFB6 | 921 | -306 | -4201 | -4365 |
| NDUFB7 | -4184 | -1979 | -3246 | -4170 |
| NDUFB8 | -2995 | -2896 | -5046 | -5273 |
| NDUFB9 | -988 | -3409 | -4338 | -4737 |
| NDUFC1 | -662 | -2883 | -4759 | -4694 |
| NDUFC2 | 32 | -2414 | -2946 | -4236 |
| NDUFS1 | -1531 | -4342 | -3946 | -4495 |
| NDUFS2 | -3001 | -2795 | -4572 | -4454 |
| NDUFS3 | -3536 | -2734 | -5115 | -4866 |
| NDUFS4 | -1675 | -2428 | 916 | -2652 |
| NDUFS5 | -1225 | -1909 | -4742 | -4921 |
| NDUFS6 | -1321 | -976 | -5136 | -4922 |
| NDUFS7 | -4828 | -1892 | -5036 | -4759 |
| NDUFS8 | -4286 | -1984 | -3538 | -4366 |
| NDUFV1 | -4188 | -2717 | -4375 | -4550 |
| NDUFV3 | -2357 | -2573 | -1934 | -3443 |
| NUBPL | -1528 | -3520 | 1662 | -451 |
| SCO1 | 3560 | 1696 | 2351 | 1489 |
| SCO2 | -1924 | -768 | 742 | -1345 |
| SDHA | -4730 | -4558 | -4419 | -4448 |
| SDHB | 429 | -3680 | -3699 | -4255 |
| SDHC | -3681 | -2980 | -3055 | -4450 |
| SURF1 | -1733 | -4070 | -1572 | -3889 |
| TACO1 | 646 | -4231 | -4409 | -4822 |
| TIMMDC1 | 211 | -1103 | -4154 | -4613 |
| TMEM126B | 1017 | 1857 | 2341 | -876 |
| TRAP1 | -5220 | -2048 | -4798 | -4947 |
| UQCR10 | -3113 | -258 | 2839 | -2153 |
| UQCRB | 401 | -3688 | -1452 | -3263 |
| UQCRC1 | -3304 | -3641 | -4077 | -4622 |
| UQCRC2 | 547 | -3880 | -3357 | -4026 |
| UQCRFS1 | -151 | -3041 | -2852 | -3937 |
| UQCRH | -1519 | -1741 | -1925 | -3886 |
| UQCRQ | -1752 | -1842 | 0 | -3044 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
| metric | value |
|---|---|
| setSize | 13 |
| pMANOVA | 0.00376 |
| p.adjustMANOVA | 0.0104 |
| s.dist | 0.917 |
| s.human | 0.112 |
| s.mouse | 0.324 |
| s.jmod | 0.623 |
| s.jsev | 0.58 |
| p.human | 0.486 |
| p.mouse | 0.0431 |
| p.jmod | 0.000101 |
| p.jsev | 0.000296 |
| Gene | jmod | jsev |
|---|---|---|
| ITGB2 | 5118 | 4990 |
| IFITM1 | 5037 | 5025 |
| VCAM1 | 4604 | 5014 |
| ICAM1 | 4616 | 4861 |
| ITGB1 | 4799 | 4169 |
| B2M | 3245 | 4801 |
| CD81 | 4169 | 3181 |
| COLEC12 | 3234 | 3605 |
| C3 | 4062 | 2169 |
| NPDC1 | 1394 | 2143 |
| ITGA4 | 1445 | 1527 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| B2M | -728 | 1582 | 3245 | 4801 |
| C3 | 4291 | 1826 | 4062 | 2169 |
| CD34 | 851 | 886 | 1167 | -2214 |
| CD81 | -4632 | 890 | 4169 | 3181 |
| COLEC12 | 4241 | 45 | 3234 | 3605 |
| ICAM1 | 1048 | 4143 | 4616 | 4861 |
| ICAM2 | -1492 | -3452 | -643 | -2244 |
| IFITM1 | 1563 | 4784 | 5037 | 5025 |
| ITGA4 | -2853 | -5106 | 1445 | 1527 |
| ITGB1 | 949 | 4584 | 4799 | 4169 |
| ITGB2 | -107 | 4962 | 5118 | 4990 |
| NPDC1 | -2106 | 1823 | 1394 | 2143 |
| VCAM1 | 2850 | 4682 | 4604 | 5014 |
Interferon alpha/beta signaling
| metric | value |
|---|---|
| setSize | 36 |
| pMANOVA | 1.57e-08 |
| p.adjustMANOVA | 2.1e-07 |
| s.dist | 0.902 |
| s.human | -0.00941 |
| s.mouse | 0.35 |
| s.jmod | 0.552 |
| s.jsev | 0.621 |
| p.human | 0.922 |
| p.mouse | 0.00028 |
| p.jmod | 1.01e-08 |
| p.jsev | 1.13e-10 |
| Gene | jsev | jmod |
|---|---|---|
| PTPN6 | 5061 | 5071 |
| IFITM1 | 5025 | 5037 |
| IFITM2 | 5025 | 5037 |
| IFITM3 | 5025 | 5037 |
| PTPN1 | 4791 | 4685 |
| RNASEL | 4948 | 4301 |
| ADAR | 4818 | 4138 |
| SAMHD1 | 4461 | 4245 |
| MX1 | 4643 | 3981 |
| IFNAR2 | 4511 | 3718 |
| OAS2 | 4319 | 3798 |
| IFNAR1 | 3976 | 4105 |
| STAT2 | 4210 | 3831 |
| TYK2 | 3460 | 4527 |
| IP6K2 | 3707 | 3634 |
| IFIT2 | 4264 | 3126 |
| SOCS3 | 3463 | 3593 |
| IRF7 | 4283 | 2607 |
| IFI27 | 2709 | 4029 |
| PSMB8 | 3816 | 2747 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ABCE1 | 4686 | 568 | -3106 | -2148 |
| ADAR | -2989 | 418 | 4138 | 4818 |
| EGR1 | 4144 | 5204 | 3612 | 2781 |
| IFI27 | -1092 | -398 | 4029 | 2709 |
| IFI35 | -3282 | 173 | 4731 | 2018 |
| IFIT2 | -1327 | 797 | 3126 | 4264 |
| IFIT3 | -787 | 1411 | 1367 | 3738 |
| IFITM1 | 1563 | 4784 | 5037 | 5025 |
| IFITM2 | -316 | 4784 | 5037 | 5025 |
| IFITM3 | 378 | 4784 | 5037 | 5025 |
| IFNAR1 | 3628 | 1079 | 4105 | 3976 |
| IFNAR2 | -1305 | 2344 | 3718 | 4511 |
| IP6K2 | 3387 | -658 | 3634 | 3707 |
| IRF1 | -1552 | 978 | -68 | 2748 |
| IRF2 | -3357 | 2245 | 2355 | -153 |
| IRF3 | -3035 | -113 | 2214 | 1120 |
| IRF4 | -1156 | 2568 | 3522 | 1377 |
| IRF7 | 769 | 4001 | 2607 | 4283 |
| IRF9 | 1257 | 132 | 2500 | 4098 |
| ISG15 | -3894 | 1725 | 1952 | 2614 |
| JAK1 | -1852 | 4199 | -1819 | -2166 |
| MX1 | -1850 | 3193 | 3981 | 4643 |
| OAS2 | 210 | 2049 | 3798 | 4319 |
| PSMB8 | -673 | 2051 | 2747 | 3816 |
| PTPN1 | 1520 | 4555 | 4685 | 4791 |
| PTPN11 | -1562 | -663 | -1115 | -2125 |
| PTPN6 | -924 | 4768 | 5071 | 5061 |
| RNASEL | 2890 | 873 | 4301 | 4948 |
| SAMHD1 | 46 | 3035 | 4245 | 4461 |
| SOCS1 | 197 | 4004 | -56 | 551 |
| SOCS3 | -283 | 5070 | 3593 | 3463 |
| STAT1 | 234 | -1726 | 2089 | 2735 |
| STAT2 | -2580 | 278 | 3831 | 4210 |
| TYK2 | -3097 | -49 | 4527 | 3460 |
| USP18 | 43 | -2551 | 1938 | 3407 |
| XAF1 | -320 | -1149 | 1887 | 3037 |
Unwinding of DNA
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.00452 |
| p.adjustMANOVA | 0.0121 |
| s.dist | 0.894 |
| s.human | -0.0363 |
| s.mouse | 0.473 |
| s.jmod | 0.437 |
| s.jsev | 0.619 |
| p.human | 0.843 |
| p.mouse | 0.00962 |
| p.jmod | 0.0168 |
| p.jsev | 0.000702 |
| Gene | jsev | mouse |
|---|---|---|
| MCM5 | 5004 | 4830 |
| MCM6 | 5003 | 4791 |
| MCM3 | 4582 | 4730 |
| MCM4 | 4186 | 4810 |
| MCM7 | 4533 | 2860 |
| MCM2 | 3813 | 2830 |
| GINS3 | 3510 | 2279 |
| GINS1 | 1857 | 1691 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| GINS1 | 439 | 1691 | -297 | 1857 |
| GINS3 | -998 | 2279 | 2629 | 3510 |
| GINS4 | -1463 | -1042 | -1037 | -1690 |
| MCM2 | -3942 | 2830 | 492 | 3813 |
| MCM3 | 595 | 4730 | 4449 | 4582 |
| MCM4 | -608 | 4810 | 4385 | 4186 |
| MCM5 | -1477 | 4830 | 4922 | 5004 |
| MCM6 | 3445 | 4791 | 5087 | 5003 |
| MCM7 | 2500 | 2860 | 4186 | 4533 |
| MCM8 | -3325 | -3250 | -2151 | -230 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
| metric | value |
|---|---|
| setSize | 13 |
| pMANOVA | 0.000218 |
| p.adjustMANOVA | 0.000937 |
| s.dist | 0.893 |
| s.human | -0.167 |
| s.mouse | 0.513 |
| s.jmod | 0.403 |
| s.jsev | 0.587 |
| p.human | 0.297 |
| p.mouse | 0.00138 |
| p.jmod | 0.012 |
| p.jsev | 0.000251 |
| Gene | jsev | mouse |
|---|---|---|
| E2F8 | 4648 | 5093 |
| CCNE1 | 4677 | 4722 |
| CCNA2 | 5010 | 4262 |
| E2F1 | 4478 | 4633 |
| ZNF385A | 4707 | 3976 |
| CDKN1A | 3687 | 5060 |
| CDK2 | 4652 | 2669 |
| E2F7 | 3320 | 3311 |
| TP53 | 2876 | 3722 |
| ARID3A | 844 | 1302 |
| CCNE2 | 464 | 146 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ARID3A | -4378 | 1302 | -320 | 844 |
| CCNA2 | 3045 | 4262 | 5064 | 5010 |
| CCNE1 | 4368 | 4722 | 4975 | 4677 |
| CCNE2 | 4646 | 146 | -2498 | 464 |
| CDK2 | 842 | 2669 | 4581 | 4652 |
| CDKN1A | -4884 | 5060 | 4244 | 3687 |
| CDKN1B | -3257 | -2434 | -5100 | -3997 |
| E2F1 | -528 | 4633 | 4825 | 4478 |
| E2F7 | 509 | 3311 | 2055 | 3320 |
| E2F8 | -5574 | 5093 | 4516 | 4648 |
| PCBP4 | -5477 | -1858 | -2763 | 2134 |
| TP53 | 571 | 3722 | 2821 | 2876 |
| ZNF385A | -5166 | 3976 | 4706 | 4707 |
PECAM1 interactions
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.0116 |
| p.adjustMANOVA | 0.0274 |
| s.dist | 0.892 |
| s.human | -0.252 |
| s.mouse | 0.283 |
| s.jmod | 0.594 |
| s.jsev | 0.546 |
| p.human | 0.168 |
| p.mouse | 0.121 |
| p.jmod | 0.00114 |
| p.jsev | 0.00279 |
| Gene | jmod | jsev |
|---|---|---|
| PTPN6 | 5071 | 5061 |
| INPP5D | 5183 | 4907 |
| LYN | 4448 | 4762 |
| ITGAV | 4997 | 3984 |
| FYN | 4023 | 3922 |
| YES1 | 2970 | 1814 |
| ITGB3 | 2933 | 1666 |
| SRC | 2278 | 1786 |
| PLCG1 | 211 | 945 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| FYN | -2826 | 3656 | 4023 | 3922 |
| INPP5D | -2412 | 4297 | 5183 | 4907 |
| ITGAV | -814 | 50 | 4997 | 3984 |
| ITGB3 | -487 | 4884 | 2933 | 1666 |
| LYN | 779 | 3955 | 4448 | 4762 |
| PLCG1 | -3921 | -4904 | 211 | 945 |
| PTPN11 | -1562 | -663 | -1115 | -2125 |
| PTPN6 | -924 | 4768 | 5071 | 5061 |
| SRC | -3876 | 1368 | 2278 | 1786 |
| YES1 | -176 | -2920 | 2970 | 1814 |
Gluconeogenesis
| metric | value |
|---|---|
| setSize | 22 |
| pMANOVA | 2.11e-06 |
| p.adjustMANOVA | 1.56e-05 |
| s.dist | 0.886 |
| s.human | -0.574 |
| s.mouse | -0.36 |
| s.jmod | -0.378 |
| s.jsev | -0.427 |
| p.human | 3.12e-06 |
| p.mouse | 0.00346 |
| p.jmod | 0.00216 |
| p.jsev | 0.000523 |
| Gene | human | jsev |
|---|---|---|
| ALDOA | -5529 | -4913 |
| PC | -5181 | -4892 |
| PGAM2 | -5334 | -4722 |
| SLC37A4 | -4723 | -5286 |
| ENO3 | -4628 | -4877 |
| GPI | -5165 | -4175 |
| MDH2 | -4322 | -4902 |
| SLC25A12 | -5302 | -3705 |
| FBP2 | -3295 | -5366 |
| TPI1 | -3347 | -4952 |
| SLC25A11 | -4072 | -3734 |
| GOT2 | -3673 | -3752 |
| G6PC3 | -3040 | -4150 |
| GOT1 | -3725 | -3151 |
| PGK1 | -1402 | -5245 |
| MDH1 | -1082 | -3063 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ALDOA | -5529 | -3456 | -5077 | -4913 |
| ENO1 | -4047 | 2457 | 4835 | 4869 |
| ENO2 | -2006 | 896 | 3640 | 2788 |
| ENO3 | -4628 | -2836 | -4524 | -4877 |
| FBP2 | -3295 | -3202 | -5317 | -5366 |
| G6PC3 | -3040 | -1482 | -3934 | -4150 |
| GOT1 | -3725 | -1245 | -66 | -3151 |
| GOT2 | -3673 | -3069 | -2435 | -3752 |
| GPI | -5165 | -4103 | -3511 | -4175 |
| MDH1 | -1082 | -3617 | -1363 | -3063 |
| MDH2 | -4322 | -2835 | -2729 | -4902 |
| PC | -5181 | -3670 | -4711 | -4892 |
| PCK2 | -2297 | 373 | 3437 | 4228 |
| PGAM2 | -5334 | -2908 | -4929 | -4722 |
| PGK1 | -1402 | -3489 | -4709 | -5245 |
| SLC25A1 | -2666 | 3703 | -1471 | 123 |
| SLC25A11 | -4072 | -3816 | -2656 | -3734 |
| SLC25A12 | -5302 | -4516 | -4962 | -3705 |
| SLC25A13 | 4263 | 3579 | 3936 | 3385 |
| SLC37A1 | -2569 | -200 | 1130 | 1105 |
| SLC37A4 | -4723 | -5017 | -4950 | -5286 |
| TPI1 | -3347 | -4444 | -4481 | -4952 |
Mitochondrial Fatty Acid Beta-Oxidation
| metric | value |
|---|---|
| setSize | 30 |
| pMANOVA | 1.98e-07 |
| p.adjustMANOVA | 2.07e-06 |
| s.dist | 0.884 |
| s.human | -0.336 |
| s.mouse | -0.548 |
| s.jmod | -0.385 |
| s.jsev | -0.469 |
| p.human | 0.00144 |
| p.mouse | 2.08e-07 |
| p.jmod | 0.000261 |
| p.jsev | 8.89e-06 |
| Gene | mouse | jsev |
|---|---|---|
| PCCA | -5170.0 | -5226.0 |
| HADH | -5152.0 | -4670.0 |
| PCCB | -4114.0 | -5464.0 |
| ACAD11 | -4547.0 | -4657.0 |
| ACAD10 | -4860.0 | -3979.0 |
| DECR1 | -4749.0 | -3796.0 |
| ECI1 | -3389.0 | -4833.0 |
| ECHS1 | -4743.0 | -3440.0 |
| ACADVL | -4268.0 | -3582.0 |
| MMAA | -4296.0 | -3389.0 |
| HADHB | -3584.0 | -3877.0 |
| MCEE | -4720.0 | -2818.0 |
| ACOT13 | -3079.0 | -4231.0 |
| ACOT1 | -5116.5 | -2537.5 |
| ACOT2 | -5116.5 | -2537.5 |
| ACOT11 | -5285.0 | -2291.0 |
| NDUFAB1 | -3233.0 | -3628.0 |
| MCAT | -2796.0 | -4024.0 |
| ACAA2 | -4959.0 | -2073.0 |
| ACADM | -4508.0 | -2069.0 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ACAA2 | -2310 | -4959.0 | -2053.0 | -2073.0 |
| ACAD10 | -4523 | -4860.0 | -3584.0 | -3979.0 |
| ACAD11 | 419 | -4547.0 | -4497.0 | -4657.0 |
| ACADL | -1013 | -3903.0 | 479.0 | -80.0 |
| ACADM | -1699 | -4508.0 | -859.0 | -2069.0 |
| ACADS | -4620 | -3965.0 | -301.0 | -2180.0 |
| ACADVL | -4908 | -4268.0 | -2959.0 | -3582.0 |
| ACOT1 | 1576 | -5116.5 | -2952.5 | -2537.5 |
| ACOT11 | -5215 | -5285.0 | -2573.0 | -2291.0 |
| ACOT13 | -2969 | -3079.0 | -3461.0 | -4231.0 |
| ACOT2 | -2887 | -5116.5 | -2952.5 | -2537.5 |
| ACOT7 | -713 | 3019.0 | -935.0 | 440.0 |
| ACOT9 | 475 | 4939.0 | 3489.0 | 2794.0 |
| ACSF2 | -5103 | 1452.0 | 498.0 | 713.0 |
| DBI | -2835 | 4369.0 | -2025.0 | -2436.0 |
| DECR1 | -2595 | -4749.0 | -3489.0 | -3796.0 |
| ECHS1 | -3861 | -4743.0 | -2029.0 | -3440.0 |
| ECI1 | -3940 | -3389.0 | -4689.0 | -4833.0 |
| HADH | -2763 | -5152.0 | -4020.0 | -4670.0 |
| HADHA | -3176 | -2481.0 | -2545.0 | -3338.0 |
| HADHB | -2017 | -3584.0 | -3537.0 | -3877.0 |
| MCAT | -626 | -2796.0 | -3992.0 | -4024.0 |
| MCEE | -811 | -4720.0 | -254.0 | -2818.0 |
| MECR | -3164 | -1709.0 | -580.0 | -2115.0 |
| MMAA | 2782 | -4296.0 | -839.0 | -3389.0 |
| NDUFAB1 | 1143 | -3233.0 | -1919.0 | -3628.0 |
| PCCA | -2576 | -5170.0 | -4771.0 | -5226.0 |
| PCCB | -165 | -4114.0 | -5306.0 | -5464.0 |
| PCTP | -322 | -1688.0 | 1392.0 | 2361.0 |
| THEM4 | -3585 | -498.0 | -1009.0 | -3717.0 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.
| metric | value |
|---|---|
| setSize | 96 |
| pMANOVA | 5.01e-28 |
| p.adjustMANOVA | 6.86e-26 |
| s.dist | 0.882 |
| s.human | -0.177 |
| s.mouse | -0.358 |
| s.jmod | -0.464 |
| s.jsev | -0.635 |
| p.human | 0.00273 |
| p.mouse | 1.47e-09 |
| p.jmod | 4.17e-15 |
| p.jsev | 5.97e-27 |
| Gene | jsev | jmod |
|---|---|---|
| NDUFAF6 | -5376 | -5277 |
| NDUFB8 | -5273 | -5046 |
| NDUFB4 | -5147 | -5054 |
| NDUFA7 | -5425 | -4728 |
| ECSIT | -5003 | -5106 |
| NDUFS6 | -4922 | -5136 |
| NDUFS3 | -4866 | -5115 |
| NDUFS7 | -4759 | -5036 |
| TRAP1 | -4947 | -4798 |
| NDUFA12 | -4687 | -5055 |
| NDUFAF5 | -5002 | -4687 |
| NDUFS5 | -4921 | -4742 |
| NDUFC1 | -4694 | -4759 |
| NDUFA13 | -4788 | -4526 |
| TACO1 | -4822 | -4409 |
| SLC25A27 | -4646 | -4574 |
| NDUFA5 | -4422 | -4680 |
| NDUFB9 | -4737 | -4338 |
| NDUFS2 | -4454 | -4572 |
| NDUFAF1 | -4705 | -4302 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ACAD9 | -4536 | -4526 | -3774 | -4279 |
| COQ10A | -3522 | -2636 | -3298 | -4456 |
| COQ10B | 4324 | 4226 | -581 | -2292 |
| COX11 | -2836 | -1161 | -4331 | -3619 |
| COX14 | -2749 | -4337 | -2334 | -3781 |
| COX16 | -2239 | -1928 | -3032 | -5048 |
| COX18 | -553 | 631 | -1589 | -1593 |
| COX19 | 3037 | 3465 | -1018 | -2770 |
| COX20 | 1096 | -2260 | -2841 | -2946 |
| COX4I1 | -2336 | -1282 | -2577 | -3829 |
| COX5A | -2490 | -2534 | -3091 | -4127 |
| COX5B | -2538 | 456 | -2535 | -3988 |
| COX6A1 | 2247 | 2225 | 2160 | 3365 |
| COX6B1 | -2212 | -851 | -1781 | -3712 |
| COX6C | -18 | -841 | -1021 | -3527 |
| COX7B | 142 | -725 | -361 | -3184 |
| COX7C | -1482 | -175 | -1756 | -2432 |
| COX8A | -4298 | 2625 | 2143 | 3026 |
| CYC1 | -4110 | -4002 | -3222 | -4341 |
| ECSIT | -2633 | -2826 | -5106 | -5003 |
| ETFA | 3143 | -2742 | -462 | -2287 |
| ETFB | -3583 | -2721 | -4137 | -4750 |
| ETFDH | 1872 | -4553 | -2700 | -3396 |
| LRPPRC | 1645 | -4358 | -3038 | -3737 |
| MT-CO1 | -3141 | -4085 | -3674 | -4681 |
| MT-CYB | -1344 | -2337 | -2487 | -4813 |
| MT-ND1 | -353 | -2196 | -3440 | -4873 |
| MT-ND2 | -1111 | -2072 | -2744 | -4949 |
| MT-ND4 | -2068 | -1583 | -2533 | -4907 |
| MT-ND5 | -3217 | -2307 | -2314 | -4573 |
| MT-ND6 | 810 | -4559 | -2351 | -4538 |
| NDUFA1 | -734 | 309 | -3280 | -3960 |
| NDUFA10 | -1937 | -3098 | -2972 | -4446 |
| NDUFA11 | -1025 | -1131 | -4153 | -4509 |
| NDUFA12 | -1304 | -656 | -5055 | -4687 |
| NDUFA13 | -2233 | -2537 | -4526 | -4788 |
| NDUFA2 | -1279 | -1963 | -4039 | -4693 |
| NDUFA3 | -3772 | -590 | -3702 | -4761 |
| NDUFA4 | -393 | -679 | -3216 | -4029 |
| NDUFA5 | 530 | -1658 | -4680 | -4422 |
| NDUFA6 | -77 | -3365 | 2217 | -2218 |
| NDUFA7 | -465 | -1812 | -4728 | -5425 |
| NDUFA8 | -600 | -2489 | -3140 | -4344 |
| NDUFA9 | -2843 | -2060 | -3862 | -3986 |
| NDUFAB1 | 1143 | -3233 | -1919 | -3628 |
| NDUFAF1 | 1167 | -4234 | -4302 | -4705 |
| NDUFAF2 | 3487 | -3224 | 1598 | -907 |
| NDUFAF3 | -3550 | -1257 | -810 | -2450 |
| NDUFAF4 | 3722 | -2005 | -3122 | -4016 |
| NDUFAF5 | 28 | -973 | -4687 | -5002 |
| NDUFAF6 | -2534 | -4067 | -5277 | -5376 |
| NDUFAF7 | 2955 | -455 | -808 | -1681 |
| NDUFB10 | -3343 | -2081 | -3566 | -4256 |
| NDUFB11 | -2085 | -2840 | 2200 | -1800 |
| NDUFB2 | -3701 | -958 | -3669 | -4852 |
| NDUFB3 | 845 | -1919 | -2561 | -3232 |
| NDUFB4 | -311 | -1512 | -5054 | -5147 |
| NDUFB5 | -2021 | -1171 | -1281 | -3475 |
| NDUFB6 | 921 | -306 | -4201 | -4365 |
| NDUFB7 | -4184 | -1979 | -3246 | -4170 |
| NDUFB8 | -2995 | -2896 | -5046 | -5273 |
| NDUFB9 | -988 | -3409 | -4338 | -4737 |
| NDUFC1 | -662 | -2883 | -4759 | -4694 |
| NDUFC2 | 32 | -2414 | -2946 | -4236 |
| NDUFS1 | -1531 | -4342 | -3946 | -4495 |
| NDUFS2 | -3001 | -2795 | -4572 | -4454 |
| NDUFS3 | -3536 | -2734 | -5115 | -4866 |
| NDUFS4 | -1675 | -2428 | 916 | -2652 |
| NDUFS5 | -1225 | -1909 | -4742 | -4921 |
| NDUFS6 | -1321 | -976 | -5136 | -4922 |
| NDUFS7 | -4828 | -1892 | -5036 | -4759 |
| NDUFS8 | -4286 | -1984 | -3538 | -4366 |
| NDUFV1 | -4188 | -2717 | -4375 | -4550 |
| NDUFV3 | -2357 | -2573 | -1934 | -3443 |
| NUBPL | -1528 | -3520 | 1662 | -451 |
| SCO1 | 3560 | 1696 | 2351 | 1489 |
| SCO2 | -1924 | -768 | 742 | -1345 |
| SDHA | -4730 | -4558 | -4419 | -4448 |
| SDHB | 429 | -3680 | -3699 | -4255 |
| SDHC | -3681 | -2980 | -3055 | -4450 |
| SLC25A14 | 3815 | 1859 | 2420 | 2905 |
| SLC25A27 | -2457 | -4829 | -4574 | -4646 |
| SURF1 | -1733 | -4070 | -1572 | -3889 |
| TACO1 | 646 | -4231 | -4409 | -4822 |
| TIMMDC1 | 211 | -1103 | -4154 | -4613 |
| TMEM126B | 1017 | 1857 | 2341 | -876 |
| TRAP1 | -5220 | -2048 | -4798 | -4947 |
| UCP2 | -4905 | 5008 | 5034 | 4864 |
| UCP3 | -682 | -5325 | -501 | -2029 |
| UQCR10 | -3113 | -258 | 2839 | -2153 |
| UQCRB | 401 | -3688 | -1452 | -3263 |
| UQCRC1 | -3304 | -3641 | -4077 | -4622 |
| UQCRC2 | 547 | -3880 | -3357 | -4026 |
| UQCRFS1 | -151 | -3041 | -2852 | -3937 |
| UQCRH | -1519 | -1741 | -1925 | -3886 |
| UQCRQ | -1752 | -1842 | 0 | -3044 |
rRNA processing in the mitochondrion
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.000651 |
| p.adjustMANOVA | 0.00238 |
| s.dist | 0.868 |
| s.human | -0.0385 |
| s.mouse | -0.367 |
| s.jmod | -0.422 |
| s.jsev | -0.663 |
| p.human | 0.825 |
| p.mouse | 0.0352 |
| p.jmod | 0.0153 |
| p.jsev | 0.000142 |
| Gene | jsev | jmod |
|---|---|---|
| NSUN4 | -4731 | -4958 |
| MT-CO1 | -4681 | -3674 |
| MT-ND1 | -4873 | -3440 |
| MT-ND2 | -4949 | -2744 |
| TRMT10C | -3502 | -3681 |
| MT-ND4 | -4907 | -2533 |
| TFB1M | -3644 | -3294 |
| MT-CYB | -4813 | -2487 |
| MT-ND5 | -4573 | -2314 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ELAC2 | 1509 | 1558 | 116 | -232 |
| HSD17B10 | -1183 | -483 | 3980 | 7 |
| MT-CO1 | -3141 | -4085 | -3674 | -4681 |
| MT-CYB | -1344 | -2337 | -2487 | -4813 |
| MT-ND1 | -353 | -2196 | -3440 | -4873 |
| MT-ND2 | -1111 | -2072 | -2744 | -4949 |
| MT-ND4 | -2068 | -1583 | -2533 | -4907 |
| MT-ND5 | -3217 | -2307 | -2314 | -4573 |
| NSUN4 | -824 | -4993 | -4958 | -4731 |
| TFB1M | 1526 | -3343 | -3294 | -3644 |
| TRMT10C | 4759 | -8 | -3681 | -3502 |
Biotin transport and metabolism
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.0205 |
| p.adjustMANOVA | 0.0439 |
| s.dist | 0.864 |
| s.human | -0.0212 |
| s.mouse | -0.535 |
| s.jmod | -0.425 |
| s.jsev | -0.528 |
| p.human | 0.907 |
| p.mouse | 0.00341 |
| p.jmod | 0.0199 |
| p.jsev | 0.00387 |
| Gene | mouse | jsev |
|---|---|---|
| MCCC2 | -4933 | -5496 |
| PCCA | -5170 | -5226 |
| ACACB | -4961 | -5154 |
| MCCC1 | -4657 | -5074 |
| PCCB | -4114 | -5464 |
| PC | -3670 | -4892 |
| HLCS | -3873 | -2364 |
| SLC5A6 | -42 | -578 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ACACB | -5331 | -4961 | -4461 | -5154 |
| BTD | 2551 | 2179 | -691 | 82 |
| HLCS | -755 | -3873 | 1640 | -2364 |
| MCCC1 | 3993 | -4657 | -4587 | -5074 |
| MCCC2 | 2192 | -4933 | -4965 | -5496 |
| PC | -5181 | -3670 | -4711 | -4892 |
| PCCA | -2576 | -5170 | -4771 | -5226 |
| PCCB | -165 | -4114 | -5306 | -5464 |
| PDZD11 | 1667 | 488 | 4863 | 4121 |
| SLC5A6 | -433 | -42 | 72 | -578 |
Metabolism of steroid hormones
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.00967 |
| p.adjustMANOVA | 0.0236 |
| s.dist | 0.852 |
| s.human | -0.118 |
| s.mouse | 0.387 |
| s.jmod | 0.57 |
| s.jsev | 0.487 |
| p.human | 0.48 |
| p.mouse | 0.0203 |
| p.jmod | 0.000632 |
| p.jsev | 0.00348 |
| Gene | jmod | jsev |
|---|---|---|
| TSPO | 5040.0 | 4935.0 |
| AKR1B15 | 4932.5 | 4750.5 |
| SRD5A3 | 4329.0 | 4061.0 |
| HSD17B12 | 3999.0 | 4080.0 |
| AKR1B1 | 5232.0 | 2524.0 |
| STARD3NL | 3048.0 | 3718.0 |
| HSD17B11 | 3273.0 | 3408.0 |
| FDXR | 2759.0 | 1964.0 |
| FDX1 | 2586.0 | 196.0 |
| STARD4 | 359.0 | 1135.0 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| AKR1B1 | -3253 | 4739.0 | 5232.0 | 2524.0 |
| AKR1B15 | -4451 | 3831.5 | 4932.5 | 4750.5 |
| FDX1 | 2324 | 4010.0 | 2586.0 | 196.0 |
| FDXR | -4099 | -3258.0 | 2759.0 | 1964.0 |
| HSD11B1 | -1946 | -3016.0 | 1251.0 | -1454.0 |
| HSD17B11 | 1292 | -624.0 | 3273.0 | 3408.0 |
| HSD17B12 | 2106 | 5029.0 | 3999.0 | 4080.0 |
| SRD5A3 | 3444 | 2915.0 | 4329.0 | 4061.0 |
| STARD3 | -137 | -1744.0 | -1174.0 | -996.0 |
| STARD3NL | -862 | 4495.0 | 3048.0 | 3718.0 |
| STARD4 | -288 | 3536.0 | 359.0 | 1135.0 |
| TSPO | -5099 | 4073.0 | 5040.0 | 4935.0 |
Carnitine metabolism
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.00465 |
| p.adjustMANOVA | 0.0125 |
| s.dist | 0.847 |
| s.human | -0.435 |
| s.mouse | -0.567 |
| s.jmod | -0.272 |
| s.jsev | -0.365 |
| p.human | 0.0126 |
| p.mouse | 0.00112 |
| p.jmod | 0.118 |
| p.jsev | 0.0364 |
| Gene | mouse | human |
|---|---|---|
| RXRA | -4162 | -5473 |
| THRSP | -4608 | -4269 |
| PRKAA2 | -5128 | -3192 |
| SLC22A5 | -2919 | -4611 |
| PRKAG2 | -3507 | -3210 |
| PPARD | -2321 | -4175 |
| PRKAB2 | -2801 | -2312 |
| SLC25A20 | -1428 | -3480 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| CPT1A | -357 | 328 | 4510 | 5027 |
| CPT2 | 551 | -5257 | -3103 | -3679 |
| MID1IP1 | 2046 | -1707 | 2907 | 498 |
| PPARD | -4175 | -2321 | -2662 | -4382 |
| PRKAA2 | -3192 | -5128 | -4433 | -4644 |
| PRKAB2 | -2312 | -2801 | -5287 | -5447 |
| PRKAG2 | -3210 | -3507 | 2557 | 2493 |
| RXRA | -5473 | -4162 | -5068 | -5295 |
| SLC22A5 | -4611 | -2919 | -2099 | -2741 |
| SLC25A20 | -3480 | -1428 | -2575 | -3131 |
| THRSP | -4269 | -4608 | -1027 | -2266 |
LDL clearance
| metric | value |
|---|---|
| setSize | 14 |
| pMANOVA | 0.00411 |
| p.adjustMANOVA | 0.0112 |
| s.dist | 0.842 |
| s.human | 0.0217 |
| s.mouse | 0.219 |
| s.jmod | 0.561 |
| s.jsev | 0.588 |
| p.human | 0.888 |
| p.mouse | 0.157 |
| p.jmod | 0.000278 |
| p.jsev | 0.00014 |
| Gene | jsev | jmod |
|---|---|---|
| SOAT1 | 5009 | 5179 |
| LIPA | 4904 | 5001 |
| NPC2 | 4961 | 4553 |
| AP2A2 | 4428 | 4599 |
| CLTA | 4255 | 4231 |
| AP2B1 | 3611 | 4135 |
| LDLRAP1 | 3411 | 4367 |
| AP2S1 | 2810 | 3327 |
| CLTC | 2329 | 1436 |
| AP2M1 | 1208 | 2325 |
| NCEH1 | 1118 | 1278 |
| NPC1 | 1289 | 1075 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| AP2A1 | -3601 | -419 | 557 | -341 |
| AP2A2 | -1050 | 5032 | 4599 | 4428 |
| AP2B1 | -1147 | 2235 | 4135 | 3611 |
| AP2M1 | -2724 | 3345 | 2325 | 1208 |
| AP2S1 | 1766 | 1968 | 3327 | 2810 |
| CLTA | 1209 | 1656 | 4231 | 4255 |
| CLTC | 2256 | -2783 | 1436 | 2329 |
| LDLR | -3915 | 4198 | -1139 | 1485 |
| LDLRAP1 | -694 | 2012 | 4367 | 3411 |
| LIPA | 2052 | 3420 | 5001 | 4904 |
| NCEH1 | 4335 | -4692 | 1278 | 1118 |
| NPC1 | -3415 | -5283 | 1075 | 1289 |
| NPC2 | 784 | 2242 | 4553 | 4961 |
| SOAT1 | 1669 | 2586 | 5179 | 5009 |
Diseases associated with the TLR signaling cascade
| metric | value |
|---|---|
| setSize | 16 |
| pMANOVA | 0.00101 |
| p.adjustMANOVA | 0.00341 |
| s.dist | 0.841 |
| s.human | -0.175 |
| s.mouse | 0.318 |
| s.jmod | 0.581 |
| s.jsev | 0.489 |
| p.human | 0.225 |
| p.mouse | 0.0279 |
| p.jmod | 5.78e-05 |
| p.jsev | 0.000713 |
| Gene | jmod | jsev |
|---|---|---|
| NFKB2 | 5046 | 4427 |
| TLR4 | 4766 | 4680 |
| TLR6 | 4182 | 4247 |
| CHUK | 4768 | 3474 |
| MYD88 | 3596 | 4492 |
| TLR5 | 4915 | 3233 |
| IKBKB | 3745 | 3772 |
| TLR3 | 2993 | 3656 |
| IRAK4 | 3206 | 3409 |
| NFKB1 | 3098 | 3001 |
| TICAM1 | 3748 | 1892 |
| TRAF3 | 2679 | 1622 |
| RELA | 1895 | 1422 |
| NFKBIA | 1291 | 312 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| CD36 | -580 | -3811 | 1234 | -738 |
| CHUK | 214 | 950 | 4768 | 3474 |
| IKBKB | -4057 | 574 | 3745 | 3772 |
| IRAK4 | -568 | 1962 | 3206 | 3409 |
| MYD88 | 2710 | 4649 | 3596 | 4492 |
| NFKB1 | -4195 | 3288 | 3098 | 3001 |
| NFKB2 | -3892 | 3309 | 5046 | 4427 |
| NFKBIA | -4225 | 4067 | 1291 | 312 |
| RELA | 1772 | 4501 | 1895 | 1422 |
| TICAM1 | 1613 | 4341 | 3748 | 1892 |
| TIRAP | -2918 | -3605 | -2745 | -5024 |
| TLR3 | -310 | -3683 | 2993 | 3656 |
| TLR4 | 1057 | 4885 | 4766 | 4680 |
| TLR5 | -3207 | 922 | 4915 | 3233 |
| TLR6 | 881 | 1288 | 4182 | 4247 |
| TRAF3 | -3782 | 2446 | 2679 | 1622 |
Diseases of Immune System
| metric | value |
|---|---|
| setSize | 16 |
| pMANOVA | 0.00101 |
| p.adjustMANOVA | 0.00341 |
| s.dist | 0.841 |
| s.human | -0.175 |
| s.mouse | 0.318 |
| s.jmod | 0.581 |
| s.jsev | 0.489 |
| p.human | 0.225 |
| p.mouse | 0.0279 |
| p.jmod | 5.78e-05 |
| p.jsev | 0.000713 |
| Gene | jmod | jsev |
|---|---|---|
| NFKB2 | 5046 | 4427 |
| TLR4 | 4766 | 4680 |
| TLR6 | 4182 | 4247 |
| CHUK | 4768 | 3474 |
| MYD88 | 3596 | 4492 |
| TLR5 | 4915 | 3233 |
| IKBKB | 3745 | 3772 |
| TLR3 | 2993 | 3656 |
| IRAK4 | 3206 | 3409 |
| NFKB1 | 3098 | 3001 |
| TICAM1 | 3748 | 1892 |
| TRAF3 | 2679 | 1622 |
| RELA | 1895 | 1422 |
| NFKBIA | 1291 | 312 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| CD36 | -580 | -3811 | 1234 | -738 |
| CHUK | 214 | 950 | 4768 | 3474 |
| IKBKB | -4057 | 574 | 3745 | 3772 |
| IRAK4 | -568 | 1962 | 3206 | 3409 |
| MYD88 | 2710 | 4649 | 3596 | 4492 |
| NFKB1 | -4195 | 3288 | 3098 | 3001 |
| NFKB2 | -3892 | 3309 | 5046 | 4427 |
| NFKBIA | -4225 | 4067 | 1291 | 312 |
| RELA | 1772 | 4501 | 1895 | 1422 |
| TICAM1 | 1613 | 4341 | 3748 | 1892 |
| TIRAP | -2918 | -3605 | -2745 | -5024 |
| TLR3 | -310 | -3683 | 2993 | 3656 |
| TLR4 | 1057 | 4885 | 4766 | 4680 |
| TLR5 | -3207 | 922 | 4915 | 3233 |
| TLR6 | 881 | 1288 | 4182 | 4247 |
| TRAF3 | -3782 | 2446 | 2679 | 1622 |
Glycogen storage diseases
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.000547 |
| p.adjustMANOVA | 0.00205 |
| s.dist | 0.837 |
| s.human | -0.408 |
| s.mouse | -0.0607 |
| s.jmod | -0.443 |
| s.jsev | -0.579 |
| p.human | 0.0193 |
| p.mouse | 0.727 |
| p.jmod | 0.011 |
| p.jsev | 0.000889 |
| Gene | jsev | jmod |
|---|---|---|
| EPM2A | -5208 | -5248 |
| SLC37A4 | -5286 | -4950 |
| GAA | -4786 | -4482 |
| GYS1 | -5377 | -3617 |
| G6PC3 | -4150 | -3934 |
| UBC | -2624 | -3012 |
| PPP1R3C | -3287 | -1014 |
| NHLRC1 | -2390 | -1276 |
| GBE1 | -2934 | -530 |
| GYG1 | -2165 | -86 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| EPM2A | -577 | -4759 | -5248 | -5208 |
| G6PC3 | -3040 | -1482 | -3934 | -4150 |
| GAA | -4956 | -3345 | -4482 | -4786 |
| GBE1 | 528 | -3411 | -530 | -2934 |
| GYG1 | -3842 | 4405 | -86 | -2165 |
| GYS1 | -5339 | -4632 | -3617 | -5377 |
| NHLRC1 | -3424 | 3888 | -1276 | -2390 |
| PPP1R3C | -4970 | 4020 | -1014 | -3287 |
| RPS27A | 777 | 1828 | 1917 | 2182 |
| SLC37A4 | -4723 | -5017 | -4950 | -5286 |
| UBC | 2657 | 4450 | -3012 | -2624 |
Leading Strand Synthesis
| metric | value |
|---|---|
| setSize | 14 |
| pMANOVA | 0.0102 |
| p.adjustMANOVA | 0.0248 |
| s.dist | 0.833 |
| s.human | 0.226 |
| s.mouse | 0.391 |
| s.jmod | 0.469 |
| s.jsev | 0.518 |
| p.human | 0.143 |
| p.mouse | 0.0112 |
| p.jmod | 0.00236 |
| p.jsev | 0.000787 |
| Gene | jsev | jmod |
|---|---|---|
| POLA1 | 4937 | 4806 |
| PCNA | 5029 | 4692 |
| RFC5 | 3800 | 4626 |
| PRIM1 | 4535 | 3078 |
| RFC3 | 3774 | 3371 |
| PRIM2 | 3722 | 2952 |
| POLD3 | 3524 | 2866 |
| POLD1 | 2423 | 3405 |
| POLD4 | 2934 | 2030 |
| POLA2 | 2237 | 2161 |
| RFC1 | 1150 | 4058 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| PCNA | 1319 | 5050 | 4692 | 5029 |
| POLA1 | 1932 | 1814 | 4806 | 4937 |
| POLA2 | -173 | -1978 | 2161 | 2237 |
| POLD1 | -3191 | 576 | 3405 | 2423 |
| POLD2 | -4763 | 1480 | -4324 | -3663 |
| POLD3 | 3469 | 1091 | 2866 | 3524 |
| POLD4 | -2066 | 3699 | 2030 | 2934 |
| PRIM1 | 309 | 3693 | 3078 | 4535 |
| PRIM2 | 3527 | 4411 | 2952 | 3722 |
| RFC1 | 4620 | 1087 | 4058 | 1150 |
| RFC2 | 617 | -1165 | -406 | 967 |
| RFC3 | 2139 | 4084 | 3371 | 3774 |
| RFC4 | 3525 | 959 | 824 | -36 |
| RFC5 | 1398 | 3500 | 4626 | 3800 |
Polymerase switching
| metric | value |
|---|---|
| setSize | 14 |
| pMANOVA | 0.0102 |
| p.adjustMANOVA | 0.0248 |
| s.dist | 0.833 |
| s.human | 0.226 |
| s.mouse | 0.391 |
| s.jmod | 0.469 |
| s.jsev | 0.518 |
| p.human | 0.143 |
| p.mouse | 0.0112 |
| p.jmod | 0.00236 |
| p.jsev | 0.000787 |
| Gene | jsev | jmod |
|---|---|---|
| POLA1 | 4937 | 4806 |
| PCNA | 5029 | 4692 |
| RFC5 | 3800 | 4626 |
| PRIM1 | 4535 | 3078 |
| RFC3 | 3774 | 3371 |
| PRIM2 | 3722 | 2952 |
| POLD3 | 3524 | 2866 |
| POLD1 | 2423 | 3405 |
| POLD4 | 2934 | 2030 |
| POLA2 | 2237 | 2161 |
| RFC1 | 1150 | 4058 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| PCNA | 1319 | 5050 | 4692 | 5029 |
| POLA1 | 1932 | 1814 | 4806 | 4937 |
| POLA2 | -173 | -1978 | 2161 | 2237 |
| POLD1 | -3191 | 576 | 3405 | 2423 |
| POLD2 | -4763 | 1480 | -4324 | -3663 |
| POLD3 | 3469 | 1091 | 2866 | 3524 |
| POLD4 | -2066 | 3699 | 2030 | 2934 |
| PRIM1 | 309 | 3693 | 3078 | 4535 |
| PRIM2 | 3527 | 4411 | 2952 | 3722 |
| RFC1 | 4620 | 1087 | 4058 | 1150 |
| RFC2 | 617 | -1165 | -406 | 967 |
| RFC3 | 2139 | 4084 | 3371 | 3774 |
| RFC4 | 3525 | 959 | 824 | -36 |
| RFC5 | 1398 | 3500 | 4626 | 3800 |
N-glycan antennae elongation in the medial/trans-Golgi
| metric | value |
|---|---|
| setSize | 17 |
| pMANOVA | 0.00209 |
| p.adjustMANOVA | 0.00637 |
| s.dist | 0.819 |
| s.human | -0.125 |
| s.mouse | 0.339 |
| s.jmod | 0.497 |
| s.jsev | 0.542 |
| p.human | 0.373 |
| p.mouse | 0.0156 |
| p.jmod | 0.000388 |
| p.jsev | 0.00011 |
| Gene | jsev | jmod |
|---|---|---|
| B4GALT6 | 5059 | 5176 |
| B4GALT5 | 4775 | 5090 |
| MGAT2 | 4689 | 4557 |
| MAN2A1 | 4572 | 4635 |
| ST8SIA2 | 4419 | 4308 |
| MGAT5 | 3970 | 3847 |
| FUCA1 | 4160 | 3307 |
| ST3GAL4 | 3879 | 3269 |
| ST6GAL1 | 3481 | 3401 |
| B4GALT4 | 1989 | 2920 |
| B4GALT2 | 2202 | 2626 |
| FUT8 | 1710 | 2862 |
| B4GALT1 | 2853 | 1646 |
| MGAT4A | 1526 | 945 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| B4GALT1 | -1303 | 2572 | 1646 | 2853 |
| B4GALT2 | -4996 | 2201 | 2626 | 2202 |
| B4GALT3 | 967 | 1161 | -437 | 929 |
| B4GALT4 | 1630 | -697 | 2920 | 1989 |
| B4GALT5 | -4031 | 4137 | 5090 | 4775 |
| B4GALT6 | 2689 | 3059 | 5176 | 5059 |
| FUCA1 | 109 | 1311 | 3307 | 4160 |
| FUT8 | 3296 | 436 | 2862 | 1710 |
| MAN2A1 | 3982 | 1416 | 4635 | 4572 |
| MAN2A2 | -4882 | -5102 | -2984 | -4713 |
| MGAT2 | 1407 | 4919 | 4557 | 4689 |
| MGAT4A | 266 | 3290 | 945 | 1526 |
| MGAT4B | -4664 | -1201 | -1241 | -491 |
| MGAT5 | 2998 | 2710 | 3847 | 3970 |
| ST3GAL4 | -2921 | 3742 | 3269 | 3879 |
| ST6GAL1 | -5343 | 1742 | 3401 | 3481 |
| ST8SIA2 | -5378 | 3934 | 4308 | 4419 |
Sema3A PAK dependent Axon repulsion
| metric | value |
|---|---|
| setSize | 15 |
| pMANOVA | 0.00335 |
| p.adjustMANOVA | 0.00965 |
| s.dist | 0.819 |
| s.human | -0.184 |
| s.mouse | 0.392 |
| s.jmod | 0.52 |
| s.jsev | 0.461 |
| p.human | 0.217 |
| p.mouse | 0.00861 |
| p.jmod | 0.000487 |
| p.jsev | 0.002 |
| Gene | jmod | jsev |
|---|---|---|
| CFL1 | 4808 | 4934 |
| FES | 4762 | 4710 |
| HSP90AA1 | 4262 | 4735 |
| SEMA3A | 4328 | 3872 |
| FYN | 4023 | 3922 |
| PLXNA1 | 4663 | 3167 |
| LIMK1 | 3652 | 3667 |
| PAK2 | 3826 | 3302 |
| PLXNA3 | 2150 | 2442 |
| NRP1 | 1663 | 2281 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| CFL1 | -902 | 4689 | 4808 | 4934 |
| FES | 555 | 4482 | 4762 | 4710 |
| FYN | -2826 | 3656 | 4023 | 3922 |
| HSP90AA1 | 3638 | 5227 | 4262 | 4735 |
| HSP90AB1 | -637 | 4599 | 725 | -382 |
| LIMK1 | -4814 | 4145 | 3652 | 3667 |
| NRP1 | -112 | -4228 | 1663 | 2281 |
| PAK1 | -5374 | -4850 | 1733 | -1431 |
| PAK2 | 1514 | 4774 | 3826 | 3302 |
| PLXNA1 | -4446 | -536 | 4663 | 3167 |
| PLXNA2 | -5347 | 3695 | -1669 | -813 |
| PLXNA3 | -5067 | 3032 | 2150 | 2442 |
| PLXNA4 | -319 | -838 | 2295 | -170 |
| RAC1 | 2510 | 1446 | -622 | -925 |
| SEMA3A | 2667 | 1059 | 4328 | 3872 |
Voltage gated Potassium channels
| metric | value |
|---|---|
| setSize | 11 |
| pMANOVA | 0.00812 |
| p.adjustMANOVA | 0.0203 |
| s.dist | 0.817 |
| s.human | -0.529 |
| s.mouse | -0.361 |
| s.jmod | -0.365 |
| s.jsev | -0.352 |
| p.human | 0.00239 |
| p.mouse | 0.038 |
| p.jmod | 0.0361 |
| p.jsev | 0.0433 |
| Gene | human | jmod |
|---|---|---|
| KCNC4 | -4866 | -5240 |
| KCNA7 | -5097 | -4423 |
| KCNB1 | -5072 | -4337 |
| KCNQ5 | -3722 | -5020 |
| KCNQ4 | -5576 | -1345 |
| KCNC1 | -3310 | -2084 |
| KCNC3 | -365 | -3302 |
| KCNH2 | -3500 | -249 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| KCNA1 | 4576 | 2112 | -2239 | -4008 |
| KCNA7 | -5097 | -3460 | -4423 | -4799 |
| KCNAB2 | -3172 | 4989 | 4856 | 4828 |
| KCNB1 | -5072 | -5028 | -4337 | -4915 |
| KCNC1 | -3310 | -5281 | -2084 | -3641 |
| KCNC3 | -365 | 1013 | -3302 | -3776 |
| KCNC4 | -4866 | -5240 | -5240 | -4979 |
| KCNH2 | -3500 | -1473 | -249 | -165 |
| KCNQ1 | -3853 | 561 | 1684 | 563 |
| KCNQ4 | -5576 | -4997 | -1345 | 2187 |
| KCNQ5 | -3722 | -4731 | -5020 | -4133 |
Formation of tubulin folding intermediates by CCT/TriC
| metric | value |
|---|---|
| setSize | 17 |
| pMANOVA | 1.62e-05 |
| p.adjustMANOVA | 9.07e-05 |
| s.dist | 0.813 |
| s.human | -0.0956 |
| s.mouse | 0.683 |
| s.jmod | 0.255 |
| s.jsev | 0.346 |
| p.human | 0.495 |
| p.mouse | 1.09e-06 |
| p.jmod | 0.0687 |
| p.jsev | 0.0135 |
| Gene | mouse | jsev |
|---|---|---|
| TUBB6 | 5170 | 5047 |
| TUBA1C | 5092 | 5030 |
| TUBA1B | 4883 | 5054 |
| TUBB2B | 4929 | 4923 |
| TUBB2A | 4418 | 5046 |
| TUBA1A | 3686 | 4737 |
| CCT3 | 4877 | 2966 |
| CCT2 | 4178 | 2474 |
| CCT4 | 3304 | 2367 |
| CCT8 | 3767 | 1771 |
| CCT7 | 3353 | 538 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| CCT2 | 3786 | 4178 | 508 | 2474 |
| CCT3 | 2315 | 4877 | 1413 | 2966 |
| CCT4 | 943 | 3304 | 2181 | 2367 |
| CCT5 | 3058 | 2619 | -2824 | -1408 |
| CCT6A | 2916 | 3012 | -3374 | -782 |
| CCT7 | 434 | 3353 | -2059 | 538 |
| CCT8 | 4129 | 3767 | 1169 | 1771 |
| TCP1 | 4460 | 1203 | 59 | -35 |
| TUBA1A | -5183 | 3686 | 3799 | 4737 |
| TUBA1B | -5279 | 4883 | 4983 | 5054 |
| TUBA1C | -4840 | 5092 | 5026 | 5030 |
| TUBA4A | -5297 | 2057 | -3275 | -4243 |
| TUBA8 | -1107 | -884 | -2996 | -3153 |
| TUBB2A | -4633 | 4418 | 4726 | 5046 |
| TUBB2B | -4661 | 4929 | 4804 | 4923 |
| TUBB4B | 428 | 4865 | 2872 | -2918 |
| TUBB6 | -5015 | 5170 | 5184 | 5047 |
Regulation of IFNA signaling
| metric | value |
|---|---|
| setSize | 12 |
| pMANOVA | 0.0255 |
| p.adjustMANOVA | 0.0529 |
| s.dist | 0.81 |
| s.human | -0.0391 |
| s.mouse | 0.345 |
| s.jmod | 0.49 |
| s.jsev | 0.543 |
| p.human | 0.814 |
| p.mouse | 0.0386 |
| p.jmod | 0.0033 |
| p.jsev | 0.00112 |
| Gene | jsev | jmod |
|---|---|---|
| PTPN6 | 5061 | 5071 |
| PTPN1 | 4791 | 4685 |
| IFNAR2 | 4511 | 3718 |
| IFNAR1 | 3976 | 4105 |
| STAT2 | 4210 | 3831 |
| TYK2 | 3460 | 4527 |
| SOCS3 | 3463 | 3593 |
| USP18 | 3407 | 1938 |
| STAT1 | 2735 | 2089 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| IFNAR1 | 3628 | 1079 | 4105 | 3976 |
| IFNAR2 | -1305 | 2344 | 3718 | 4511 |
| JAK1 | -1852 | 4199 | -1819 | -2166 |
| PTPN1 | 1520 | 4555 | 4685 | 4791 |
| PTPN11 | -1562 | -663 | -1115 | -2125 |
| PTPN6 | -924 | 4768 | 5071 | 5061 |
| SOCS1 | 197 | 4004 | -56 | 551 |
| SOCS3 | -283 | 5070 | 3593 | 3463 |
| STAT1 | 234 | -1726 | 2089 | 2735 |
| STAT2 | -2580 | 278 | 3831 | 4210 |
| TYK2 | -3097 | -49 | 4527 | 3460 |
| USP18 | 43 | -2551 | 1938 | 3407 |
Defects in vitamin and cofactor metabolism
| metric | value |
|---|---|
| setSize | 17 |
| pMANOVA | 0.00052 |
| p.adjustMANOVA | 0.00198 |
| s.dist | 0.804 |
| s.human | 0.104 |
| s.mouse | -0.523 |
| s.jmod | -0.368 |
| s.jsev | -0.476 |
| p.human | 0.458 |
| p.mouse | 0.000191 |
| p.jmod | 0.00868 |
| p.jsev | 0.000678 |
| Gene | mouse | jsev |
|---|---|---|
| MMAB | -5307 | -5486 |
| MCCC2 | -4933 | -5496 |
| PCCA | -5170 | -5226 |
| MCCC1 | -4657 | -5074 |
| PCCB | -4114 | -5464 |
| PC | -3670 | -4892 |
| MMACHC | -3331 | -4403 |
| MMAA | -4296 | -3389 |
| HLCS | -3873 | -2364 |
| LMBRD1 | -1899 | -2911 |
| MMADHC | -1034 | -3914 |
| CD320 | -722 | -3300 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| ABCD4 | 474 | -3548 | 2714 | 3585 |
| BTD | 2551 | 2179 | -691 | 82 |
| CD320 | -2411 | -722 | -2665 | -3300 |
| HLCS | -755 | -3873 | 1640 | -2364 |
| LMBRD1 | 308 | -1899 | -1916 | -2911 |
| MCCC1 | 3993 | -4657 | -4587 | -5074 |
| MCCC2 | 2192 | -4933 | -4965 | -5496 |
| MMAA | 2782 | -4296 | -839 | -3389 |
| MMAB | -5333 | -5307 | -5274 | -5486 |
| MMACHC | 1919 | -3331 | -3497 | -4403 |
| MMADHC | 3225 | -1034 | -3150 | -3914 |
| MTR | 2923 | -4468 | 5111 | 3341 |
| MTRR | 2165 | 3238 | -5110 | -5401 |
| PC | -5181 | -3670 | -4711 | -4892 |
| PCCA | -2576 | -5170 | -4771 | -5226 |
| PCCB | -165 | -4114 | -5306 | -5464 |
| TCN2 | -1714 | -2155 | 4264 | 3881 |
HS-GAG degradation
| metric | value |
|---|---|
| setSize | 16 |
| pMANOVA | 4.75e-05 |
| p.adjustMANOVA | 0.000239 |
| s.dist | 0.801 |
| s.human | -0.436 |
| s.mouse | -0.0137 |
| s.jmod | 0.472 |
| s.jsev | 0.479 |
| p.human | 0.00256 |
| p.mouse | 0.925 |
| p.jmod | 0.00108 |
| p.jsev | 0.000919 |
| Gene | jsev | jmod |
|---|---|---|
| GUSB | 4989 | 5113 |
| NAGLU | 4536 | 4350 |
| SDC3 | 4440 | 4205 |
| SDC2 | 3706 | 5024 |
| GLB1 | 4940 | 3750 |
| GLB1L | 3749 | 3461 |
| SGSH | 3172 | 3944 |
| IDS | 2739 | 4432 |
| SDC1 | 3689 | 2694 |
| HSPG2 | 1555 | 2954 |
| SDC4 | 2280 | 948 |
| GPC6 | 1335 | 806 |
| AGRN | 637 | 762 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| AGRN | -4860 | -2933 | 762 | 637 |
| GLB1 | -2225 | 919 | 3750 | 4940 |
| GLB1L | -1811 | -415 | 3461 | 3749 |
| GPC1 | -5224 | -2945 | -1709 | -3119 |
| GPC4 | -5125 | -3474 | -1582 | -950 |
| GPC6 | -2364 | 157 | 806 | 1335 |
| GUSB | 1911 | 4124 | 5113 | 4989 |
| HSPG2 | -5306 | -403 | 2954 | 1555 |
| IDS | -2452 | -3595 | 4432 | 2739 |
| IDUA | -3833 | -4704 | 75 | -679 |
| NAGLU | -3677 | -709 | 4350 | 4536 |
| SDC1 | -2028 | 211 | 2694 | 3689 |
| SDC2 | 1745 | 4453 | 5024 | 3706 |
| SDC3 | -4577 | 2789 | 4205 | 4440 |
| SDC4 | -2372 | 5120 | 948 | 2280 |
| SGSH | 705 | -510 | 3944 | 3172 |
GPVI-mediated activation cascade
| metric | value |
|---|---|
| setSize | 18 |
| pMANOVA | 0.00372 |
| p.adjustMANOVA | 0.0104 |
| s.dist | 0.801 |
| s.human | 0.158 |
| s.mouse | 0.461 |
| s.jmod | 0.445 |
| s.jsev | 0.454 |
| p.human | 0.245 |
| p.mouse | 0.00071 |
| p.jmod | 0.00109 |
| p.jsev | 0.000863 |
| Gene | mouse | jsev |
|---|---|---|
| PTPN6 | 4768 | 5061 |
| RAC2 | 4915 | 4754 |
| RHOG | 4895 | 4444 |
| PDPN | 4554 | 4340 |
| LYN | 3955 | 4762 |
| RHOA | 4164 | 3790 |
| FYN | 3656 | 3922 |
| RHOB | 5095 | 2500 |
| PIK3CB | 4963 | 1168 |
| CDC42 | 749 | 2006 |
| PIK3R3 | 573 | 1031 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| CDC42 | 3291 | 749 | 2631 | 2006 |
| FYN | -2826 | 3656 | 4023 | 3922 |
| LYN | 779 | 3955 | 4448 | 4762 |
| PDPK1 | 3426 | 2206 | -1071 | -1809 |
| PDPN | -3276 | 4554 | 4460 | 4340 |
| PIK3CA | 363 | 2791 | -3820 | -2091 |
| PIK3CB | 2744 | 4963 | -128 | 1168 |
| PIK3R1 | 2880 | -3125 | 470 | -293 |
| PIK3R3 | 3171 | 573 | 3257 | 1031 |
| PTPN11 | -1562 | -663 | -1115 | -2125 |
| PTPN6 | -924 | 4768 | 5071 | 5061 |
| RAC1 | 2510 | 1446 | -622 | -925 |
| RAC2 | 39 | 4915 | 4775 | 4754 |
| RHOA | 535 | 4164 | 3888 | 3790 |
| RHOB | 4588 | 5095 | 2449 | 2500 |
| RHOG | -1197 | 4895 | 3856 | 4444 |
| VAV2 | -4915 | -895 | 3883 | 3880 |
| VAV3 | 185 | -1059 | 5086 | 4850 |
Activation of PPARGC1A (PGC-1alpha) by phosphorylation
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.036 |
| p.adjustMANOVA | 0.071 |
| s.dist | 0.801 |
| s.human | -0.38 |
| s.mouse | -0.425 |
| s.jmod | -0.356 |
| s.jsev | -0.435 |
| p.human | 0.0376 |
| p.mouse | 0.0199 |
| p.jmod | 0.0515 |
| p.jsev | 0.0172 |
| Gene | jsev | mouse |
|---|---|---|
| PRKAA2 | -4644 | -5128 |
| PRKAG3 | -4477 | -5250 |
| PRKAB2 | -5447 | -2801 |
| MAPK14 | -4963 | -1623 |
| PRKAG1 | -3339 | -1793 |
| PPARGC1A | -1176 | -4971 |
| MAPK11 | -76 | -332 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| MAPK11 | -3355 | -332 | 385 | -76 |
| MAPK12 | -5219 | 639 | -4847 | -5328 |
| MAPK14 | -1549 | -1623 | -5009 | -4963 |
| PPARGC1A | -4174 | -4971 | 1257 | -1176 |
| PRKAA2 | -3192 | -5128 | -4433 | -4644 |
| PRKAB1 | 3419 | 1802 | 2841 | 1787 |
| PRKAB2 | -2312 | -2801 | -5287 | -5447 |
| PRKAG1 | 2091 | -1793 | -2801 | -3339 |
| PRKAG2 | -3210 | -3507 | 2557 | 2493 |
| PRKAG3 | -5491 | -5250 | -3894 | -4477 |
Acyl chain remodelling of PS
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.0214 |
| p.adjustMANOVA | 0.0456 |
| s.dist | 0.797 |
| s.human | 0.216 |
| s.mouse | 0.215 |
| s.jmod | 0.569 |
| s.jsev | 0.468 |
| p.human | 0.236 |
| p.mouse | 0.239 |
| p.jmod | 0.00183 |
| p.jsev | 0.0105 |
| Gene | jmod | jsev |
|---|---|---|
| OSBPL8 | 4810 | 4898 |
| PLA2R1 | 4962 | 3912 |
| MBOAT1 | 4282 | 4476 |
| PLA2G4A | 3090 | 3258 |
| OSBPL10 | 4359 | 1777 |
| LPCAT4 | 2128 | 3383 |
| OSBPL5 | 2269 | 1813 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| LPCAT3 | 4204 | -2695 | -1775 | -40 |
| LPCAT4 | -1175 | 3771 | 2128 | 3383 |
| MBOAT1 | 3900 | 4812 | 4282 | 4476 |
| OSBPL10 | 4 | 918 | 4359 | 1777 |
| OSBPL5 | -4817 | -555 | 2269 | 1813 |
| OSBPL8 | 4859 | 4375 | 4810 | 4898 |
| PLA1A | -1368 | 2247 | 3471 | -101 |
| PLA2G12A | 2253 | -2025 | 2070 | -804 |
| PLA2G4A | 598 | 3676 | 3090 | 3258 |
| PLA2R1 | 64 | -3616 | 4962 | 3912 |
Phase 0 - rapid depolarisation
| metric | value |
|---|---|
| setSize | 17 |
| pMANOVA | 0.000166 |
| p.adjustMANOVA | 0.000732 |
| s.dist | 0.791 |
| s.human | -0.57 |
| s.mouse | -0.235 |
| s.jmod | -0.315 |
| s.jsev | -0.384 |
| p.human | 4.79e-05 |
| p.mouse | 0.0933 |
| p.jmod | 0.0247 |
| p.jsev | 0.0062 |
| Gene | human | jsev |
|---|---|---|
| CAMK2A | -5481 | -5305 |
| CACNG6 | -5231 | -5499 |
| CAMK2B | -5451 | -5148 |
| SCN4A | -5555 | -5045 |
| CACNB1 | -5240 | -5194 |
| SCN1B | -4856 | -5291 |
| RANGRF | -3984 | -4355 |
| CALM1 | -4423 | -3447 |
| CAMK2G | -2079 | -5461 |
| SCN3B | -3858 | -541 |
| FGF13 | -838 | -883 |
| CACNA1C | -759 | -113 |
Click HERE to show all gene set members
| human | mouse | jmod | jsev | |
|---|---|---|---|---|
| CACNA1C | -759 | -665 | -676 | -113 |
| CACNB1 | -5240 | -5313 | -4662 | -5194 |
| CACNG6 | -5231 | -4520 | -5182 | -5499 |
| CALM1 | -4423 | 96 | -3387 | -3447 |
| CAMK2A | -5481 | -4398 | -4383 | -5305 |
| CAMK2B | -5451 | -4200 | -4629 | -5148 |
| CAMK2D | -2204 | 4108 | 4438 | 896 |
| CAMK2G | -2079 | -4927 | -5103 | -5461 |
| FGF11 | -3862 | -3708 | 1144 | 2877 |
| FGF13 | -838 | 612 | 3921 | -883 |
| RANGRF | -3984 | 156 | -3485 | -4355 |
| SCN1B | -4856 | -5279 | -5102 | -5291 |
| SCN2A | 540 | 314 | -1112 | -1680 |
| SCN3A | 2425 | 4392 | 663 | 1528 |
| SCN3B | -3858 | 2958 | -1755 | -541 |
| SCN4A | -5555 | -5052 | -4441 | -5045 |
| SCN5A | -5264 | 3492 | 4747 | 4551 |
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.0.2 (2020-06-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 18.04.5 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.7.1
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.7.1
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] parallel stats4 stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.1.0 GGally_2.0.0
## [3] ggplot2_3.3.2 reshape2_1.4.4
## [5] beeswarm_0.2.3 gplots_3.1.0
## [7] gtools_3.8.2 tibble_3.0.4
## [9] dplyr_1.0.2 echarts4r_0.3.3
## [11] edgeR_3.30.3 limma_3.44.3
## [13] DESeq2_1.28.1 SummarizedExperiment_1.18.2
## [15] DelayedArray_0.14.1 matrixStats_0.57.0
## [17] Biobase_2.48.0 GenomicRanges_1.40.0
## [19] GenomeInfoDb_1.24.2 IRanges_2.22.2
## [21] S4Vectors_0.26.1 BiocGenerics_0.34.0
## [23] mitch_1.0.10
##
## loaded via a namespace (and not attached):
## [1] bitops_1.0-6 bit64_4.0.5 progress_1.2.2
## [4] RColorBrewer_1.1-2 rprojroot_1.3-2 tools_4.0.2
## [7] backports_1.1.10 R6_2.4.1 KernSmooth_2.23-17
## [10] DBI_1.1.0 colorspace_1.4-1 withr_2.3.0
## [13] prettyunits_1.1.1 tidyselect_1.1.0 gridExtra_2.3
## [16] bit_4.0.4 compiler_4.0.2 desc_1.2.0
## [19] labeling_0.4.2 caTools_1.18.0 scales_1.1.1
## [22] genefilter_1.70.0 stringr_1.4.0 digest_0.6.26
## [25] rmarkdown_2.5 XVector_0.28.0 pkgconfig_2.0.3
## [28] htmltools_0.5.0 highr_0.8 fastmap_1.0.1
## [31] htmlwidgets_1.5.2 rlang_0.4.8 RSQLite_2.2.1
## [34] shiny_1.5.0 generics_0.0.2 farver_2.0.3
## [37] jsonlite_1.7.1 BiocParallel_1.22.0 RCurl_1.98-1.2
## [40] magrittr_1.5 GenomeInfoDbData_1.2.3 Matrix_1.2-18
## [43] Rcpp_1.0.5 munsell_0.5.0 lifecycle_0.2.0
## [46] stringi_1.5.3 yaml_2.2.1 MASS_7.3-53
## [49] zlibbioc_1.34.0 plyr_1.8.6 grid_4.0.2
## [52] blob_1.2.1 promises_1.1.1 crayon_1.3.4
## [55] lattice_0.20-41 splines_4.0.2 annotate_1.66.0
## [58] hms_0.5.3 locfit_1.5-9.4 knitr_1.30
## [61] pillar_1.4.6 geneplotter_1.66.0 XML_3.99-0.5
## [64] glue_1.4.2 evaluate_0.14 vctrs_0.3.4
## [67] httpuv_1.5.4 testthat_2.3.2 gtable_0.3.0
## [70] purrr_0.3.4 reshape_0.8.8 assertthat_0.2.1
## [73] xfun_0.18 mime_0.9 xtable_1.8-4
## [76] later_1.1.0.1 survival_3.2-7 AnnotationDbi_1.50.3
## [79] memoise_1.1.0 ellipsis_0.3.1END of report